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A B S T R A C T
Background
Oral cavity and oropharyngeal cancers are frequently described as part of a group of oral cancers or head and neck cancer. Treatment of
oral cavity cancer is generally surgery followed by radiotherapy, whereas oropharyngeal cancers, which are more likely to be advanced
at the time of diagnosis, are managed with radiotherapy or chemoradiation. Surgery for oral cancers can be disfiguring and both
surgery and radiotherapy have significant functional side effects, notably impaired ability to eat, drink and talk. The development of
new chemotherapy agents, new combinations of agents and changes in the relative timing of surgery, radiotherapy, and chemotherapy
treatments may potentially bring about increases in both survival and quality of life for this group of patients.
Objectives
To determine whether chemotherapy, in addition to radiotherapy and/or surgery for oral cavity and oropharyngeal cancer results in
improved survival, disease free survival, progression free survival, locoregional control and reduced recurrence of disease. To determine
which regimen and time of administration (induction, concomitant or adjuvant) is associated with better outcomes.
Search methods
Electronic searches of the Cochrane Oral Health Group’s Trials Register, CENTRAL, MEDLINE, EMBASE, AMED were undertaken
on 1st December 2010. Reference lists of recent reviews and included studies were also searched to identify further trials.
Selection criteria
Randomised controlled trials where more than 50% of participants had primary tumours in the oral cavity or oropharynx, and
which compared the addition of chemotherapy to other treatments such as radiotherapy and/or surgery, or compared two or more
chemotherapy regimens or modes of administration, were included.
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Data collection and analysis
Eighty-nine trials which met the inclusion criteria were assessed for risk of bias and data were extracted by two or more review authors.
The primary outcome was total mortality. Trial authors were contacted for additional information or for clarification.
Main results
There is evidence of a small increase in overall survival associated with induction chemotherapy compared to locoregional treatment
alone (25 trials), hazard ratio (HR) of mortality 0.92 (95% confidence interval (CI) 0.84 to 1.00, P = 0.06). Post-surgery adjuvant
chemotherapy is associated with improved overall survival compared to surgery ± radiotherapy alone (10 trials), HR of mortality
0.88 (95% CI 0.79 to 0.99, P = 0.03), and there is some evidence that this improvement may be greater with concomitant adjuvant
chemoradiotherapy (4 trials), HR of mortality 0.84 (95% CI 0.72 to 0.98, P = 0.03). In patients with unresectable tumours, there
is evidence that concomitant or alternating chemoradiotherapy is associated with improved survival compared to radiotherapy alone
(26 trials), HR of mortality 0.78 (95% CI 0.73 to 0.83, P < 0.00001). These findings are confirmed by sensitivity analyses based on
studies assessed at low risk of bias. There is insufficient evidence to identify which agent(s) and/or regimen(s) are the most effective.
The additional toxicity attributable to chemotherapy in the combined regimens remains unquantified.
Authors’ conclusions
Chemotherapy, in addition to radiotherapy and surgery, is associated with improved overall survival in patients with oral cavity and
oropharyngeal cancers. Induction chemotherapy may prolong survival by 8 to 20% and adjuvant concomitant chemoradiotherapy may
prolong survival by up to 16%. In patients with unresectable tumours, concomitant or alternating chemoradiotherapy may prolong
survival by 10 to 22%. There is insufficient evidence as to which agent or regimen is most effective and the additional toxicity associated
with chemotherapy given in addition to radiotherapy and/or surgery cannot be quantified.
P L A I N L A N G U A G E S U M M A R Y
Chemotherapy for mouth and throat cancer
Oral cavity (mouth) cancer is usually detected earlier and treated with surgery and radiotherapy. Oropharyngeal (throat) cancer may
be advanced when it is found and is treated with radiotherapy. Both treatments may be associated with disfigurement and decreased
ability to eat, drink and talk. Treatment with chemotherapy (drugs which kill cancer cells), in addition to radiotherapy (and surgery
where possible) offers prolonged survival. Chemotherapy given at the same time as radiotherapy, is more effective than chemotherapy
given before radiotherapy, and may reduce the need for surgery. The improvement in overall survival with the use of chemotherapy is
estimated to be between 8% and 22%. The additional side effects of combined chemoradiotherapy (nausea, vomiting, diarrhoea, hair
loss, and infections) were not measured.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Induction chemotherapy plus Locoregional treatment (LRT) versus LRT alone for the treatment of oral cavity and oropharyngeal cancer
Patient or population: patients with oral cavity and oropharyngeal cancer
Settings: hospital
Intervention: induction chemotherapy plus locoregional treatment (LRT)
Comparison: locoregional treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
locoregional treatment induction chemotherapy
plus locoregional treat-
ment (LRT)
Total Mortality
Hazard Ratio
Follow-up: 3-8 years
Low risk population1 HR 0.92
(0.84 to 1)2
4051
(25 studies)
⊕©©©
very low3,4
200 per 1000 186 per 1000
(171 to 200)
Medium risk population1
500 per 1000 471 per 1000
(441 to 500)
High risk population1
700 per 1000 670 per 1000
(636 to 700)
Total Mortality
Follow-up: 3-8 years
Low risk population1 HR 0.80
(0.67 to 0.97)5
968
(4 studies)
⊕⊕⊕©
moderate4
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200 per 1000 163 per 1000
(139 to 195)
Medium risk population1
500 per 1000 426 per 1000
(371 to 489)
High risk population1
700 per 1000 618 per 1000
(554 to 689)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; HR: Hazard ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Control risk based on 5 year mortality data in McGurk 2005
2 Analysis conducted on all included studies
3 Four studies at low risk of bias, 12 are unclear and 9 are at high risk of bias
4 Studies included patients with other head and neck cancers
5 Analysis conducted on included studies at low risk of bias
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B A C K G R O U N D
Description of the condition
Oral cancers are a significant disease group globally with more
than 404,000 new cases worldwide in 2002 (Parkin 2005;
Warnakulasuriya 2009). Oral cancers are the sixth most common
cancer worldwide, accounting for an estimated 4% of all cancers.
The incidence and mortality from oral cancers varies geographi-
cally; the highest age standardised rates of oral cancers are reported
in parts of Europe (France, Hungary), Botswana and south central
Asia (Sri Lanka, Pakistan, Banglasdesh and India) (Parkin 2005).
There is overwhelming evidence that tobacco use, alcohol con-
sumption and betel quid chewing are the main risk factors in the
aetiology of intraoral cancer (La Vecchia 1997; Macfarlane 1995).
There is also strong evidence that low socio-economic status is
associated with a higher incidence and poorer survival of oral can-
cers (Faggiano 1997). There is a higher incidence of oral cancers
in men (Freedman 2007) that is generally attributed to a greater
exposure to the known risk factors and vast majority of cases occur
in men over 50 (Warnakulasuriya 2009) and among low socio-
economic groups (Conway 2008). However, the ratio of males to
females diagnosed with oral cancers has declined from approxi-
mately 5:1 in the 1960s to less than 2:1 in 2002 (Parkin 2005).
Another recent trend is the increasing incidence of oral cavity and
oropharyngeal cancers in younger adults in the European Union
and the United States (Warnakulasuriya 2009).
The epidemiological data concerning ’oral cancer’ obscures the
fact that ’oral cancer’ includes both oral cavity and oropharyn-
geal cancers which have clinically different aetiology, are generally
diagnosed at different stages and managed in different ways. Pa-
tients with oral cavity cancers generally present with early stage
disease and the primary treatment is surgery or radiotherapy or
both. However, oropharyngeal cancers are likely to be advanced
at the time of diagnosis and primary treatment is more likely to
be radiation therapy or chemoradiation. It is now recognised that
oral infection with human papilloma virus (HPV) is strongly asso-
ciated with the development of oropharyngeal cancer where HPV
infection is found in 40% to 60% of patients (D’Souza 2007),
and HPV is thought to be associated with the increased incidence
of oropharyngeal cancer (Hammarstedt 2006). The link between
oncogenic HPV and oropharyngeal cancer is strong and has been
documented innumerous studies, fufilling the epidemiological cri-
teria for disease causality, especially in the development of oropha-
ryngeal cancer in non-smokers (Sturgis 2007). The proportion
of patients with oropharyngeal cancer who are HPV positive has
increased dramatically over recent years (Attner 2010; Ryerson
2008) but it is interesting to note that this group of patients have
significantly improved rates of both overall survival and disease
free survival (Fakhry 2006; Fakhry 2008; Licitra 2006).
The most common cancer of the oral cavity is the squamous cell
carcinoma that arises from the lining of the oral cavity; over 95%
of all oral cavity cancers are squamous cell carcinomas. Despite
significant technical advances in the treatment of oral cancer, it
still has a significant mortality with 128,000 deaths recorded, rep-
resenting nearly half of the incident cases (48%) (Parkin 2001).
Survival following a diagnosis of oral cavity or oropharyngeal can-
cer remains poor with 5-year survival around 50% overall, with
only limited improvement in the past 3 decades (Warnakulasuriya
2009).
Description of the intervention
The primary treatment modality for oral cavity cancer in most
countries has been surgery, whereas oropharyngeal cancer, which is
often diagnosed at a more advanced stage, may be inoperable and
is more commonly treated with radiation or chemoradiation. Post-
operative radiotherapy is added for late stage disease but chemo-
therapy has historically been used in a relatively small proportion
of cases (Funk 2002). Surgery for oral cancers can be disfiguring
and both surgery and radiotherapy have significant functional side
effects, notably impaired ability to eat, drink and talk. As a con-
sequence there has been considerable research into non-surgical
treatment modalities such as chemotherapy and radiotherapy. A
major determination of survival in the treatment of oral cancer is
that it commonly spreads to the lymph nodes of the neck (cervical
lymph nodes) (Haddadin 2000; Hughes 1993; Partridge 2000;
Pentenero 2005; Shah 1990). In low volume disease, chemother-
apymay have an important role to play in the control/treatment of
metastatic disease, and may be equally as effective as radiotherapy
and surgery (Fanucchi 2006; Harari 2005).
Chemotherapy is the administration of anticancer or ’cytotoxic’
drugs. These drugs work by attacking rapidly dividing cancer cells,
disrupting the growth of the cancer cells and destroying them.
The drugs used in chemotherapy affect the life cycle of the can-
cer cells, most commonly by damaging the deoxyribonucleic acid
(DNA) of the cells so that they can no longer reproduce. Because
the drugs enter the body’s circulatory system their effect is sys-
temic and therefore this offers greater applicability in higher stage
tumours where there is a higher risk of metastases to other parts
of the body. Different types of chemotherapeutic agents interrupt
the life cycle of cancer cells at different stages; thus combining
two or three different agents into a chemotherapy regimen may
produce a greater and/or longer lasting effect on the tumour than
single agent chemotherapy. However as well as increased benefits,
combinations of chemotherapeutic agents may also be associated
with increased toxicity, effects which may be exacerbated by the
simultaneous used of radiotherapy.
How the intervention might work
Chemotherapy agents can be classified into groups according to
their mode of action (Additional Table 1). It is common to give
two or more chemotherapy drugs together and this is commonly
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referred to as ’combinational therapy’. A commonly used stan-
dard chemotherapy regimen for oral cancer, for the past 20 years
has been a combination of cisplatin and 5 fluorouracil (Specenier
2007). Most chemotherapy drugs are administered directly into
the bloodstream but other modes, including oral, intramuscular
or intratumoural administration may also be used. The timing of
chemotherapy can vary. It may be given as ’induction’ therapy,
early treatment in order to shrink a tumour prior to surgery or ra-
diotherapy, concurrentlywith radiotherapy (concomitant, concur-
rent or synchronous chemoradiotherapy), or may be provided fol-
lowing treatment with surgery or radiotherapy (adjuvant) (Pignon
2009). Sequential therapy usually refers to induction chemother-
apy followed by concurrent chemoradiotherapy.
Chemotherapy regimens are cycles of treatment, with drugs ad-
ministered daily for one or more days, followed by rest days, de-
pending on the combination of agents and dosages used. Chemo-
therapy is often associated with adverse effects, which are usually
temporary, but may be quite severe, and are the result of the che-
motherapy drugs targetting all dividing cells in the body: normal
cells as well as cancer cells. Adverse effects vary amongst patients
and treatment type, but can include tiredness, anaemia, nausea/
vomiting, diarrhoea or constipation, hair loss, mucositis and sus-
ceptibility to infections. The rest days included in chemotherapy
regimens allow time for adverse events to resolve before the next
treatment cycle begins.
Why it is important to do this review
The management of advanced oral cavity and oropharyngeal can-
cers is problematic and has traditionally relied on surgery and ra-
diotherapy, both of which are associated with substantial adverse
effects. Although there have been new treatments developed there
has been limited improvement in survival over the past 3 decades
(Warnakulasuriya 2009). Oropharyngeal cancers have relatively
’silent’ symptoms which may not be present during the early stages
of the disease, which is a possible explanation for the fact that
stage of disease at diagnosis has not altered in the past 40 years
despite public education (McGurk 2005). Tumour recurrence and
the development ofmultiple primary tumours are themajor causes
of treatment failure (Day 1992; Partridge 2000; Woolgar 2003).
Surgical treatment may be disfiguring and result in a substantially
reduced quality of life as patients are socially isolated, due to diffi-
culties with altered appearance, speech, eating and drinking. The
development of new chemotherapy agents, new combinations of
agents and changes in the relative timing of treatments may bring
about increases in both survival and quality of life.
This review of chemotherapy will attempt to answer the broad
question ’Does treatment with chemotherapy, in addition to ra-
diotherapy and/or surgery, improve the outcomes for patients with
oral cavity and oropharyngeal cancers?’. It is undertaken as part
of a series of Cochrane reviews looking at the treatment modali-
ties of oral cavity and oropharyngeal cancers categorised into four
intervention groups: surgery (Oliver 2007), chemotherapy, radio-
therapy (Glenny 2010) and immunotherapy/biotherapy (Pavitt
2007).
For this chemotherapy review we will include all randomised con-
trolled trials where more than 50% of participants included have
primary tumours in the oral cavity or oropharynx. Only trials
where patients in each treatment arm receive different chemother-
apy (either different agents, dosages, timing or mode of admin-
istration) plus or minus radiotherapy and/or surgery, or chemo-
therapy versus no chemotherapy will be included.
O B J E C T I V E S
Primary objective
To determine whether chemotherapy, in addition to radiotherapy
and/or surgery for oral cavity and oropharyngeal cancer, results
in increased overall survival, disease free survival, progression free
survival, locoregional control and reduced recurrence.
Secondary objective
To determine which chemotherapeutic agents, and which treat-
ment regimen(s) (induction, concomitant or adjuvant) are associ-
ated with the best outcome in terms of overall survival, disease free
survival, progression free survival, recurrent disease and quality of
life
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials comparing chemotherapy treatment,
with either chemotherapy combined with locoregional treatment
(radiotherapy or surgery), a different chemotherapy regimen, or
chemotherapy given at different times relative to locoregional
treatment (either induction, concomitant or adjuvant chemother-
apy) will be included in the review provided there is a minimum
follow-up of 6 months. It is anticipated that there will be no stud-
ies comparing chemotherapy with placebo (although if there are
such studies they will be included).
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Types of participants
Patients with oral cancer as defined by the International Classifi-
cation of Diseases for Oncology (ICD-O) codes as C01-C06 (oral
cavity including mouth, tongue, gum, or palate), tonsil (ICD-O:
C09) or oropharynx, (ICD-O: C10) will be included, but trials
where patients have cancer of hypopharynx (ICD-O: C13), na-
sopharynx (ICD-O: C11), larynx (ICD-O: C32) or lip (ICD-
O: C00) will be excluded (WHO 1992). Clinical trials have fre-
quently recruited patients with any type of squamous cell carci-
noma of the head and neck - i.e. primary tumours in oral cavity,
oropharynx, other pharynx or larynx. Where trials report the re-
sults separately for the different primary tumour sites, data from
oral cavity and oropharynx are used. However, excluding trials of
treatments for head and neck cancer where data from all primary
tumour sites are combined would result in the loss of a great deal
of information. We have therefore decided that trials which in-
clude patients with head and neck cancer including cases of oral
cavity and oropharyngeal cancer will be included, provided data
are available separately for those participants who have cancer of
the oral cavity or oropharynx, or where patients with oral cavity/
oropharyngeal cancers make up more than 50% of trial partici-
pants.
Cancers will be primary squamous cell carcinomas arising from
the oralmucosa.Histological variants of squamous cell carcinomas
will be included (adenosquamous, verrucous, basaloid, papillary
etc) although they are known to have differing natural history
to the majority of conventional squamous cell carcinomas they
have a common aetiology, their incidence is low and they are
generallymanaged in the sameway.Oral carcinoma in situ (OCIS)
is considered to be an early or incipient form of cancer that may, if
left untreated long enough, transform into invasive squamous cell
cancer. OCIS is usually treated with surgery alone. However any
trials of chemotherapy for OCIS identified will be included in this
review. Epithelial malignancies of the salivary glands, odontogenic
tumours, all sarcomas and lymphomas will be excluded as these
have a different aetiology and are managed differently.
Types of interventions
Chemotherapy defined as cytotoxic or antineoplastic drug(s) given
by any mode of administration (oral, intravenous, intra-arterial,
intramuscular or intratumoural) to patients with squamous cell
cancer of the oral cavity or oropharynx, with the intent of killing
or damaging the cancer cells preventing the development or spread
of the cancer.
Patients may be randomised to treatment with chemotherapy plus
other treatments (such as surgery, radiotherapy or other medical
therapies) but the comparison must be either between chemother-
apy and other treatments (no chemotherapy), or chemotherapy A
compared with chemotherapy B (different agent, timing or mode
of administration). The treatments received and compared must
be the primary treatment for the tumour and patients should not
have received any prior intervention other than diagnostic biopsy,
or surgery. Therefore trials where participants present with recur-
rent or metastatic disease will be excluded.
Trials where all participants receive the same chemotherapy regi-
men and are randomised to other treatments such Chinese herbal
medicine, a radiosensitiser (for example amifostine) and/or a
chemosensitiser (for example leucovorin or vitamins), where these
’other treatments’ are the intervention being compared (i.e. they
are the only difference in intervention between the experimental
and control groups) will be excluded.
Trials of targeted therapies, or monoclonal antibodies will be eval-
uated in a separate review which will evaluate immunotherapies
and targeted therapies.
Types of outcome measures
Primary outcome measures will be:
• Total mortality (either a hazard ratio for death, or where
this is not estimable, the numbers of deaths per treatment group
at a specific time point)
• Disease free survival
• Progression free survival or time to recurrence
• Locoregional control
• Locoregional recurrence.
Search methods for identification of studies
This review is part of a series of Cochrane reviews on the treatment
modalities for treating oral cavity and oropharyngeal cancer. The
reviews have been broadly divided into four themes: concerning
surgery, chemotherapy, radiotherapy or immunotherapy/targeted
therapies. A search strategy was developed that would encompass
the four broad themes simultaneously and further adapted for use
in the following databases (date of the most recent searches as
indicated):
• MEDLINE via OVID (1950 to 1st December 2010)
(Appendix 1)
• The Cochrane Oral Health Group’s Trials Register (to 1st
December 2010) (Appendix 2)
• The Cochrane Central Register of Controlled Trials
(CENTRAL) (The Cochrane Library 2010, Issue 4) (Appendix 3)
• EMBASE via OVID (1980 to 1st December 2010)
(Appendix 4)
• Allied and Complementary Medicine Database (AMED)
via OVID (1985 to 1st December 2010) (Appendix 5).
Current Controlled trials (www.controlled-trials.com) was
searched for oral cancer or oropharyngeal cancer on 25th January
2010.
Because studies involving oral cancer are often included with those
of the head and neck, a broad search was undertaken to include
all possible studies. The searches attempted to identify all rele-
vant trials irrespective of language. The reference list of related re-
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view articles and articles considered to be potentially relevant were
checked for further trials. Authors of identified trials and known
specialists in the field were contacted in an attempt to identify any
additional published or unpublished trials.
Sensitive search strategies were developed for each database using a
combination of free text andMeSH terms; these were based on the
search strategy developed forMEDLINE (Appendix 1) but revised
appropriately for each database. The search strategy combined the
subject search with the Cochrane Highly Sensitive Search Strategy
(CHSSS) for identifying randomised trials in MEDLINE: sensi-
tivity maximising version (2009 revision) as referenced in Chapter
6.4.11.1 and detailed in box 6.4.c of the Cochrane Handbook for
Systematic Reviews of Interventions version 5.0.2 (updated Septem-
ber 2009) (Higgins 2009). Handsearching was done as part of the
Cochrane Collaboration’s worldwide handsearching programme,
see the Cochrane Master List of journals being searched for more
information.
The reference lists of related reviews and all articles obtained were
checked for further trials. Authors of trial reports and specialists in
the field known to the review authors were written to concerning
further published and unpublished trials.
The original search strategy was deployed for all four reviews at the
same time i.e. encompassing all the oral cancer treatment modal-
ities and combinations of treatment with identified papers being
then classified into subsets of treatment modalities: surgery, che-
motherapy, radiotherapy and immunotherapy/biotherapy.
Data collection and analysis
Selection of studies
The titles and abstracts (when available) of all reports identified
through the electronic searches were scanned independently by
two review authors for eligibility for the oral cancer reviews. For
studies appearing to meet the inclusion criteria, or for which there
were insufficient data in the title and abstract to make a clear deci-
sion, the full report was obtained. The full reports obtained from
all the electronic and other methods of searching were assessed in-
dependently by two review authors to establish whether the stud-
ies met the inclusion criteria or not. Disagreements were resolved
by discussion. Where resolution was not possible, a third review
author was consulted.
Data extraction and management
All studies meeting the inclusion criteria underwent a risk of bias
assessment and data extraction using a specially designed compre-
hensive data extraction form. Studies rejected at this or subsequent
stages were recorded in the Characteristics of excluded studies ta-
ble, and reasons for exclusion recorded.
As the majority of trials were for head and neck cancers the pro-
portion of oral/oropharyngeal cancer patients was recorded (Ad-
ditional Table 2). In all trials where only combined head and neck
data were presented, the authors were contacted to see if separate
data for the oral cavity/oropharyngeal cancer patients could be
made available. Head and neck cancer trials with only combined
data (i.e. no outcome data available by primary tumour site) where
greater than 50% of participants presented with oral/oropharyn-
geal cancer were included in this review. However, where separate
’pure’ oral/oropharyngeal cancer data were available for a trial,
these ’pure’ data were extracted and analysed and the combined
head and neck data ignored. Where possible oral and oropharyn-
geal cancer data were also analysed separately.
Data were extracted by at least two review authors independently
using a specially designed data extraction form. The data extrac-
tion form was piloted on several papers and modified before use.
Any disagreement was discussed and a third review author con-
sulted where necessary. However, group discussion was often re-
quired following data extraction due to the complexity of the data
presented. When necessary authors were contacted for clarifica-
tion or missing information.
For each trial the following data were recorded:
• Year of publication, country of origin and source of study
funding
• Details of the participants including demographic
characteristics and criteria for inclusion and exclusion,
proportion with oral cavity and oropharyngeal cancer
• Details of the type of intervention, timing and duration
• Details of the outcomes reported, including method of
assessment, and time intervals.
Assessment of risk of bias in included studies
For the studies included in this review assessment of risk of bias was
conducted by at least one review author using the Cochrane risk
of bias assessment tool (Higgins 2009). We assessed six domains
for each included study: sequence generation, allocation conceal-
ment, blinding (of patient, carer, outcome assessor), completeness
of outcome data, risk of selective outcome reporting and risk of
other potential sources of bias. An overall risk of bias assessment
was also made.
For this systematic review we assessed risk of bias according to the
following:
• Sequence generation: use of a random number table, use of
a computerised system, central randomisation by statistical co-
ordinating centre, randomisation by an independent service
using minimisation technique, permuted block allocation or
Zelan technique. If the paper merely stated randomised or
randomly allocated with no further information this was assessed
as being unclear.
• Allocation concealment: centralised allocation including
access by telephone call or fax, or pharmacy-controlled
randomisation, sequentially numbered, sealed, opaque envelopes.
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• Blinding: in most of the included studies blinding of
patients and clinical carers to treatment allocation was not done.
Unless the trial was specifically described as double blind, or
there was a statement about blinding in the methods section of
the paper it was assumed that blinding of patients, clinical staff
and outcome assessors did not occur.
• Outcome data: outcome data were considered complete if
all patients randomised were included in the analysis of the
outcome(s). However, in trials of treatment for cancer this is
rarely the case. Trials where less than 10% of those randomised
were excluded from the analysis, and where reasons for
exclusions were described for each group, and where both
numbers and reasons were similar in each group, were assessed as
being at low risk of bias due to incomplete outcome assessment.
Where post-randomisation exclusions were greater than 10%, or
reasons were not given for exclusions from each group, or where
rates and reasons were different for each group, the risk of bias
due to (in)complete outcome data was assessed as unclear.
• Selective outcome reporting: a trial was assessed as being at
low risk of bias due to selective outcome reporting if the
outcomes of interest described in the methods section, were
systematically reported in the results section. Where reported
outcomes did not include those outcomes specified or expected
in trials of treatments for oral cancer, or where additional
analyses were reported this domain was assessed as unclear.
• Other bias: imbalance in potentially important prognostic
factors between the treatment groups at baseline, or the use of a
co-intervention in only one group (for example nasogastric
feeding) are examples of potential sources of bias noted.
Data synthesis
The primary outcome is total mortality expressed as hazard ratio
of death. These data were entered into the meta-analysis using the
inverse variance method. If hazard ratios were not quoted in stud-
ies, but there were Kaplan-Meier estimates and the numbers at risk
over a range of time intervals were reported, we then calculated
the log hazard ratio and the standard error (SE) from the avail-
able summary statistics (observed events, expected events, vari-
ance, confidence intervals, P values or Kaplan-Meier estimates -
survival curves) according to themethods proposed by Parmar et al
(Parmar 1998), or these data were requested from authors. Where
possible we have presented total mortality as log hazard ratios, ei-
ther calculated from Kaplan-Meier graphs, or from data presented
in the MACH-NCmeta-analyses (Pignon 2000 or Pignon 2009).
For dichotomous outcomes, the estimates of effect of an interven-
tion were expressed as risk ratios together with 95% confidence in-
tervals. Total mortality at a specific timepoint, disease free survival
and progression free survival were analysed in two ways depending
on the data presented in study reports, or obtained from authors.
Some trials were deemed to meet the review’s inclusion criteria
but insufficient data were presented to enable these trials to be
included in the ’Analyses’ section. Providing these trials had used
an appropriate statistical approach theywere included in the review
and their salient findings summarised in the text of the ’Results’
section of the review.
Due to the different natural history and treatment regimens for
oral cavity and oropharyngeal cancers we planned to analyse these
separately if possible. Investigation of clinical heterogeneity (to
examine the types of participants, interventions and outcomes in
each study) was planned but there were insufficient data. Meta-
analyses were conducted only if there were studies of similar com-
parisons reporting the same outcome measures. Risk ratios were
combined for dichotomous data, and hazard ratios for survival
data, using fixed-effect models, unless there were more than four
trials to be combined, when random-effects were used. Where the
same meta-analysis contained subgroups with varying numbers of
trials, a decision as to whether to use a fixed-effect or random-ef-
fects model was based on the degree of heterogeneity of the larger
subgroups of studies. In this situation where heterogeneity was low
a fixed-effect model was chosen. The significance of any discrep-
ancies in the estimates of the treatment effects from the different
trials was assessed bymeans of Cochran’s test for heterogeneity and
the I2 statistic, and any heterogeneity investigated.
A sensitivity analysis (to examine the effects of randomisation, allo-
cation concealment, blinded outcome assessment (if appropriate)
and quality of follow-up/completeness of data set) was planned.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
There were some 5000 papers identified from the search strategy.
These were put into a bibliographic database and the titles and
abstracts were screened against the inclusion criteria for this review.
Full text copies of papers that appeared to meet our inclusion
criteria were obtained and from these 89 included trials (many
with multiple publications) were identified. Some of the included
studies had 100%of participants with oral cavity or oropharyngeal
cancer and others included participants with primary tumours in
other sites (Additional Table 2).
There were 89 trials included in this review. Trials were undertaken
all over the world with 17 based in the USA, 15 in France, 12 in
Italy, 6 in Germany, 6 in India, 4 in Spain, 2 each in Canada, UK,
South America and Scandinavia, 1 trial in Russia, 1 trial in Aus-
tralasia, 3 conducted worldwide,13 multicentre trials in Europe
and 3 multicentre trials in Asia. A total of 16,767 patients were
randomly allocated to treatments and individual trials varied in
size between 23 and 966 participants. Participants were recruited
over periods ranging between 1 and 10 years, with the first study
starting recruitment in 1965 (Richard 1974) and the most recent
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completing recruitment in 2007 (Gladkov 2007; Gupta 2009).
Fifty trials described the stage of cancer of patients eligible for in-
clusion (6 trials included patient with stages 2-4, 44 stages 3-4)
and 23 trials described cancer stage using the more specific TNM
system (Patel 2005) (3 trials included patients with T2-T4 tu-
mours and a further 3 with T1-T4 tumours). The remaining 16
trials did not specify the disease stage(s) in their inclusion criteria.
The clinical heterogeneity of the included studies is substantial,
and one of the strengths of this review lies in presenting an overall
summary of the results of this body of research undertaken across
the world over the past 45 years.
Twenty-eight of the included studies were included in a published
meta-analysis produced by the MACH-NC Collaborative Group
(Pignon 2000) and a further 13 included studies were included in
a subsequent meta-analysis published by the same group (Pignon
2009). With the permission of these authors we have used the
published data for total mortality from these meta-analyses, be-
cause they are from individual patient data from the included trials
(details of the data source for total mortality data are recorded in
Additional Table 2, and in the Characteristics of included studies
tables. For the remainder of the included trials we have extracted
data from the published papers, and sought clarification from the
authors where necessary.
Only 23 of the included trials restricted inclusion to patients with
oral cavity and oropharyngeal cancer. In the remainder of trials
included in this review at least 50% of included participants had
either oral cavity or oropharyngeal cancer (for details seeAdditional
Table 2).
Risk of bias in included studies
We assessed each included study for risk of bias with the Cochrane
risk of bias assessment tool using the six domains described in
the methods section. All of the included studies are described as
randomised with the method of sequence generation described as
either adequate or unclear.
In most studies of chemotherapy, blinding of patients and clini-
cians would be difficult and possibly unethical. Where blinding of
patients, carers or outcome assessors is not mentioned in the text,
we have assumed that there was no blinding.We have taken a prag-
matic approach and assumed that where outcomes are objective
(e.g.mortality, overall survival) the lack of blinding in the included
studies is unlikely to result in bias. However, it is acknowledged
that for outcomes which may be seen as more subjective, such as
progression free survival, disease free survival or recurrence, the
absence of blinding of trial personnel, especially of those assessing
these outcomes may represent a potential risk of bias. Only three
of the included studies used blinding of either patients or outcome
assessors (Figure 1).
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Assessment of possible selective reporting was based on the printed
paper and it is acknowledged that even when the planned out-
comes are listed in the methods section and reported in the results
section of a paper, selective outcome reporting may still be a risk.
However, in most cases, the only information available to us was
that included in the published article so assessment was based on
this information unless otherwise stated. Eight trials were assessed
as being unclear with regard to selective reporting of outcomes,
because insufficient information was available to the review au-
thors from the published paper and contact with the authors.
In 15 trials, some outcome data were missing and it was unclear
whether missing data from those who withdrew or were excluded
represented a possible risk of bias. In two studies (Mohr 1994;
Szabo 1999) outcome data were missing on more than 25% of
those randomised and reasons and distribution of those not in-
cluded were not described. In our assessment this represents a sig-
nificant risk of bias in these two studies.
Various other potential sources of bias were identified in 20 tri-
als. Eight trials presented so little information it was not possible
to make a clear assessment. In seven trials there was a degree of
imbalance between the randomised groups at baseline which may
have introduced a bias to the results. Two trials gave inconsistent
descriptions of methods used, and another three trials included a
co-intervention which may result in bias (see ’Risk of bias’ tables
in the Characteristics of included studies on each study for details,
and summary in Figure 1).
We have described our assessment of the risk of bias of the stud-
ies included for each comparison under the heading Effects of
interventions (below). Overall 21 of the 89 included trials were
assessed as being at low risk of bias for the outcome of total mor-
tality.
Effects of interventions
See: Summary of findings for the main comparison Induction
chemotherapy plus Locoregional treatment (LRT) versus LRT
alone for the treatment of oral cavity and oropharyngeal cancer;
Summary of findings 2 Surgery +/- RT + chemotherapy
compared to surgery +/- RT alone for oral cavity and
oropharyngeal cancer; Summary of findings 3 Concomitant
chemoradiotherapy compared to radiotherapy alone for oral cavity
and oropharyngeal cancer
The searches revealed two published meta-analyses of individual
patient data (IPD) (Pignon 2000; Pignon 2009) which gave log
hazard ratios and standard errors for total mortality and some data
were pertinent to this systematic review; these data were included
providing the trials met our own inclusion criteria. As the Pignon
data were calculated from IPD we considered these data to be
more precise than figures we calculated from the often scant data
presented in trial manuscripts. Therefore these Pignon 2000 and
2009 data take precedence over our data where both types of data
were available.We contacted Pignon for relevant site-specific data;
however his teamwere unable to provide these until they were able
to finalise their own publications - their IPD data were protected
under strict agreement by those contributing data for their use and
distribution.
As described in the methods section, the primary outcome of this
review is total mortality expressed as hazard ratio for death. For ob-
vious reasons clinicians prefer to use the more positive term over-
all survival when communicating information about treatment
effectiveness with patients, but the data from the trials is based
on deaths. We have used the positive term overall survival in the
interpretation of the hazard ratios for mortality. However, where
hazard ratios cannot be estimated from the data presented in each
trial, any dichotomous data available from the trials for numbers
of deaths per treatment group at a specified time point, these data
have been presented in the meta-analysis.
Additional Table 2 records the percentages of patients included
in each trial, who have oral cavity cancer, oropharyngeal cancer
and the combined percentage. Where data from one of the meta-
analyses published by Pignon has been used this is also recorded.
Comparison 1: Induction chemotherapy plus locoregional treat-
ment (LRT) versus LRT alone.
Comparison 2: Surgery ± radiotherapy + chemotherapy versus
surgery ± radiotherapy alone.
Comparison 3: Concomitant chemoradiotherapy versus radio-
therapy alone (non-resectable).
Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B
(± LRT).
The structure of the text for each comparison varies according to
the nature of the individuals trials included, but follows the same
order as the meta-analyses.
Comparison 1: Induction chemotherapy plus
locoregional treatment (LRT) versus LRT alone
There are 26 randomised controlled trials (Brunin 1989; Depondt
1993; Domenge 2000; Fazekas 1980; Giglio 1997; Holoye
1985; Jaulerry 1992; Knowlton 1975; Lewin 1997; Licitra 2003;
Luboinski 1985; Maipang 1995; Mazeron 1992; Mohr 1994;
Nervi 1978; Olmi 2003; Paccagnella 1994; Petrovich 1981;
Richard 1974; Richard 1991; Salvajoli 1992; Schuller 1988; Szabo
1999; Szpirglas 1988;Tejedor 1992;Volling 1999) included in this
comparison, under eight outcome subgroups. Each trial compares
the addition of induction chemotherapy to locoregional treat-
ment (either radiotherapy or surgery or both) with locoregional
treatment alone. All of the trials in this group provided data for
analysis of total mortality, eight trials (Brunin 1989; Domenge
2000;Holoye 1985; Olmi 2003; Paccagnella 1994; Richard 1991;
Tejedor 1992; Volling 1999) for disease free survival, two trials
(Domenge 2000; Olmi 2003) provided data for analysis of pro-
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gression free survival and four trials (Knowlton 1975; Licitra 2003;
Richard 1974; Szabo 1999) reported the dichotomous outcome
of overall survival at either 1 or 5 years of follow-up. One trial
(Licitra 2003) also reported the dichotomous outcomes of disease
free survival and disease related mortality after 5 years of follow-
up.
Cisplatin is the most common chemotherapy agent, used in 14
trials, either alone, or in combinationwith other chemotherapeutic
agents:
• cisplatin alone (Mohr 1994)
• cisplatin plus 5 fluorouracil (5-FU) (Domenge 2000; Lewin
1997; Licitra 2003; Paccagnella 1994)
• cisplatin plus 5-FU plus folinic acid (Giglio 1997)
• cisplatin plus 5-FU plus vindesine (Jaulerry 1992)
• cisplatin plus 5-FU plus bleomycin and methotrexate
(Mazeron 1992)
• cisplatin plus bleomycin, vinblastine plus mitomycin C
(Salvajoli 1992)
• cisplatin plus bleomycin, vindesine plus mitomycin C
(Brunin 1989)
• cisplatin plus bleomycin, vincristine plus adriamycin
(Szpirglas 1988)
• cisplatin plus bleomycin, vincristine plus methotrexate
(Schuller 1988)
• cisplatin plus bleomycin plus methotrexate (Maipang 1995)
• cisplatin plus epirubicin (Szabo 1999).
The other ’platin’ used in these trials is carboplatin, used either
in combination with 5-FU (Depondt 1993; Olmi 2003; Volling
1999) or with ftorafur (Tejedor 1992).
Methotrexate was the next most frequently studied component of
induction chemotherapy in the 26 included trials in Comparison
1. Methotrexate was administered as a single agent in four trials,
either intravenously (Fazekas 1980; Knowlton 1975) or intra-ar-
terially (directly to the target area) (Nervi 1978; Richard 1974) or
in the following combinations:
• methotrexate plus cisplatin, bleomycin and vincristine
(Schuller 1988), see above
• methotrexate plus cisplatin and bleomycin (Maipang
1995), see above
• methotrexate plus vincristine (Petrovich 1981)
• methotrexate plus bleomycin, 5-FU and cyclophosphamide
(Holoye 1985).
The remaining two trials in Comparison 1 used a combina-
tion of bleomycin and vincristine, administered intra-arterially
(Luboinski 1985; Richard 1991).
Risk of bias
None of the 26 trials incorporated blinding of patients or clinicians
and only one (Richard 1974) used blinded outcome assessment.
The lack of blinding is unlikely to have influenced the objective
outcomes of total mortality, but may have had an effect on the
assessment of the more subjective outcomes such as disease free
survival, progression free survival, locoregional control and disease
recurrence. Only seven trials had information indicating adequate
sequence generation and allocation concealment (Domenge 2000;
HNCProg 1987; Licitra 2003; Paccagnella 1994; Richard 1974;
Szabo 1999; UKHAN 2010) but two of these had incomplete
outcome assessment (Richard 1974; Szabo 1999).
Therefore our assessment is that:
• four studies had low risk of bias with regard to total
mortality (Domenge 2000; Licitra 2003; Paccagnella 1994;
Richard 1991), no blinding but adequate with regard to the
other five domains of the assessment;
• ten studies had high risk of bias with regard to all outcomes
reported (Depondt 1993; Fazekas 1980; Giglio 1997; Knowlton
1975; Lewin 1997; Mazeron 1992; Mohr 1994; Richard 1974;
Szabo 1999; Szpirglas 1988) (no blinding, unclear sequence
generation and allocation concealment and a problem in at least
one of the other domains assessed);
• twelve had unclear risk of bias with regard to total mortality
(no blinding and insufficient information provided on sequence
generation and allocation concealment) and moderate to high
risk of bias for the outcomes of disease free survival, progression
free survival, locoregional control and disease recurrence (Brunin
1989; Holoye 1985; Jaulerry 1992; Luboinski 1985; Maipang
1995; Nervi 1978; Olmi 2003; Petrovich 1981; Salvajoli 1992;
Schuller 1988; Tejedor 1992; Volling 1999).
Total mortality
• One trial by Mohr 1994 compared pre-operative
chemoradiotherapy with concomitant low dose cisplatin
followed by surgery to surgery alone. This trial is included in this
comparison because the chemotherapy is the first treatment used
in these patients, but the trial is not truly a trial of induction
chemotherapy versus none, and should be considered as a
separate subgroup. In this trial, 377 patients were randomly
allocated to chemoradiotherapy treatment followed by surgery or
surgery alone, but only 268 patients were included in the
outcome data. An additional 25 patients randomised to pre-
operative chemoradiotherapy subsequently refused surgery (these
patients had larger tumours than the group average), 23 patients
were not evaluated due to ’protocol violations’ and a further 61
randomised patients are not accounted for in the outcome.
Sequence generation and allocation concealment are unclear
from the information given in the paper. Although the results
from this trial showed a statistically significant reduction in total
mortality in favour of the chemoradiotherapy group, the results
from this trial must be interpreted with caution as there is a high
risk of bias, and missing data from 29% of randomised patients
could potentially alter the conclusions from this trial. This trial
has not been included in the meta-analysis.
13Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The remaining 25 trials in this group compared induction chemo-
therapy plus locoregional treatment with locoregional treatment
alone Analysis 1.1.
None of the seven trials (Depondt 1993; Domenge 2000; Olmi
2003 (oropharyngeal cancer only); Lewin 1997; Licitra 2003 (pri-
mary tumour in oral cavity only); Paccagnella 1994; Volling 1999)
that compared platin chemotherapy (either cisplatin or carbo-
platin) plus 5-FU plus radiotherapy, to radiotherapy alone, found
a statistically significant reduction in total mortality due to the
addition of this chemotherapy regimen (Comparisons 1.1.1). The
trial by Lewin 1997 was the only trial in this group which pro-
vided data for the outcome of total mortality for patients with oral
cavity cancers only, and these data showed no difference between
induction chemotherapy with cisplatin/5-FU plus LRT compared
to LRT alone (Analysis 1.1, Comparison 1.1.1). The pooled esti-
mate showed no strong evidence of a difference between induction
therapy with a platin plus locoregional treatment and locoregional
treatment alone (hazard ratio (HR) 0.90, 95% confidence interval
(CI) 0.80 to 1.02, P = 0.09).
There were four trials of induction chemotherapywith methotrex-
ate alone (Fazekas 1980; Knowlton 1975; Nervi 1978; Richard
1974). Two of these used intra-arterial administration of
methotrexate and three trials provided outcome data for patients
with oral cavity and oropharyngeal cancer (Fazekas 1980; Nervi
1978; Richard 1974). Nervi 1978 showed a reduction in total
mortality which just attained statistical significance, favouring the
group who received induction therapy with methotrexate plus ra-
diotherapy compared to those who received radiotherapy alone
(Analysis 1.1, Comparison 1.1.12). The overall pooled estimate
for total mortality in the four trials of induction chemotherapy
with methotrexate alone showed no evidence of a difference (HR
0.90, 95% CI 0.72 to 1.14, P = 0.38) (Analysis 1.1, Comparison
1.1.13).
Four trials comparedmethotrexate in combinationwith other che-
motherapy agents (Schuller 1988;Maipang 1995; Petrovich 1981;
Holoye 1985 - two of these trials are included in the cisplatin
group above), and none showed evidence of any benefit.
There were two trials that used a combination of bleomycin and
vincristine, administered intra-arterially to patients with a primary
tumour in the oral cavity (Luboinski 1985; Richard 1991). Pool-
ing the data from both trials (total of 342 randomised patients
evaluated) shows a statistically significant benefit in favour of intra-
arterial induction chemotherapy with bleomycin and vincristine
(HR 0.67, 95% CI 0.50 to 0.91, P = 0.01) (Analysis 1.1, Com-
parison 1.1.15).
Summary of results of Comparison 1: Induction
chemotherapy plus LRT versus LRT alone
Induction regimen No of trials Total mortality (HR for death) P value
Either cisplatin or carboplatin
plus 5FU
7 HR 0.94, (95% CI 0.86 to 1.04) P = 0.09
Containing cisplatin or carbo-
platin
10 Not applicable
Methotrexate alone 4 HR 0.90, (95% CI 0.72 to 1.14) P = 0.38
Containing methotrexate, 2 Not applicable
Bleomycin + vincristine 2 HR 0.67, (95% CI 0.50 to 0.91) P = 0.01
Overall* 25 HR 0.92, (95% CI 0.84 to 1.00) P = 0.06
* Data from Mohr 1994 is not included in this summary.
Overall, the 25 included trials of induction chemotherapy plus
locoregional treatment versus locoregional treatment alone showed
some evidence of a small benefit for overall survival (HR 0.92,
95% CI 0.84 to 1.00, P = 0.06).
Sensitivity Analysis - Total Mortality
A sensitivity analysis was undertaken incorporating only the four
trials assessed as being at low risk of bias (Domenge 2000; Licitra
2003; Paccagnella 1994; Richard 1991). The pooled estimate for
total mortality based on these four trials is (HR 0.80, 95% CI
0.67 to 0.97, P = 0.02) (analysis not shown) which suggests that
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induction chemotherapy may have a benefit (up to 20%) for over-
all survival.
Disease free survival
Two of the three trials which compared induction chemother-
apy with carboplatin and 5-FU plus LRT to LRT alone (Olmi
2003; Volling 1999), reported the outcome of disease free survival
(Analysis 1.2). When combined by meta-analysis these two trials
(total of 332 patients) provided evidence of a benefit for disease
free survival in favour of induction chemotherapywith carboplatin
and 5-FU (HR 0.66, 95% CI 0.48 to 0.89, P = 0.007).
Likewise the two trials that compared induction chemotherapy
with cisplatin and fluorouracil plus LRT to LRT alone (Domenge
2000; Paccagnella 1994) individually showed no difference in dis-
ease free survival, but when datawere pooled (total of 655 patients)
there was a statistically significant benefit in favour of induction
chemotherapy (Comparison 1.2.3) (HR 0.78, 95% CI 0.62 to
0.97, P = 0.03).
There was no evidence of a difference in disease free survival
between groups treated with induction chemotherapy compris-
ing carboplatin/ftorafur (Tejedor 1992), cisplatin/bleomycin/vin-
desine/mitomycin C combination (Brunin 1989), bleomycin/
vincristine (Richard 1991) or bleomycin/cyclophosphamide/
methotrexate/5-FU (Holoye 1985) (Comparisons 1.2.2, 1.2.4,
1.2.5, 1.2.6).
Pooling the data on disease free survival from all of the eight trials
of different chemotherapy regimens showed evidence of an overall
benefit favouring induction chemotherapy (HR 0.78, 95% CI
0.67 to 0.90, P = 0.001).
Progression free survival
Progression free survival was reported byDomenge 2000 andOlmi
2003 (Analysis 1.3), and the estimate from pooling these data
showed some evidence of a benefit favouring induction chemo-
therapy (HR 0.80, 95% CI 0.64 to 1.00, P = 0.05).
Disease free survival and recurrent disease after 5 years of
follow-up
Licitra 2003 reported disease free survival at 5 years (Comparison
1.4.1), and locoregional recurrence (Comparison 1.5.1). There
was no evidence of a difference between groups treated with in-
duction chemotherapy plus LRT compared to LRT alone for ei-
ther of these outcomes.
Comparison 2: Surgery ± radiotherapy +
chemotherapy versus surgery ± radiotherapy alone
There are 11 trials in this comparison (Argiris 2008; Bernier 2004;
Bitter 1979; Cooper 2004; HNCProg 1987; Lam 2001; Laramore
1992; Rao 1994; Rentschler 1987; Szpirglas 1979; UKHAN
2010). All of the patients included in the trials in this comparison
had surgical resection with curative intent. Following surgery pa-
tients were randomised to post-operative (adjuvant) chemother-
apy ± radiotherapy or surgery ± radiotherapy In this comparison,
10 of the 11 studies reported the outcome of total mortality. For
the HNCProg 1987 a publication of the subset analysis of the oral
cavity and oropharyngeal patients provided data for analysis for the
outcome of disease free survival. Disease free survival is reported
in a total of eight trials in this comparison (Argiris 2008; Bitter
1979; Cooper 2004; HNCProg 1987; Laramore 1992; Rao 1994;
Rentschler 1987; UKHAN 2010) and two reported progression
free survival (Bernier 2004; UKHAN2010). Locoregional control
was reported by one trial (Cooper 2004).
Risk of bias
In Comparison 2, none of the trials incorporated blinding of pa-
tients, carers or those assessing outcomes. We consider that ab-
sence of blinding is unlikely to have influenced the estimation of
the objective outcomes of total mortality. Therefore our assess-
ment of risk of bias with regard to total mortality is;
• five studies are at low risk of bias for total mortality (Bernier
2004; HNCProg 1987; Rao 1994; Rentschler 1987; UKHAN
2010) as these have adequate sequence generation and allocation
concealment and no other threats to validity in the domains
assessed;
• Argiris 2008; Bitter 1979; Cooper 2004; Lam 2001;
Laramore 1992; Szpirglas 1979 are at unclear risk of bias for
total mortality due to inadequate information presented on
sequence generation, allocation concealment, incomplete
outcome data and/or other issues.
• no trials in this comparison were assessed as high risk of bias
for the outcome of total mortality
However with regard to the more subjective outcomes of disease
free survival, progression free survival, locoregional control and
disease recurrence our assessment is that risk of bias is unclear for
all trials in this comparison.
Effects of interventions
As the trials in this comparison evaluate a range of chemotherapy
regimens in patients who also undergo surgery, the results below
are presented in five subgroups for all of the reported outcomes in
the table below, summarising total mortality in the 10 trials that
reported this outcome.
Interventions in this comparison included:
• post-surgery chemotherapy (MTX) versus post-operative
radiotherapy (Bitter 1979)
• pre- and post-surgery chemotherapy (levamisole/UFT)
versus surgery alone (Lam 2001) (no radiotherapy)
• post-surgery chemotherapy (MTX) verus surgery alone
(Rao 1994) (no radiotherapy)
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• surgery ± radiotherapy + chemotherapy (MTX/BLM/
citrovorum) versus surgery ± radiotherapy (Szpirglas 1979)
• post-surgery chemotherapy (cis/5-FU) then radiotherapy
versus post-surgery radiotherapy alone (Laramore 1992)
• pre- and post-surgery chemotherapy (MTX) then
radiotherapy versus post-surgery radiotherapy alone (Rentschler
1987)
• post-surgery concomitant chemoradiotherapy (cisplatin)
versus post-surgery radiotherapy alone (Bernier 2004; Cooper
2004)
• post-surgery concomitant chemoradiotherapy (carboplatin)
versus post-surgery radiotherapy alone (Argiris 2008)
• post-surgery concomitant chemoradiotherapy (MTX or
VBMF) versus post-surgery radiotherapy alone (UKHAN 2010)
• pre-surgery chemotherapy, then surgery + radiotherapy
then chemotherapy versus post-surgery radiotherapy alone
(HNCProg 1987) (no data for total mortality).
Total mortality
One small trial (Bitter 1979) compared post-surgery chemother-
apy with post-operative radiotherapy in 33 patients who had
undergone surgery, and found no difference between the two
treatments with regard to total mortality or disease free survival
(Analysis 2.1 and Analysis 2.2 respectively).
Two trials compared surgery plus post-operative chemotherapy
with surgery alone (no patients in these trials had radiother-
apy). Rao 1994(participants with primary tumour in the oral
cavity) randomised 116 post-operative patients to receive either
methotrexate or no further treatment and in Lam 2001, 65 pa-
tients who had been given levamisole prior to surgery, were ran-
domised to post-surgery UFT (oral formulation of tegafur and
uracil) plus levamisole or no further treatment. Both of these stud-
ies showed no statistically significant difference between surgery
plus chemotherapy and surgery alone with regard to total mortality
(total mortality data for Rao 1994 from Pignon 2000). However,
Rao 1994 showed a statistically significant difference in favour
of adjuvant methotrexate chemotherapy in post-surgery patients
with regard to the outcomes of disease free survival (Analysis 2.2,
HR 0.47, 95% CI 0.26 to 0.87, P = 0.02), and disease recurrence
at 2 years (Analysis 2.5, risk ratio (RR) 0.62, 95% CI 0.4 to 0.97).
Szpirglas 1979 randomised patients with primary tumours in the
oral cavity, who had undergone standard therapy (surgery ± radio-
therapy) to either chemotherapywith a combinationofmethotrex-
ate/bleomycin/leucovorin or no further treatment. There was no
statistically significant difference between the groups in this trial
for total mortality (Analysis 2.1, Comparison 2.1.4).
Rentschler 1987 randomly allocated patients to adjuvant che-
motherapy versus standard treatment of surgery and radiother-
apy alone. The chemotherapy group received methotrexate once a
week for 4 weeks pre-operatively, followed by surgery, then weekly
methotrexate for 4 weeks, followed by a course of radiotherapy
followed by a final eight doses of weekly methotrexate. The com-
parison group received surgery followed by radiotherapy. There
was no statistically significant difference between the groups in
this trial for either total mortality or disease free survival (Analysis
2.1, Comparison 2.1.5; Analysis 2.2, Comparison 2.2.3).
Another trial, Laramore 1992 randomly allocated post-surgery pa-
tients to either three cycles of cisplatin/5-FU followed by radio-
therapy or post-surgery radiotherapy alone. There was no statis-
tically significant difference between the groups compared with
regard to total mortality (Analysis 2.1, Comparison 2.1.6), or dis-
ease free survival (Analysis 2.2, Comparison 2.2.4).
Post-surgery concomitant chemoradiotherapy was compared with
post-surgery radiotherapy alone in four trials. Two trials (Bernier
2004; Cooper 2004) with 334 and 459 patients respectively, com-
pared concomitant cisplatin plus radiotherapy with radiother-
apy alone. Another smaller trial with 72 patients randomised pa-
tients to concomitant carboplatin plus radiotherapy or radiother-
apy alone (Argiris 2008) and the large UKHAN2010 study which
included both patients with unresectable tumours and a post-
operative group of 253 patients, randomly allocated the latter
group of patients to either concomitant chemoradiotherapy (ei-
ther methotrexate alone or vincristine/bleomycin/methotrexate/
fluorouracil) or radiotherapy alone.
In the trial by Bernier 2004, 56% of the included patients had oral
cavity or oropharyngeal cancer and in Cooper 2004, 70% of the
patients included had oral cavity or oropharyngeal cancer and also
two ’high risk factors’ (any two of histological evidence of inva-
sion of at least two lymph nodes, extracapsular extension of nodal
disease, microscopically involved mucosal margins of resection).
These two trials evaluated the same interventions and when data
from these two studies are pooled, the overall effect estimate shows
a reduction in total mortality favouring chemoradiotherapy with
cisplatin (HR0.80, 95%CI 0.66 to 0.97, Comparison 2.1.7). The
trial by Cooper 2004 also showed a statistically significant bene-
fit favouring cisplatin chemoradiotherapy in disease free survival
(HR 0.78, 95% CI 0.62 to 0.99, Comparison 2.2.5) and locore-
gional recurrence (HR 0.61, 95% CI 0.41 to 0.91, Comparison
2.4.1). There was also a statistically significant difference between
the groups in favour of cisplatin plus radiotherapy with regard to
progression free survival in Bernier 2004 (HR 0.75, 95% CI 0.57
to 0.99, Comparison 2.3.1).
Argiris 2008 found no statistically significant difference between
concomitant carboplatin plus radiotherapy and radiotherapy alone
for the outcomes of either total mortality or disease free survival.
The post-surgery patients (n = 253) in the UKHAN 2010 trial
were randomised to post-surgery chemotherapy with methotrex-
ate or VBMF (vincristine/bleomycin/methotrexate/fluorouracil)
or post-surgery radiotherapy alone. There was no statistically sig-
nificant difference between these two groups in total mortality
(Analysis 2.1, Comparison 2.1.9), disease free survival (Analysis
2.2, Comparison 2.2.7) or in progression free survival (Analysis
2.3, Comparison 2.3.2).
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However, the combined estimate of total mortality from the
pooled data from any concomitant chemoradiotherapy regimen
versus radiotherapy alone in post-operative patients (four trials
Argiris 2008; Bernier 2004; Cooper 2004; UKHAN 2010) shows
evidence of a reduction in total mortality in favour of concomitant
chemoradiotherapy (HR 0.84, 95% CI 0.72 to 0.98, P = 0.03
Analysis 2.1 Comparisons 2.1.7 to 2.1.9).
Summary of results of Comparison 2: Surgery ± radiotherapy
+ chemotherapy versus surgery ± radiotherapy alone
Regimen No of trials Total mortality (HR for death) P value
Post-surgery chemotherapy ver-
sus post-surgery radiotherapy
1 HR 0.32, (95% CI 0.08 to 1.35) P = 0.12
Post-surgery chemotherapy ver-
sus surgery alone (no radiother-
apy)
2 HR 0.84, (95% CI 0.50 to 1.39) P = 0.49
Post-surgery chemotherapy (±
radiotherapy) versus surgery
alone (± radiotherapy)
1 HR 1.01, (95% CI 0.50 to 2.05) P = 0.98
Post-surgery chemother-
apy + radiotherapy versus post-
surgery radiotherapy alone
2 HR 0.95, (95% CI 0.79 to 1.14) P = 0.56
Post-surgery concomi-
tant chemoradiotherapy versus
post-surgery radiotherapy alone
4 HR 0.84, (95% CI 0.72 to 0.98) P = 0.03
Overall 10 HR 0.88, (95% CI 0.79 to 0.99) P = 0.03
The overall pooled estimate based on the ten trials in this compari-
son, shows some evidence of a reduction in total mortality favour-
ing adjuvant chemotherapy, (HR 0.88, 95% CI 0.79 to 0.99, P =
0.03).
Sensitivity Analysis - Total Mortality
When only trials assessed as being at low risk of bias for this out-
come (Bernier 2004; Rentschler 1987; Rao 1994; UKHAN2010)
are included in the meta analysis, the pooled estimate for total
mortality is (HR 0.88, 95% CI 0.74 to 1.05, P = 0.16), the same
estimate as when all the trials are included but with a reduction in
precision.
Disease Free Survival
Disease free survival was reported by eight trials in this comparison,
and all evaluated different agents, administered either prior to
radiotherapy or concomitantly. Rao 1994 was the only trial that
showed a difference in disease free survival between the groups,
favouring adjuvant methotrexate compared to surgery alone.
The three trials (Argiris 2008; Cooper 2004; UKHAN 2010) re-
ported disease free survival for concomitant adjuvant chemoradio-
therapy, and the pooled estimate for these trials shows no evidence
of a difference in disease free survival, (HR 0.87, 95% CI 0.73 to
1.04, P = 0.12 Analysis 2.2 estimate not shown on forest plot).
The remaining trial in Comparison 2 reported data for disease free
survival only. The HNCProg 1987 trial randomly allocated 462
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patients to one of three treatment regimens: either A, standard
therapy (surgery plus radiotherapy), or B, 5 days of induction
chemotherapy with cisplatin and bleomycin, followed by surgery
and radiotherapy, or C, 5 days of induction chemotherapy with
cisplatin and bleomycin, followed by surgery and radiotherapy,
plus adjuvant cisplatin (subsequent chemotherapy). We extracted
data from a published subgroup analysis of the oral cavity and
oropharyngeal cancer patients (n = 192) (HNCProg 1987). Group
C is compared to Group A in Analysis 2.2 (Comparison 2.2.8)
which found no statistically significant difference between these
groups with regard to disease free survival.
Overall there is weak evidence from meta-analysis of these trials
of a possible improvement in disease free survival as a result of
adjuvant chemotherapy (HR 0.89, 95% CI 0.78 to 1.01, P =
0.06).
Comparison 3: Concomitant chemoradiotherapy
versus radiotherapy alone (non-resectable)
This category included 29 trials (Adelstein 2003; Bensadoun
2006; Brizel 1998; Browman 1994; Budach 2005; Chauhan 2008;
Corvo 2001;Denis 2004;Dobrowsky 2000; Eschwege1988;Grau
2003;Gupta 2001;Haddad 1996;Huguenin 2004; Jeremic 1997;
Jeremic 2000; Krishnamurthi 1990; Kumar 1996; Merlano 1992;
Morita 1980; Parvinen 1985; Ruo 2010; Salvajoli 1992; Shanta
1980; Smid 1995; Staar 2001; UKHAN 2010; Weissler 1992;
Wendt 1998).
Two trials evaluated a combination of induction and concomi-
tant chemoradiotherapy (Kumar 1996; Shanta 1980), and two
evaluated alternating chemo/radiotherapy (Corvo 2001; Merlano
1992). These trials are presented separately from the trials that
describe concomitant chemoradiotherapy alone. Within this re-
view we have used the term concomitant chemoradiotherapy to
describe chemotherapy and radiotherapy that is administered at
the same time, usually on the same days. Other publications use
the terms concurrent or combined and radiochemotherapy, RCT
or CRT to refer to this type of treatment.
Risk of bias
Only two of the trials clearly include blinding of patients and/
or outcome assessors (Browman 1994; Shanta 1980). Browman
1994 is assessed as unclear risk of bias for total mortality due to a
lack of information about the method of sequence generation and
allocation concealment, but in Shanta 1980 there were inconsis-
tencies between the groups at baseline, with an unclear effect of
the risk of bias in this trial. Overall the risk of bias for the outcome
of total mortality was assessed as follows;
• Low risk of bias; 9 trials (Brizel 1998; Corvo 2001; Denis
2004; Dobrowsky 2000; Eschwege 1988; Grau 2003; Huguenin
2004; Merlano 1992; UKHAN 2010);
• Unclear risk of bias; the remaining 20 trials assessed as
unclear due to insufficient information being provided for one or
more of the domains assessed;
• High risk of bias; none of the trials in this comparison was
assessed as being at high risk of bias for total mortality.
Effects of interventions
Three trials included patients with cancer of the oral cavity
only (Krishnamurthi 1990; Morita 1980; Shanta 1980); two in-
cluded patients with cancer of the oropharynx only (Denis 2004;
Eschwege 1988); two included patients with cancer of either the
oropharynx or hypopharynx (Bensadoun 2006; Staar 2001). The
remaining trials included mixed head and neck cancer patients, of
whommore than 50% were patients with cancer of the oral cavity
or oropharynx.
Fourteen trials recruited patients with non-resectable tumours
only (Adelstein 2003; Bensadoun 2006; Brizel 1998; Budach
2005; Chauhan 2008;Haddad 1996; Jeremic 1997; Jeremic 2000;
Kumar 1996; Merlano 1992; Salvajoli 1992; Smid 1995; Staar
2001; Wendt 1998).
Staging was presented in two main ways: UICC staging or TNM.
Of the 17 trials reporting UICC staging, 14 recruited patients
with Stage 3 to 4. Twelve trials reported the TNM classification;
tumours ranged from T1 to T4.
Data presented in this section are either from the published pa-
per or from a previously published meta-analysis (Pignon 2000)
based on individual patient data (data supplied to Pignon by the
investigators of the included trials). Trials in this comparison are
in three subgroups, and each outcome is described in turn:
• induction plus concomitant chemoradiotherapy 2 trials
(Kumar 1996; Shanta 1980)
• concomitant chemoradiotherapy 26 trials* (only 24
provided data for hazard ratio for total mortality)
• alternating chemo and radiotherapy 2 trials (Corvo 2001;
Merlano 1992).
*Shanta 1980 is also included in this group.
Induction plus concomitant chemoradiotherapy
• Cyclophosphamide + MTX plus concomitant
chemoradiotherapy (5-FU) (Kumar 1996).
• Bleomycin (IM) (Shanta 1980).
Two trials evaluated the combination of induction and concomi-
tant chemotherapy (Kumar 1996; Shanta 1980). Data on total
mortality were available for both trials. No data on disease free sur-
vival, locoregional control or progression free survival were avail-
able for either trial. The data from these two trials are not included
in the forest plots because it was felt that induction plus concomi-
tant chemoradiotherapy was a sufficiently different intervention
from concomitant chemoradiotherapy alone and combining these
could skew the estimates inappropriately.
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One trial, conducted in India (Kumar 1996), compared treat-
ment with induction cyclophosphamide and MTX followed by
concomitant 5-FU, to radiotherapy alone in 38 participants with
previously untreated inoperable primary malignancy of the oral
cavity, oropharynx and laryngopharynx. No statistically signifi-
cant difference was shown between the combined chemoradio-
therapy group and radiotherapy alone with regard to total mortal-
ity (Kumar 1996 (data from Pignon 2009)) (Analysis not shown).
A trial of 157 patients with histologically proven squamous cell
carcinoma of the buccal mucosa was undertaken by Shanta 1980.
It evaluated the administration of bleomycin and radiotherapy
versus radiotherapy alone. Bleomycin was administered intra-ar-
terially (IA) (n = 42), intravenously (IV) (n = 22) or intramus-
cularly (IM) (n = 20). IA and IV cases received bleomycin and
radiotherapy concomitantly, and results from these groups are de-
scribed below. The groupwho received IMbleomycin commenced
chemotherapy 2 weeks prior to the radiotherapy, and continued
during radiotherapy (Analysis 3.1, Comparison 3.1.2). Based on
data presented in Pignon 2000, for trial coded WIA-OC5c there
was no evidence of a benefit with regard to total mortality for
IM bleomycin plus radiotherapy compared to radiotherapy alone
(Shanta 1980). (Analysis not shown).
Concomitant chemoradiotherapy
Twenty-six trials evaluated chemotherapy in combination with
radiotherapy versus radiotherapy alone. Thirteen trials evaluated
a platin (either alone or in combination with other chemotherapy
agents) plus radiotherapy, compared to radiotherapy alone:
• cisplatin (Adelstein 2003; Huguenin 2004*; Jeremic 2000*)
• cisplatin or carboplatin (Jeremic 1997*; Ruo 2010)
• cisplatin + 5-FU (Adelstein 2003; Bensadoun 2006; Brizel
1998*; Haddad 1996; Weissler 1992)
• carboplatin + 5-FU (Staar 2001*; Denis 2004)
• cisplatin + 5-FU + CA-foliant (Wendt 1998)
• cisplatin + bleomycin (Salvajoli 1992)
• 1-FU (Browman 1994)
• MTX (Gupta 2001)
• MTX +/- vincristine, bleomycin, 5-FU (UKHAN 2010)
• gemcitabine (Chauhan 2008)
• mitomycin (Dobrowsky 2000*; Grau 2003)
• mitomycin + bleomycin (Smid 1995)
• mitomycin + 5-FU (Budach 2005*)
• bleomycin (Eschwege 1988; Morita 1980; Parvinen 1985;
Shanta 1980)
• pepleomycin (Krishnamurthi 1990)
(*studies with hyperfractionated radiotherapy).
Trials presented data on total mortality, disease free survival, lo-
coregional control or progression free survival.
Total mortality
Total mortality data was available from 24 of the trials in this
group (all except Chauhan 2008 and Krishnamurthi 1990). Five
trials compared concomitant chemoradiotherapy with a platin, to
radiotherapy alone. (Adelstein 2003 (data from Pignon 2009 Int
0126a); Huguenin 2004 (data from Pignon 2009); Jeremic 1997;
Jeremic 2000 (data from Pignon 2009) and Ruo 2010).
One trial compared either cisplatin or carboplatin plus standard
fraction radiotherapy with radiotherapy alone (n = 159) (Jeremic
1997) and one compared carboplatin plus radiotherapy to radio-
therapy alone in 164 patients (Ruo 2010). Participants recruited
were those with histologically confirmed locally advanced, non-
metastatic, unresectable squamous cell carcinoma (SCC) of the
head and neck. The other three trials in this group recruited pa-
tients with SCC of the head and neck and randomised them to cis-
platin plus radiotherapy or radiotherapy alone (Adelstein 2003 (n=
182); Huguenin 2004 (n = 224); Jeremic 2000 (n = 130)). Two tri-
als in this group used hyperfractionated radiotherapy (Huguenin
2004; Jeremic 1997) and the other three used standard fractiona-
tion. When the estimates from all five trials of a platin plus radio-
therapy versus radiotherapy alone were combined by meta-anal-
ysis, a hazard ratio for total mortality of 0.66 (95% CI 0.57 to
0.77) was calculated, in favour of the combined chemoradiother-
apy arm. (See summary of results table below.) No statistical het-
erogeneity was identified (P = 0.77, I² = 0%).
Eight trials evaluated the effect of a platin plus 5-FU administered
concomitantly to radiotherapy (Adelstein 2003; Bensadoun 2006;
Brizel 1998; Denis 2004; Haddad 1996; Staar 2001; Weissler
1992; Wendt 1998). In two trials the intervention was carbo-
platin + 5-FU (Denis 2004 (data from Pignon 2009); Staar 2001
(oropharyngeal cancer only)) . The remaining six trials evalu-
ated concomitant chemotherapy with cisplatin + 5-FU (Adelstein
2003 (data from Pignon 2009 Int 0126b); Bensadoun 2006
(oropharyngeal cancer only); Brizel 1998 (IPD data for oral cavity
and oropharyngeal cancer patients supplied by authors); Haddad
1996; Weissler 1992; Wendt 1998). The participants in all six tri-
als had similar diagnoses, predominantly unresectable, Stage III/
IV SCC of the head and neck. It should be noted that the trial by
Wendt 1998 also administered CA-foliant along with the cisplatin
and radiotherapy. For the eight trials of concomitant platin (either
cisplatin or carboplatin) + 5-FU, the pooled estimate shows evi-
dence of a reduction in total mortality (HR 0.71, 95% CI 0.62 to
0.81, P < 0.00001) with no significant heterogeneity (I² = 0%, P
= 0.77) (Analysis 3.1, Comparison 3.1.2).
One trial compared a combination of cisplatin and bleomycin plus
radiotherapy with radiotherapy alone in 90 patients with head and
neck cancer in Brazil. No statistically significant difference was
shown in terms of total mortality between the chemoradiother-
apy group and radiotherapy alone (Salvajoli 1992) (Analysis 3.1,
Comparison 3.1.3).
Browman 1994 compared chemoradiotherapy with concomitant
1-FU to radiotherapy alone. The trial recruited 175 participants
with histologically confirmed SCC of the head and neck (Stage III
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or IV). Data from Pignon 2000 showed no statistically significant
difference between 1-FUplus radiotherapy and radiotherapy alone
(Analysis 3.1, Comparison 3.1.4).
A trial of FU and mitomycin plus radiotherapy showed a statis-
tically significant reduction in total mortality compared to radio-
therapy alone (Analysis 3.1, Comparison 3.1.5) (Budach 2005
(data from Pignon 2009)). This trial recruited 386 patients with
unresectable, Stage III/IV SCC of the head and neck and used
hyperfractionated radiotherapy.
No statistically significant difference was shown in total mortality
when methotrexate was used as a single agent chemotherapy com-
bined with radiotherapy compared to radiotherapy alone in one
trial (Analysis 3.1, Comparison 3.1.6) (Gupta 2001 (data from
Pignon 2000)).
A large multicentre trial of patients with locally advanced squa-
mous cell carcinoma of the head and neck, judged suitable for rad-
ical radiotherapy as either initial treatment or following surgery,
used a factorial design (UKHAN 2010). The chemotherapy regi-
men used was either methotrexate alone or methotrexate in com-
bination with vincristine, bleomycin and 5-FU. Chemotherapy
started on either days 1-14 concurrent with radiotherapy (SIM)
or 14 and 28 days after completing radiotherapy (SUB). Neither
the concomitant (SIM) regimen, nor the concomitant plus sub-
sequent (SIM + SUB) regimen showed a statistically significant
difference between the chemotherapy plus radiotherapy arm com-
pared to radiotherapy alone (Comparisons 3.1.7 and 3.1.8 respec-
tively).
Bleomycin as single agent chemotherapy concomitant with ra-
diotherapy was compared to radiotherapy alone in four trials
(Eschwege 1988; Morita 1980; Parvinen 1985; Shanta 1980 (all
data from Pignon 2000)), all undertaken in the 1980s. In these
trials primary tumours were located in oropharynx only (Eschwege
1988), tongue only (Morita 1980), buccal mucosa (Shanta 1980)
and both oral cavity and oropharynx (Parvinen 1985) and the
dose of bleomycin varied between 5 and 15 mg/dose, delivered
between 2 & 5 times weekly to a total of 60-150 mg. Three of
these trials found no difference between bleomycin plus radio-
therapy and radiotherapy alone. In the trial by Shanta 1980, 157
patients were randomised to either bleomycin and radiotherapy
or radiotherapy alone. Bleomycin was administered intra-arteri-
ally (IA) (n = 42), intravenously (IV) (n = 22) or intramuscularly
(IM) (n = 20) compared to radiotherapy alone (n = 73), and the
IA and IV groups received bleomycin and radiotherapy concomi-
tantly. (The IM group in this trial received bleomycin for 2 weeks
before starting radiotherapy and also during radiotherapy - results
reported above). There is some discrepancy between the numbers
of patients in each subgroup in the original paper compared to
the numbers per group in the data presented in Pignon 2000. The
data included in Comparison 3.1.9 is from Pignon 2000 WIA
OC5b from the IV + IA bleomycin groups combined (n = 38)
versus radiotherapy alone (n = 41), and shows a significant benefit
associated with bleomycin plus radiotherapy in this study. Overall
these four trials show considerable clinical and statistical hetero-
geneity (I2 = 85%, P = 0.0002 ) which suggests that these data
should not be pooled.
Bleomycin and mitomycin were combined with radiotherapy in
one trial (Smid 1995) of patients with inoperable head and neck
cancer. There was no difference between the groups with regard
to total mortality in this trial (Comparison 3.1.10).
Mitomycin C as single agent plus concomitant radiotherapy was
compared to radiotherapy alone in two large trials with 558 and
239 patients with head and neck cancer respectively (Dobrowsky
2000; Grau 2003 (data from Pignon 2000)). There was no differ-
ence between chemoradiotherapy with Mitomycin C and radio-
therapy alone (HR 0.92, 95% CI 0.76 to 1.12) in the pooled data
from these two trials.
Summary of results of Comparison 3: Concomitant
chemoradiotherapy versus radiotherapy alone (non-
resectable)
Regimen No of trials Total mortality (HR for death) P value
Concomitant platin 5∗ HR 0.66, (95% CI 0.57 to 0.77) P < 0.00001
Concomitant platin + 5-FU 8∗ HR 0.71, (95% CI 0.62 to 0.81) P < 0.00001
Concomitant bleomycin 4 Data not pooled due to considerable het-
erogeneity
Concomitant mitomycin 2 HR 0.92, (95% CI 0.76 to 1.12) P = 0.42
Concomitant other 6 Not applicable
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(Continued)
Alternating chemoradiotherapy 2 HR 0.69, (95% CI 0.53 to 0.90) P = 0.006
Concomitant chemoradiother-
apy**
24 HR 0.79, (95% CI 0.74 to 0.84) P < 0.00001
Concomitant + alternating
CRT***
26 HR 0.78, (95% CI 0.73 to 0.83) P < 0.00001
Note:Multiarmtrialsmaybeincludedinmorethanonesubgroupinthistable.
∗ Adelstein 2003 included in both these subgroups (different com-
parisons).
** 24 trials of ’truly concomitant’ regimens are included in this
estimate (Analysis 3.1.1 to 3.1.11).
*** 26 trials of ’truly concomitant’ or alternating regimens are
included in this estimate (Analysis 3.1.1 to 3.1.12).
Combining the data from the 24 trials of concomitant chemora-
diotherapy shows evidence of a 21% reduction in total mortality
with concomitant chemoradiotherapy compared to radiotherapy
alone (HR 0.79, 95% CI 0.74 to 0.84, P < 0.00001).
Alternating chemo and radiotherapy
Two trials assessed alternating chemo and radiotherapy versus ra-
diotherapy alone (Corvo 2001; Merlano 1992). Both used a com-
bination of cisplatin + 5-FU, but each used different radiother-
apy regimens. Merlano 1992 recruited 157 patients with biopsy-
confirmed, unresectable SCC of the head and neck. Patients were
randomised to receive either cisplatin and 5-FU, alternating with
standard fraction radiotherapy (2 Gy per day, 5 days per week), or
radiotherapy alone. Corvo 2001 randomised 136 patients, with
stage II-IV SCC of the head and neck to either cisplatin and 5-FU,
alternating with three 2-week courses of standard fraction radio-
therapy, or radiotherapy alone. The radiotherapy alone group re-
ceived high dose, partly accelerated radiotherapy (PA-RT), with a
final second course using concomitant boost technique. No statis-
tically significant difference was shown between the two treatment
groups (data from Pignon 2009), but this trial was stopped early
due to low accrual. Despite the differences in the radiotherapy
regimens in the control arms of these two studies, the pooled data
show some evidence of a benefit in favour of alternating chemora-
diotherapy (HR 0.69, 95% CI 0.53 to 0.90, P = 0.006) (Com-
parison 3.1.12).
In Merlano 1992, which compared a chemoradiotherapy regimen
comprising cisplatin and 5-FU alternated with radiotherapy to
radiotherapy alone, there was a statistically significant increase in
locoregional control in favour of the chemoradiotherapy group
(Comparison 3.3.7) and no difference between the groups with
regard to disease free survival (Comparison 3.2.4).
When the alternating regimens are combined with the concomi-
tant trials, there is a statistically significant, 22% reduction in total
mortality associated with treatment with concomitant chemora-
diotherapy in 26 trials of patients with non-resectable head and
neck cancer where more than 50% of patients have a primary tu-
mour in either oral cavity or oropharynx (HR 0.78, 95% CI 0.73
to 0.83, P < 0.00001).
Sensitivity Analysis - Total Mortality
When the meta-analysis is based only on the seven trials of truly
concomitant regimens assessed as being at low risk of bias with
regard to total mortality, (Brizel 1998; Denis 2004; Dobrowsky
2000; Eschwege 1988; Grau 2003; Huguenin 2004; UKHAN
2010) the pooled estimate for total mortality is (HR 0.90, 95%
CI 0.81 to 0.99, P = 0.03).
The hazard ratio for total mortality for either concomitant or al-
ternating chemotherapy, based on studies at low risk of bias (n =
9) is HR 0.87 (95% CI 0.79 to 0.95, P = 0.003) (both Corvo
2001; Merlano 1992 are assessed as being at low risk of bias for
this outcome).
These sensitivity analyses suggests that the finding of a benefit
associated with concomitant or alternating chemoradiotherapy is
robust, and the size of the benefit is somewhere between 10% and
22%.
Disease free survival
Analysis 3.2. Nine trials of concomitant chemoradiotherapy also
reported the outcome of disease free survival.
Four trials evaluated a combination of a platin (either cisplatin or
carboplatin) plus 5-FU. Brizel 1998 and Bensadoun 2006 com-
pared concomitant cisplatin + 5-FU plus radiotherapy versus ra-
diotherapy alone. In a trial of 122 patients with cancer of the
head and neck (Brizel 1998), there was no statistically significant
difference in disease free survival between the chemoradiotherapy
group and radiotherapy alone. However, in a trial of 123 patients
with cancer of the oropharynx alone (Bensadoun 2006), a statis-
tically significant difference in favour of combined chemoradio-
therapy was shown for disease free survival. Denis 2004 and Staar
2001 both compared carboplatin + 5-FU plus radiotherapy ver-
sus radiotherapy alone in 222 and 263 patients respectively, and
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both found a benefit for disease free survival in favour of concomi-
tant chemoradiotherapy that attained statistical significance in the
larger trial (Staar 2001). Staar 2001 also reported disease free sur-
vival for those patients with primary tumours of the oropharynx
(HR 0.69, 95% CI 0.52 to 0.91, these data not shown on for-
est plot).The pooled estimate from the four trials of concomitant
chemoradiotherapy with a platin plus 5-FU showed evidence of
a benefit for concomitant chemoradiotherapy (HR 0.70, 95% CI
0.59 to 0.84, P < 0.0001) with little heterogeneity (I2 = 2%, P =
0.38) (Analysis 3.2).
A trial of 164 patients randomised to either concomitant carbo-
platin and radiotherapy or radiotherapy alone found no statisti-
cally significant difference in disease free survival (Ruo 2010).
The trial byGupta 2001 presented data for disease free survival sep-
arately for oral cavity cancer and oropharyngeal cancer. There was
a statistically significant benefit in disease free survival for patients
with oral cavity or oropharyngeal cancers favouring methotrexate
administered concomitant to radiotherapy compared to radiother-
apy alone (Gupta 2001) (Analysis 3.2, Comparison 3.2.4).
In a small trial of 64 patients with non-resectable cancer of the
head andneck (Smid 1995) compared a combinationof bleomycin
andmitomycin C, plus concomitant radiotherapy, to radiotherapy
alone. A statistically significant difference in disease free survival
was found overall (Analysis 3.2, Comparison 3.2.5).
In the UKHAN multicentre trial of either methotrexate (MTX)
alone or MTX in combination with vincristine, bleomycin and
5-FU, there was a statistically significant increase in disease free
survival when the chemotherapy was given concomitantly to ra-
diotherapy (UKHAN 2010) (Analysis 3.2, Comparison 3.2.6).
No statistically significant difference was shown when the chemo-
therapy was given both simultaneously and subsequently (SIM +
SUB) to radiotherapy (Analysis 3.2, Comparison 3.2.7).
Overall in the eight trials, there was evidence of a benefit for disease
free survival in favour of concomitant chemoradiotherapy (HR
0.77, 95%CI 0.70 to 0.84, P < 0.00001)with a little heterogeneity
(I2 = 18.6%, P = 0.29) Analysis 3.2
Locoregional control
Analysis 3.3.
Seven trials of concomitant chemoradiotherapy presented data
for this outcome (Budach 2005; Gupta 2001; Haddad 1996;
Huguenin 2004; Ruo 2010; Staar 2001; Wendt 1998).
Only one of four trials evaluating the effect of cisplatin as single
agent chemotherapy given concomitantly to radiotherapy assessed
locoregional control (Huguenin 2004). Hyperfractionated radio-
therapy was used in the trial of 224 patients with SCC of the
head and neck. No statistically significant difference was found
between treatment groups. Ruo 2010 reported locoregional con-
trol as the primary outcome measure in this trial which compared
carboplatin plus radiotherapy with radiotherapy alone, and found
a difference favouring concomitant chemoradiotherapy that just
attained statistical significance. The pooled estimate of concomi-
tant platin plus radiotherapy showed some evidence of a bene-
fit favouring concomitant chemoradiotherapy (HR 0.78, 95% CI
0.65 to 0.94, P = 0.008) (Analysis 3.3, Comparison 3.3.1).
Three of the seven trials that compared a platin + 5-FU + ra-
diotherapy to radiotherapy alone, presented data on locoregional
control (Haddad 1996; Staar 2001; Wendt 1998). Haddad 1996
andWendt 1998 both administered cisplatin plus 5-FU concomi-
tantly with radiotherapy (Wendt 1998 also administered CA-fo-
liant along with the cisplatin and radiotherapy). There was some
evidence of a benefit in locoregional control in favour of concomi-
tant platin plus 5-FU when these trials were pooled (HR 0.75,
95%CI0.61 to 0.93, P =0.009) (Analysis 3.3,Comparison3.3.2).
No statistically significant difference was shown in locoregional
control between concomitant methotrexate plus radiotherapy
compared with radiotherapy alone (Gupta 2001), in the group of
patients with a primary tumour in either the oral cavity or orophar-
ynx (Analysis 3.3, Comparison 3.3.3).
Budach 2005 combined mitomycin and 5-FU with hyperfrac-
tionated radiotherapy. A statistically significant increase in locore-
gional control was found for concomitant mitomycin+ 5-FU+ ra-
diotherapy compared to hyperfractionated radiotherapy alone in
this study (Analysis 3.3, Comparison 3.3.4).
Overall the pooled estimate from these seven trials showed evi-
dence of a benefit for locoregional control associated with con-
comitant chemoradiotherapy (HR 0.73, 95% CI 0.64 to 0.82, P
= 0.02) with some heterogeneity (I2 = 39.7%, P = 0.17) (Data not
shown on forest plot).
Progression free survival
Analysis 3.4.
Four trials of concomitant chemoradiotherapy presented data for
the outcome of progression free survival for concomitant chemora-
diotherapy compared to radiotherapy alone, and a further two
evaluated alternating regimens.
Two trials compared cisplatin plus radiotherapy with radiotherapy
alone (Huguenin 2004; Jeremic 2000). Both trials used hyperfrac-
tionated radiotherapy. Pooling of data from these trials showed no
evidence of a difference for progression free survival between the
combined chemoradiotherapy group and radiotherapy alone (HR
0.84, 95% CI 0.66 to 1.08, P = 0.18).
Browman 1994 found no difference between concomitant
chemoradiotherapy with 1-FU and radiotherapy alone with regard
to progression free survival (Analysis 3.4, Comparison 3.4.2).
In the trial by Budach 2005 comparing concomitant mitomycin
and 5-FU and hyperfractionated radiotherapy, to hyperfraction-
ated radiotherapy alone, there was a statistically significant benefit
in terms of progression free survival (Analysis 3.4, Comparison
3.4.3).
Overall these four trials showed a statistically significant benefit
for progression free survival in favour of concomitant chemora-
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diotherapy (HR 0.75, 95% CI 0.63 to 0.89, P = 0.001) with little
heterogeneity (I2 = 19%, P = 0.30) .
Alternating Regimens
Both trials which compared alternating chemoradiotherapy with
radiotherapy alone (Corvo 2001; Merlano 1992) presented data
on progression free survival. However, the pooled estimate from
these two trials found no evidence for a difference in progression
free survival between concomitant chemoradiotherapy and radio-
therapy alone (HR 0.82, 95% CI 0.62 to 1.07, P = 0.14).
When the alternating and concomitant regimens were combined
the pooled estimate for progression free survival based on all 6 tri-
als showed evidence of a benefit favouring concomitant chemora-
diotherapy (HR 0.77, 95% CI 0.67 to 0.89, P = 0.0004)
Locoregional control (complete response to treatment)
Analysis 3.5.
Four trials reported complete response to treatment (Chauhan
2008; Dobrowsky 2000; Krishnamurthi 1990; Parvinen 1985).
No statistically significant differencewas seen in complete response
rate for patients with head and neck cancer treated with mito-
mycin and hyperfractionated radiotherapy compared to hyper-
fractionated radiotherapy alone (Dobrowsky 2000) (Comparison
3.5.1) or bleomycin and radiotherapy compared to radiotherapy
alone (Parvinen 1985) (Comparison 3.5.2). A single study com-
pared gemcitabine plus concomitant radiotherapy with radiother-
apy alone (Chauhan 2008) and found a statistically significant im-
provement in complete response rate in favour of chemoradiother-
apy (Comparison 3.5.3). Krishnamurthi 1990 compared radio-
therapy with pepleomycin alone, radiotherapy plus pepleomycin
plus hyperthermia, and radiotherapy plus hyperthermia alone
and evaluated patients for complete tumour response. The pe-
pleomycin plus radiotherapy group combined had a higher com-
plete response rate compared to radiotherapy and hyperthermia
alone (Analysis 3.5, Comparison 3.5.4). However, no post-treat-
ment follow-up is reported in this paper so it is unknown whether
this initial tumour response was followed by a difference in sur-
vival for these patients.
Due to the substantial clinical and statistical heterogeneity between
these four trials, data were not pooled.
Comparison 4: Chemotherapy A (± LRT) versus
chemotherapy B (± LRT)
This comparison includes a total of 28 trials in which two che-
motherapy regimens are compared head to head. Chemotherapy
regimens in these trials differ in terms of agents used and tim-
ing relative to radiotherapy. There are also comparisons between
sequential chemotherapy followed by radiotherapy and concomi-
tant chemoradiotherapy. They are grouped into five subsections:
• Induction chemotherapy; Regimen A versus Regimen B
• Induction chemotherapy followed by sequential
chemoradiotherapy
• Concomitant chemoradiotherapy; Regimen A versus
Regimen B
• Induction chemotherapy followed by radiotherapy versus
concomitant chemoradiotherapy
• Comparisons between other chemotherapy regimens.
Data has been extracted for analysis with regard to the outcomes
of total mortality in 20 trials (Adelstein 1993; Browman 1986;
Chauvergne 1988; De Andres 1995; Garden 2004; Gasparini
1993; Gonzalez-Larriba 1997; Gupta 2009; Le 2006; Marechal
1987; Merlano 1991; Paccagnella 2010; Pinnaro 1994; Posner
2007; Rasch 2010; Rischin 2005; Rischin 2010; Segura 2002;
UKHAN2010; Vermorken 2007), disease free survival (Gasparini
1993; Gupta 2009; HNCProg 1987; Merlano 1991; Rasch 2010;
Rischin 2005; Rischin 2010), progression free survival (Adelstein
1993; Gonzalez-Larriba 1997; Paccagnella 2010; Pinnaro 1994;
Posner 2007; UKHAN 2010; Vermorken 2007), locoregional
control (Rasch 2010; Rischin 2005; Rischin 2010), and the di-
chotomous outcomes of total mortality at 2-5 years (Olasz 2000),
disease free survival at 5 years (De Andres 1995), locoregional
control (Buffoli 1992; Gladkov 2007; Merlano 1991; Molinari
1982; Prevost 2005; Vermorken 2007) and locoregional recur-
rence (Olasz 2000). It was not possible to extract data in a form
suitable to include in these analyses from Vokes 1990.
Risk of bias
None of the trials in this comparison include blinding of patients,
carers or outcome assessors. Five trials describe adequate sequence
generation and allocation concealment methods, with no addi-
tional risks in the other domains assessed and can be considered at
low risk of bias for objective outcomes of total mortality (Buffoli
1992; HNCProg 1987; Rischin 2005; Rischin 2010; UKHAN
2010), with an increased risk of bias for the more subjective out-
comes. The remaining 23 trials are assessed as being at unclear risk
of bias due to insufficient information available for assessment in
one ormore domains risk of bias (Adelstein 1993; Browman 1986;
Chauvergne 1988; De Andres 1995; Garden 2004; Gasparini
1993; Gladkov 2007; Gonzalez-Larriba 1997; Gupta 2009; Le
2006;Marechal 1987;Merlano 1991;Molinari 1982;Olasz 2000;
Paccagnella 2010; Pinnaro 1994; Posner 2007; Prevost 2005;
Rasch 2010; Segura 2002; Szpirglas 1979;Vermorken2007;Vokes
1990).
Effects of interventions
The treatment regimens being compared vary with regard to the
chemotherapeutic agents used, the timing of the chemotherapy
relative to radiotherapy and surgery, and the use of subsequent
therapy (either further chemotherapy or concomitant chemora-
diotherapy) after the initial regimen is completed. This group are
described below under five subheadings.
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Induction chemotherapy: Regimen A versus Regimen B
The first group of nine trials included in this comparison
(Browman 1986; Chauvergne 1988; De Andres 1995; Gonzalez-
Larriba 1997; HNCProg 1987; Marechal 1987; Olasz 2000;
Segura 2002; Vermorken 2007), randomised patients with inop-
erable oral cancer to one of two different regimens of chemother-
apy administered as first line (induction) therapy, and all except
HNCProg 1987 and Olasz 2000 provided data to estimate the
hazard ratios for total mortality.
Four of these trials compared cisplatin followed by 5-FU as a 120
hour continuous infusion (PF), with the following:
• cisplatin and UFT (oral formulation of tegafur and uracil)
(Gonzalez-Larriba 1997)
• carboplatin and 5-FU (De Andres 1995)
• cisplatin and vinorelbine (Segura 2002)
• cisplatin and 5-FU and docetaxel (TPF regimen) - in
Vermorken 2007 (TAX 323 study).
Cisplatin alone was compared with either cisplatin plus etopo-
side (Marechal 1987) or cisplatin/methotrexate/bleomycin/vin-
cristine combination (Chauvergne 1988). Browman 1986 com-
pared methotrexate and 5-FU given simultaneously to the same
drugs given sequentially. In the HNCProg 1987 induction che-
motherapy with cisplatin plus bleomycin was compared with the
same induction chemotherapy regimen plus adjuvant cisplatin as
subsequent chemotherapy, and the main outcome reported was
disease free survival. Vermorken 2007 in the TAX 323 study com-
pared cisplatin and 5-FU (PF) with cisplatin plus docetaxel plus
5-FU (TPF).
In six of these trials patients went on to receive radiotherapy, and
in two studies (Browman 1986; Chauvergne 1988) there was no
mention of planned subsequent radiotherapy, but this may have
taken place, outside of the clinical trial, as part of usual clinical
practice in these centres.
A further small study in Hungary randomised patients to in-
duction chemotherapy with either bleomycin, vincristine, cis-
platin and methotrexate or bleomycin, vincristine and methotrex-
ate (Olasz 2000). Three weeks after the end of chemotherapy pa-
tients had surgery for lymph node excision. After 2 years follow-
up the locoregional recurrence rate was significantly lower in the
BVCM group (RR 0.50, 95% CI 0.26 to 0.96) (Analysis 4.8) and
there was no difference in total mortality (RR 0.58, 95% CI 0.30
to 1.15) (Analysis 4.5).
The TAX 323 trial (Vermorken 2007) was the only trial to find
a statistically significant difference in total mortality between the
induction regimens compared. There was a reduction in total mor-
tality favouring the TPF regimen used as induction (HR 0.73,
95% CI 0.57 to 0.95) (Analysis 4.1, Comparison 4.1.7) and also
an increase in progression free survival (HR 0.72, 95% CI 0.57 to
0.91) (Analysis 4.3, Comparison 4.3.2).
There was no difference between the regimens compared with
regard to the outcome of disease free survival (reported by one
trial (HNCProg 1987) (Analysis 4.2)). None of these nine trials
reported data on disease free survival at 5 years or the hazard ratio
for locoregional control.
Disease free survival after 5 years follow-up in the trial by De
Andres 1995 showed a statistically significant benefit in favour of
cisplatin/5-FU (HR 0.51, 95% CI 0.28 to 0.92) (Analysis 4.6).
Induction chemotherapy followed by sequential
chemoradiotherapy
Two trials compared different agents used in induction chemo-
therapy followed by concomitant chemoradiotherapy (Le 2006;
Posner 2007).
Le 2006 randomly allocated 62 patients to either two cycles of
cisplatin plus 5-FU, followed by concomitant chemoradiotherapy
with cisplatin, 5-FU and radiotherapy 5 times per week or two
cycles of cisplatin, 5-FU and tirapazamine followed by concomi-
tant chemoradiotherapy. Posner 2007, in the TAX 324 trial, a
much larger study of 501 patients, compared three cycles of in-
duction chemotherapy with cisplatin/FU followed by concomi-
tant chemoradiotherapy (weekly carboplatin and radiotherapy 5
tiimes weekly for 7 weeks), with a different induction regimen,
cisplatin, docetaxel and 5-FU (TPF) also followed by the same
concomitant chemoradiotherapy with weekly carboplatin.
There was no difference between the two groups in Le 2006, but
the TAX 324 trial (Posner 2007) found that the group who re-
ceived cisplatin/5-FU/docetaxel showed a statistically significant
reduction in total mortality (HR 0.70, 95% CI 0.54 to 0.90,
Analysis 4.1) and increase in progression free survival (HR 0.71,
95% CI 0.56 to 0.90, Analysis 4.3) compared to the cisplatin/5-
FU (PF) group.
Concomitant chemoradiotherapy: Regimen A versus
Regimen B
Concomitant chemoradiotherapy regimens were compared in
seven randomised controlled trials (Garden 2004; Gasparini
1993; Gladkov 2007; Rasch 2010; Rischin 2005; Rischin 2010;
UKHAN2010). Data were presented with regard to the outcomes
of total mortality (Garden 2004; Gasparini 1993; Rasch 2010;
Rischin 2005; Rischin 2010; UKHAN2010), disease free survival
(Gasparini 1993; Rasch 2010; Rischin 2005; Rischin 2010), pro-
gression free survival (UKHAN 2010) and locoregional control
(Gladkov 2007; Rasch 2010; Rischin 2005; Rischin 2010).
Gasparini 1993 compared two concomitant chemoradiotherapy
regimens in 63 patients who received three cycles of chemotherapy
starting on days 1, 21 and 42 of radiotherapy. One group received
cisplatin and the other carboplatin. This trial showed no difference
between the two regimens in either total mortality (Analysis 4.1)
or disease free survival (Analysis 4.2) and commented that there
were differences in the spectra of toxicities associated with the two
regimens, but a similar severity.
Garden 2004 randomised 242 patients to one of three chemora-
diotherapy regimens; either radiotherapy with weekly concomi-
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tant cisplatin plus FU for 7 weeks, radiotherapy with concomi-
tant hydroxyurea plus FU every alternate week for 13 weeks, or
radiotherapy with concomitant cisplatin plus paclitaxel weekly for
7 weeks. There was no statistically significant difference between
any of the regimens with regard to total mortality (Comparisons
4.1.13 to 4.1.15 in Analysis 4.1).
In a small trial Gladkov 2007 compared different frequency of
concomitant chemoradiotherapy. All 64 patients received daily ra-
diotherapy, 2Gy 5 times a week together with either daily cisplatin
(n = 22), weekly cisplatin (n = 26) or cisplatin once every 3 weeks
(n = 12). No statistically significant difference between any of the
groups was found with regard to locoregional control (Analysis
4.7).
Rasch 2010 compared intra-arterial chemoradiotherapy with in-
travenous chemoradiotherapy in 239 patients with unresectable
tumours. Patients randomised to the intra-arterial group had ar-
teriography prior to the start of treatment to determine whether
intra-arterial chemotherapy was feasible. Ten patients in the in-
tra-arterial group for whom intra-arterial chemotherapy was not
feasible were treated according to the intravenous protocol. After
a median follow-up of 33 months this study found no difference
between the groups with regard to the primary outcome locore-
gional control (Analysis 4.4), or total mortality (Analysis 4.1), or
disease free survival (Analysis 4.2).
Rischin 2005 reported a trial of 122 patients randomly allocated
to chemoradiotherapy with either concomitant cisplatin and FU
(chemoboost), or cisplatin and tirapazamine (TPZ). There was
no statistically significant difference between the two regimens
with regard to total mortality (Analysis 4.1), disease free survival
(Analysis 4.2) and locoregional control (Analysis 4.4).
Rischin 2010, in a large a large international trial of 861 patients
with low risk of bias, compared concomitant chemoradiotherapy
with cisplatin plus tirapazamine to concomitant chemoradiother-
apy with cisplatin alone and found no difference between the two
arms with regard to total mortality (Analysis 4.1), disease free sur-
vival (Analysis 4.2) or locoregional control (Analysis 4.4).
The UKHAN 2010 trial used a factorial design for a total of
966 patients, 253 who had undergone surgery and a further 713
untreated patients whose tumours were considered unresectable.
Non-surgical patients were randomised to either radiotherapy
alone or one of three chemoradiotherapy regimens: concomi-
tant chemoradiotherapy (SIM), radiotherapy followed by chemo-
therapy (SUB) or concomitant chemoradiotherapy followed by
chemotherapy (BOTH); post-operative patients were randomised
to either concomitant chemoradiotherapy (SIM) or radiotherapy
alone.
UKHAN is a multicentre trial (34 centres) and each participating
centre nominated one, or both of two chemotherapy protocols,
either single agent methotrexate (24 centres, 433 randomised to
this treatment, 417 received treatment), or a multiagent combi-
nation of vincristine, bleomycin, methotrexate and fluorouracil
(12 centres, 165 randomised to this treatment and 153 received
treatment). In comparing the three chemoradiotherapy regimens
against each other, data from both the single and multiagent
chemotherapy regimens are combined, to give an overall com-
parison of concomitant chemoradiotherapy, chemotherapy with
subsequent radiotherapy and both concomitant and subsequent
chemoradiotherapy. UKHAN 2010 found the concomitant regi-
mens showed a statistically significant reduction in total mortality
compared to radiotherapy followed by chemotherapy (SUB regi-
men) (Comparison 4.1.17), and a larger benefit in favour of con-
comitant chemoradiotherapy on progression free survival (Com-
parison 4.3.4), compared to the radiotherapy followed by chemo-
therapy (SUB) regimens.
Induction chemotherapy followed by radiotherapy versus
concomitant chemoradiotherapy
Two trials (Adelstein 1993; Pinnaro 1994) compared a regi-
men of chemotherapy followed by radiotherapy, with a concomi-
tant chemoradiotherapy regimen in previously untreated patients.
Adelstein 1993 (data for total mortality from Pignon 2000) com-
pared three cycles of induction cisplatin and 5-FU, then surgery
followed by 7 weeks of radiotherapy 5 times per week for 7 weeks,
with a cycle of the same chemotherapy regimen given concomi-
tantly with 3 weeks of radiotherapy, 5 times per week, followed
by a second chemotherapy cycle starting 5-7 weeks after the first
cycle followed by surgery. Pinnaro 1994 randomly allocated pa-
tients to three cycles of cisplatin/5-FU induction chemotherapy
followed by up to 7 weeks of radiotherapy, (5 times per week)
or cisplatin once every 3 weeks during a 7-week course of radio-
therapy. Broadly these two trials compare induction chemother-
apy with concomitant chemoradiotherapy and although neither
show a statistically significant difference in total mortality, when
estimates from them are pooled there is a reduction in total mor-
tality favouring induction chemotherapy (HR 0.68, 95% CI 0.47
to 0.97). (Data not shown.)
Gupta 2009 compared induction chemotherapy with cisplatin +
5-FU (PF regimen) followed by concomitant chemoradiotherapy
(weekly low dose cisplatin) with concomitant chemoradiother-
apy alone in patients with oropharyngeal cancer. Paccagnella 2010
compared induction chemotherapy with cisplatin +5-FU + doc-
etaxel (TPF regimen) followed by chemoradiotherapy (cisplatin
+ 5-FU in weeks 1 and 6 of radiotherapy) with chemoradiother-
apy alone. Pooling the data from these two trials which broadly
compare induction chemotherapy plus chemoradiotherapy with
chemoradiotherapy alone shows no difference with regard to total
mortality (HR 0.66, 95% CI 0.35 to 1.24). (Data not shown.)
None of these four trials showed any statistically significant dif-
ference between the regimens compared. All four trials presented
data for total mortality (Analysis 4.1), one (Gupta 2009) for dis-
ease free survival (no difference between groups) and three tri-
als reported progression free survival (Adelstein 1993; Paccagnella
2010; Pinnaro 1994) but showed no statistically significant differ-
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ence between the regimens compared (Analysis 4.3, Comparisons
4.3.7 to 4.3.9).
The next two trials compared induction chemotherapy followed
by radiotherapy with an alternating chemoradiotherapy regi-
men. Merlano 1991 compared chemotherapy with bleomycin,
methotrexate, vinblastine and leucovorin, followed by 7 weeks of
radiotherapy 5 times per week, with a regimen that alternated che-
motherapy and radiotherapy. Buffoli 1992, in a similar approach,
compared four cycles of induction chemotherapy with bleomycin,
methotrexate and hydroxyurea, followed by a total of 60 Gy of
radiotherapy, with a regimen whereby patients had 20 Gy radio-
therapy, then four cycles of chemotherapy over 4 weeks, followed
by the remaining 40 Gy of radiotherapy.
Merlano 1991 found a statistically significant difference in to-
tal mortality between the two treatments in favour of alternating
chemoradiotherapy (Analysis 4.1 comparison 4.1.24), but no dif-
ference in the dichotomous outcome of tumour response at the
end of treatment (Analysis 4.7 comparison 4.7.1). Buffoli 1992 re-
ported 5-year disease free survival, and locoregional control at the
end of treatment and found no difference between the sequential
and alternating chemoradiotherapy regimens (Analysis 4.6). Total
mortality was reported in this trial but data were not presented
according to the intervention patients received.
Comparisons between other chemotherapy regimens
There are three other trials included in this comparison although
none of these contributed total mortality data to the analyses.
Vokes 1990 described a small trial of 29 patients, who were ran-
domly allocated to either four cycles of cisplatin, fluorouracil and
methotrexate or four cycles of cisplatin, fluorouracil, methotrex-
ate and bleomycin alternating with cisplatin and and 5-FU. Af-
ter induction chemotherapy locoregional therapy was planned but
32% of Arm A and 15% of Arm B did not receive LRT as per
protocol. The aim of the study was to demonstrate a greater than
50% complete response rate to induction chemotherapy, but as
this was not evident after 29 patients were randomised, the study
was stopped early. There were changes to the planned treatment
protocol in the small number of patients includedmake it difficult
to draw valid conclusions from this trial.
Prevost 2005 is a trial of 197 patients who were allocated to in-
duction chemotherapy with either cisplatin plus 5-FU or cisplatin
and etoposide, to be followed by radiotherapy. Data are given for
tumour response, although it is not clear as to the timing of this
evaluation (likely to be at the completion of chemotherapy). There
is a 48% increase in tumour response in the cisplatin etoposide
group (RR 1.48, 95%CI 1.04 to 2.11) (Analysis 4.7) which is sta-
tistically significant. The paper states that there was no difference
in survival between the two groups.
Molinari 1982 randomised 85 patients to either 500 mg
methotrexate as intra-arterial infusion over 10 days or 95 mg of
bleomycin as intra-arterial infusion over 13 days. Patients were
evaluated for tumour response 10-15 days after the end of treat-
ment and greater than 50% tumour regression was found in
21% of the patients in the methotrexate group and 60% of the
bleomycin group, a statistically significant difference favouring
bleomycin (RR 0.35, 95% CI 0.19 to 0.66) (Analysis 4.7). How-
ever, the trial did not look at any longer term outcomes such as
total mortality.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Surgery +/- RT + chemotherapy compared to surgery +/- RT alone for oral cavity and oropharyngeal cancer
Patient or population: patients with oral cavity and oropharyngeal cancer
Settings: hospital
Intervention: surgery +/- RT + chemotherapy
Comparison: surgery +/- RT alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
surgery +/- RT alone surgery +/- RT + che-
motherapy
Total Mortality
Hazard Ratio
Follow-up: 3-8 years
Low risk population1 HR 0.88
(0.79 to 0.99)
2017
(10 studies)
⊕⊕©©
low2,3
200 per 1000 178 per 1000
(162 to 198)
Medium risk population1
500 per 1000 457 per 1000
(422 to 497)
High risk population1
700 per 1000 653 per 1000
(614 to 696)
Total Mortality
Follow-up: 3-8 years
Low risk population1 HR 0.88
(0.74 to 1.05)4
758
(4 studies)
⊕⊕⊕©
moderate3
200 per 1000 178 per 1000
(152 to 209)
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Medium risk population1
500 per 1000 457 per 1000
(401 to 517)
High risk population1
700 per 1000 653 per 1000
(590 to 718)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; HR: Hazard ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Based on 5-year mortality data in McGurk 2005
2 Four studies are at low risk of bias and 6 are at unclear risk of bias
3 Studies included patients with other head and neck cancers
4 Analysis conducted on included studies at low risk of bias
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Concomitant chemoradiotherapy compared to radiotherapy alone for oral cavity and oropharyngeal cancer
Patient or population: patients with oral cavity and oropharyngeal cancer
Settings: hospital
Intervention: concomitant chemoradiotherapy
Comparison: radiotherapy alone
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
radiotherapy alone concomitant chemora-
diotherapy
Total Mortality
Hazard Ratio
Follow-up: 3-8 years
Low risk population1 HR 0.78
(0.73 to 0.83)2
4734
(26 studies)
⊕⊕©©
low3,4
200 per 1000 160 per 1000
(150 to 169)
Medium risk population1
500 per 1000 418 per 1000
(397 to 437)
High risk population1
700 per 1000 609 per 1000
(585 to 632)
Total Mortality
Hazard Ratio
Follow-up: 3-8 years
Low risk population1 HR 0.87
(0.79 to 0.95)5
2266
(9 studies)
⊕⊕⊕©
moderate4
200 per 1000 176 per 1000
(162 to 191)
Medium risk population1
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500 per 1000 453 per 1000
(422 to 482)
High risk population1
700 per 1000 649 per 1000
(614 to 681)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; HR: Hazard ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Based on 5-year mortality data in McGurk 2005
2 Analysis based on all included studies
3 Nine trials are at low risk of bias, and remaining 17 at unclear risk of bias
4 Trials include patients with other head and neck cancers
5 Analysis based on included studies at low risk of bias
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D I S C U S S I O N
Summary of main results
This systematic review was undertaken to answer the question
’Does treatment with chemotherapy, in addition to radiotherapy
and/or surgery, improve the outcomes for patients with oral cavity
and oropharyngeal cancers?’. A wide range of chemotherapeutic
agents, regimens and timing of chemotherapy treatments relative
to radiotherapy and surgery are evaluated in the 89 randomised
controlled trials included in this systematic review. Only 21 of the
included studies can be considered at low risk of bias with regard
to the outcome of total mortality. A total of 16,767 patients were
randomly allocated to treatments in trials where at least 50% of
the patients with head and neck cancers had primary tumours in
either the oral cavity or oropharynx.
We have divided the included trials into four major comparisons,
according to the type of regimens, and stage of disease of the
participants. Our primary outcome is total mortality as measured
by hazard ratio for mortality. A reduction in the hazard ratio for
mortality can be interpreted as an improvement in overall survival.
Comparison 1: Induction chemotherapy plus
locoregional treatment versus locoregional
treatment alone
The first comparison concerned the addition of induction chemo-
therapy to locoregional treatment (either radiotherapy or surgery
or both) for oral cavity and oropharyngeal cancer. A wide range of
chemotherapeutic agents were used in the trials included in this
comparison. These included cisplatin, carboplatin, adriamycin,
bleomycin, cyclophosphamide, epirubicin, methotrexate, mito-
mycin C, vinblastine,vincristine, vindesine, 5-FU, either as sin-
gle agents, or more commonly as combinations of two or more
agents. The pooled estimate from seven trials of induction chemo-
therapy with a regimen including either cisplatin or carboplatin
plus 5-FU showed no evidence of a difference in overall survival
between the induction chemotherapy arm and locoregional treat-
ment alone. Likewise four trials of methotrexate alone showed no
evidence of a difference in overall survival between those who had
induction chemotherapy and those who had locoregional treat-
ment alone. However the two trials of induction therapy with
bleomycin plus vincristine did show evidence of improvement in
overall survival (hazard ratio (HR) 0.67, 95% confidence interval
(CI) 0.50 to 0.91, P = 0.01). Overall, meta-analysis of 25 trials
of induction chemotherapy plus locoregional treatment versus lo-
coregional treatment alone showed some evidence of a small im-
provement in overall survival (HR 0.92, 95% CI 0.84 to 1.00,
P = 0.06). A sensitivity analysis based on pooling data from the
four studies assessed as being at low risk of bias for this outcome
showed HR 0.80, 95% CI 0.67 to 0.97, P = 0.02, which suggests
that induction therapy may be associated with a benefit (up to
20%) for overall survival.
Comparison 2: Surgery ± radiotherapy +
chemotherapy versus surgery ± radiotherapy alone
There were 11 trials in this comparison, involving a range of
chemotherapeutic agents, with most regimens including either
methotrexate or a platin (either cisplatin or carboplatin). Overall,
in the 10 trials that reported total mortality, there was some evi-
dence of a benefit in overall survival associated with the addition
of chemotherapy to radiotherapy after surgery (HR 0.88, 95% CI
0.79 to 0.99, P = 0.03). Sensitivity analysis based on four of these
studies assessed as being at low risk of bias, showed the same point
estimate (HR 0.88, 95% CI 0.74 to 1.05, P = 0.16) confirming
the size of the benefit, but indicating reduced precision.
However it appears that timing of post-operative chemotherapy,
relative to post-operative radiotherapy, may be important. In the
four trials that evaluated concomitant chemoradiotherapy after
surgery there was evidence of a benefit in overall survival in favour
of concomitant chemoradiotherapy after surgery compared to ra-
diotherapy alone (HR 0.84, 95% CI 0.72 to 0.98, P = 0.03).
Comparison 3: Concomitant chemoradiotherapy
versus radiotherapy alone (non-resectable)
Of the 29 trials included in this comparison two evaluated a com-
bination of induction and concomitant chemotherapy, 26 evalu-
ated concomitant chemoradiotherapy and a further two evaluated
alternating chemotherapy and radiotherapy regimens.
The induction plus concomitant trials used different agents and
regimens and neither found a statistically significant benefit as-
sociated with chemotherapy over radiotherapy alone. These trials
combined included less than 200 patients and had an unclear risk
of bias.
The two trials of alternating chemoradiotherapywere both assessed
as being at low risk of bias and both used cisplatin/5-FU, but
used different radiotherapy alone regimens as controls. The pooled
estimate shows evidence of a reduction in total mortality favouring
the alternating regimens (HR 0.69, 95% CI 0.53 to 0.90, P =
0.006)
The remaining 26 trials in this comparison evaluated concomitant
chemoradiotherapy regimens compared to radiotherapy alone, and
24 provided data for calculation of a hazard ratio for total mor-
tality. More than half of the trials used a chemotherapy regimen
which included either cisplatin or carboplatin. From these 24 tri-
als, there is evidence of a reduction of total mortality (improve-
ment in overall survival) in the order of 20% (HR 0.79, 95% CI
0.74 to 0.84, P < 0.00001). Senstivity analysis based on the 7
studies at low risk of bias confirmed this finding (HR 0.90, 95%
CI 0.81 to 0.99, P = 0.03) albeit with a reduced magnitude of
effect (10% benefit).
Pooling data from 26 trials of either alternating or concomitant
chemoradiotherapy showed a benefit in overall survival favouring
chemoradiotherapy (HR0.78, 95%CI0.73 to 0.83, P <0.00001).
Sensitivity analysis based on the 9 studies at low risk of bias con-
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firmed this finding (HR 0.87, 95% CI 0.79 to 0.95, P = 0.003)
suggesting that concomitant or alternating chemoradiotherapy is
associated with a benefit in overall survival of 10 to 22%.
Summary of results for Comparisons 1-3 (Induction
chemotherapy, adjuvant chemotherapy and concomitant
chemoradiotherapy)
Timing of chemotherapy reg-
imen
No of trials Total mortality (HR for death) P value
Induction chemotherapy 25 HR 0.92, (95% CI 0.84 to 1.00) P = 0.06
Adjuvant chemotherapy 10 HR 0.88, (95% CI 0.79 to 0.99) P = 0.03
Concomitant chemoradiother-
apy or
alternating chemoradiotherapy
26 HR 0.78, (95% CI 0.73 to 0.83) P < 0.00001
Comparison 4: Chemotherapy A (± LRT) versus
chemotherapy B (± LRT)
Comparison four included 28 trials which directly compared dif-
ferent chemotherapeutic agents, different regimens, and different
timing relative to locoregional treatment. The analyses show that
many of the regimens compared showed no statistically significant
differences in the outcomes evaluated. Those that showed a statis-
tically significant difference between the regimens compared are
summarised below.
In a large trial with direct comparisons (UKHAN2010) concomi-
tant chemoradiotherapy resulted in improved overall survival com-
pared to either radiotherapy alone, radiotherapy followed by che-
motherapy or concomitant chemoradiotherapy followed by che-
motherapy, in patients who had not undergone surgery. However,
in the post-operative group (adjuvant setting) there was no differ-
ence in mortality between concomitant chemoradiotherapy and
radiotherapy alone in this trial.
Docetaxel was the new chemotherapy agent added to the com-
monly used cisplatin/5-FU (PF) regimen in both the TAX324 and
TAX 323 trials (Posner 2007; Vermorken 2007) in the induction
setting. Both these trials showed a statistically significant increase
in overall survival (43% and 36% respectively) associated with the
TPF regimen (docetaxel/cisplatin/5-FU). Vermorken 2007 (n =
358) compared induction chemotherapy with TPF to PF followed
by radiotherapy, whereas Posner 2007 (n = 539) compared TPF
induction with PF induction and then followed both arms with
chemoradiotherapy using carboplatin. Following these results, the
trial by Paccagnella 2010 (n = 101) compared TPF induction reg-
imen followed by cisplatin/5-FU (PF) chemoradiotherapy versus
PF concomitant chemoradiotherapy alone, and found no statis-
tically significant difference in total mortality or progression free
survival associated with the addition of induction chemotherapy.
It may be that Paccagnella 2010 lacked power to detect a differ-
ence as this trial included fewer participants compared to TAX
323 or TAX 324, or perhaps the delay in the start of concomitant
chemoradiotherapy associated with the prior induction chemo-
therapy regimen is the reason for the poorer outcome. All three of
these trials included a similar proportion of oral cavity and oropha-
ryngeal cancer patients (64% to 70%). There is not clear evidence
as to which regimen of chemotherapy is the most effective.
Overall completeness and applicability of
evidence
We originally sought to evaluate the benefits of chemotherapy in
addition to locoregional therapies, against the potential increase
in the adverse effects of treatment associated toxicity. However,
we found very little quantitative data in the reports of the ran-
domised controlled trials concerning harms associated with treat-
ment, and almost all data were in a form unsuitable for analysis.
Toxicities and adverse events were often reported as numbers of
events rather than numbers of patients with adverse events, and
there was considerable variation in the way harms were reported
(e.g. all adverse events, moderate to severe adverse events, those
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requiring treatment interruption/cessation, causes of death).
We have therefore reluctantly modified the original protocol for
this systematic review and have reported only the benefits associ-
ated with chemotherapy, in terms of survival and response to treat-
ment. However we acknowledge that the addition of chemother-
apy to radiotherapy and/or surgery is associated with additional
toxicity. From the data available in the trials it is not possible to
quantify the expected increase in toxicity associated with a given
agent or regimen. Overall toxicity is related to the chemothera-
peutic agent(s) and the dose and duration of therapy, but may
also be related to factors including the age, bodyweight and over-
all health status of the individual patient(s). Close monitoring of
patients undergoing chemotherapy for oral cavity and oropharyn-
geal cancers will detect adverse effects at an early stage, and enable
clinicians to modify or interrupt chemotherapy to avoid and/or
manage severe toxicity.
The other issue that we have encountered in this systematic review
is that the majority of the research trials have specified squamous
cell carcinoma of the head and neck in the inclusion criteria. Only
11 of the included trials specifically recruited participants with
oral cavity cancer only and a further five included only those with
oropharyngeal cancer. The authors of three trials provide us with
separate data (see Additional Table 2 for details). In the remaining
68 trials included in this systematic review at least 50% of partic-
ipants had either oral cavity or oropharyngeal cancer. We have in-
cluded these trials because we believe that they contribute impor-
tant information concerning the effectiveness of chemotherapy in
oral cavity and oropharyngeal cancers, in the absence of separate
data in the research literature. However, we acknowledge that tri-
als on the two specific cancer sites, or combined trials where the
data are reported separately by primary tumour site, would yield
much better information to guide clinical practice in these two
conditions which have imported differences in aetiology, presenta-
tion and management. We look forward to trials on oral cavity or
oropharyngeal cancer alone being available for inclusion in future
updates of this review.
Quality of the evidence
Only three of the trials included in this systematic review used
blinding of either the participants (Browman 1994) or the out-
come assessors (Richard 1974; Shanta 1980). It is recognised that
blinding is difficult to maintain in trials of chemotherapy and it
may not be either possible or indeed ethical, to blind trial partic-
ipants or their clinicians to the treatment being administered, as
different agents and regimens require differences in monitoring
patients for both benefits and harms. It is likely thatmany outcome
assessments are performed by the clinicians treating the patients.
However blinded outcome assessment would be a pragmatic step
to reduce the risk of bias for the more subjective outcomes.
For objective outcomes such as total mortality, trials assessed as
adequate with regard to the domains of sequence generation, al-
location concealment, complete outcome data and absence of se-
lective reporting, have been assessed as being at low risk of bias.
Only 21 of the 89 included studies (24%) meet these criteria, and
can be considered at low risk of bias. The more recent trials are
more likely to have low risk of bias.
Agreements and disagreements with other
studies or reviews
The updated MACH-NCmeta-analysis of chemotherapy in head
and neck cancer Pignon 2009 also found no statistically signif-
icant difference in overall survival associated with the use of in-
duction chemotherapy, and found a statistically significant ben-
efit in favour of concomitant chemoradiotherapy. Pignon 2009
calculated an overall hazard ratio for death and showed that the
addition of chemotherapy to locoregional therapies was associated
with an absolute benefit of 4.5% at 5 years. A significant interac-
tion between timing of chemotherapy and treatment was noted.
We have not calculated an overall estimate in this way. Our in-
clusion criteria specified that at least 50% of the participants in
included trials in this systematic review had a primary tumour of
the oral cavity or oropharynx and we assessed risk of bias for each
of the included trials. The overall findings of this Cochrane sys-
tematic review that
• induction chemotherapy was not associated with a
statistically significant improvement in overall survival compared
to locoregional treatment alone;
• post-surgery adjuvant chemotherapy improved overall
survival compared to surgery ± radiotherapy alone, and there was
an additional benefit of adjuvant concomitant
chemoradiotherapy compared to sequential chemotherapy and
radiotherapy;
• concomitant chemoradiotherapy was associated with a
statistically significant improvement overall survival compared to
radiotherapy alone in patients whose tumours were considered
unresectable;
• in direct comparisons
◦ the addition of docetaxel to the frequently used
chemotherapy regimen of cisplatin and 5-FU may be associated
with a decrease in mortality,
◦ concomitant chemoradiotherapy reduces mortality
compared to the same regimen given prior to radiotherapy
support the conclusions reached in the MACH-NCmeta-analysis
Pignon 2009, and a recent reviewof series of trials of taxanes (either
docetaxel or paclitaxel) being added to chemotherapy regimens for
treatment of head and neck cancers (Specenier 2007). It is possible
that the observed improvement in survival in oropharyngeal cancer
over time may partly be explained by an increasing proportion of
HPV-related oropharyngeal cancer, rather than purely explained
by improvement in treatments (Licitra 2006).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is some evidence that induction chemotherapy results in a
small increase in overall survival compared to locoregional treat-
ment alone, which is confirmed by a sensitivity analysis of trials
at low risk of bias. There is evidence that adjuvant chemoradio-
therapy, and specifically concomitant adjuvant chemotherapy, im-
proves overall survival compared to these treatments given sequen-
tially. In patients with unresectable tumours, there is evidence that
concomitant chemoradiotherapy is associated with an improve-
ment in overall survival of between 10 and 22%. The additional
toxicity associated with the combined regimens remains unquan-
tified. While the addition of docetaxel to cisplatin and 5-FU dur-
ing induction chemotherapy appears to improve overall survival
further, it remains unclear whether the combination of induc-
tion chemotherapy (with or without docetaxel) plus concomitant
chemoradiotherapy improves overall survival.
Implications for research
Further research on the use of other taxanes, such as paclitaxel,
in addition to the standard regimen of cisplatin/5-FU is currently
underway in patients with advanced head and neck cancers. Trials
of chemotherapy regimens in single cancer sites are desirable to
identify differences in response between oral cavity and oropha-
ryngeal tumours. This will require multicentre collaborations in
order to conduct trials of sufficient size and statistical power. Re-
search to identify the high risk subgroups most likely to benefit
from post-operative concomitant chemoradiotherapy is desirable
because these regimens are associated with substantial toxicities.
Given the substantial toxicities associated with chemotherapy it
would also be desirable for future trials to report toxicities per pa-
tient treated, rather than summarising the most common toxici-
ties experienced. This would enable patients and their doctors to
better estimate the benefits and harms of treatment so that indi-
viduals could make more informed treatment plans.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Adelstein 1993
Methods Randomised controlled trial conducted in: Cleveland USA
Number of centres: 1
Recruitment period: November 1985 to June 1988
Funding source: PS Grant #P30 CA 43703 from National Cancer Institute DHHS
Trial identification number: CMGH
Participants Inclusion: adults with histologically proven, measurable squamous cell carcinoma of the head
& neck (excluding nasopharynx) with no prior treatment except for “minimal surgery”
Exclusion: T1N0 or M1 disease, serum creatinine > 20 mg/dl, bilirubin > 2.5 mg/dl or
abnormal pre-treatment haemogram
48 patients randomised
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 24): SEQ induction chemotherapy 3 cycles 5-FU 1000 mg/m2/day as continuous
infusion on days 1-5 + cisplatin 100 mg/m2 IV on day 1
Gr B (n = 24): SIM 30 Gy external beam radiotherapy in 15 daily fractions over 3 weeks
together with 1000 mg/m2 FU on days 1-4 of radiotherapy and cisplatin 75 mg/m2 IV on
day 1 of RT. Weeks 5-7 a second cycle of chemotherapy given but no further radiotherapy
A minimum of 8 weeks after SIM and 9 weeks after SEQ patients were evaluated for surgery.
Where resection with clear margins was deemed possible, based on extent of disease after
induction treatment surgery was undertaken
Outcomes Overall survival local response, toxicity, relapse free survival
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information on sequence generation given
Allocation concealment? Unclear No information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All those randomised accounted for in analy-
sis
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Adelstein 1993 (Continued)
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Yes
Adelstein 2003
Methods Randomised controlled trial conducted in: USA
Number of centres: 2
Recruitment period: March 1992 to December 1999
Funding source: Public Health Service Grants CA23318, CA66636, CA21115, CA04919,
CA73590, CA58416, VA14028, CA04920 & CA16116
Trial identification number: Int 126a & Int 0126b
Participants Inclusion: adults with histologically confirmed squamous cell or undifferentiated carcinoma
of head & neck, excluding a primary tumour originating in nasopharynx, paranasal sinus,
or parotid gland. Stage 3 or 4, (AJCC1988) M0, unresectable (criteria specified) ECOG
performance status 0,1 with adequate haematological, renal, hepatic function and normal
serum calcium
Exclusion: prior treatment for cancer, any previous cancer fromwhich patient had been disease
free for less than 5 years, pregnant or lactating women
295 randomised, 271 evaluable
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 97): radiotherapy - total dose of 70 Gy given in single daily 2 Gy fractions plus
concomitant cisplatin (100 mg/m2) intravenously on days 1, 22 & 43 of RT
Gr B (n = 96): 3 cycles of 4 days continuous infusion of 5-FU (1000 mg/m2/day) + cisplatin
bolus 75 mg/m2 on day 1 repeated every 4 weeks, together with concomitant RT 36 Gy
during first cycle chemotherapy and remainder during 3rd chemotherapy cycle 30-40Gy
Gr C (n = 102): radiotherapy - total dose of 70 Gy given in single daily 2 Gy fractions
Outcomes Total mortality, disease specific survival (unable to use these data)
Notes Data for total mortality taken from Pignon 2009
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Patients stratified by primary tumour site, tu-
mour extent (T1-3 vs T4) & nodal status (N0
vs N1 vs N2-3), and then randomly assigned
to treatment - no details on sequence genera-
tion given
Allocation concealment? Unclear No information given
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Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Numbers and reasons for exclusion and with-
drawal clearly stated and similar in each group
(2 in each group did not receive the allo-
cated treatment and 7, 10 and 7 patients from
groups A, B &C respectively were either inel-
igible or had no data)
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Unclear In toxicity results (table 4, p 95) data from
ineligible patients are included. ?ineligible pa-
tients are included in other outcome data
Argiris 2008
Methods Randomised controlled trial conducted in: USA
Number of centres: Multicentre
Recruitment period: April 1994 to April 2002
Funding: Not stated
Participants Inclusion: patients with previously untreated pathologically confirmed squamous cell car-
cinoma of head & neck, M0, who have had surgical resection. Patients were deemed high
risk due to either: 3 or more positive lymph nodes, extracapsular spread in 1 lymph node,
perineural invasion at primary site, intravascular invasion, surgical margins less that 5 mm.
Aged over 18 years, PS 0-2, adequate haematological & biochemistry parameters
Exclusion: history of previous malignancy in past 5 years, previous chemotherapy or radio-
therapy
76 randomised, 72 evaluated
Interventions Comparison 2: Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy
alone
Gr A (n = 36): radiotherapy 1.8 Gy /day, 5x per week to total dose of 59.4 Gy over 6.5 weeks
+ carboplatin 100 mg/m2 over 60 mins IV, weekly, prior to RT for 6 weeks
Gr B (n = 36): radiotherapy 1.8 Gy /day, 5x per week to total dose of 59.4 Gy over 6.5 weeks
Outcomes Primary outcome disease free survival, also total mortality, toxicity, patterns of relapse
Notes Planned to have sample size of 100 patients per arm to give adequate power. However due
to slow accrual (76 patients over 8 years), authors calculated that power of study to detect a
15% difference between groups in 2 year DFS was 48%
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Randomly assigned, no stratification fac-
tors”.No information on sequence generation
provided
Allocation concealment? Unclear No information on allocation concealment
provided
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear 4/76 subsequently found to be ineligible and
2 refused treatment. Not stated which groups
these were from
Free of selective reporting? Yes Planned outcomes of DFS, OS, patterns of
relapse and toxicity reported
Free of other bias? Unclear There is some imbalance between groups at
baseline - Gr A has 80% of larynx cancer pa-
tients and Gr B has 70% of oral cavity cancer
patients. Details of high risk features of Gr A
largely unknown (table 1)
Bensadoun 2006
Methods Randomised controlled trial conducted in: France
Number of centres: 8
Recruitment period: November 1997 to March 2002
Funding source: N/A
Participants Inclusion: patients with unresectable Stage 4 (T4 or large pan pharyngeal T3) previously un-
treated squamous cell carcinoma of the oropharynx or hypopharynx, histologically confirmed
(N0- N3, M0 with Karnofsky Performance Status > 60% and adequate haematological, renal
and liver function)
171 patients recruited (123 oropharynx, 40 hypopharynx, 54 T3 and 109 T4) 163 evaluable
Age: Gr A 72:10 Gr B 72:9
M/F: 144:19 OC+OP = 123/163 = 75%
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
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Gr A (n = 81): radiotherapy with chemotherapy. 3 cycles (starting on days 1, 22, 43) of
cisplatin (100 mg/m2 on day 1) followed by 5-day infusion of 5-FU (750 mg/m2/d reduced
to 430 mg/m2/d for the second and third courses) given concurrently with radiotherapy
Gr B (n = 82): radiotherapy 2 daily fractions of 1.2 Gy 5 days a week for 7 weeks. 2 parallel
opposed fields were used, Max spinal cord dose = 40.8Gy. At 57.6 Gy the fields were reduced
to include the primary only. The total dose was 80.4 Gy to the oropharynx and 75.6 Gy to
the hypopharynx
Outcomes Total mortality, disease free survival and specific survival all presented as Kaplan-Meier with
log rank tests for 5 years
Notes Sample size calculation given: “For an expected gain of roughly 20% overall survival at 2
years in the tested arm with an α risk of 0.05 and a β risk of 0.20 (ie 80% study power) the
inclusion of a minimum of 68 patients in each arm was essential. It was decided (given the
possibility that some patients would be lost to the trial) to include 80 patients per arm, (160
in all) over 54 months (4.5 years)”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Carried out centrally by independent service
using a minimisation technique with strati-
fication according to location of primary tu-
mour
Allocation concealment? Yes No other information given but likely to have
been concealed
Blinding of participants? No Open label
Blinding of carers? No Open label
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 8 patients excluded from analysis, (4 died be-
fore trial commenced, 2 patients erroneously
included, 2 patients refused treatment and
lost to follow-up)
Free of selective reporting? Yes Primary and secondary outcomes clearly
stated and results presented
Free of other bias? Unclear Nutritional support was provided to those
who required it - 54/81 (67%) of Gr A and
38/82 (46%) of Gr B. Possible indication of
differences in disease severity between groups
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Methods Randomised controlled trial conducted pan-Europe
Multicentre (27 centres)
Recruitment period: July 1987 - July 1990. It was planned to recruit 338 patients but the
trial stopped after the 178th event (death or progression of disease). An interim analysis was
conducted and published and a final analysis followed after an additional 26months of follow-
up
Funding source: Industrial (Roberts Laboratories, USA) and Government/charity (Ligue Na-
tionale Francaise Contre le Cancer, France)
Trial Number: EORTC 22931
Participants Inclusion: patients with stage III or IV SCC of the H&N (87 with oral cavity and 101 with
oropharynx equivalent to 56% oral cavity/oropharynx cancer patients). (Included patients
with stage pT3-pT4 any nodal stage (N) except pT3 N0 of the larynx, with negative resection
margins, or a tumour stage of 1 or 2 and no distant metastasis (M0). Patients with stage T1
or T2 N0 or N1 who had unfavourable pathological findings (extranodal spread, positive
resection margins, perineural involvement or vascular tumour embolism) were also eligible,
as were those with OC or OP tumours with involved lymph nodes at level IV-V). Tumour
stage T1-T4, N0-N4, M0)
Results presented on intention-to-treat, protocol deviations presented for each arm
Patient were recruited from specialist radio-oncology clinics
334 randomised. Aged 18-70 year
Interventions Comparison 2: Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy
alone
Gr A (n = 167): surgery with curative intent followed by concomitant CT (cisplatin 100 mg/
m2 on days 1, 22 and 43 of the radiotherapy regimen) plus RT PORT (66 Gy over a period
of 6.5 weeks)
Gr B (n = 167): surgery with curative intent followed by RT PORT (66 Gy over a period of
6.5 weeks)
Outcomes Total mortality (presented as hazard ratios for death). Follow-up period: 8 years
Death or recurrent disease (presented as hazard ratios for disease progression (authors defini-
tion of disease progression includes death)). Follow-up period: 8 years
Complications of treatment - toxicity/adverse events
Notes Data for total mortality taken from Pignon 2009
Progression free survival: hazard ratios for death or recurrent disease given in text and used to
calculate log [hazard ratio] SE
Power: “trial was designed to detect and increase in progression free survival of 15% (40-
55%) with a 2-sided 5% significance level and a statistical power of 80%”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisa-
tion performed centrally by EORTC DATA
co-ordinating centre. Randomisation was by
Pocock minimisation technique stratified by
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centre, site and T stage (T1-T3 vs T4)
Allocation concealment? Yes Allocation was revealed by telephone call or
internet connection to randomisation centre
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Insufficient information provided
Incomplete outcome data addressed? Yes All randomised participants accounted for
and included in analysis
Free of selective reporting? Yes Primary and secondary outcomes clearly
stated and results reported
Free of other bias? Yes
Bitter 1979
Methods Randomised controlled trial conducted in: assumed to be Germany & Austria
Number of centres: 13
Recruitment period: not explicitly stated - “2 years ago”
Funding source: not stated
Participants Inclusion: adults with operable T3, Nx M0 tumours of buccal cavity. 100% OC
Interventions Comparison 2: Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy
alone
Gr A (n = 16): received post-operative chemotherapymethotrexate, bleomycin and vincristine
(dosages and regimen not stated)
Gr B (n = 17): received post-operative radiotherapy cobalt -60 (regimen and dosage not stated)
Mean age Gr A: 51 years, Gr B: 55 years
Outcomes Locoregional recurrence, total mortality, disease free survival
Notes It was planned to enrol 100 patients into the trial but after 33 patients enrolled a clear
difference in outcome was evident and recruitment was stopped. Information from translation
by A Bluemle
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information on sequence generation given
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Allocation concealment? Unclear No information on allocation concealment
given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All 33 patients randomised to treatment are
included in the analysis of outcomes at 2 years
Free of selective reporting? Unclear No primary or secondary outcomes specified
Free of other bias? Unclear Numbers of patients from each hospital are
different in Groups A & B - potentially this
could mean that the groups varied with re-
spect to extent of disease at baseline
Brizel 1998
Methods Randomised controlled trial conducted in USA
Multicentre trial (2 institutions)
Recruitment period: June 1990 to December 1995
Funding source: Government - National Cancer Institute
Participants Inclusion: patients with advanced head & neck cancer recruited (previously untreated Stage 3
or Stage 4, N0-N3, M0 SCC for patients with cancer of the tongue T2N0 were also eligible)
, 116 were evaluable. Most patients had unresectable disease
122 randomised
*Our analysis based on IPD data provided by authors (100% OC/OP from IPD data authors
provided). Adults aged 18-75 years eligible
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 26*): concomitant CT (5 days of cisplatin by daily bolus of 12 mg/m2/day to a
total of 60 mg/m2 and 5-FU by continuous infusion 600 mg/m2/day.) CT was administered
during weeks 1 and 6 of hyperfractionated radiotherapy with 2 further cycles planned on
completion of radiotherapy. RT consisted of 1.25 Gy twice daily with a 6-hour interfraction
interval, to a total of 70 Gy, over 7-week period
Gr B (n = 32*): hyperfractionated RT alone, 1.25 Gy twice daily with a 6-hour interfraction
interval, to a total of 75 Gy over a 6-week period
Outcomes Total mortality* IPD
Disease free survival *IPD
Toxicity data/adverse events
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Notes *Authors provided IPD data on patients with cancer of the tongue, tonsil and oral cavity (58
patients in total)
Total mortality: log [hazard ratio] SE calculated from IPD data for total mortality
Death or recurrent disease free survival: log [hazard ratio] SE calculated IPD data for disease
free survival
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Strategy designed by biostatistics unit. PI tele-
phone the protocol officer to receive the pa-
tients treatment allocation. A permuted block
design was used with equal opportunity of
assignment to Gr A or Gr B and randomi-
sation stratified by resectability of the cancer
and haemoglobin concentration (< 12 or > 12
g per dl)
Allocation concealment? Yes Third party allocation by biostatistics unit
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? Unclear Insufficient information given
Incomplete outcome data addressed? Yes All randomised participants accounted for
and included in analysis
Free of selective reporting? Yes Primary and secondary outcomes clearly
stated and results presented
Free of other bias? Yes No additional threats to validity
Browman 1986
Methods Randomised controlled trial conducted in: Canada
Number of centres: multicentre
Recruitment period: October 1980 - September1982
Funding source: not stated
Participants Inclusion: histologically confirmed and measurable squamous cell carcinoma of head & neck,
stage III or stage IV disease with a known primary site or recurrent disease, aged less than 75
years, ECOG performance status 0-2, normal hepatic, renal and bone function
Exclusion: third space fluid accumulation, evidence of distant metastatic disease beyond head
and neck region
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Total of 82 patients randomised, 47 cases previously untreated, 30/47 untreated cases of oral
cavity cancer
Review has used data from 30/47 cases of previously untreated oral cavity cancer
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 23 prev untreated): sequential MTX, 200 mg/m2, IV bolus at time 0, then 5-FU
600 mg/m2, IV bolus 1 hour after MTX, then calcium leucovorin 10 mg/m2 orally every 6
hours x 6 doses, starting 24 hours after MTX
Gr B (n = 24 prev untreated): simultaneous 5-FU, 600 mg/m2, IV bolus at time 0, MTX,
200 mg/m, IV bolus within 15 minutes of 5-FU, calcium leucovorin, 10 mg/m2 orally every
6 hours x 6 doses, starting 24 hours after MTX
Outcomes Response rate
Survival presented as Kaplan-Meier survival curves for up to 48 months
Notes Only oral cavity new cases, with no previous treatment are included in this review. Data for
this subgroup are available. 35 participants in this trial have recurrent disease and 32 of these
had prior treatment
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Insufficient information given
Allocation concealment? Unclear Insufficient information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised participants accounted for
and included in analysis
Free of selective reporting? Yes Primary outcomes clearly stated and results
reported
Free of other bias? Yes No additional threats to validity
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Methods Randomised controlled trial conducted in Canada
Multicentre trial (4 institutions)
Recruitment period: April 1987-August 1991
Funding source: Government National Cancer Insitute of Canada, Medical Research Council
of Canada
Trial identification number: Ontario
Participants 267 patients were recruited and 175 randomised with histologically confirmed SSC of the
head & neck Stage III or IV (21 (12%) with cancer of the oral cavity and 74 (42%) with
oropharyngeal cancer, combined 54% OC/OP cancer patients. Withdrawls and drop outs
accounted for
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 88): concomitant fluorouracil I-FU 1.2 g/day delivered in dextrose/saline solution
over a 72-hour infusion period beginning 6 hours after the first weekly RT dose, in the first
and third weeks of RT. RT consisted of 66 Gy by conventional fractionation scheme of 2 Gy
per day, 5 times a week for 6.5 weeks
Gr B (n = 87): placebo + RT alone. Placebo was saline in the diluting solution used for the
CT administration
RT consisted of 66 Gy by conventional fractionation scheme of 2 Gy per day, 5 times a week
for 6.5 weeks
In both groups the first 50Gywas delivered to the treatment volumewith appropriate prophy-
lactic margins. The cord dose was 40 Gy. The final 16 Gy was delivered as a sequential boost
to the initial macroscopic disease, including electron field when required. Doses delivered to
subclinical disease areas was 50 Gy
Outcomes Disease free survival (presented as Kaplan-Meier estimates). Follow-up period: 4 years
Total mortality* IPD
Toxicity/adverse events
Notes log [hazard ratio] SE calculated from data provided from Pignon 2000
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Carried out centrally according to a computer
generated series of numbers using stratified
(by treatment centre, primary disease site and
tumour stage) block randomisation with vari-
able block size
Allocation concealment? Yes Treatment centres contacted a central ran-
domisation office to obtain allocation
Blinding of participants? Yes Patients randomised to receive either radio-
therapy + 1-FU or radiotherapy + placebo
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Blinding of carers? Unclear Insufficient information provided
Blinding of outcome assessors? Unclear Insufficient information provided
Incomplete outcome data addressed? Yes All randomised participants accounted for
and included in analysis
Free of selective reporting? Yes Primary and secondary outcomes clearly
stated and results presented
Free of other bias? Yes No additional threats to validity
Brunin 1989
Methods Randomised controlled trial conducted in France
Single centre
Recruitment period: March 1983 - June 1986
Funding source: unclear
Trial identification number: HNCGIC02
Participants Inclusion: adults with advanced stage III or IV SCC of the H&N (37 (37%) with oral cavity
- tongue, floor of mouth, retro-molar fossa and gingiva and 37 (37%) with oropharynx
equivalent to 74% combined OC/OP cancer patients) T2-T4, N0-N3
Patients were recruited from specialist cancer hospital
Median age of Gr A: 54.8 years and Gr B: 54.4 years. 100 randomised, analysed Gr A: 44/48
and Gr B: 46/52 events/patients
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 48): induction chemotherapy with cisplatin 20 mg/m2/day in 2-hour continuous
infusions on days 1-4; bleomycin 12.5 mg/m2/day given as a continuous infusion on days
1-4; vindesine 2.5 mg/m2/day given by i.v. on day 1; mitomycin C 10 mg/day given given
by i.v. on day 2 and methylprednisolone 60 mg/m2/day on days 1-4. The patients started a
second cycle on day 21 and radiotherapy 2 or 3 weeks after completion of the second cycle
of chemotherapy
Gr B (n = 52): radiotherapy of the primary tumour and cervical lymph node areas up to a
dose of 50-55 Gy
Patients were re-evaluated by radiotherapist and head& neck surgeon by clinical examination,
computed tomography, and if necessary, fibroscopic examination under general anaesthetic.
If the regression was judged satisfactory (i.e. > 50%) radiotherapy was completed to a total
tumour dose of 65-75 Gy in 1.8 to 2.2 Gy per fraction. If there was a poor response, surgery
was performed
Outcomes Total mortality* IPD
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Insufficient information given
Allocation concealment? Unclear Insufficient information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised participants accounted for
and included in analysis
Free of selective reporting? Yes Primary and secondary outcomes clearly
stated and results presented
Free of other bias? Yes No additional threats to validity identified
Budach 2005
Methods Randomised controlled trial conducted in: Germany
Number of centres: 10
Recruitment period: March 1995 to June 1999
Funding source: Grant from Deutsche Krebshilfe eV
Trial identification number: ARO 95-06
Participants Inclusion: patients with previously untreated, unresectable, stage 3 or 4 (UICC) squamous
cell carcinoma of the head and neck (oropharynx, hypopharynx, & oral cavity) M0, aged 18-
70 years, Karnofsky Performance Status > 70%
Exclusion: previous or synchronic cancer, surgery, previous CT or RT, severe vascular risk
factors, insulin dependant diabetes mellitus, symptomatic liver cirrhosis, HIV, pregnancy,
serum creatinine > 1.5 mg/dl or clearance < 80 mL
Age: 54.5 (33-71) Gr A= 55 (35-71) Gr B= 54 (33-71)
M/F: 322:62 Gr A = 165:29 Gr B= 157:33
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 190): (C-HART) concomitant CT&RT. FU administered as a continuous infusion
for 120 hours at 600 mg/m2/d on days 1-5, and on days 5 & 36 MMC was administered as a
single bolus injection of 10mg/m2. RT (HART = hyperfractionated accelerated radiotherapy)
consisted of matched opposing lateral fields and an anterior neck fieldmatched below. Central
lead shielding was used to protect the larynx, spinal cord and lung apices. Radiotherapy was
performed with 6MV photons with up to 36-40 Gy when the posterior neck was blocked to
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shield the spinal cord max of 45Gy to cord, total dose 70.6 Gy
Gr B (n = 194): (HART = hyperfractionated accelerated radiotherapy) consisted of matched
opposing lateral fields and an anterior neck field matched below. Central lead shielding was
used to protect the larynx, spinal cord and lung apices. Radiotherapy was performed with 6
MV photons with up to 36-40 Gy when the posterior neck was blocked to shield the spinal
cord max of 45 Gy to cord RT alone & total dose of 77.6 Gy
Outcomes Locoregional control, total mortality, progression free survival, freedom from metastasis rates
shown as Kaplan-Meier curves with log rank test and cox regression analysis
Data are given at 2, 3 and 5 years follow-up
Hazard ratios are given
Data for total mortality taken from Pignon 2009
Notes NOTE: RADIOTHERAPY DIFFERS between groups - C-HART has lower total dose com-
pared to HART
Sample size calculation given “Estimating a 15% difference between HART and C-HART
with respect to LRC, a first kind error of 5%, a power of 85% and accrual of 4 years, a follow-
up of 2 years, and a loss to follow-up of 10% for a time base of survival of 3 years, a total
sample size of 350 patients was calculated to test a 2 sided alternative hypothesis of differences
between HART and C-HART using the log rank test”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “Randomisation carried out in blocks of 4
patients to obtain fully balanced treatment
groups”. Randomisation scheme allowed for
stratification by stage, site and centre
Allocation concealment? Unclear No information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Post-randomisation exclusions and with-
drawals clearly described in each group. 7
patients were withdrawn form the C-HART
and four from HART another 32 C-HART
and 15 HART were excluded due to incor-
rect radiotherapy or chemotherapy, non-com-
pliance or death (total 20% in C-HART &
10% in HART) intention-to-treat, available
for therapy andper protocol populations anal-
ysed
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Free of selective reporting? Yes Outcomes clearly described and reported
Free of other bias? Yes
Buffoli 1992
Methods Randomised controlled trial conducted in: Brescia, Italy
Number of centres: 1
Recruitment period: January 1981 to November 1983
Funding source: not stated
Participants Inclusion: previously untreated patients with histologically and clinically confirmed diagnosis
of upper aerodigestive tract cancer, T3 or T4, anyN. Aged < 75 years, primary tumour in either
oral cavity, oropharynx, larynx or hypopharynx, measurable disease, Karnofsky performance
status ≥ 60%, adequate haematological function, no evidence of liver, lung, heart or kidney
disease
49 randomised, 49 evaluated 36/49 = 73% had oral cavity or oropharyngeal primary tumours
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 29): induction CT. Day 1 2 g/m2 hydroxyurea orally + 15 mg/m2 IV bleomycin,
Day 2 50mg/m2 IVmethotrexate + 6 hours later 45mg/m2 IV folinic acid. Day 1&2 repeated
on Day 3&4, and these 4 days of CT repeated every week for 4 weeks. On week 5 RT started,
2 Gy/day, 5 days/week to total dose of 60 GY over 6 weeks
Gr B (n = 29): alternating RT/CT/RT. 2 weeks of RT 2 Gy/day 5 x/week (20 Gy) as first
phase, then CT - Day 1 2 g/m2 hydroxyurea orally + 15 mg/m2 IV bleomycin, Day 2 50 mg/
m2 IV methotrexate + 6 hours later 45 mg/m2 IV folinic acid. Day 1&2 repeated on Day
3&4, and these 4 days of CT repeated every week for 4 weeks. Then final 40 Gy of RT over
4 weeks to total dose of 60 Gy
Radiotherapy was given using a single Co60 6Mv machine, with an single protocol for all
the patients, using 2 opposing and parallel fields to include the primary tumour and lymph
nodes to a total dose of 42 Gy. The treatment was then modified to exclude the spinal area,
& spinal nodes were irradiated with electron fields until the prescribed total dose was reached
Outcomes Tumour response at end of CT, 2 months after end of treatment, OS & DFS at 5 years
Notes From translation by Dr Nicoletta Bobola. No sample size calculation was performed. Objec-
tives were to investigate the feasibility and curability of combined RT/CT
Pignon 2000 data not used as discrepancy between this paper and Buffoli 1992 with regard
to direction of effect and denominators in each group
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Sequence generation was bymeans of random
numbers generated by computer. Allocations
were placed in sealed envelopes
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Allocation concealment? Yes Sealed envelopes were distributed by Insitute
secretary as each patient was included in the
study
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised patients included in evalua-
tion of survival, tumour response and toxici-
ties
Free of selective reporting? Yes Planned outcomes of OS, DFS at 5 years and
tumour response reported
Free of other bias? Yes No additional threats to validity identified
Chauhan 2008
Methods Randomised controlled trial conducted in: India
Number of centres: 1
Recruitment period: November 2000 to March 2003
Funding source: not stated
Participants Adults with locally advanced (T3,T4, any N, M0) previously untreated squamous cell carci-
noma of the head & neck. Patients had unresectable disease or had refused surgery, KPS ≤
70% (sic), adequate liver function, bone marrow reserve and renal function
80 randomised 40 in each group, 84% oral or oropharyngeal cancer
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 40): radiation therapy 2 Gy per fraction, one fraction per day, 5 times per week to
a total dose of 64 Gy + gemcitabine, 100 mg/m2 IV over 30 minutes, once a week 1-2 hours
before radiation therapy
Gr B (n = 40): radiation therapy 2 Gy per fraction, one fraction per day, 5 times per week to
a total dose of 64 Gy
In both groups treatment was individualised according to the site & extent of disease, and
the spinal cord was excluded from radiation after dose of 44 Gy
Outcomes Toxicity (haematological, skin reaction, mucositis, nausea, vomiting, weight loss) and locore-
gional control
Notes
Risk of bias
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Item Authors’ judgement Description
Adequate sequence generation? Unclear “Prospectively randomised”, no details of se-
quence generation methods given
Allocation concealment? Unclear No information on allocation concealment
given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised patients included in toxicity
and locoregional control outcomes
Free of selective reporting? Yes Planned outcomes of toxicity and locore-
gional control reported
Free of other bias? Yes Groups appear well balanced at baseline
Chauvergne 1988
Methods Randomised controlled trial conducted in: France
Number of centres: not stated
Recruitment period: August 1981 to November 1985
Funding source: not stated
Participants Inclusion: adults with advanced squamous cell carcinoma of head & neck initially assessed as
inoperable. Mean age Gr A 54 (sd 7.8) & Gr B 53.1 (sd 7.3)
143/241 = 59% oral cavity/oropharyngeal cancer
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 119) induction CT cisplatin 80 mg/m2 every 3 weeks for 3 cycles
Gr B (n = 122) induction CT cisplatin 80 mg/m2 (day 4) + vincristine 1 mg/m2 (Day 1) +
methotrexate 10 mg/m2/d (Days 1-3) and bleomycin 10 mg/m2/d (Days 1-3), repeated every
3 weeks for 3 cycles
Outcomes Total mortality, relapse free survival, toxicity
Notes From translation by A-M Glennie
Risk of bias
Item Authors’ judgement Description
76Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Chauvergne 1988 (Continued)
Adequate sequence generation? Unclear “Randomly assigned”, no details of sequence
generation given
Allocation concealment? Unclear Insufficient information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 2 post-randomisation exclusions in each
group - unlikely to bias results
Free of selective reporting? Yes Total mortality, relapse free survival and tox-
icity planned and reported
Free of other bias? Yes No significant differences between the groups
at baseline
Cooper 2004
Methods Randomised controlled trial conducted in USA
Multicentre (12 centres) mixture of general and specialist centres. Part of the Radiation
Therapy Oncology Group (RTOG). Supported by the Eastern and South West Oncology
groups (ECOG & SWOG). Intergroup phase 3 trial: RTOG 9501, ECOG R9051 and
SWOG 9501
Recruitment period: September 1995 - April 2000
Funding source: Government - National Cancer Institute, grants (CA 21661 & CA 32115)
Participants Inclusion: adults with squamous cell carcinoma of oral cavity, oropharynx, larynx or hy-
popharynx who had undergone complete resection, had high risk characteristic, (any 2 of
histological evidence of invasion of at least 2 lymph nodes, extracapsular extension of nodal
disease, microscopically involved mucosal margins of resection)
459 randomised, 416 evaluable patients (consisting of 27% OC, 43% OP - combined 70%
OC/OP)
Interventions Comparison 2: Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy
alone
Both groups underwent total surgical resection of all visible and palpable disease
Gr A (n = 228): surgery plus post-operative concomitant RCT (cisplatin 100 mg/m2 intra-
venously on days 1, 22, 43) plus RT - 60 Gy in 30 fractions over a period of weeks with or
without a boost of 6 Gy in 3 additional fractions over a period of 3 days to high risk sites
Gr B (n = 231): surgery plus radiotherapy alone - 60 Gy in 30 fractions over a period of weeks
with or without a boost of 6 Gy in 3 additional fractions over a period of 3 days to high risk
sites
Radiotherapy was initiated as soon after surgery as adequate healing had occurred, typically
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Cooper 2004 (Continued)
4-6 weeks post-surgery but no later than 8 weeks (56 calendar days)
Outcomes Total mortality (presented as hazard ratio for death. Additionally, authors provide overall
survival presented as Kaplan-Meier estimates). Follow-up period: 5 years
Death or recurrent disease (presented as hazard ratio for disease or death.) Follow-up period:
5 years
Recurrent disease (presented as hazard ratio for local or regional reoccurrence). Follow-up
period: 5 years (median 45.9 months)
Complications of treatment - toxicity/adverse events
Notes Data for total mortality taken from Pignon 2009
Sample size calculation given: randomisation of 398 eligible patients was required to have the
statistical power to detect an absolute improvement of 15% in 2-year rate of local or regional
recurrence, with 0.80 statistical power and significance level of 0.05
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation stratified by age (<70 vs 70+)
and presence or absence of tumour in mar-
gins, andwas performed at headquarters using
the permuted block allocation (Zelan) where
treatment assignments balanced by institu-
tion and then according to patient factors
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Reasons for post-randomisation exclusions
clearly described and similar in both groups
Free of selective reporting? Yes Pre-specified outcomes described and re-
ported
Free of other bias? Yes
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Corvo 2001
Methods Randomised controlled trial conducted in Italy
Multicentre centre (6 institutions)
Recruitment period: 1992-1998
Funding source: government
Trial identification number: INRC-HN-9
Participants 136 patients randomised and evaluable with advanced stage II (unfavourable tongue cancer)
-IV SCC of the head and neck (consisting of 26 (19%) OC, 52 (38%) OP - combined 57%
OC/OP)
Withdrawals and drop outs accounted for
Patients were adults aged < 75 years
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 70): alternating CT and RT. Treatment consisted of 4 cycles of iv cisplatin (20 mg/
of body surface area/day for 5 consecutive days) and 5-FU (200 mg/m2 of body surface area/
day for 5 consecutive days, weeks 1, 4 and 7) alternated with 3 2-week courses of RT (20 Gy/
course, 2 Gy/day, 5 days/week)
Gr B (n = 66): high dose, partly accelerated RT (PA-RT). Treatment consisted of partly
accelerated RT with a final second course using concomitant boost technique. Total planned
dose of PA-RT was 75 Gy in 40 fractions over 6 weeks
Outcomes Disease free survival (presented as Kaplan-Meier estimates). Follow-up period: 4 years
Total mortality (overall survival presented as Kaplan-Meier estimates). Follow-up period: 4
years
Notes Data for total mortality taken from Pignon 2009
NOTE: RADIOTHERAPY DIFFERS BETWEEN TWO GROUPS
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “Randomisation was performed by making
a telephone call to a central office that had
responsibility over randomisation and data
management”. Randomisation was stratified
by institution
Allocation concealment? Yes Maintained by central office, accessed by tele-
phone
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
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Corvo 2001 (Continued)
Incomplete outcome data addressed? Yes Analysis by intention-to-treat. Exclusions,
withdrawals and discontinuation clearly de-
scribed for each group
Free of selective reporting? Yes
Free of other bias? Yes
De Andres 1995
Methods Randomised controlled trial conducted: Spain
Number of centres: 1
Recruitment period: May 1986 to December 1988
Funding source: not stated
Participants Inclusion: adults aged < 70 years with histologically proven squamous cell carcinoma of head
& neck Stage 4,M0, without prior treatment. Patients must have assessable disease, Karnofsky
performance status > 70%, serum creatinine < 130 µmol/l or creatinine clearance > 50 ml/
min, ALT/AST < 100 IU/L, WBC > 3500/µl, & platelets > 100, 000/µl
96 patients randomised, 1 withdrew consent prior to start of treatment
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
GrA (n=49): cisplatin 100mg/m2 onday 1+FU500mg/m2 by continuous infusionover 120
hours, repeated every 21 days. All patients were given metoclopromide and diphenhydramine
as antiemetics
Gr B (n = 47): carboplatin 400 mg/m2 by continuous infusion over 24 hours + FU 5000
mg/m2 by continuous infusion over 120 hours repeated every 21 days. Patients were given
metoclopromide as antiemetic
Patients from both groups were then offered radiotherapy 1.8 to 2 Gy/day, 5 times/week to
a total dose of 65-70 Gy
Outcomes Tumour response, toxicity
Notes Trial stopped early due to significant differences detected in favour of control arm. 5-year
follow-up is available on the patients randomised before the trial was stopped
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No information on sequence generation given
Allocation concealment? Unclear No information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
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De Andres 1995 (Continued)
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 1 patient randomised withdrew consent prior
to start of treatment but other 95 patients in-
cluded in evaluation. 2 patients lost to follow-
up after treatment completion
Free of selective reporting? Yes Planned outcomes of response and toxicity
were reported
Free of other bias? Yes
Denis 2004
Methods Randomised controlled trial conducted pan-France
Multicentre centre (8 institutions)
Recruitment period: July 1994 - September 1997.
Funding source: government - French Ministry of Health
Trial identification number: GORTEC study (’Groupe d’Oncolgie Radiothérape Tête et Cou
- GORTEC) 9401
Participants 226 adults aged less than 75 years recruited and 222 were evaluable all with histologically
confirmed SCC of the oropharynx (base of the tongue, tonsillar fossa or posterior wall and
soft palate; T1-T4 stage III-IV, N1-N3, M0)
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A: concomitant CT (carboplatin and 5-FU) plus RT (n = 109)
Gr B: RT alone (n = 113)
CT was concomitant (administered weeks 1, 4 and 7) and consisted of 3 cycles of a 4-day
regimen containing carboplatin (daily bolus dose of 70 mg/m2/day) and 5-FU (600 mg/m2/
day by continuous infusion over 24 hours). CT was administered during the RT treatment
period. Patients also received antiemetics (metoclopramide and dexamethasone). The CT
cycle was initiated on days 1, 22 and 43
RT consisted of conventional fractionation 70 Gy in 35 2 Gy fractions, 1 fraction per day. If
there were no palpable lymph nodes, 44 Gy was delivered in the lower part of the neck and
in the spinal lymph nodes, and 56 Gy was delivered in the cervical areas adjacent to involved
lymph node areas. The dose to the spinal cord was kept below 44 Gy
Outcomes Disease free survival (presented as Kaplan-Meier estimates). Follow-up period: 4 years
Total mortality (overall survival presented as Kaplan-Meier estimates). Follow-up period: 4
years
Complications of treatment - early(acute) and late toxicity
Notes Data for total mortality taken from Pignon 2009
Risk of bias
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Denis 2004 (Continued)
Item Authors’ judgement Description
Adequate sequence generation? Yes “Randomly assigned to a treatment group by
a central office ..... Randomisation balanced
by institution and clinical stage”
Allocation concealment? Yes Performed centrally
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Withdrawals clearly described in each group
Free of selective reporting? Yes
Free of other bias? Yes
Depondt 1993
Methods Randomised controlled trial conducted in France
Multicentre (9 centres) mixture of cervicofacial surgery or radiotherapy departments
Recruitment period: January 1988 - July 1991
Funding source: unknown
Trial identification number: CFHNS
Participants Inclusion: adults < 70 years, T2-T4 epidermoid carcinoma of head & neck, life expectancy
greater than 12 weeks and Karnofsky performance status > 70%
Exclusion: tumours localised to glottis or sinuses, multiple tumour sites, distant metastases,
previous treatment for upper aerodigestive tract tumours, unresectable, contraindications to
chemotherapy
324 randomised 300 analysed. 79/300 patients with OC and 106/300 with OP (26% OC,
35% OP - combined 61% OC/OP)
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 150): induction CT (3 cycles of carboplatin (400 mg/m2/day) day 1 and 5-FU
(1 g/m2) days 1-5, repeated every 3 weeks) plus locoregional treatment (all receive RT some
receive surgery)
Gr B (n = 150): radiotherapy (all receive RT some receive surgery)
Radiotherapy consisted of Cobalt-60 at 75 Gy when used alone on tumours and palpable
nodes, this dose was reduced to 45-50 Gy on node area in N0 patients. Baslingual and T2
tonsillar tumours were exposed to cobalt-60 45-50 Gy, followed by brachytherapy 30-35 Gy.
Surgical excision sites were irradiated at 45-75 Gy depending on the degree of resection. The
level of radiation applied to cervical nodes depended on histologic status: N0 patients 45 Gy,
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Depondt 1993 (Continued)
N+ patients 55-60 Gy and N+R+ patients 70-75 Gy
LRT for T2 cancer consisted of brachytherapy combined with lymph node dissection
LRT for T3 and T4 tongue cancer consisted of radiation and surgery. For floor of the mouth
cancer-surgical removal of primary tumour followed by cobalt-60 treatment, depending on
the nodal status and resection results. For oropharyngeal tumours on the base of the tongue,
posterior pharyngeal wall and T2 tumours of the tonsillar fossa - cobalt-60 alone. T3-T4
tonsillar fossa surgery and radiotherapy
Outcomes Total mortality* IPD
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data.
Preliminary report for oral cancer patients
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No details given
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear 24/324 (7%) patients randomised were sub-
sequently excluded. (17 dropped out, 1 was
randomised twice and 6were found to be inel-
igible) but not stated which groups they were
from
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Unclear Patients were initially randomised to locore-
gional control (radiotherapy and/or surgery)
alone or locoregional control plus chemother-
apy.However there was considerable variation
between patients as to the nature of LRT re-
ceived (brachytherapy, radiotherapy, surgery)
and those who had tumour regression had
cobalt-60 treatment regardless of LRT strat-
egy to which they were originally assigned
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Dobrowsky 2000
Methods Randomised controlled trial conducted in: Vienna, Austria
Number of centres: 1
Recruitment period: October 1990 to December 1997
Funding source: Medizinischwissenschaftlicher Fonds des Burgermeisters der Bundeshaupt-
stadt Wien
Trial idenitfication: Vienna
Participants Inclusion: adults with T1-4, N0-3 histologically confirmed squamous cell carcinoma of head
& neck
Exclusion: distant metastases
239 randomised, 239 evaluated. OC 29%, OP 44%, OC+OP = 73%
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Conventional RT versus HFx Acc RT versus HFx Acc RT + concomitant CT
Gr A (n = 81): conventional fraction radiotherapy - total of 70 Gy delivered over 7 weeks, 2
Gy/dose, 5 doses per week
Gr B (n = 78): (V-CHART) continuous hyperfractionated accelerated radiotherapy given
over 17 consecutive treatment days. Day 1 2.5 Gy, Day 2-17 1.65 Gy/fraction, 2 fractions
per day, with 6 hour minimum inter fraction, interval to total dose of 55.3 Gy
Gr C (n = 80): (V-CHART +MMC) continuous hyperfractionated accelerated radiotherapy
given over 17 consecutive treatment days. Day 1 2.5 Gy, Day 2-17 1.65 Gy/fraction, 2
fractions per day, with 6 hour minimum inter fraction, interval to total dose of 55.3 Gy +
bolus injection 20 mg/m2 mitomycin C on day 5 prior to RT dose
Outcomes (Primary), tumour response, toxicity
Notes Study power: “ a difference in survival of 15% (from 25-40%) after 3 years between 2 of
the treatment groups was detected with a probability of 85% at a significance level of 0.05
(unilateral test)”. Recruitment was stopped early after an interim analysis in 1998 showed
significant benefit for accelerated RT + MMC
OS Data from Pignon 2009 is included in the analysis (3.1.15) ln (HR)= -0.15, SE = 0.18
However OS estimate calculated from Fig 1, p 122 of paper gives ln (HR)= -0.35, Se ln(HR)
= 0.19 (non significant difference)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation was stratified by stage (T&N)
site, age, performance status and gender. Ran-
domisation was performed by Documenta-
tion Office of first Surgical University Clinic,
Vienna. Details on method of sequence gen-
eration not described
Allocation concealment? Yes Patients were allocated to treatment groups
by means of a phone call from investigator to
randomisation centre
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Dobrowsky 2000 (Continued)
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All 239 randomised patients are included in
the outcome assessment
Free of selective reporting? Yes Primary outcome is overall survival and tu-
mour response and toxicity also reported
Free of other bias? Yes 4 patients were randomised twice but second
randomisation was discarded
Domenge 2000
Methods Randomised controlled trial conducted in France
Recruitment period: 1986-1992
Funding source: government and industry
Trial identification number: GETTEC neo1 (LRT = RT) (French Groupe d’Etude des
Tumeurs de la Tête et du Cou) and GETTEC neo2 (LRT = RT + surgery)
Participants 318 adults aged 18-70 years with biopsy confirmed SCC of all sites of the oropharynx except
for the posterior wall and the anterior surface of the epiglottis, classified as T2-T4, N0-N2b,
M0. The trial was interrupted after 6 years of accrual as the accrual rate was so low
Exclusions: contraindications to chemotherapy, previous treatment for malignancy, multiple
tumours
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 157): induction CT (cisplatin (100 mg/m2) given in 1 hour iv infusion on day 1
followed by a 24-hour iv infusion of 5-FU (1000 mg/m2/day) for 5 days. This treatment was
repeated on day 22 unless tumour progression exceeded 25% and repeated again on day 43
only if tumour regression had been observed) plus LRT (LRT = RT + surgery n = 71, LRT =
RT alone n = 86)
Gr B (n = 161): LRT ( LRT = surgery + RT n = 73, or RT alone n = 88)
LRT consisted of surgery + RT or RT alone. RT alone commenced 2-3 weeks after the end
of the CT. Post-operative RT, within 10 weeks of surgery consisted of daily 2 Gy fractions, 5
fractions per week over 7 weeks to a total of 70 Gy. In all cases the posterior spinal area was
treated with 42 Gy
In patients with free margins, 50 Gy to the bilateral superior and inferior cervical areas, with
a boost of 15 Gy in cases of extracapsular spread
In patients with positive surgical margins, 65 Gy were delivered in 6.5 weeks to the tumour
site and bilateral superior cervical areas, and 50 Gy to the inferior cervical areas with a boost
of 15 Gy in the case of extracapsular spread
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Domenge 2000 (Continued)
Outcomes Disease free survival (presented as Kaplan-Meier estimates). Follow-up period: 8 years
*Total mortality (overall survival presented as Kaplan-Meier estimates). Follow-up period: 8
years
Notes Disease free survival: hazard ratios for death or recurrent disease given in text and used to
calculate log [hazard ratio] SE
*Pignon data for GETTEC neo1 and GETTEC neo2 are identical to the trial report just split
according to LRT strata. Used combined overall data from published trial in review
Sample size calculation given - planned to include 760 participants in the study, 400 in the
surgery group and 360 in the RT group to give 90% power to detect a 10% difference in
survival (α = 5%)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “Patients were randomised by telephone ....
randomisation was stratified by centre and lo-
cal treatment (surgery +/- Radiotherapy or ra-
diotherapy alone)”
Allocation concealment? Yes Randomisationperformed centrally, allocated
by telephone
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Withdrawals and drop outs accounted for
Free of selective reporting? Yes
Free of other bias? Yes
Eschwege 1988
Methods Randomised controlled trial conducted pan-Europe (France, Belgium, Italy, Germany)
Multicentre centre (15 institutions, data from only 13 used in final analysis)
Recruitment period: April 1973- December 1974
Funding source: unknown
Trial identification number: EORTC73-0
Participants Inclusion: adults with histologically confirmed SCC of the oropharynx (base of the tongue,
tonsillar fossa or posteriorwall and soft palatewhohad tumours > 2 cmor infiltrating regardless
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Eschwege 1988 (Continued)
of nodal statusT2-T4, N1-N3, M0)
Exclusions: previous treatment, second primary tumour, poor general status, bone marrow
depression, kidney failure, chronic pulmonary disease, diabetes mellitus
224 patients randomised and 199 evaluable
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 107): concomitant CT (15 mg BLM administered IM or IV twice a week from the
start of RT for 5 weeks. Each injection of BLM was given 2 hours prior to the session of RT
to a total dose of 150 mg) plus RT
Gr B (n = 92): RT alone
RT comprised irradiation of the primary tumour and lymph nodes to a dose of 70 Gy for 7-
8.5 weeks, while clinically uninvolved nodes received 50-55 Gy for 5-6 weeks
Outcomes Total mortality* IPD
Complications of treatment - toxicity/adverse events
Notes *Data supplied from Pignon 2000
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes ”Tables of random numbers were used to pre-
pare randomisation envelopes for each cen-
tre. The randomisation was stratified accord-
ing to institution and was balanced after every
4. Generation of randomisation sequence and
concealment performed by statistical unit
Allocation concealment? Yes Generation of randomisation sequence and
concealment performed by statistical unit
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes “25 patients were excluded for different rea-
sons; these patients were well balanced within
the two treatment groups”
Free of selective reporting? Yes Primary and secondary outcomes clearly
stated and results presented
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Eschwege 1988 (Continued)
Free of other bias? Yes 2/15 centres were excluded from the analysis
because they each only randomised one pa-
tient. This is unlikely to have influenced the
results of the trial
Fazekas 1980
Methods Randomised controlled trial conducted pan-USA
Multicentre centre (16 RTOG institutions)
Recruitment period: 1968-1972
Funding source: unclear
Trial identification number: RTOG 6801
Participants Inclusion: adults with histologically confirmed squamous cell carcinoma or lymphoepithe-
lioma, either T1-2 with N2-3 cervical nodes or T3-4 N0-3 neck disease. Patients with history
of previous malignancy but not H&N location were accepted into trial providing they had
not received previous chemotherapy and must have been disease-free for > 5 years
Exclusion: previous chemotherapy for malignancy or previous surgery or radiotherapy to head
& neck area, distant metastases, 2 simultaneous tumours, general medical reasons such as <
60% standard weight,WBC < 3500, platelets < 100,000 or severely abnormal renal or hepatic
function
712 randomised, 638 evaluable
(146 (23%) with oral cavity and 354 (56%) with oropharynx, combined OC/OP = 79%)
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 340): chemotherapy (methotrexate) 25 mg every third day for 5 injections followed
by RT
Gr B (n = 340): RT alone - RT was to begin immediately if possible and no later than 2
weeks of completion of CT. For both groups RT comprised irradiation to primary tumour
and cervical nodal drainage area. Doses from 5500 to 8000 rad in 5-10 weeks
Surgical intervention (either resection of the primary site or radical neck dissection) was
permitted after the completion of RT
Outcomes Total mortality* IPD
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisation stratified by primary site,
stage and institution. Generation of randomi-
sation sequence unclear
Allocation concealment? Unclear No details given
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Fazekas 1980 (Continued)
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear 712 participants randomised, 44 later found
to be ineligible and further 33 lost to fol-
low-up (11%). Not clear how many were
from each group, but paper states that “more
patients who received combined treatment
failed to complete irradiation (9%) than
the irradiation group alone (4%)” suggesting
some imbalance between groups
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Yes
Garden 2004
Methods Randomised controlled trial conducted in: USA
Number of centres: multicentre
Recruitment period: July 1997 to June 1999
Funding source: National cancer Institute Grants (CA 21661, CCOP U10, CA 37422,
STATU 10, CA 32115)
Trial name: RTOG 97-03
Participants Inclusion: patients aged >18 years, with Karnofsky performance status >/= 70%, with his-
tologically confirmed squamous cell carcinoma of the head and neck, previously untreated.
Adequate bone marrow, hepatic, renal and coagulation function was required for participation
in trial
Exclusion: prior or synchronous malignancy, clinically significant heart disease
231 randomised
Interventions Comparison 4: Regimen A versus Regimen B versus Regimen C
Gr A (n = 78): radiotherapy 70 Gy in 35 fractions over 7 weeks plus with cisplatin 10 mg/m
2 daily + 5-FU 400 mg daily, for final 10 days of RT
Gr B (n = 76): radiotherapy 70 Gy in 35 fractions (every other week for 13 weeks) with 1 g
HU every 12 hours (to total of 11 doses /cycle) + FU 800 mg/m2/day by continuous infusion
concurrent with RT. Treatment given every second week for 13 weeks
Gr C (n = 77): (RT + cisplatin + paclitaxel) - radiotherapy 70 Gy in 35 fractions (over 7
weeks) + paclitaxel 30 µg/m2 every Monday + cisplatin 20 mg/m2 every Tuesday before R
Outcomes Tolerance, toxicity, locoregional control, disease free survival, overall survival
Notes HR for total mortality calculated from Kaplan-Meier curves
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation was stratified by Karnofsky
Performance Status(90-100 vs 70-80). Ran-
domisation method of Zelen was used to ob-
tain balance (only those patients randomised
to the experimental groups 1 and 3 were re-
quired to give consent). Patients were con-
sented and randomised to groups 1 and 3
Allocation concealment? Yes Patients were enrolled and randomised by a
telephone call to the RTOG centre
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear 10 post-randomisation exclusions - not stated
which groups these patients were from. 231/
241 were included in the acute toxicity and
disease recurrence results
Free of selective reporting? Yes Many outcomes described and reported
Free of other bias? Yes
Gasparini 1993
Methods Randomised controlled trial conducted in: Italy
Number of centres: 1
Recruitment period: May 1989 to September 1992
Funding source: not stated
Participants Inclusion: adults aged 18-75, with histologically proven squamous cell carcinoma of the
head and neck, previously untreated and unresectable, stage 3-4 disease (UICC-TNM) M0,
Karnofsky performance status ≥ 70, normal renal function, adequate bone marrow function
& life expectancy > 6 months
Exclusion: second neoplasms, active infection, history of nephropathy
63 screened, 53 randomised
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 27): CDDP - cisplatin 80 mg/m2 IV infusion on days 1, 21 & 42 starting 2 hours
after the start of RT given as daily fractions 5 days/week, to a total of 64 Gy
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Gasparini 1993 (Continued)
Gr B (n = 26): CRP - carboplatin 375 mg/m2 as short IV infusion on days 1, 21 & 42, 2
hours after start of RT for 60 mins. RT given as daily fractions 5 days/week, to a total of 64
Gy
Both groups received ondansetron
Outcomes Disease free survival, total mortality
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation stratified by clinical stage,
performance status and primary site and treat-
ment was balanced in blocks of 4, using a list
of random numbers
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All patients assigned to treatment groups were
included in analyses of DFS & OS
Free of selective reporting? Yes Primary and secondary outcomes described
and reported
Free of other bias? Yes
Giglio 1997
Methods Randomised controlled trial conducted in: Argentina
Number of centres: 1
Recruitment period: February 1992 to December 1994
Funding source: not stated
Trial identification number: IAR-92
Participants Inclusion: adults with inoperable squamous cell carcinoma of head & neck
68 patients randomised
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 37): cisplatin 20 mg/m2 + 5-FU 300 mg/m2 + folinic acid 20 mg/m2 on days 1-4
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Giglio 1997 (Continued)
in weeks 1, 4, 7 & 10 alternating with radiotherapy 2 Gy/day in weeks 2-3 & 1.5 Gy/day in
2 fractions separated by 6 hours intervals on weeks 5&6, and 8&9 to total dose of 80 Gy
Gr B (n = 17): hyperfractionated radiotherapy alone - 2 fractions of 1.2 Gy/day separated by
6-hour intervals for 6.5 weeks to total dose of 79.2 Gy
Outcomes Tumour response (end of treatment) toxicity, time to progression
Notes Data for taken from Pignon 2009 (based on Giglio 1999)
Translation from original Spanish by L Fernandez-Mauleffinch
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Rrandomised”. No information on sequence
generation given. Planned 2:1 ratio GrA: GrB
Allocation concealment? Unclear No information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear 15 did not complete treatment (11 from Gr
A & 4 from Gr B- reasons given) and unclear
how many were included in outcome assess-
ment
Free of selective reporting? Yes Planned outcomes - response, toxicity, sur-
vival, time to progression reported
Free of other bias? Yes Groups appear similar at baseline
Gladkov 2007
Methods Randomised controlled trial conducted in: Russia
Number of centres: 1 (Chelybinsk Regional Oncology Centre)
Recruitment period: 2005-7
Funding source: not stated
Participants Inclusion: stage II, III & IV oral cavity and oropharyngeal cancer, without prior treatment
64 randomised, median age 54
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 22): radiotherapy + cisplatin (6 mg/m2 IV once per day)
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Gr B (n = 26): radiotherapy + cisplatin (40 mg/m2 IV once per week) + NaCl (up to 2500
ml intravenously)
Gr C (n = 12): radiotherapy + cisplatin (100 mg/m2 IV once per 3 weeks) + NaCl (up to
2500 ml intravenously)
Pre-medication with antiemetics, glucocorticoids, metoclopramide. Duration of CT is not
specified
RT consisted of 2 Gy daily fractions 5 days per week to a total dose 68-70 Gy
Outcomes Tumour response, adverse events
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “Randomization was performed using the
computer generator of random numbers”
Allocation concealment? Unclear Insufficient Information provided
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised patients accounted for and in-
cluded in analysis
Free of selective reporting? Yes Primary and secondary outcomes clearly
stated and results presented
Free of other bias? Yes No additional threats to validity
Gonzalez-Larriba 1997
Methods Randomised controlled trial conducted in: Spain
Number of centres: 1
Recruitment period: 1988 to 1992
Funding source: not stated
Participants Adults with locally advanced squamous cell or undifferentiated cancer of the head & neck,
histologically confirmed, with locoregional spread, stage 3-4, M0, Karnofsky performance
status ≥ 70%, no previous treatment, evaluable/measurable tumour lesions, adequate renal
& liver function, no previous neoplasia
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Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 34): cisplatin 100 mg/m2 day 1 + continuous 5-FU 1000 mg/m2 on days 2-6. 4x
21-day cycles
Gr B (n = 33): cisplatin 100 mg/m2 on day 1+ uracil 300 mg/m2/day in 3 doses on days 2-
20. 4x 21-day cycles
Patients in both groups who had a response to induction chemotherapy were then given
radiotherapy
Outcomes Total mortality, progression free survival
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Randomly assigned” - no further details
given
Allocation concealment? Unclear No information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised patients included in the anal-
yses
Free of selective reporting? Yes Primary and secondary outcomes described
and reported
Free of other bias? Yes
Grau 2003
Methods Randomised controlled trial conducted pan-world (Bulgaria, India, Malaysia, Pakistan, Sri
Lanka and Turkey)
Multicentre centre (7 institutions)
Recruitment period: February 1996 - December 1999
Funding source: government and industry - IAEA Co-ordinated Research Project E3.30.13
Trial identification number: IAEA-MMC
Participants Inclusion: patients with locally advanced (UICC TNM St 3 & 4) squamous cell carcinoma
of the pharynx, larynx & oral cavity, aged over 18 years, WHO performance status < 2, with
normal haematological, liver and kidney function
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Exclusion: prior or planned surgical excision
558 patients were recruited with advanced head & neck cancer. Insufficient accrual and
reporting led to the exclusion of 3 centres. The final evaluable study population consisted of
478 patients from 7 centres. Patients had stage III (n = 223) or stage IV (n = 255), (T1-T2,
T3-T4; N0, N1-N3>) SCC oral cavity n = 230 (48%) oropharynx n = 140 (29%) combined
OC/OP = 77%
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 251): concomitant CT (mitomycin C as an iv infusion over at least 15 min in a
dose of 15 mg/m2. To reduce the risk of extravasation of MMC, it was recommended not to
inject in cubital veins or below the wrist. MMC was administered at the end of the first week
of RT. On the day of drug treatment, RT was given first and the interval between RT and
MMC was at least 2 hours.) + RT (conventional)
Gr B (n = 227): RT (conventional) alone
No patients received surgery. All were advanced tumours, but treatment was with curative
intent
RT for both groups consisted of external RT given by Co-60 or linear accelerator. The
treatment was given by photons or electrons at a dose of 0.5-5 Gy per minute. The fields
covering the clinical target volume (CTV) included the primary tumour in T- andN-position,
allowing a margin of approximately 2 cm (at least 1 cm, depending on size of tumour and
technique used). In cases of involved palpable lymph nodes, the neighbouring (more caudal)
lymph node group was included in the CTV i.e at least 3 cm distally from the lower part of
the palpable lymph node. The fields covering the gross tumour volume (GTV) included only
macroscopic tumour tissue i.e the tumour and possible lymph node metastases with at least a
1 cm margin. All fields were treated each time. RT was administered in 5 fractions/week, to
a centrally absorbed dose of 2 Gy per fraction. The CTV dose was at least 46 Gy. The spinal
cord region did not receive more than 50 Gy total. The GTV received a minimum dose of
66 Gy in 33 fractions
Outcomes Limited data available not in a useable form to include in ’Analyses’, OS data taken from
Pignon 2009
Complications of treatment - toxicity/adverse events
Notes Sample size calculation given - “planned to accrue 1000 patients based on the following
assumptions. If the true frequency of persistent locoregional tumour control was changed by
15% (from 45 to 60%), the probability calculated by a double sided test, was greater than 99%
for a significant difference (P < 0.05). If the true frequency of tumour control was changed
by 10% (from 45 to 55%) the probability of observing a significant difference (P < 0.05) was
greater than 85%.” Study randomised 558 patients and analysed data from 478
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation was stratified by tumour lo-
calisation (oropharynx, hypopharynx, larynx,
buccal mucosa, other oral cavity), tumour
stage (T1-2 vs T3-4) nodal stage (N0 vs N1-
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3), institution. Generation of randomisation
sequence and concealment were performed
centrally using a random permuted block size
of 4 with a 1:1 ratio between arms
Allocation concealment? Yes The randomisation results were returned to
the investigator with a working day by fax
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 3/10 centres not included in analysis (1 centre
randomised only 1patientwhodied pre-treat-
ment), 2 centres provided insufficient data (n
= 13 & 66 patients respectively). This exclu-
sion is unlikely to have influenced the results
of the study
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Yes
Gupta 2001
Methods Randomised controlled trial conducted in Manchester, UK
Single centre (Christie Hospital, Manchester)
Recruitment period: 1978-1984
Funding source: government and industry
Trial identification number: MANCHESTER
Participants Inclusion: patients recruited with advanced, histologically confirmed, squamous cell carci-
noma of head & neck (T3 - T4, including oral cavity and oropharynx cancer patients n =
173) (consisting of 22% OC, 33% OP - combined 55% OC/OP)
Exclusion: aged > 75 years, poor general condition, previous treatment
Total 313 patients randomised
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 156): 100 mg/m2 of methotrexate by IV the first dose 24 hours prior to RT, then
on day 14 of the 3-week course of RT
Gr B (n = 157): RT alone
RT for both groups comprised Megavoltage RT using a 4 MeV linear accelerator in 15-16
fractions over 3 weeks. The radiation dose prescribed was that considered at the Institute to
be the level of tolerance of the volume irradiated and was not reduced because of the addition
of CT
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271 (87%) patients received dose equal or in excess of 50 Gy in 15-16 fractions over 3 weeks
Outcomes Total mortality* IPD
Disease free survival (presented as Kaplan-Meier estimates) for OC andOP. Follow-up period:
5 years
Total mortality (overall survival presented as Kaplan-Meier estimates) OC and OP. Follow-
up period: 5 years
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data: log [hazard ratio] SE calculated
from data presented in Kaplan-Meier estimates for primary disease free survival
Death or recurrent disease free survival: log [hazard ratio] SE calculated from data presented
in Kaplan-Meier estimates for cancer specific free survival
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Randomly allocated” - stratified for both site
of disease and stage of disease
Allocation concealment? Unclear Insufficient information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes No withdrawals/drop outs - all patients ran-
domised accounted for and included in the
analyses
Free of selective reporting? Yes Primary and secondary outcomes described
and reported
Free of other bias? Yes
Gupta 2009
Methods Randomised controlled trial conducted in: India
Number of centres:1
Recruitment period: March 2005 to July 2007
Funding source: not stated
Participants Inclusion: biopsy proven, previously untreated St III or IV squamous cell carcinoma of
oropharynx with measurable disease, ECOG performance status 0-1, neutrophils > 1500/
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mm3, platelets > 100,000/mm3 , total bilirubin < 1.25 x upper limit of normal, creatinine
clearance > 50 ml/min
Eclusion: ECOG performance status > 2, treatment protocol changed during study, previous
chemotherapy or radiotherapy, any abnormal organ function
105 randomised
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 48): induction PF: 2-3 cycles of 3 weekly cisplatin 75 mg/m2 on Day 1, + 5-FU
800 mg/m2 IV over 9 hours on days 1-3, followed by concomitant chemoradiotherapy 1.8-
2.2 Gy/fraction, 5 fraction/week to total dose 65-70 Gy + weekly cisplatin 35 mg/m2 IV
Gr B (n = 57): concomitant chemoradiotherapy 1.8 - 2.2 Gy/fraction, 5 fraction/week to
total dose 65-70 Gy + weekly cisplatin 35 mg/m2 IV
Outcomes Tumour response, acute toxicity, disease free survival
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Stratified by age, stage, ECOG performance
status then ’randomised’. No details of se-
quence generation method described
Allocation concealment? Unclear Allocation concealment not described
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear 18/48 = 38% excluded fromGr A (8 protocol
violations during induction CT, 2 took com-
plementarymedications, 3 had RT elsewhere,
3 went straight to surgery)
11/57 = 19% excluded from control arm (2
died, 1 had TB, 4 protocol violations, 3 took
herbal medications)
Free of selective reporting? Yes Appears that planned outcomeswere reported
Free of other bias? Yes
98Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Haddad 1996
Methods Randomised controlled trial conducted in: Creteil, France
Number of centres: 2
Recruitment period: April 1987 to October 1992
Participants Inclusion: adults with inoperable squamous cell carcinoma of oral cavity, oropharynx, larynx
or hypopharynx
Exclusion: previous treatment, tumourT1N0, presence ofmetastases, Karnofsky performance
status < 70%, contraindications to chemotherapy
67 randomised, 56 analysed (28 in each group)
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
All patients received induction chemotherapy at baseline, comprising 3 cycles of 2-hour
continuous infusion cisplatin + 5 day infusion 5-FU on days 1, 22 and 43
Gr A (n = 34): starting day 64, RT 1.8 Gy daily, 5x/week to total dose of 70 Gy + 2-hour
infusion cisplatin 50 mg/m2 + 5 mg/kg 5-FU IM 3x/week, repeated on days 79, 93 & 107
after the start of induction CT
Gr B (n = 33): RT alone - 1.8 Gy daily, 9 Gy/week for 8 weeks to total dose of 70 Gy
Outcomes Total mortality, locoregional control
Notes Original paper in French - risk of bias information based on information translated by J-H
Vergnes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisation stratified by stage (1&2 vs 3&
4), lymph node involvement (N0 vs N1−2 vs
N3), and primary tumour site (OC vs OP vs
L vs HyphP)
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Post-randomisation clearly described and
numbers similar in both groups. In Gr A, 3/
34 died during induction CT, 2/34 refused
further treatment &1/34 protocol violation)
. In Gr B 2/33 died during induction CT, 2/
33 refused further treatment & 1 protocol vi-
olation
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Free of selective reporting? Unclear Little information available
Free of other bias? Unclear Little information available
HNCProg 1987
Methods Randomised controlled trial conducted in: USA
Number of centres: multicentre
Recruitment period: 1978 to 1982
Funding source: contract with National Cancer Institute/National Institutes of Health
Trial identification number: HNCP
Participants Inclusion: adults with stages 2 (pyriform sinus), 3 & 4 (oral cavity, hypopharynx & larynx)
resectable head & neck squamous cell cancers
462 randomised, 443 “assessable”
Interventions Comparison 2: Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy
alone
Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 69): standard care - surgery followed by radiotherapy (S)
Gr B (n = 62): induction CT - 1 cycle cisplatin 100 mg/m2 + bleomycin 15 mg/m2 for 5 days
+ standard care (surgery followed by radiotherapy) (I)
Gr C (n = 61): induction CT+ standard care + subsequent CT -1 cycle cisplatin 100 mg/m2 +
bleomycin 15 mg/m2 for 5 days + standard care + monthly cisplatin 80 mg/m2 for 6 months
(M)
Outcomes Disease free survival
Notes Data taken from the subgroup of oral cavity patients published separately in Jacobs 1990, not
Pignon 2000
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Stratified by institution, primary tumour site
and stage and randomised to treatment at a
central site
Allocation concealment? Yes Randomisation was done by a phone call to a
central office
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
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Incomplete outcome data addressed? Yes Stated that “patients were analysed in the
group to which they were randomised even
if they did not complete the entire treatment
program, except for one patient”. Data used
are from Jacobs 1990, a subset analysis
Free of selective reporting? Yes Planned outcomes clearly defined and analy-
ses presented
Free of other bias? Yes
Holoye 1985
Methods Randomised controlled trial conducted in: USA
Number of centres: 3 hospitals
Recruitment period: July 1979 to September 1982
Funding source: not stated
Trial identification number: MCW-1
Participants Inclusion: stage 2 squamous cell carcinoma of pyriform sinus, or stage 3 or 4 SCC of oral
cavity, oropharynx, nasopharynx, nasal cavity , paranasal sinus larynx or hypopharynx
Exclusion: T3 N0 lesions of glottic larynx and stage 3 tonsil cancer, distant metastases, life
expectancy less than 12 months, granulocytes < 2000/mm3, white blood cells < 3500/mm3 ,
platelets < 100,000/mm3 , hepatic disease (edema, ascites, hypoalbuminaemia, raised serum
bilirubin), concurrent malignancy, chronic mental illness, addiction to drugs or alcohol
133 patients screened; 83 randomised, 83 evaluated
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 43): neoadjuvant CT consisted of 4 drugs given over 5 days; bleomycin 10 units in
1000 ml of 5% dextrose in 0.25% saline i.v. over 8 hours for 12 doses over 4 days; cytoxan
200 mg/m2/day i.v. for 5 consecutive days; methotrexate 30 mg/m2/day in 50 ml of 5%
dextrose in water i.v. over no more than 5 mins on days 1 and 5; 5-FU 400 mg/m2/day i.v.
for 5 consecutive days
Patients showing tumour regression underwent second round of CT after 3-week interval
Gr B (n = 40): RT (pre-operative irradiation followed by radical resection of primary tumour
and regional lymph nodes, or primary irradiation with or without lymph node dissection)
Outcomes Tumour response
Survival (Kaplan-Meier)
Disease free survival (Kaplan-Meier)
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data
Study stopped early following advice from statistician
Risk of bias
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Item Authors’ judgement Description
Adequate sequence generation? Unclear No information given
Allocation concealment? Unclear No information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised patients included in analysis
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Yes
Huguenin 2004
Methods Randomised controlled trial conducted in: Switzerland & Italy
Number of centres: 12
Recruitment period: July 1994 to July 2000
Funding source: not stated. States no conflict of interest
Trial identification number: SAKK 10-94
Participants Inclusion: adults aged 20-75, with SCC of H&N, with WHO performance status ≤ 2, with
adequate haematological, renal, cardiovascular and neurological function
Exclusion: those with tumours of nasopharynx or paranasal sinuses, metastatic disease
24 patients randomised, 223 analysed.
Age: Gr A median age 57 years (range 38-74); Gr B median age 53.5 years (range 33-73)
M/F Gr A 101/11; Gr B 89/23
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 112): concomitant CT (cisplatin 20 mg/m2 on 5 days, of weeks 1 and 5) plus RT
Hfx RT, 1.2 Gy twice daily with interfraction interval of 6 hours, 5x/week to a median dose
of 74.4 Gy
Gr B (n = 112): RT Hfx RT (1.2 Gy twice daily with interfraction interval of 6 hours, 5x/
week to a median dose of 74.4 Gy)
Outcomes Total mortality
Time to LR failure
Time to treatment failure
Notes OS data taken from Pignon 2009
Adverse events: acute toxicity (no significant difference between groups)
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “Randomisation was performed using the
minimisation method at the Swiss Institute
for Applied Cancer Research Co-ordination
and was stratified by institution, site of pri-
mary tumour and nodal stage”
Allocation concealment? Yes Randomisation performed centrally
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 4 withdrawals Gr A, protocol violations de-
scribed in detail for each group, intention-to-
treat analysis
Free of selective reporting? Yes
Free of other bias? Yes
Jaulerry 1992
Methods Randomised controlled trial conducted in France
Number of centres: 1
Recruitment period: 1986 to1989
Funding source: unclear
Participants 108 recruited and randomised patients with advanced stage III or IV SCC of the H&N
Patient were recruited from specialist cancer hospital
Adults were recruited with a median age of Gr A: 54 years and Gr B: 56 years
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 55): cisplatin 40 mg/m2/day IV by continuous infusion on Days 2, 3, 4 of each
cycle + 5-FU 600 mg/m2/day IV by continuous infusion on Days 1-5 + vindesine 3 mg/m
2/day IT on days 1 & 5, repeated every 3 weeks for 3 cycles. 3 weeks after end of CT, RT
commenced to the primary tumour and cervical lymph node areas to total dose of 55-70 Gy
in fractions of 1.8 to 2.2 Gy
Gr B (n = 53): RT only of the primary tumour and cervical lymph node areas to total dose of
55-70 Gy in fractions of 1.8 to 2.2 Gy
In both groups patients were re-evaluated by radiotherapist and head & neck surgeon by
103Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Jaulerry 1992 (Continued)
clinical examination, computed tomography, and if necessary, fibroscopic examination under
general anaesthetic. If the regression was judged satisfactory (i.e. > 50%) radiotherapy was
completed to a total tumour dose of 65-75 Gy. If there was a poor response surgery was
performed, otherwise radiotherapy was continued to full dose
Outcomes Survival, tumour response, toxicity
Notes *Total mortality: log [hazard ratio] SE calculated from data provided from Pignon 2000;
based on individual patient data
Presents data from 2 trials. Trial 1 previously published as Brunin 1989 (included in review)
and risk of bias information for Trial 2 below is taken from Brunin 1989 as Jaulerry 1992
states that trial design was same in both studies
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Insufficient information given
Allocation concealment? Unclear Insufficient information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised patients included in the out-
come data used from Pignon 2000
Free of selective reporting? Yes Tumour response, toxicity and overall survival
planned and reported
Free of other bias? Yes
Jeremic 1997
Methods Randomised controlled trial conducted in Yugoslavia
Single centre
Funding source: unknown
Recruitment period: January 1988 -December 1990. The trial stopped in 1990 before patient
accrual had reached its number due to staff relocation
Trial identification: KRAGUJEVAC
Participants 159 patients recruited with histologically confirmed locally advanced, non-metastatic (M0)
, unresectable stage III-IV squamous cell carcinoma of the head and neck including oral
cavity and oropharynx cancer patients. Karnofsky permance status > 50%, age > 18 years and
adequate haematological, renal and hepatic function (parameters specified) with no previous
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treatment
(26 patients with OC 16% and 59 patients with OP, 37% combined OC/OP = 53%)
Patients aged 34-70 years (median 59 years)
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 53): concomitant CT (low dose daily 6 mg/m2 of cisplatin CDPP) plus standard
fraction radiotherapy (70 Gy)
Gr B (n = 53): concomitant CT (low dose daily 25 mg/m2 of carboplatin CBDCA) plus
standard fraction radiotherapy (70 Gy)
Gr C (n = 53): control - standard fraction RT alone (70 Gy)
Carboplatin (CBDCA) is CDDP analogue with similar properties but with less renal, ear, or
neurotoxicity
RT target volume included the primary tumour, the lymph nodes of the neck and supraclav-
icular fossa. The tumour bearing area received 70 Gy and the uninvolved neck and supraclav-
icular nodes 45 Gy. Daily fractions of 1.8 Gy
Outcomes Total mortality* IPD (Gr A and Gr B versus Gr C)
Toxicity/adverse events - acute and late high-grade toxicity
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000;
Sample size calculation given: 85 patients were thought to be required per arm to detect a
difference in the 3-year survival rate of 20% with a significance level of P,0.05 and a power of
0.8 assuming a baseline survival rate of 25%. However study closed to accrual in December
1990 before these numbers were reached. The 159 participants were sufficient to show a 25%
difference in survival rate between groups
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Patients were randomised” - no further de-
tails given
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All patients randomised are accounted for and
included in analysis
Free of selective reporting? Yes Planned outcomes clearly described and re-
ported
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Free of other bias? Yes
Jeremic 2000
Methods Randomised controlled trial conducted in: Yugoslavia
Number of centres: 1
Recruitment period: January 1991 to March 1993
Funding source: government. Grants-in-Aid for Scientific Research (B)10557087, 11470190,
and 11877152 from the Japanese Ministry of Education, Science, and Culture
Trial identification number: KRAGUJEVAC2
Participants Inclusion: adults with histologically confirmed, locally advanced, non-metastatic, (Stage 3 or
4, M0) squamous cell carcinoma of the nasopharynx, oropharynx, oral cavity, or larynx, with
Karnofsky performance status >/= 50%, wbc > 4000, platelets > 100,000, creatinine < 1.5
mg/dl, bilirubin < 1.5 mg/dl, a measurable tumour mass and no previous treatment
Exclusion: serious concomitant disease, history of previous or concurrent cancer, tumours of
nasal cavity, paranasal sinuses, or salivary gland
154 patients recruited, 130 randomised (27/130 patients with OC 21% and 48/130 patients
with OP, 37% combined OC/OP = 58%)
(Withdrawals and drop outs accounted for). Patients aged 39-70 years, median 60 years
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 65): concomitant CRT - low-dose daily 6mg/m2 of cisplatin (CDDP) as IV bolus in
the interfraction interval on every RT treatment day plus Hyperfractionated (Hfx) radiation
therapy - 2 daily fractions of 1.1 Gy with interfraction interval of 4.5-6 hours
Gr B (n = 65): hyperfractionated radiotherapy alone 2 daily fractions of 1.1 Gy with inter-
fraction interval of 4.5-6 hours
RT target volume included the primary tumour, the lymph nodes of the neck and supraclav-
icular fossa. The primary tumour and upper neck nodes were treated with 2 lateral opposed
fields with 50.6 Gy in 46 fractions in 23 treatment days over 4.5 weeks, after which reduced
lateral fields were used to boost the dose to the primary tumour and involved nodes to 77
Gy in 70 fractions in 35 treatment days over 7 weeks. The dose to the spinal cord was kept
at 50.6 Gy. The uninvolved lower neck and supraclavicular nodes were treated with a single
anterior field and with a total dose of 50.6 Gy
In case of acute high-grade (> grade 3) toxicity, patients temporarily interrupted their treatment
for up to 2 weeks, but no dose reductions (for either Hfx RT or CDDP) were allowed. Even
in cases of treatment interruptions (for both Hfx RT and CDDP), subsequent treatment was
not modified
Outcomes Disease free survival (presented as Kaplan-Meier estimates). Follow-up period: 8 years
Total mortality (overall survival presented as Kaplan-Meier estimates). Follow-up period: 8
years
Toxicity/adverse events - acute and late toxicity
Notes OS data available from Pignon 2009
Log [hazard ratio] SE calculated from data presented in Kaplan-Meier estimates
Requested info from authors on randomisation - no response
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Sample size calculation given - “a total of 129 patients in the 2 treatment groups were thought
to be required to detect a difference in the 2-year survival rate of 25% with a significance level
of P < 0.05 and a power of 0.8, assuming a baseline survival rate of 45%”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Randomised” - no details given
Allocation concealment? Unclear No information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised participants included in the
analyses
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Yes
Knowlton 1975
Methods Randomised controlled trial conducted in: USA
Number of centres: 1
Recruitment period: not stated
Funding source: not stated
Participants 96 patients with biopsy proven advanced squamous cell carcinoma of the head & neck
Age: median 57 years
M/F: Gr A 40/8; Gr B 35/13
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Phase 1
Gr A (n = 28): neoadjuvant CT (0.2 mg/kg methotrexate IV per day for 5 days) + RT (4 or 6
MeV liner accelerations or a 2 MeV Van de Graaf treatment 5 days/week. Minimum tumour
dose 6000-6600 rads in 6-6.5 weeks at rate of 1000 rads/weekly)
Gr B (n = 28): RT (4 or 6 MeV liner accelerations or a 2MeV Van de Graaf treatment 5 days/
week. Minimum tumour dose 6000-6600 rads in 6-6.5 weeks at rate of 1000 rads/weekly)
After 56 patients randomised it was decided to increase chemotherapy dose
Phase 2
Gr A (n = 20): high dose neoadjuvant CT (240 mg/m2 methotrexate IV per day on Days 1, 5
& 9, followed by leucovorin 75 mg/m2 IV over 6-hour period, then every 6 hours as 15 mg/
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Knowlton 1975 (Continued)
m2 for 4 doses ) + RT (4 or 6 MeV linear accelerations or a 2 MeV Van de Graaf treatment
5 days/week. Minimum tumour dose 6000-6600 rads in 6-6.5 weeks at rate of 1000 rads/
week)
Gr B (n = 20): RT (4 or 6 MeV liner accelerations or a 2MeV Van de Graaf treatment 5 days/
week. Minimum tumour dose 6000-6600 rads in 6-6.5 weeks at rate of 1000 rads/week)
Outcomes Overall survival, toxicity
Notes Adverse events: no difference in groups reported, but Table IV shows difference between
groups for phase 2 toxicity
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Patients were randomised” no details given
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised participants included in the
analysis
Free of selective reporting? Yes
Free of other bias? Unclear Little information provided but chemother-
apy doses increased after first 56 participants
randomised. In phase 2, there was shorter
follow-up and Gr A study participants had
higher toxicity
Krishnamurthi 1990
Methods Randomised controlled trial conducted in: India
Number of centres: 1
Recruitment period: January 1984 to August 1987
Funding source: grant fromDepartment of Science&Tecnology,Government of India, under
Project number 1/37/82 - STP - III
Participants Inclusion: T3 -T4histologically confirmed squamous cell carcinoma of buccalmucosa with or
without cervical nodemetastases, except for thosewith fixedN3masses outside submandibular
region. Those with external fungation, muscle invasion were eligible
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Exclusion: distant metastases, total trismus
114 randomised, 101 evaluated
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 37): pepleomycin (5 mg IV bolus in 10 ml normal saline given 24 hours prior to
RT) + RT (minimum tumour dose of 2.5 Gy per fraction 3 times per week to total dose of
55-60 Gy)
Gr B (n = 38): placebo + RT (minimum tumour dose of 2.5 Gy per fraction 3 times per week
to total dose of 55-60 Gy) + hyperthermia (deep tissue heating to 42º C using a capacitive
unit generating radiofrequency radiations of 8 MHz)
Gr C (n = 39): pepleomycin (5 mg IV bolus in 10 ml normal saline given 24 hours prior to
RT) + RT (minimum tumour dose of 2.5 Gy per fraction 3 times per week to total dose of
55-60 Gy ) + hyperthermia
Outcomes Locoregional response
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “UsedMRC sealed envelope technique” refer-
ring to the method used by Bradford Hill in
1947 trial of streptomycin for tuberculosis. A
table of random numbers was used to allocate
participants to groups
Allocation concealment? Yes Allocation was concealed in sealed envelopes
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Reasons for post-randomisation exclusions
given and numbers small and similar in each
group (6/37, 4/38 & 3/36 excluded in each
group - reasons given)
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Yes
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Kumar 1996
Methods Randomised controlled trial conducted in: India
Number of centres: 1
Recruitment period: April 1990 to March 1991
Funding source: not stated
Trial identification number: Lucknow1
Participants 38 participants with previously untreated inoperable primary malignancy of the oral cavity
(n = 9, 24%), oropharynx (n = 16, 42%), laryngopharynx (n = 13)
Exclusion: metastatic disease, deranged liver/kidney function, Karnofsky performance status
< 60
Mean age (sd): Gr A 52.3 years (10.4); Gr B 53.8 years (12.5)
M/F: Gr A 19/2; Gr B 14/3
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 21): induction CT (cyclophosphamide 600 mg/m2 and methotrexate 60 mg/m2 i.
v. bolus on days 1 and 14, followed by concomitant 5-FU 600 mg/m2 i.v. bolus on days 28,
35, 42, 49 followed by RT- 35 fractions over 7 weeks (delivered by shrinking field technique)
to total dose of 70 Gy
Gr B (n = 17): RT- 35 fractions over 7 weeks (delivered by shrinking field technique) to total
dose of 70 Gy
Outcomes Tumour response, progression of disease, acute morbidity, late morbidity
Notes OS data taken from Pignon 2009, Group A received both induction and concomitant che-
motherapy
Adverse events: deaths due to treatment (Gr A n = 7; Gr B n = 0)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “Randomised using a table of random digits”
Allocation concealment? Unclear Not described
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised patients accounted for in anal-
ysis
Free of selective reporting? Yes
Free of other bias? Yes
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Lam 2001
Methods Randomised controlled trial conducted in Hong Kong
Single centre
Recruitment period: 1993-1995
Funding source: unknown
Participants Inclusion: adults with Stage 3 or 4 (T2-T4 N0-N3, M0) squamous cell carcinoma of oral
cavity, oropharynx, hypopharynx, or larynx with no distant metastases, who were undergoing
planned resection
65 patients randomised, 63 evaluated
32% of sample with oral cavity, 21% oropharynx = 53% combined OC/OP
Interventions Comparison 2: Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy
alone
Gr A (n = 31): prior to surgery treated with levamisole 50 mg 3 times/day for 3 days (repeated
every 2 weeks in case surgery postponed). Adjuvant post-operative chemotherapy with lev-
amisole and UFT (futraful & uracil) was commenced in the third week after surgery. Each
cycle included levamisole 50 mg 3 times/day from day 1-3 and UFT 200 mg 3 times/day
from day 8-14. The cycle was repeated every 2 weeks with no treatment break and lasted for
1 year or until tumour recurrence (n = 31)
Gr B (n = 34): control - surgery no chemotherapy (n = 34)
All patients received curative surgical treatment.
Outcomes Overall survival
Notes Sample size calculation given - “the sample size was estimated to be 65 cases, according to
the tumour response rate to UFT in phase II trials of head and neck cancers and the survival
benefit of levamisole/fluorouracil in colorectal cancer (α value = 0.05 and β= 0.2)”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisation is stratified by tumour site,
stage & prior radiotherapy. Generation of al-
location sequence is unclear
Allocation concealment? Yes Allocation was revealed by drawing sealed en-
velopes
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 2 patients (6%) from Gr A excluded from
analysis due to post-operative death
Free of selective reporting? Yes Survival outcome planned and reported
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Lam 2001 (Continued)
Free of other bias? Yes
Laramore 1992
Methods Randomised controlled trial conducted in USA
Multicentre. Intergroup study IG-0034 - co-operative groups participating: Radiation Ther-
apy Oncology Group (RTOG), South West Oncology Group (SWOG), Cancer and
Leukaemia Group B (CALGB), Northern California Oncology Group (NCOG) and South
East Group (SEG)
Recruitment period: January 1985-January 1990
Funding source: USA government
Trial identification: Int 0034
Participants Inclusion: adults, aged over 18 years, with histologically confirmed, resectable, squamous cell
carcinoma of head & neck, with primary tumour sites in oral cavity, oropharynx & larynx.
Karnofsky performance status >/= 60%, WBC >/= 4000, platelets >/= 100,000, creatinine
clearance > 60 ml/min
Exclusion: distant metastases, prior or concurrent malignancy, prior treatment with radio-
therapy, chemotherapy or surgery
696 patients were registered, 499 patients were randomised, 448 were evaluable Gr A 223, Gr
B 225. Some 43 evaluable patients were carried over from the original RTOG 83-22 trial. 122
patients with oral cavity cancer (27%) and 113 patients with oropharyngeal cancer (25%),
combined OC/OP = 52%
Interventions Comparison 2: Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy
alone
All patients in both groups underwent total surgical resection of all visible and palpable disease,
then were staged according to primary tumour site, pathological stage, tumour margin status,
risk factors (high risk defined as extracapsular nodal extension,surgical margins less than 5
mm or carcinoma in situ at margins) and low risk absence of these. Patients were randomised
within 3 weeks of surgery and post-operative treatment started within 4 weeks of surgery
Gr A (n = 223): post-operative CT (cisplatin 100 mg/m2) on day 1 with infusion of 5-FU at
1 g/m2 over 24 hours on days 1-5 with the sequence repeated every 21 days plus radiotherapy
- 50-54 Gy to low risk treatment volumes and 60 Gy to high risk volumes, delivered at 1.8-
2.0 Gy per fraction on a 5 day-a-week basis
Gr B (n = 225): control - post-operative radiotherapy 50-54 Gy to low risk treatment volumes
and 60 Gy to high risk volumes, delivered at 1.8-2.0 Gy per fraction on a 5 day-a-week basis
Radiotherapy was initiated 2-3 weeks after completion of the preceding modality
Outcomes Disease free survival. Follow-up period: 4 years
Total mortality. Follow-up period: 4 years
Total mortality* IPD
Recurrence (locoregional recurrence). Follow-up period: 4 years
Complications of treatment - toxicity/adverse events
Notes *Some data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from
data provided from Pignon 2000; based on IPD: Gr A: 161/251 and control Gr B: 163/248
(events/patients)
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Laramore 1992 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Patients were stratified by tumour location,
pathological staging and surgical margins.
Then randomisation was performed by head-
quarters office. Generation of allocation se-
quence is adequate (author personal commu-
nication)
Allocation concealment? Yes Allocation concealment is adequate (author
personal communication)
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear Of the 51 randomised patients excluded from
the analyses, reasons are given for 42 but pa-
per does not state how many patients were
randomised to each group and how many of
each group were then included in analysis
Free of selective reporting? Yes Tumour response, overall survival, patterns of
recurrence described and reported
Free of other bias? Yes No additional threats to validity identified
Le 2006
Methods Randomised controlled trial conducted in USA
Single centre
Recruitment period: July 1996- June 2001
Funding source: government - Public Health Sevice Grant CA67166 awarded by theNational
Cancer Institute
Participants Inclusion: adults aged more than 17 years with resectable stage 4 squamous cell carcinoma
of the head & neck with metastases to cervical lymph nodes. ECOG performance status 0-
2, no prior radiotherapy or chemotherapy, adequate bone marrow, hepatic & renal function,
no concurrent malignancy, no prior malignancy within 5 years
Original report on 62 patients where OP + OC = 69% of H&N SCC. However, authors
provided IPD data on 43 oropharynx (n = 39) and oral cavity patients (n = 4). Gr A n = 25/
33 OC/OP only Gr B n = 18/29 OC/OP only
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Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
2 cycles of induction chemotherapy with cisplatin 100 mg/m2/day on days 1 & 22 + contin-
uous infusion 5-FU (1000 mg/m2/day) for 120 hours/cycle on days 1 & 22
Gr A (n = 33): induction CT + concomitant CRT A: 2 cycles of induction chemotherapy
with tirapazamine* prior to cisplatin 100 mg/m2/day on days 1 & 22 + continuous infusion
5-FU (1000 mg/m2/day) for 120 hours/cycle on days 1 & 22. Followed by 2 more cycles
of concomitant chemoradiotherapy (tirapazamine* 1-2 hours prior to cisplatin 20 mg/m2/
day on days 43, 45, 47 & 71, 73, 75 + continuous infusion 5-FU (600 mg/m2/day) for 120
hours/cycle on days 43 to 47 & 71 to 75) together with conventional RT administered within
3 hours of the end of tirapazamine infusion - dose of the parallel opposed fields at the central
axis was 2 Gy per fraction per day given 5 days per week up to a total dose of 66-70 Gy to the
areas of the macroscopic tumour. The dose to the supraclavical region was 50 Gy prescribed
at a depth of 3 cm and delivered in 25 fractions
*The first 4 patients had tirapazamine (TPZ) induction doses of 300 mg/m2 and 160 mg/
m2 during concomitant chemoradiotherapy (Level 1). Next 4 patients received 330 mg/m2
TPZ induction and 260 mg/m2 concomitant (Level 2). Remaining 25 patients had 300 mg/
m2 TPZ during induction phase and 220 mg/m2 during concomitant phase (Level 3 n = 25)
Gr B (n = 29): induction CT (PF regimen) + concomitant CRT B: 2 cycles of induction
chemotherapy with cisplatin 100 mg/m2/day on days 1 & 22 + continuous infusion 5-FU
(1000 mg/m2/day) for 120 hours/cycle on days 1 & 22. Then 2 more cycles concomitant
chemoradiotherapy consisting of cisplatin at a dose of 20 mg /m2 given 3 times per week
(Monday, Wednesday and Friday) and continuous infusion 5-FU at a dose of 600 mg /m2
for 96 hours per cycle in weeks 1 and 5 of RT
Patients who did achieve a complete response at 50 Gy underwent surgical resection and those
achieving CR at the primary site and in the neck completed RT to a total dose of 66 Gy to
the primary site and involved lymph nodes
Outcomes Total mortality**IPD (Gr A versus Gr B) over 5 years
Toxicity - acute toxicity
Notes **IP provided by author and used to calculate log [hazard ratio] SE for site specific cancers i.
e. OP&OC and OP alone
Phase II RCT - Primary endpoint was complete lymph node response
Sample size calculation given “Assuming a complete lymph node response rate of 50% in
the control arm, we estimated that 60 patient would yield 80% power to detect a 32%
improvement rate with TPZ with a 2-sided level of significance = 0.05”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Stratified by tumour site, nodal status (N0
vs N2-3), mean tumour oxygen tension (</
= 12 mm vs > 12mm). Randomisation used
permuted block procedure
Allocation concealment? Unclear No information given
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Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Nnot mentioned
Incomplete outcome data addressed? Yes All randomised participants (except one who
withdrew prior to any treatment) were in-
cluded in analyses
Free of selective reporting? Yes Primary outcome of lymphnode response and
secondary outcome of survival and toxicity
planned and reported
Free of other bias? Unclear There were more patients with T3 and T4
tumours in the non-TPZ arm and this dif-
ference was statistically significant (P = 0.03)
, and more patients with N3 Lymph nodes in
the TPZ arm although difference not statisti-
cally significant (P = 0.35)
Lewin 1997
Methods Randomised controlled trial conducted in Norway, Denmark and Sweden
Multicentre centre (18 Scandinavian centres)
Recruitment period: 1986-1991
Funding source: government/charity - Swedish Cancer Society
Trial identification number: SHNG-85
Participants Inclusion: adults with squamous cell carcinoma of oral cavity, oropharynx, hypopharynx,
larynx, stages 2-4 (some variation between centres), both resectable & unresectable, Zubrod
Performance Status 0-2, life expectancy >/= 3 months
Exclusion: those with clinical evidence of distant metastases, or any medical condition that is
contraindication to chemotherapy
461 patients were randomised, 423 met the inclusion criteria, 374 (81%) were evaluable
(175/423 (41%) with oral cavity and 144 (34%) with oropharynx, combine OC/OP = 75%)
356 patients had non-resectable cancer and 67 had resectable cancer of the OC
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 233): neoadjuvant CT - cisplatin 100 mg/m2 IV on day 1 + 5-FU 1000/m2/day
on days 1-5, repeated every 21 days for 3 cycles followed by radiotherapy 64-70 Gy, 2 Gy per
fraction 5 times per week. A few patients regardless of treatment arm received a boost dose of
brachytherapy to tumours of the OC
Gr B (n = 228): RT alone - 64-70 Gy, 2 Gy per fraction 5 times per week. A few patients
regardless of treatment arm received a boost dose of brachytherapy to tumours of the OC
Tumour response evaluation was performed 1-2 months after RT. Surgery was considered in
cases with resectable residual tumour
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Outcomes Total mortality* IPD
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data
Sample size calculation:“to detect a survival benefit of 15% with a power of 80% 320 patients
would be required....... a p value of 5% was considered significant”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation process: stratified by primary
site, resectability, sex and institution. The ran-
dom permuted blocks methods was used for
randomisation
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear 374/461 (81%) of those randomised are
evaluable. 38/461 (8%) found to be ineligi-
ble after randomisation, and further 49/461
(11%) not evaluable. Paper states that “Many
patients were lost to clinical follow-up after 2
months”
Free of selective reporting? Yes Tumour response 2 months after RT and sur-
vival outcomes planned and reported
Free of other bias? Unclear “Slight imbalance between treatment arms in
the different subsites due to misclassification”
OC patients 54% in Gr A & 46% in Gr B.
?other imbalances ext between groups - no
table of baseline characteristics/group given
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Licitra 2003
Methods Randomised controlled trial performed in Italy
Multicentre trial (4 centres)
Recruitment period: June 1989-December 1999
Funding source: external but source unknown
Participants Inclusion: adults with biopsy-proven, resectable, stage T2-T4, N0-N2, M0 - previously un-
treated oral cavity SCC. T2 lesions were included if > 3 cm. Tumours extending into orophar-
ynx were acceptable, provided that the lesion was contained in the oral cavity by more than
50%
198 randomised 191 evaluable
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 99): surgery plus chemotherapy - cisplatin 100 mg/m2 and fluorouracil 1000 mg/m
2 (5-FU) given as 120-hour infusion, for 3 cycles every 21 days. Patients with either progressive
or stable disease after 2 cycles were addressed for surgical resection. Patients received the third
cycle only when a response ≥ 50% tumour regression was observed
Gr B (n = 99): control - surgery alone (n = 99, evaluable patients n = 95)
Surgical choice left to judgement of clinician. Macroscopic safe margin of 1.5 cm mandatory
After surgical resection, high risk patients received post-operative radiotherapy, started 4-5
weeks after surgery (13/63)
Outcomes Disease free survival. Follow-up period: 5 years
Total mortality. Follow-up period: 5 years
Disease-related mortality. Follow-up period: 5 years
Recurrent disease - primary site, new primary site, distant metastases. Follow-up period: 5
years
Length of hospital stay
Complications of treatment - toxicity/adverse events (morbidity)
Notes Log [hazard ratio] SE calculated from data presented in Kaplan-Meier estimates
Sample size calculation given: “The required sample size for the trial was 258 patients equally
divided in the 2 study arms. This was calculated by using the Freedman’s formula, based on
the following assumptions: 50% 5 year risk of cancer recurrence in the control group, 5%
type 1 error probability level (for a 2 sided test) and 90% power to detect a 20% absolute risk
reduction in the treatment arm.” Because of difficult patient accrual, the study was closed
after enrolling 198 patients. Study power thus diminished to 78%. the authors note that “the
lack of statistical significance was not because of low power”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “Randomly assigned ... after stratification by
institution and nodal stage (N0 vs N1-3)”
Allocation concealment? Yes Randomisation was performed on the phone
by central operations office in accordance
with stratified lists from permuted blocks of
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Licitra 2003 (Continued)
length 4
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Post-randomisation withdrawals and exclu-
sions clearly described for each group. 96% of
those randomised are evaluable
Free of selective reporting? Yes Planned outcomes clearly described and re-
ported
Free of other bias? Yes
Luboinski 1985
Methods Randomised controlled trial performed in France
Single centre trial. Part of the EORTC Head & Neck Group. GETTEC neo1
Recruitment period: not stated
Funding source: not stated
Participants Inclusion: patients with tumours of the floor of mouth (100% oral cavity) with extension to
the mandible or with a borderline or more than 2 cm with the mandible. Tumour stage T2-
T4, N0-N3 (n = 126)
Exclusion: patients with prior treatment or severe disease requiring major reconstruction
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 64): neoadjuvant intra-arterial chemotherapy, 15 mg of bleomycin daily for 12
days by continuous infusion and 1 mg of vincristine on days 1, 5 and 9 in 1-hour infusions +
surgery alone or with post-operative radiotherapy (determined by the quality of the margins
and extension to cervical nodes)
Gr B (n = 62): control - surgery alone or with post-operative radiotherapy (determined by
the quality of the margins and extension to cervical nodes)
CT was given intra-arterially on 1 or both sides depending on extent of tumour
Surgery was performed 10-21 days after completion of chemotherapy. It consisted of com-
posite resection with or without interruption of the mandible. Margins were large as possible.
Patients classified as N0 were treated by bilateral suprahyoid neck dissection. A radical neck
dissection was undertaken if histologically confirmed node metastasis. For patients with ho-
molateral node involvement a radical neck dissection was performed with ipsilateral modified
neck dissection
Radiotherapy was an optional treatment, performed 3-6 weeks post-operatively determined
by the quality of the margins and extension to cervical nodes (data not presented by +/-
radiotherapy treatment)
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Luboinski 1985 (Continued)
Outcomes Overall survival
Notes Radiotherapy is an optional treatment for non-responders
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No details given
Allocation concealment? Unclear No information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear 74% of those randomised actually received IA
chemotherapy. Not clear how many partici-
pants were included in the outcome assess-
ments
Free of selective reporting? Unclear Preliminary results only reported. Unclear as
to which were planned primary or secondary
outcome measures
Free of other bias? Unclear Considerable variation in the treatment
within each group
Maipang 1995
Methods Randomised controlled trial performed in Thailand
Single centre trial - Songklangarind Hospital a referral centre for southern Thailand
Recruitment period: October 1988 - June 1993
Funding source: Thai government
Trial identification: Songkhla
Participants Inclusion: adults aged less than 75 years with histologically proven squamous cell carcinoma
of oral cavity, oropharynx, hypopharynx, or larynx, with ECOG performance status of 0-
2, adequate renal, hepatic & bone marrow function (parameters specified), stage 3-4 disease
with resectable tumour, free of infection & distant metastases, no other primary cancer within
5 years, available for long term follow-up
Exclusion: tumours of nasopharynx and paranasal sinuses
54 patients randomised 76% OC, 9% OP, combined OC/OP = 85%
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Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 30): neoadjuvant (induction) chemotherapy with cisplatin 20 mg/m2 a 2-hour
continuous intravenous infusion on days 1-5, bleomycin 10mg/m2/day was given as a contin-
uous infusion from days 3-7. On days 15 and 22, methotrexate 40 mg/m2 was administered
intravenously. A second induction cycle started on day 29. Chemotherapy was followed by
surgery as per pre-CT plan, and then patients had post-operative radiotherapy within 6 weeks
- 6000 rads to primary tumour and 4500 rads to nodes
Gr B (n = 24): control - standard treatment of surgery followed by post-operative radiotherapy
- 6000 rads to primary tumour and 4500 rads to nodes
The extent of surgery was determined prior to chemotherapy and consisted of ipsilateral (and/
or contralateral) neck dissection and resection of the primary tumour Reconstruction was
performed by local skin flap, myocutaneous flap, or microvascular free flap
Outcomes Total mortality* IPD
Notes *Some data supplied from Pignon 2000
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Randomly allocated” - no details given
Allocation concealment? Unclear No information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised patients included in analyses
Free of selective reporting? Yes Tumour response and survival outcomes
planned and reported
Free of other bias? Yes
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Marechal 1987
Methods Randomised controlled trial conducted in: France
Number of centres: 1
Recruitment period: not stated
Funding source: grants from FNLCC & ’Ligue Departmentate de L’Aube’
Participants Inclusion:males, with previously untreated unresectable, biopsy proven, stage 3 or 4 squamous
cell carcinoma of head & neck, an evaluable/measurable tumour, life expectancy > 2 months,
Karnofsky performance status > 40%, WBC > 4000/mm3 , platelets > 100,000/mm3 , serum
creatinine < 130 µmol/l
136 randomised, 117 evaluated
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 69): day 1 hydration and diuresis protocol followed by cisplatin 100 mg/m2 IV as
bolus, 3 courses at 3 week intervals
Gr B (n = 67): etoposide 100 mg/m2 orally days 1-5 and cisplatin 100 mg/m2 on day 4,
repeated at 3 week intervals
108 of the 136 participants underwent further radiotherapy. Details not provided
Outcomes Overall survival, tumour response, toxicity, median survival
Notes Sample size calculation given: “the aim of the trial was to demonstrate a 205 superiority of
Group b (cisplatin-etoposide) compared to Group A (cisplatin alone) giving and error of the
first kind of α = 0.05 and an error of the second kind of β = 0.2 the target sample size was n
= 64 patients for each group”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Stratified by primary tumour site, presence/
absence of associated tumour, tumour stage
(t1-2 vs T3-4), and nodal stage (N0-1 vs N2-
3).Nodetails of sequence generationmethods
given
Allocation concealment? Unclear No information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 9 excluded from Gr A (2 deaths & 7 severe
toxicity) and 10 excluded fromGr B (8 deaths
& 2 ’other’), unlikely to have resulted in bias
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Marechal 1987 (Continued)
Free of selective reporting? Yes Tumour response, toxicity, and overall sur-
vival reported
Free of other bias? Yes No other threats to validity identified
Mazeron 1992
Methods Randomised controlled trial performed in France
Multicentre trial (2 centres) specialist department/centres within general hospital
Recruitment period: December 1982 - October 1986
Funding source: unknown
Participants Inclusion: biopsy proven squamous cell carcinoma of the oropharynx or oral cavity without
metastases
Exclusion: stage 1 disease, presence of distant metastases, previous or concurrent malignancy,
prior treatment, contraindications to chemotherapy, Karnofsky performance status </= 60%
131 randomised, 116 evaluable
Oral cavity cancer patients 43/116 (37%); oropharyngeal cancer patients 73/116 (63%);
combined OC/OP = 100%
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 63): neoadjuvant CT followed by LRT: bleomycin 10 mg/m2/day as a continuous
infusion from day 1-5, methotrexate 120 mg/m2 as a 2-hour continuous infusion followed
24 hours later by folinic acid, 10 mg orally every 6 hours for 24 hours. 5-FU, 600 mg/m2, was
given as a short intravenous infusion 2 hours after methotrexate on day 2. Cisplatin 120 mg/
m2 was administered as a 2-hour continuous infusion on day 4 with appropriate hydration
infusion and antiemetics. The chemotherapy cycle was repeated on days 29 and 57. LRT RT
+/- surgery
Gr B (n = 68): locoregional treatment alone (i.e.RT +/- surgery)
Treatment modality of locoregional treatment determined prior to randomisation. Standard
treatment for resectable patients consisted of en bloc or composite resection of the primary in
conjunction with neck dissection. The mandible was resected when necessary and various flap
techniques were used for reconstruction. Frozen sections were used to assess margins during
surgery. All patients received post-operative radiotherapy consisting of 55 Gy given at 1.8 Gy
per fraction; 5 fractions/week for a period of 6 weeks. The area of residual disease was boosted
to 70 Gy in case of incomplete resection
Outcomes Overall survival
Notes *Data supplied from Pignon 2000
Risk of bias
Item Authors’ judgement Description
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Adequate sequence generation? Unclear Prior to randomisation stratified by site (OC
vsOP), tumour size (T1-2 vs T3-4) and nodal
status (N0 vs N1-3). No details given on se-
quence generation
Allocation concealment? Unclear No information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Reasons and numbers for post randomisation
exclusions described and are similar in each
group
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Unclear “Patients with unresectable disease were as-
signed to external radiotherapy alone” (p 86)
- not sure if these patients are included in the
control group
Merlano 1991
Methods Randomised controlled trial conducted in: Italy
Number of centres: 7
Recruitment period: August 1983 to December 1986
Funding source: government/charity - Italian Research Council
Trial identification number: INRC HN-7
Participants Inclusion: adults with inoperable, stage 3 & 4 squamous cell carcinoma of head & neck, aged
< 76 years, ECOG performance status </= 3, no major impairment of kidney, liver, bone
marrow, heart or lung function. No metastases
Exclusion: prior treatment for malignancy, distant metastases, squamous cell carcinoma of
paranasal sinuses or larynx, life expectancy < 3 months, age > 76 years, major abnormalities
of liver, hear, bone marrow, lung or kidney
116 were randomised (29/116, 25% with oral cavity and 55/116, 47% with oropharynx
equivalent to 72% oral cavity/oropharynx cancer patients)
Interventions Comparison 4: Induction chemotherapy + RT versus alternating CT + RT
GrA (n = 55): induction chemotherapy.Day 1 vinblastine 6mg/m2 IV, followed by bleomycin
30 IU IM 6 hours later, Day 2 methotrexate 200 mg IV, Day 3 leucovorin rescue 45 mg
orally. Cycle repeated every 14 days for 4 cycles, followed by RT within 3 weeks 70 Gy to the
involved areas and 50 Gy to the uninvolved neck nodes at 2 Gy fractions, 5 fractions/week
GrB (n=61): alternating combination chemotherapy:Day 1 vinblastine 6mg/m2 IV, followed
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by bleomycin 30 IU IM 6 hours later, Day 2 methotrexate 200 mg IV, Day 3 leucovorin
rescue 45 mg orally.Total of 4 cycles CT. 2 cycles CT then RT started, 20 Gy each course - 2
Gy in 10 fractions over 2 weeks (60 Gy to the affected areas and 50 Gy to uninvolved areas).
RT was administered after the second, third and forth chemotherapy courses
In Gr B RTwas individualised according to site, extent of the disease with differential loading,
shrinkingfield andboosting dose. Tumours of theOCandOPwere treated through 2 opposite
fields with dose distribution 2:1 to the involved side in unilateral tumours
Outcomes Total mortality* IPD
Toxicity
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data: Gr A: 51/55 and control Gr
B:46/61 (events/patients) (note error in Pignon paper he has groups wrong way round but
results favour alternating therapy group)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Prospectively randomised” and stratified by
T and N status
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes No withdrawals or drop outs - all patients
evaluable for survival
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Unclear Little information available
Merlano 1992
Methods Randomised controlled trial conducted in Italy
Multicentre centre (12 Italian centres)
Recruitment period: February 1987 - December 31st 1990
Funding source: government/charity
Trial identification number: INRC HN-8
Participants Inclusion: adults aged < 76 years, with histologically confirmed squamous cell carcinoma of
pharynx, larynx and oral cavity, unresectable, Stage 3 or 4, M0, ECOG performance status
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0-3, no major impairment of hepatic, renal, bone marrow, pulmonary or cardiac function,
life expectancy >/= 6 months, no other neoplasm, resident near study centre
157 patients recruited and evaluable (46/157, 29% with oral cavity and 53/157, 34% with
oropharynx equivalent to 63% oral cavity/oropharynx cancer patients). Accrual was lower
than the planned 180 due to participating centres refusing to recruit to Gr B in light of the
poorer response observed in the interim analysis
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 80): CT (cisplatin, 5-FU) alternating with RT. Treatment consisted of 4 cycles
(weeks 1, 4, 7 & 10) of intravenous cisplatin 20 mg/m2 of body surface/day and 5-FU 200
mg/m2/day for 5 consecutive days, alternating with RT in 3, 2-week courses (weeks 2 & 3,
5 & 6, and 8 & 9) at 20 Gy/course, 2 Gy fraction/day 5 days /week
Gr B (n = 77): RT alone up to 70 Gy, 2 Gy fraction/day 5 days /week n = 77
At the end of the treatment patients were re-evaluated. Patients with complete response re-
ceived no further treatment. Patients with partial response underwent surgical evaluation and
some, independent of treatment group, received optional surgical treatment. Those with un-
resectable disease and in GrA, received a booster dose to residual tumours, up to a total dose
of 70 Gy and those in Gr B received no further treatment unless their disease progressed.
Patients with no response (stable disease) underwent palliative chemotherapy treatment. Pa-
tients with disease progression during treatment were withdrawn from the study and treated
with palliative chemotherapy
Outcomes Disease free survival (presented as Kaplan-Meier estimates). Follow-up period: 6 years
Total mortality* IPD
Notes Log [hazard ratio] SE calculated from data presented in Kaplan-Meier estimates
*Data supplied from Pignon 2000
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation process: stratified by primary
site, resectability, sex and institution. The ran-
dom permuted blocks methods was used for
randomisation. Specific lists of random num-
bers were available to each participating cen-
tre. Treatment assignment was balanced in
blocks of 6-8
Allocation concealment? Yes Allocation was obtained by a phone call to
central trial centre
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
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Incomplete outcome data addressed? Yes No withdrawals or drop outs. All patients as-
signed to treatment groups were included in
analysis of PFS and survival
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Yes
Mohr 1994
Methods Randomised controlled trial performed in Germany as part of DOSAK study
Multicentre trial (7 centres)
Recruitment period: January 1989 - June 1992
Funding source: charitable foundation-Deutsche Krebshilfe, Mildred Scheel Stiftung
Participants Inclusion: adults with advanced biopsy proven squamous cell carcinoma of oral cavity and
oropharynx, with a minimum tumour size of 2 cm, T2-T4, N0-3, M0
Exclusion: lip carcinoma
377 patients recruited, paper states 316 evaluable, only 268 included in outcomes
OC/OP cancers; combined OC/OP = 100%
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 141): pre-operative RT conventional fractionated irradiation on the primary and
regional nodes, (5 x 2 Gy per week) to a total dose of 36 Gy and pre-operative CT, low dose
12.5 mg cisplatin/m2/d on first 5 days of radiotherapy, followed by radical surgery
Gr B (n = 127): radical surgery alone
Radical surgery was defined by DOSAK and performed after a delay of 10-14 days
Outcomes Overall survival from Kaplan-Meier graph
Notes Part of DOSAK study
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Stratified by primary site of tumour, depth of
infiltration, stage of lymph node disease and
age of patient; generated 17 TPI subgroups
similarly distributed between arms of study.
No information on sequence generation given
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
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Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? No 109/377 = 29% of those randomised are not
included in the analysis of the 2 treatments
being compared. 23/377 due to protocol vio-
lations, 25/377 randomised to RT + surgery
did not have surgery, and remainder “incom-
plete files” but allocated treatment group not
stated
Free of selective reporting? Yes L/R recurrence, mortality, survival planned
and reported
Free of other bias? Unclear Baseline comparability for TPI and stage, but
no information as to how many of those ran-
domised are included in these figures
Molinari 1982
Methods Randomised controlled trial conducted in:France & Italy
Number of centres: not stated
Recruitment period: 1973 to 1977
Funding source: not stated
Participants Inclusion: adults with histologically proven squamous cell carcinoma of the head and neck,
with or without neck nodes, no metastases
Exclusion: female, diabetic, > 70 years of age, previous treatment, second primary tumour,
contraindications to chemotherapy such as kidney failure, bone marrow depletion, chronic
pulmonary disease, neck nodes which prevented the catheterisation of the arteries for chemo-
therapy
72 patients randomised
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT) Intrarterial
Gr A (n = 36): intra-arterial MTX 50 mg/day over 8 hours for 10 days + intramuscular
leucovorin 6 mg every 6 hours starting 2 hours after MTX
Gr B (n = 36): intra-arterial BLM 15 mg/day over 12-20 hours for 13 days
Patients in both groups were then offered either radiotherapy or surgery “depending on the
routine protocol of each participating centre”. The outcome of regression of the tumour was
evaluated prior to the start of radiotherapy or surgery
Outcomes Tumour regression expressed as percentage of initial tumour size, toxicity
Notes
Risk of bias
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Item Authors’ judgement Description
Adequate sequence generation? Unclear No information on sequence generation pro-
vided. Patients were paired according to age,
primary tumour site, tumour extension and
clinical nodes. Treatment was allocated ran-
domly to the first patient of the pair and the
second patient received the alternative treat-
ment
Allocation concealment? Yes Randomisation and pairing performed by
central office and accessed by telephone
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All 72 patients randomised are included in the
tumour regression analysis
Free of selective reporting? Yes Planned outcomes of tumour regression and
toxicity reported
Free of other bias? Yes
Morita 1980
Methods Randomised controlled trial conducted in: Japan
Number of centres: 1
Recruitment period: not stated
Funding source: not stated
Participants Inclusion: adults with squamous cell carcinoma of the tongue, T2-3, N0, 1
45 patients randomised
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 23): radiotherapy plus bleomycin 5 mg/day, 5 times/week to a total dose of 60 mg
Gr B (n = 22): radiotherapy, 400 rads
Patients in both groups were them offered Phase 2 treatment with interstitial radium needles
Outcomes Overall survival
Notes Data from Pignon 2000
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear No details on method of randomisation given
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear Unclear how many patients are included in
the outcomes assessment
Free of selective reporting? Unclear Unclear outcome reporting
Free of other bias? Unclear Authors provide insufficient detail concern-
ing methods used to enable reader to evaluate
sources of bias
Nervi 1978
Methods Randomised controlled trial conducted in: Italy
Number of centres: not stated
Recruitment period: 1966 to 1971
Funding source: Stefano Siglienti Fund and generous gift of Mrs L Shenker
Participants Inclusion: adults with squamous cell carcinoma of head & neck without clinical evidence of
disease beyond neck
142 patients, oral cavity (82 cases, 58%) oropharynx (35 cases, 25%) maxillary antrum (25
cases)
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone (intrarterial)
Gr A (n = 72): neoadjuvant intra-arterial methotrexate 3-5 mg/day for 25 to 35 days to a total
dose of 90-120 mg followed by RT - 40-50 Gy over 4-5 weeks followed by a boost dose of
20-25 Gy for maxillary, or 30-35 Gy by interstitial radium therapy for intraoral tumours
Gr B (n = 70): RT - 40-50 Gy over 4-5 weeks followed by a boost dose of 20-25 Gy for
maxillary, or 30-35 Gy by interstitial radium therapy for intraoral tumours
Outcomes Overall survival
Notes Data from Arcangeli 1983
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Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Patients were stratified by site of cancer and
then randomised
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All patients included in analyses
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Yes
Olasz 2000
Methods Randomised controlled trial conducted in: Hungary
Number of centres: 1
Recruitment period: January 1996 to November 1998
Funding source: not stated
Participants Adults with primary tumour T2-4, with N0-2, M0, with no prior treatment & Karnofsky
performance status 70-100
Interventions Comparison 4: Chemotherapy A (± LRT) versus Chemotherapy B (± LRT)
Gr A (n = 19): (BVM) Days 1 & 2, 4 mg/m2 bleomycin IM every 12 hours, Day 3, 1.5 mg/m
2 vincristine IV, day 4 60 mg/m2 methotrexate IV & day 5 7 mg/m2 leucovorin IM. Cycle 2
started on Week 2 and dose of vincristine is increased by 25%, methotrexate dose is increased
by 100%. Weeks 3 & 4 no chemotherapy, & Week 5 Cycle 3 at the increased doses
Gr B (n = 19): (BVCM) Days 1 & 2, 4 mg/m2 bleomycin IM, day 3 1.5 mg/m2 vincristine
IV, day 4 30 mg/m2 cisplatin IV (together with anti-emetic ondansetron, and usual hydration
protocol), Day 5 60 mg/m2 methotrexate IV & Day 6 7 mg/m2 leucovorin IM. Cycle 2
started on Week 2 and dose of vincristine is increased by 25%, methotrexate dose is increased
by 100% and cisplatin dose in increased by 50%. Weeks 3 & 4 no chemotherapy, & Week 5
Cycle 3 at the increased doses
3 weeks after the end of chemotherapy all patients had surgery for lymph node resection.
Repeat surgery was undertaken after recurrence of cancer
Outcomes Local control, overall survival, time to recurrence
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Notes From translation by Daniel Bereczki
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisation was not stratified, details of
sequence generation not given
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised patients are included in the
the outcome assessments
Free of selective reporting? Yes Outcomes lo local control, overall survival,
time to recurrence and site of recurrence
planned and reported
Free of other bias? Yes Groups appear similar at baseline
Olmi 2003
Methods Randomised controlled trial conducted in: Italy
Number of centres: 18
Recruitment period: January 1993 to June 1998
Funding source: Consiglio Nazionalle della Recherche
Trial number: ORO-9301
Participants Inclusion: histologically proven squamous cell carcinoma of oropharynx, Stage III or IV, M0,
no prior surgery radiotherapy or chemotherapy, age < 70 years, Karnofsky performance status
≥ 70% or ECOG performance status 0-2, adequate bone marrow reserve, renal, hepatic,
cardiac and pulmonary function (criteria specified), available for follow-up, informed consent
Exclusion: T1N1 & T2N1 disease, previous tumours, active infectious disease, psychosis
192 randomised, 182 evaluated
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 64): 66-70 Gy in 33-35 fractions (2 Gy/fraction) 5 days per week over 6.5-7 weeks.
50 Gy to uninvolved neck nodes, tolerance dose for spinal cord 44 Gy + carboplatin 75 mg/
m2 IV over 30 min Days 1-4 and 5-FU 1000 mg/m2/day IV by continuous infusion over 96
hours on days 1-4, 3 courses on weeks 1, 5, & 9
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Gr B (n= 65): 64-67.2 - 2 fractions of 1.6 Gy daily, 4-6 hours apart, 5x/week. After 38.4 Gy
over 2 weeks, 2 week split planned, followed by the second phase same as first
Gr C (n = 63): 66-70 Gy in 33-35 fractions (2 Gy/fraction) 5 days per week over 6.5-7 weeks.
50 Gy to uninvolved neck nodes, tolerance dose for spinal cord 44 Gy
Outcomes 5-year survival, toxicity, overall survival, locoregional disease control, relapse free survival,
event free survival
Notes OS data taken from Pignon 2009
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisation performed by InstitutoMario
Negri, Milan. Patients were stratified by cen-
tre and stage (Stage 3&4 N0-N1 vs St IV N2-
N3). No details on sequence generation given
Allocation concealment? Unclear Allocation concealment not described
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Missing data and exclusions described (2, 4 4
excluded in Gr A, B, C respectively), numbers
similar in each group
Free of selective reporting? Yes Long term follow-up in Fallai 2006
Free of other bias? Yes Groups similar at baseline
Paccagnella 1994
Methods Randomised controlled trial conducted in Italy
Multicentre
Recruitment period: March 1986 - February 1990
Funding source: unknown
Trial number: GSTTC-86
Participants Inclusion: histologically confirmed squamous cell carcinoma of hypopharynx, oropharynx,
oral cavity and paranasal sinuses, Stage 3-4, M0, previously untreated, < 70 years old, Karnof-
sky performance status >/= 50% and normal cardiac, hepatic and renal function, white blood
cell count > 4000/µl, and platelets > 100,000/µl
Exclusion: previous or concurrent malignancy
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237 patients recruited (66 operable). 37/237 = 16% oral cavity, 135/237 = 57% oropharynx,
combined = 73% of sample
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 118, operable n = 34): initial chemotherapy (cisplatin IV 100 mg/m2 on day
1 followed by fluorouracil 1000 mg/m2 by continuous IV infusion on days 1-5, repeated
every 21 days for 4 cycles) followed by locoregional treatment, including surgery. Standard
hydration and antiemetic protocols were administered. Operable patients then had surgical
resection followed by 45-50 Gy of radiotherapy
Gr B (n = 119, operable n = 32): locoregional treatment alone
Evaluation for surgery on T & N (removal of the primary tumour and total neck dissection)
was performed prior to randomisation
For operable patients locoregional treatment comprised resection (as determined in initial
evaluation) followed by 45-50 Gy adjuvant radiotherapy. For inoperable patients locoregional
treatment comprised radical irradiation using either MeV linear accelerator or 60-Co equip-
ment with a planned dose of 65-70 Gy to the involved areas at a 2 Gy fraction per day, 5
fractions per week. A dose of 45-50 Gy was also planned to the uninvolved neck. Spinal cord
shield placed after 44 Gy had been administered
Outcomes *Total mortality (overall survival presented as Kaplan-Meier estimates)
Follow-up period: 5 years
Death or recurrent disease (disease free survival presented as Kaplan-Meier estimates). Follow-
up period: 5 years
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data
Sample size calculation given: “to accept the alternative hypothesis of a 2-year survival of 40%
for group A and 25% for group B, with α = 0.05 and power (1-β = 0.80) it was planned to
enrol 59 patients/year for 4 years”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Stratified by institution, initial tumour stage
(III versus IV) and Karnofsky PS (< 70 vs >/=
70) . Generation of randomisation sequence
performed by Central Operations Office by
phone and assignment was balanced in blocks
of 4-6
Allocation concealment? Yes Allocation obtained by telephone call to trial
office at Padua general hospital
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
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Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised patients included in analysis
Free of selective reporting? Yes Outcomes of overall survival, tumour re-
sponse and time to relapse planned and re-
ported
Free of other bias? Yes No other threat to validity identified
Paccagnella 2010
Methods Randomised controlled trial conducted in: Italy
Number of centres: 18
Recruitment period: January 2003 to January 2006
Funding source: Sanofi Aventis Italy
Participants Inclusion: stage 3-4 M0 squamous cell carcinoma of head & neck, with ECOG performance
status 0-2, unresectable, primary tumours in oral cavity, oropharynx or hypopharynx, adequate
haematological, renal and hepatic function, no peripheral neuropathy or altered hearing
Exclusion: primary tumour in larynx, weight loss greater than 20% in previous 3 months
OC 18/101 = 18%, OP 53/101 = 52%, OC+OP = 70%
Interventions Comparison 4: Induction CT then concomitant CRT versus concomitant CRT alone
Gr A (n = 50): induction chemotherapy with TPF - docetaxel 75 mg/m2 day 1 then cisplatin
80mg/m2 (30min infusion day 1) + 5-FU 800mg/m2/day for 96 hour continuous iv infusion
starting after cisplatin, repeated every 3 weeks for 3 cycles. 5-6 weeks later, concomitant
chemoradiotherapy standard fractionated RT 2 Gy/day, 5x/week for 7 weeks to total dose of
70 Gy to primary and 50-60 to neck + cisplatin 20 mg/m2/day on days 1-4 and 5-FU 800
mg/m2/day in 96 hour continuous IV infusion on weeks 1& 6 of RT
Gr B (n = 51): concomitant chemoradiotherapy only; standard fractionated RT 2 Gy/day,
5x/week for 7 weeks to total dose of 70 Gy to primary and 50-60 to neck + cisplatin 20 mg/
m2/day on days 1-4 and 5-FU 800 mg/m2/day in 96 hour continuous IV infusion on weeks
1& 6 of RT
Outcomes Median PFS and OS. Median duration of follow-up 42 months
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Registration and randomisation carried out
centrally but no information on sequence
generation provided
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Allocation concealment? Yes Treatment allocation obtained by phone or
fax to centre
Blinding of participants? No Open study
Blinding of carers? No Open study
Blinding of outcome assessors? Yes “Radiologic responses in our study were cen-
trally reviewed by an internal committee in a
blinded fashion to minimise possible bias”
Incomplete outcome data addressed? Yes 1 patient found to be ineligible in Gr B, and
further 8 not evaluable. (Gr A; 1 incorrect
treatment, 1 protocol deviation, 2 withdrew
consent) (Gr B; 1 dropped out pre-treatment,
1 early progression, 1withdrew consent, 1 had
no imaging). ITTundertaken for PFS andOS
Free of selective reporting? Yes Progression free survival, overall survival, tox-
icity reported
Free of other bias? Unclear Groups similar at baseline except that more
women with performance status 0 in Gr B.
Trial funded by Sanofi-Aventis and 2 of the 10
investigators have declared financial/other in-
terest and one of the investigators is employed
by Sanofi-Aventis
Parvinen 1985
Methods Randomised controlled trial conducted in: Finland
Number of centres: 1
Recruitment period: 1975 to 1978
Funding source: not stated
Trial identification number: TURKU
Participants Inclusion: squamous cell carcinoma of the head and neck
OC 71%, OP 8%, OC + OP = 79%
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 23) :RT and CT - radiotherapy consisting of 5 fractions per week, to total dose of
30-32 Gy over 3 weeks to primary tumour and regional lymph nodes on both sides of neck,
with bleomycin IM (7-15 mg) given 30-60 min prior to each RT treatment during weeks 1-
3 to total dose of 75-150 mg
Gr B (n = 23): RT alone - radiotherapy consisting of 5 fractions per week, to total dose of 30-
32 Gy over 3 weeks to primary tumour and regional lymph nodes on both sides of neck
Final decision about surgery made at completion of RT, and if indicated, surgery occurred 3
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weeks after RT
Outcomes Local recurrence, survival*, toxicity
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Envelope method - no details about sequence
generation
Allocation concealment? Yes Envelope method
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised patients included in analyses
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Yes Similar numbers in each group underwent
surgery post-RT
Petrovich 1981
Methods Randomised controlled trial conducted in: USA
Number of centres: 2
Recruitment period: July 1975 - February 1978
Funding source: solo cup foundation of Urbana Illinois
Participants 23 adults aged 48-70 with biopsy confirmed squamous cell carcinoma of the upper respiratory
and digestive tracts, with no prior treatment
Exclusions: prior treatment, distant metastases, initial performance status of < 50%, impaired
renal, liver function (parameters specified)
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 12): CT followed by RT. Vincristine 0.015 mg/kg IV 12 hours and 1 hour before
methotrexate 50-100 mg/kg IV in 6-hour continuous infusion, followed by citrovorum factor
given 15 mg IM every 6 hours for 12 doses. Course of chemo repeated once after 3 weeks. 2-
3 weeks after end of chemo, radiotherapy was given as for Gr B
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Gr B (n = 11): RT alone cobalt and clinac-18 linear accelerator (10 mV) given through 3
portals with an average tumour dose of 70 Gy over 7 weeks
Outcomes Complete response, partial response (> 50% reduction in tumour size), progressive disease,
total mortality
Notes Small study - likely to lack power
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Prospectively randomised” no further infor-
mation given
Allocation concealment? Unclear Not described
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Reasons for protocol violations described, and
numbers similar in both groups
Free of selective reporting? Yes Planned outcomes reported
Free of other bias? Yes
Pinnaro 1994
Methods Randomised controlled trial conducted in: Rome, Italy
Number of centres: 1
Recruitment period: February 1986 to February 1991
Funding source: CNR grant #880059444
Participants Inclusion: adults aged less than 76 years with histologically documented, measurable, stage 3
or 4 inoperable squamous cell carcinoma of the head& neck without prior treatment. Patients
who have WHO performance Status 0-2, adequate renal and hepatic function
93 patients randomised
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 44): SEQ 3 cycles of cisplatin 100 mg/m2 on day 1 + 5-FU 1000 mg/m2/day by
continuous infusion over 120 hours, followed by radiotherapy 10-20 days after last chemo-
therapy dose, 2 Gy/day to a total dose of 65-70 Gy
Gr B (n = 49): SIM 3 cycles 100 mg/m2 cisplatin on day 1 repeated every 3 weeks, followed
by radiotherapy 2 Gy/day, 5 times/week to a total dose of 65-70 Gy
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Outcomes Response, toxicity, progression free survival, overall survival, time to progression, time to
metastases
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Patients were stratified by performance status,
primary site, T stage, N stage and then ran-
domised. No details of sequence generation
given
Allocation concealment? Unclear No information given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 4 post-randomisation exclusions (3 Gr A and
1 Gr B), and a further 11 not evaluable due
to protocol violation (numbers same in each
group)
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Yes
Posner 2007
Methods Randomised controlled trial conducted in: USA, Canada, Argentina & Europe
Number of centres: 55
Recruitment period: May 1999 to December 2003
Funding source: Sanofi-Aventis
TAX 324 study
Participants Inclusion: patients over 18 with measurable, non-metastatic histologically proven Stage III
or IV squamous cell carcinoma of oral cavity, oropharynx or larynx with either unresectable
tumour or decreased surgical curability due to Stage III or IV N2 or N3 or if patient was
candidate for organ preservation, WHO performance status < 2 and adequate bone marrow,
liver and renal function
Exclusion: previous chemotherapy or radiotherapy, previous cancer diagnosis, previous surgery
for cancer of head & neck, > 20% weight loss in preceding 3 months, chronic obstructive
pulmonary disease requiring hospitalisation within previous 12 months
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539 enrolled, 38 excluded due to a computer error in randomisation, 501 randomised 334/
501 = 67% oral cavity or oropharyngeal
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 255): (TPF) docetaxel 75 mg/m2 in 1 hour infusion + 100 mg cisplatin IV over
0.5-3 hours then FU (1000 mg/m2/day) as continuous infusion for 5 days, repeated every 3
weeks for 3 cycles. Patients were given dexamethasone & antibiotic prophylaxis days 5-15 of
each cycle
Gr B (n = 246): (PF) cisplatin 100 mg/m2 IV + FU 1000 mg/m2/day as continuous infusion
for 5 days, every 3 weeks for 3 cycles
All patients received 3 cycles of induction therapy unless there was disease progression, unac-
ceptable toxicity, withdrawal of consent, reduction of < 25% at the end of cycle 2
Patients in both groups, 3-8 weeks post-cycle 3, started planned CRT, weekly carboplatin +
2 Gy/day 5x/week radiotherapy to a total dose of 70-74 Gy, followed by surgery 6-13 weeks
later
Outcomes Overall survival (primary outcome), progression free survival, relapse rate after induction
chemotherapy, toxicity
Notes Sample size/power calculation given: “The study had a power of 91% to detect a hazard ratio
for death of 0.65 on the basis of an assumed median survival of 43 months in the TPF group
and 28 months in the PF group, with use of a 2-sided log-rank test at a level of significance
of 0.05. A minimum follow-up of 24 months and a total of 227 events were required”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation performed centrally with bi-
ased coin minimisation technique. Randomi-
sationwas stratified by site of primary tumour,
N0-N1 vs N2-N3, institution
Allocation concealment? Yes Not described, but considered to
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear 539 patients enrolled but 38 (8%) excluded
due to computer randomisation error, allo-
cated groups not given
Free of selective reporting? Yes Primary and secondary outcomes clearly de-
scribed and reported
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Free of other bias? Unclear There were more T4 patients in the TPF
group (49% vs 37% P = 0.04) Bias due to
this would be likely to underestimate the ef-
fectiveness of TPF regimen. However fewer
TPF patients, compared to PF, did not com-
plete induction chemotherapy due to progres-
sive disease
Prevost 2005
Methods Randomised controlled trial conducted in: France
Number of centres: not stated
Recruitment period: December 1985 to December 1989
Funding source: not stated
Participants Inclusion: men aged < 75 years with histologically confirmed squamous cell carcinoma of head
& neck. Tumours were inoperable, with an evaluable/measurable lesion, previously untreated,
Karnofsky performance Status > 40%, expected survival > 8 weeks, adequate haematological
renal & hepatic function. Patients with multiple primary cancers were eligible
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 98): cisplatin 100 mg/m2 given as 15 min rapid IV infusion + 5-FU 1000 mg/m
2/day over 120 hours, repeated every 3 weeks for total of 3 cycles
Gr B (n = 99): etoposide (VP16) 60 mg/m2 as 2-hour infusion on days 1-5 + cisplatin 100
mg/m2 as 15 min rapid infusion on Day 4
Outcomes Tumour response, toxicity, overall survival
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Patients paired by tumour sites and UICC
stage through “sequential closed plans”. The
first patient in each pairwas allocated centrally
by statistician, and the second patient in the
pair received the alternate treatment
Allocation concealment? Unclear No information provided on allocation con-
cealment
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
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Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised patients are included in out-
comes of tumour response and toxicity
Free of selective reporting? Unclear Tumour response and toxicity outcomes
planned and reported. Results of analysis of
overall survival not reported only described as
not significantly different
Free of other bias? Unclear Email from Dr Prevost stated that “ the re-
sults were expressed according to the ’all or
none law’..... for the data analysis, only the
pairs which show a difference between both
treatments were kept”
Rao 1994
Methods Randomised controlled trial conducted in: India
Number of centres: 1
Recruitment period: January 1st 1987 to August 31st 1989
Funding source: not stated
Trial identification number: TMH R-4
Participants Inclusion: adults with clinical stage III-IV T3-T4 N0-N2b M0, with resectable squamous
cell carcinoma of the alveolobuccal complex considered potentially curable by conventional
radical surgery. Karnofsky performance status ≥ 80%, no residual disease and clear margins
after surgery
135 patients recruited, 116 evaluable patients 100% OC
Interventions Comparison 2: Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy
alone
Gr A (n = 65): adjuvant chemotherapy - methotrexate 50 mg/m2, 3 IV bolus doses on days
3, 10 and 17 post-operative. If leukopenia or low platelet count or severe mucositis injection
deferred for 1 week (evaluable n = 54)
Gr B (n = 70): control - post-operative observation (evaluable n = 62)
All patients underwent surgery. A wide excision of the lesion with resection of a segment of
the mandible along with neck dissection. Node status N0 -> supramohyoid neck dissection
with removal of nodes level I-III. Node status N1-N2 -> classical radical neck dissection with
removal of nodes levels I-V. If minor use skin closure, if large flap performed
Outcomes Disease free survival. Follow-up period: 1 and 2 years
Total mortality. Follow-up period: 1 and 2 years
Total mortality* IPD
Disease-related mortality. Follow-up period: 2 years
Recurrent disease: total. Follow-up period: 1 and 2 years
Complications of treatment - toxicity/adverse events
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Notes Very specific oral cancer location i.e. alveolobuccal complex
*Some data supplied from Pignon 2000.
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation performed by Department of
Statistics using random number tables
Allocation concealment? Yes Assignment was conveyed to the surgical unit
in sealed envelopes
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Exclusions and withdrawals described for
each group. Gr A 11/65 and Gr B 9/70
Free of selective reporting? Yes Planned outcomes described for planned 24
month follow-up. Paper reports 12month fol-
low-up
Free of other bias? Yes No other threats to validity identified
Rasch 2010
Methods Randomised controlled trial conducted in: Netherlands & New Zealand
Number of centres: 5
Recruitment period: January 2000 to November 2004
Funding source: not stated
Participants Inclusion: unresectable squamous cell carcinoma of oropharynx, oral cavity, or hypopharynx,
stage IV,T3-4, anyN,M0WHOperformance status 0-1, adequate renal function, noprevious
malignancies, cerebrovascular accident or use of anticoagulants
OC 18%, OP 63%, OC + OP = 81%
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 118): 4 x 150 mg/m2 cisplatin administered into femoral artery on days 1, 8, 15,
22 followed by systemic rescue with sodium thiosulphate together with 35x 2 Gy fractions of
radiotherapy to total dose of 70 Gy
Gr B (n = 119): 3 x 100 mg/m2 cisplatin on days 1, 22 & 43 together with 35x 2 Gy fractions
of radiotherapy to total dose of 70 Gy
Patients randomised to the intra-arterial group underwent arteriography prior to treatment.
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Those for whom intra-arterial administration was not feasible reverted to the intravenous
protocol (n = 10)
Outcomes Primary locoregional control, secondary outcomes overall survival, disease free survival, quality
of life and toxicity. Median follow-up 33 months
Notes It was estimated that to detect a difference of 15% in locoregional control (from 60% to 75%)
between treatment arms, would require 100 events in each arm to give 80% power
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomisation was stratified by centre, T
classification, N classification and site of pri-
mary tumour. No information about the
method of sequence generation is provided
Allocation concealment? Unclear Not described
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 2 patients were excluded post-randomisation.
Authors state that ITT analysis was used but
outcomes are reported as percentages only.
Compliance is described for 224/237 patients
Free of selective reporting? Yes Primary outcome is locoregional control and
secondary are disease free survival, overall sur-
vival, quality of life and toxicity
Free of other bias? Yes Groups appear similar at baseline. Intra-arte-
rial treatment was not feasible in10 patients
randomised to this group and they were then
treated by intravenous therapy but analysed
in the intra-arterial group (ITT)
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Methods Randomised controlled trial conducted in USA
Multicentre (2 centres - Loma Linda, California)
Recruitment period: January 1979 - February 1983
Funding source: not specified
Participants Inclusion: patients with potentially resectable, histologically proven, primary squamous cell
carcinoma of head & neck, WBC≥ 4000, platelets≥ 100,000 serum creatinine < 2, stage III
or IV oral cavity, oropharynx, hypopharynx, pyriform sinus, nasopharynx or larynx cancers
Exclusions: salivary gland lesions, distant metastases, prior surgery or radiation therapy to
head & neck, or prior methotrexate therapy
60 patients recruited, 55 evaluable patients (planned to accrue 100 patients but trial was
stopped early due to poor accrual)
33% cases oral cavity, 22% oropharynx, combined = 55% of sample
Interventions Comparison 2: Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy
alone
Patients were randomised to receive LRT + CT (methotrexate) or LRT alone
Gr A (n = 28): chemotherapy - escalating dose methotrexate (weekly x4) then surgery then
post-operative methotrexate (weekly x4) then radiotherapy then methotrexate (weekly x8)
Gr B (n = 27): control - surgery plus post-operative radiotherapy
For patients with primary tumours in oral cavity, oropharynx, hypopharynx, pyriform sinus
or larynx, LRT comprised both standard surgery (radical neck dissection) and post-operative
radiotherapy. Those with palpable bilateral neck nodes underwent simultaneous bilateral neck
dissection with preservation of the internal jugular vein on the least involved side
Radiotherapy started approximately 4 weeks after surgery. Once fraction of 1.8 to 2 Gy/day,
5x/week continuous course with all fields treated with 60 Co and/or 10-25 mV x-ray and 6-
20 mV electron beam. The operative field received 60 Gy when surgical margins > 1 cm or
65 Gy if surgical margins < 1 cm. Extent of radiotherapy was based on the original size and
location of the lesion before chemotherapy
Outcomes Total mortality (overall survival presented as Kaplan-Meier estimates). Follow-up period: 6
years
Death or recurrent disease (disease free survival presented as Kaplan-Meier estimates). Follow-
up period: 5 years
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Patients were stratified by primary site (6
strata) and nutritional status (2 strata). Pa-
tients were paired to minimise significant im-
balance. Allocationwas determinedusing ran-
dom number table for one patient of each pair
and the other was allocated to the alternative
treatment
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Allocation concealment? Yes Assignment was conveyed by envelopes (pre-
sumed sealed)
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 5 patients were excluded because their cancer
was deemed unresectable (4 MTX group and
1 from control group). One patient from each
group was lost to follow-up (withdrawals and
drop outs accounted for)
Free of selective reporting? Yes
Free of other bias? Yes
Richard 1974
Methods Randomised controlled trial conducted in: Gustave-Roussy Institute, Villejuif, France
Number of centres: 1
Recruitment period: June 1965 to October 1967
Funding source: unclear
Trial identification number: IGR-65
Participants 125 patients considered but only 39 included with T4
Inclusion criteria: epidermoid carcinomas of tongue, floor of mouth, soft palate, retromolar
trigone or buccal mucosa
Exclusion criteria: > 70 years old, in poor general health, unfavourable psycho-social condi-
tion, intercurrent diseases that would worsen prognosis, those with extensive lymph node in-
volvement that would make it difficult to place intra-arterial catheter, more than one primary
tumour site, previous treatment
Age: Group A 54.7; Group B 57.2
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 21): CT: methotrexate 50 mg/day intra-arterially for 6-12 days to total dose of
300-600 mg, then 14 days no treatment period followed by 30 Gy over 2 weeks, continued
up to 60 Gy
Gr B (n = 18): RT 30 Gy over 2 weeks, continued up to 60 Gy
Outcomes Mean tumour regression, overall survival
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data
Trial stopped prematurely because tumour regression with combined treatments showed clear
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advantage over radiotherapy alone
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Random allocation of treatments into groups
had been prepared by the statistician
Allocation concealment? Yes Numbers in sequence were given to patients
as theywere included in the study and a sealed
envelope marked with the same number con-
tained indication of treatment group
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? Yes 3 independent outcome assessors evaluated
each patient at each assessment visit. Com-
parsion of observers described in table 4 p 494
Incomplete outcome data addressed? Unclear Not clear how many patients were included
in the outcomes assessments at each point
Free of selective reporting? Yes Primary and secondary outcomes clearly
stated and reported
Free of other bias? Yes No other threats to validity identified
Richard 1991
Methods Randomised controlled trial conducted pan-Europe
Multicentre (5 centres) with 91% of patients recruited from 3 institutions
Recruitment period: February 1978 - January 1984
Trial identification: EORTC 78-OCP
Participants Inclusion: biopsy confirmed squamous cell carcinoma of the floor of mouth, retromolar
trigone, glosso tonsillar sulcus or anterior faucial pillar
Exclusion: T-1 staged tumour with local extension contraindicating surgery, prior treatment,
patients for whom CT or surgery was contraindicated. Metastatic disease, a second primary
tumour, or those who could not be followed up
225 randomised, 222 evaluable. 100% OC
Interventions Comparison 1: Chemotherapy plus surgery versus surgery
Gr A (n = 112): surgery plus intra-arterial chemotherapy. Vincristine was delivered at a dose
of 1 mg on days 1, 5 and 9 and bleomycin at 15 mg/day for 12 days and starting 6 hours
after vincristine on days 1, 5 and 9
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Gr B (n = 110): surgery alone
Outcomes Total mortality* IPD
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation was stratified by tumour site
(floor of mouth (FOM) versus posterior oral
cavity or oropharynx (POC) and by treat-
ment centre. Randomisation procedure was
permuted blocks
Allocation concealment? Yes Assignment was conveyed by sealed envelopes
Blinding of participants? No Not possible
Blinding of carers? No Not possible
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 5 post-randomisation exclusions (3 surgery
only arm and 2 in CT + surgery arm)
Free of selective reporting? Yes Primary and secondary outcomes clearly
stated and reported
Free of other bias? Yes Some differences between the groups at base-
line (p 822) but these were adjusted for in the
analysis
Rischin 2005
Methods Randomised controlled trial conducted in: Australia and New Zealand
Number of centres: 13 TROG specialist centres
Recruitment period: September 1998 to May 2002
Funding source: Sanofi-Synthiabo
Trial identification number: TROG 98.02
Participants Inclusion: patients aged > 18 years, previously untreated squamous cell carcinoma of the oral
cavity, oropharynx, hypopharynx, or larynx, Stage III or IV disease, ECOG performance
status 0-2, adequate haematological, renal and hepatic function
Exclusion: distant metastases, or T1N1, prior radiotherapy, prior cisplatin use, concurrent
active cancer in past 5 years (except treated non melanoma skin cancer or cervical dysplasia),
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history of unstable cardiac disease, peripheral neuropathy ≥ 2
122 patients randomised, 1 patient excluded
Age: G1- median age 56 (38-74); G2- median age 55 (43-75)
M/F: 103/18
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 63): tirapazamine 290 mg/m2, on second day of weeks 1, 4 & 7, 1 hour rest, then
75 mg/m2 cisplatin for 1 hour, then radiotherapy. In weeks 2 & 3, 160 mg/m2 tirapazamine
followed by radiation after 30 to 120 min
Gr B (n = 58): cisplatin 50 mg/m2 before radiotherapy on first day of weeks 6 & 7, with 120
hour infusion of 360 mg/m tirapazamine 290 mg/m2, fluorouracil on days 1-5 of same weeks
RT for both groups consisted of 70 Gy in 35 fractions for 7 weeks
Outcomes Locoregional control, disease free survival, overall survival
Notes Calcuated that 120 patients were required to give 80% power to detect a 22% difference in
2-year failure-free survival rate
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation charts were prepared at
trial centre (based on adaptive biased-coin
method), in ratio 1:1
Allocation concealment? Yes Allocation was obtained by a telephone call to
trial centre following patient recruitment and
registration
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 1 post-randomisation exclusion, no losses to
follow-up
Free of selective reporting? Yes
Free of other bias? Yes Although treatment varied depending on in-
dividual requirement, the paper claims that
“each centre adhered to a consistent policy on
neck management so that there was no bias
in favour of one arm or the other”
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Methods Randomised controlled trial conducted in: 16 countries in Australasia, Europe & America
Number of centres: 89
Recruitment period: September 2002 to April 2005
Funding source: Sanofi-Aventis
Participants Inclusion: previously untreated Stage III& IV squamous cell carcinoma of oral cavity, orophar-
ynx, hypopharynx, or larynx, ECOG performance status 0-2, adequate haematological, liver,
renal function, no cardiac disease, peripheral neuropathy, no hearing impairment
OC = 109/861 = 13%, OP = 465/861 = 54%, OC + OP = 67%
Interventions Comparison 4: Concomitant CIS/TPZ + RT versus concomitant CIS +RT
Gr A (n = 430): on day 1 of weeks 1, 4 & 7, tirapazamine (TPZ) 290 mg/m2 over 2 hours
followed by cisplatin 75 mg/m2 over 1 hour, followed by radiotherapy, 2 Gy per fraction, 4
fractions per week to total dose of 70 Gy using a shrinking field technique
Gr B (n = 431): on day 1 of weeks 1, 4 & 7, cisplatin 100 mg/m2 over 1 hour, followed by
radiotherapy, 2 Gy per fraction, 4 fractions per week to total dose of 70 Gy using a shrinking
field technique
Outcomes 2-year overall survival, failure-free survival, time to locoregional failure, and quality of life as
measured by Functional Assessment of Cancer Therapy-Head and Neck
Notes Sample size calculation given: “estimated that 850 patients (425 per arm) would provide 90%
power to detect a difference of 60% versus 70% for CIS versus CIS/TPZ in overall survival
at 2 years with an overall α = 0.05 with 2-sided testing”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Centralised randomisation stratified by dis-
ease stage (III vs IV), primary site (OP/L vs
HP/OC) and haemoglobin level. No details
of method of sequence generation given
Allocation concealment? Yes Centralised assignment
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 5/430 and 3/431 were excluded fromprimary
analysis due to incorrect diagnosis or early
withdrawal
Free of selective reporting? Yes Primary outcome is overall survival after 2
years follow-up, also reported failure free sur-
vival, time to locoregional failure, quality of
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life and toxicity
Free of other bias? Yes Groups similar at baseline, and chemotherapy
and radiotherapy delivery was similar in both
arms
Ruo 2010
Methods Randomised controlled trial conducted in: Italy
Number of centres: 6
Recruitment period: November 1992 to December 1995
Funding source: not stated
Participants Inclusion criteria: biopsy proven unresectable stage III or IV squamous cell cancer of head and
neck, no prior chemotherapy or radiotherapy, aged 18 to less than 70, ECOG performance
status 0-2, adequate bone marrow reserve, renal and liver function, adequate nutritional and
liquid intake
Exclusion: metastatic disease, multiple primary tumours
OC = 17%, OP = 49%, OC + OP = 66%
M/F: 129/16
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 82): carboplatin 45 mg/m2 as IV bolus 45-60 minutes prior to RT on days 1-5 of
weeks 1, 3, 5 & 7 of radiotherapy given as 2 Gy per fraction, 1 fraction per day, to total dose
of 70 Gy
Gr B (n = 82): radiotherapy given as 2 Gy per fraction, 1 fraction per day, to total dose of 70
Gy
Outcomes Locoregional recurrence free survival, disease free survival, overall survival, response rate and
toxicity
Notes Sample size calculation given: “to detect an increase of 15% in local control, in the combined
chemotherapy radiotherapy arm (with alpha error of 5% and power of 80%) required 150
participants and an additional 10% were recruited to allow for possible drop outs”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Randomised” - no further information pro-
vided
Allocation concealment? Unclear No information provided
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
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Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes In CRT group 2/82 developed distant metas-
tases and were withdrawn and further 7 died
during treatment, and in RT group 5 did not
receive treatment and further 5 died during
treatment leaving 73 & 72 patients evaluated
in each group respectively
Free of selective reporting? Yes Primary outcome locoregional recurrence free
survival, and secondary outcomes of disease
free survival, overall survival, response rate
and toxicity
Free of other bias? Unclear More patients in CRT arm had ECOG per-
formance status of 0 compared to RT group
Salvajoli 1992
Methods Randomised controlled trial conducted in: Brazil
Number of centres: 1
Recruitment period: January 1983 to December 1986
Funding source: unclear
Trial identification number: AC Camargo
Participants 90 patients with stage IV SCC of head and neck (oral cavity, oropharynx, hypopharynx),
histologically confirmed, randomised to 3 groups
Inclusion criteria: unresectable lesions, aged < 65 years, no prior treatment, no pulmonary or
cardiovascular disease, Karnofsky performance status > 50%, leucocytes > 4000, platelets >
100,000, creatinine clearance rate > 65 ml/min
Exclusion: metastatic disease, multiple primary tumours
OC = 47%, OP = 30%, OC + OP = 77%
M/F: 84/6
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A: neoadjuvant chemotherapy followed by radiotherapy - (vinblastine (4mg/m2 IV on day
1) + mitomycin (8 mg/m2 IV on day 1) + cisplatin (30 mg/m2 IV on days 2 & 4) + bleomycin
(10 mg/m2 IV on days 2 & 4)) repeated after 3 weeks if partial response observed. If disease
stable or progressive then immediate radiotherapy followed (70 Gy in 1.8 Gy fractions over
8 weeks)
Gr B: concomitant chemotherapy and radiotherapy - bleomycin 5 mg IV on days 1 & 5
followedby cisplatin (20mg/m2 IV ondays 2&3), repeated every 3weeks during radiotherapy
(70 Gy in 1.8 Gy fractions over 7 weeks)
Gr C: radiotherapy alone - 70 Gy in 1.8 Gy fractions over 7 weeks
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Outcomes Tumour response to treatment, overall survival, adverse events
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Randomised” - no further details given
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised participants accounted for
and included in analysis
Free of selective reporting? Yes Primary and secondary outcomes clearly de-
scribed and reported
Free of other bias? Yes
Schuller 1988
Methods Randomised controlled trial conducted in USA
Multicentre (22 institutes) SW USA Oncology group. Phase III trial
Recruitment period: August 1980 - January 1985
Funding source: government - National Cancer Institute, Bethesda MD USA
Trial identification: SWOG 8006
Participants 175 patients were recruited with previously untreated advanced stage, resectable histologically
confirmed SCC of H&N. 149 were evaluable (56 (38%) with oral cavity and 44 (30%) with
oropharynx equivalent to 63% oral cavity/oropharynx patients). 100 completed treatment
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 46): neoadjuvant chemotherapy plus surgery plus post-operative radiotherapy (n =
82). Neoadjuvant chemotherapy: cisplatin 50 mg/m2 IV day 1; methotrexate 40 mg/m2 IV
day 1; bleomycin 15 U/m2 IV or IM day 1 and 8 and vincristine 2 mg IV day 1 for 3 courses.
21-day rest between courses and surgery
Gr B ( n = 55): surgery plus post-operative radiotherapy (n = 76)
Common treatment: assessment for surgery and extent of surgical resection was determined
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at time of randomisation and not altered by response to chemotherapy
Outcomes Total mortality (presented as overall survival Kaplan-Meier estimates and death hazard ratios
(adjusted for stage and race)). Total mortality* IPD
Recurrent disease (presented as Kaplan-Meier estimates of time to treatment failure)
Complications of treatment - harms/death due to treatment
Notes *Total mortality: Log [hazard ratio] SE calculated from data provided from Pignon 2000;
based on individual patient data
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were randomly assigned...”
Allocation concealment? Unclear Insufficient information
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 175 entered into study but 158 eligible. Un-
clear if all 17 patients excluded at this stage
hadbeen randomised or not, but suggests they
did not receive treatment. IPD data used in
analysis
Free of selective reporting? Yes Relevant outcome data presented
Free of other bias? Yes No reported threats to validity
Segura 2002
Methods Randomised controlled trial conducted in: Valencia, Spain
Number of centres: 1
Recruitment period: October 1996 to July 1999
Funding source: not stated
Participants Inclusion: patients aged 18-75 yearswith histologically confirmed, locally advanced, squamous
cell carcinoma of head and neck, stage III or IV, non resectable, no prior treatment, ECOG
PS 0-2 with adequate renal & hepatic function
42 randomised
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Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 21): (PF) IV cisplatin 100 mg/m2 on Day 1+ 5-FU 1000 mg/m2 IV continuous
infusion Days 1-5, repeated for 3 cycles
Gr B (n = 21): (PV) IV cisplatin 100 mg/m2 on Day 1 + vinorelbine 30 mg/m2 IV on Days
1 & 8 repeated for 3 cycles
Those in both groups who showed tumour response then received local therapy
Outcomes Tumour response, toxicity, median/overall survival
Notes Published abstract, emailed first author who supplied a copy of full publication November
2009. Data from translation from original Spanish by L Fernandez-Mauleffinch
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomised using a list of random numbers
generated by computer
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 39/42 randomised patients included in the
outcomes of tumour response and survival. 2
patients in Gr A & 1 in Gr B died during
treatment
Free of selective reporting? Yes Planned outcome measures - tumour re-
sponse, toxicity and survival are reported
Free of other bias? Yes No other risks to validity identified
154Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Shanta 1980
Methods Randomised controlled trial conducted in India
Single centre
Recruitment period: 1971-1973
Funding source: government and industry - Nippon Kayaku Company, Tokyo, Indian Coun-
cil of Medical Research and the MRC, UK
Trial identification number: WIA-OC5a (1971-1972) and WIA-OC5b (1972-1973) (WIA-
OC=Cancer Institute (WIA) Oral Cavity (India))
Participants Inclusion: adults with histologically proven squamous cell carcinoma of the buccal mucosa
(100% OC) T3-T4 and N0-N3, M0. Inclusion criteria - fixed metastatic submandibular
lymph nodes were acceptable but fixed cervical lymph nodes elsewhere debarred patients from
study
157 randomised
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 84): chemotherapy (bleomycin - intra-arterial, intravenous or intramuscular) plus
radiotherapy Cobalt-60 teletherapy was delivered by 2 opposing fields in 3 fractions/week
(total TD 55-60 Gy over about 7 weeks)
CT was administered intra-arterially in 42 patients, intravenously in 22 patients and intra-
muscularly in 20 patients. Those IA and IV cases received 10-15 mg of bleomycin 2-3 times/
week, depending on the oral mucosal reaction, to a total dose of 150-200 mg. The bleomycin
was administered on the non-irradiated days. The IM cases received 30 mg bleomycin twice
a week for 2 weeks, the RT commencing 2 weeks after the first injection on a 3-fraction per
week basis. Another 30 mg bleomycin was administered IM during radiation to a total dose
of 150 mg
Gr B (n = 73): control - received physiological saline as placebo (intra-arterial, intravenous or
intramuscular) plus radiotherapy Cobalt-60 teletherapy was delivered by 2 opposing fields in
3 fractions/week (total TD 55-60 Gy over about 7 weeks)
Outcomes Total mortality* IPD
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data (N.B. numbers in trial report
do not correspond to IPD numbers used for Pignon data analysis):
W1A-OC5a deals with patients withCT administered intra-arteriallyGr 1: 22/25 and control
Gr 2: 19/25(events/patients)
W1A-OC5b deals with patients with CT administered intravenously or intramuscularly, Gr
1: 27/38 and control Gr 2: 40/41(events/patients)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Generation of randomisation sequence took
place in the tumour registry
Allocation concealment? Yes Sealed envelope technique from central tu-
mour registry
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Shanta 1980 (Continued)
Blinding of participants? Yes Not mentioned but it is likely that patients
were blinded as placebo infusions were used
Blinding of carers? Unclear Not mentioned
Blinding of outcome assessors? Yes Outcome assessment was conducted by head
and neck surgical group who were unaware of
type of treatment each patient received
Incomplete outcome data addressed? Yes
Free of selective reporting? Yes
Free of other bias? Unclear Some imbalance between groups at baseline
- BLM group had higher rate of mandibu-
lar invasion and control group more extensive
nodal involvement
Smid 1995
Methods Randomised controlled trial conducted in Slovenia
Single centre
Recruitment period: March 1991 to December 1993
Funding source: government. T3-0005 from theMinistry of Science and technology, Slovenia
Trial identification: LOHNG-91 (LOHNG=Ljubljana Oncology Head and Neck Group
(Slovenia))
Participants Inclusion: adults with previously untreated histologically confirmed inoperable squamous
cell carcinoma of the head and neck region were recruited. 64 were evaluable (10, 16%
with oral cavity and 41, 64% with oropharynx equivalent to 80% combined oral cavity/
oropharynx patients). 60 patients had stage IV and the remainder stage III cancers all were
free of metastases. Withdrawls and drop outs accounted for
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 32): concomitant CT intramuscular bleomycin 5 units twice per week, with a
planned dose of 70 units and mitomycin C 15 mg/m2 IV, after delivery of 9-10 Gy of
irradiation. The mitomycin C was planned to be repeated on the last day of RT at the
dose of 10 mg/m2 (also received nicotinamide (650 mg/day), chlorpromazine (200 mg with
bleomycin) and dicoumarol (300 mg applied on the evening and morning before mitomycin
C)). RT= 2 Gy 5 times weekly to a total dose of 66-70 Gy
Gr B (n = 32): radiotherapy alone, 2 Gy 5 times weekly to a total dose of 66-70 Gy
Outcomes Total mortality**IPD
Notes *Based on Zakotnik 1998 linked to Smid 1995
**Some data supplied from Pignon 2000.Total mortality: log [hazard ratio] SE calculated
from data provided from Pignon 2000
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Smid 1995 (Continued)
Power calculation stated. To demonstrate a 10% increase in 2-year survival in the concomitant
therapy group, it was calculated that study would need at least 100 patients (α = 0.05 β = 0.
80)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “Randomisation used was permuted blocks
and stratified by primary site and whether
tumour was inoperable locally, regionally, or
both”
Allocation concealment? Unclear Not described
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All patients entering study had evaluable data
Free of selective reporting? Yes
Free of other bias? Yes
Staar 2001
Methods Randomised controlled trial conducted in: Germany
Number of centres: 5
Recruitment period: July 1995 to April 1999
Funding source: Deutsche Krebshilfe
Trial identification number: Cologne 95
Participants 263 patients recruited from 3 universities/2 community hospitals with Stage III or IV un-
resectable advanced oro and hypopharyngeal carcinoma. Exclusion criteria prior malignant
neoplasm or previous chemo or radiotherapy
Age: median 57 years (range 28-73 years)
M/F: 204/36, 240/263 underwent therapy (1 patient died before treatment and 23 did not
start treatment)
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Gr A (n = 116): concomitant CRT: 2 cycles of 5-FU (600 mg/m2/day)/carboplatin (70 mg/
m2) in weeks 1 and 5 plus 38 days of 1.5-1.8 Gy/day to total radiation dose of 69.9 Gy with
concomitant boost in last 2.5 weeks
Gr B (n = 124): hyperfractionated accelerated RT. 38 days of 1.5-1.8 Gy/day to total radiation
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Staar 2001 (Continued)
dose of 69.9 Gy with concomitant boost in last 2.5 weeks
Participants were additionally also randomised to prophylactic G-CSF (1 centre did not give
prophylactic G-CSF, Prophylactic G-CSF administration stopped inMarch 1999 due to poor
outcomes found on interim analysis)
Outcomes Locoregional control (Kaplan-Meier), total mortality data from Pignon 2009
Notes Disease free survival data does not take into account other metastases
Adverse events: mucositis, dermatitis, WBC, anaemia, platelets, feeding problems/tube feed-
ing
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Method of randomisation not described
Allocation concealment? Unclear Method of allocation concealment not de-
scribed
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear Post-randomisation exclusions not described
by group. Some randomised to RT actually
received RCT and viceversa. 4 patients ran-
domised to RCT received RT alone and one
patient randomised to RT received RCT (n =
113 in received RCT & n = 127 received RT)
Free of selective reporting? Unclear Trial found no difference between groups
in main outcomes, reported significant out-
comes in subgroups (unclear whether these
subgroup analyses were pre planned)
Free of other bias? Unclear Prophylactic G-CSF was administered by 4/5
centres until March 1999, when it was found
to be associated with poorer response. Unsure
how this may have influenced results
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Szabo 1999
Methods Randomised controlled trial conducted in Europe (Hungary, Germany and Austria)
Multicentre (4 institutes)
Recruitment period: 1986-1991
Funding source: unknown
Participants Inclusion: adults aged less than 70 years with previously untreated, resectable, histologically
confirmed SCC of the tongue (central and posterior third, base of tongue) and/or the floor
of the mouth (with or without mandibular destruction). T2-T4 (NXM0). Tumour disease
had to be limited to 1 side (right or left)
Exclusion: prior treatment (except biopsy), T2-N0 lingual cancer curable by surgery alone,
aged > 70 years
131 randomised, and 95 evaluable had at least 5-year follow-up (with 100% oral cavity
(tongue) patients)
Age range of participants 35-69 years
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 47): pre-operative chemotherapy (Day 1 60 mg epirubicin over 12 hours, Day 2
interval, day 3 50 mg cisplatin over 12 hours, Day 4 interval, Day 5 50 mg cisplatin, Day 6
& 7 interval, then repeated days 8-14
Gr B (n = 48): pre-operative radiotherapy 46 Gy delivered in 23 fractions over 5 weeks to
both primary tumour and cervical lymphatic pathways
Both groups then underwent radical surgery of the primary tumour, radical neck dissection
and reconstruction dependent on the individual case presenting. The extent of the primary
tumour excision was governed by the original tumour size, even if complete remission was
achieved in the pre-operative treatment. Surgery was performed as early feasible following
completion of pre-treatment - within 2 weeks
Outcomes Total mortality (overall survival presented as Kaplan-Meier estimates). Follow-up period: 5
years
Quality of life - using a standardised questionnaire
Notes Totalmortality: log [hazard ratio] SE calculated fromdata presented inKaplan-Meier estimates
for overall survival
Planned to recruit 200 patients over 5 years but only recruited 95 evaluable patients over 10
years
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Generation of randomisation sequence per-
formed by Central Operations Office at Uni-
versity of Vienna, using a computer-assisted
procedure
Allocation concealment? Yes Allocation by statistics centre - telephone no-
tification
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Szabo 1999 (Continued)
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? No 36/131 (27%)patients randomised are not in-
cluded in evaluation. Reasons and treatment
allocation are not given
Free of selective reporting? Yes Primary outcomes specified and reported
Free of other bias? Yes
Szpirglas 1979
Methods Randomised controlled trial conducted in: France
Number of centres: unknown
Recruitment period: March 1992 to December 1999
Funding source: unknown
Trial identification: Pité 74
Participants 136 patients were recruited with oral cavity cancer, however in the report only the 95 with
SCC of the anterior tongue or the floor of the mouth were considered. Stratified according
to stage and initial locoregional treatment
Stage A (T1-T2 N0) and stage B (T3 N0 and T1-T2-T3 N+). Large tumours and those
associated with fixed nodes were not included in this study
95 were evaluable by protocol and also had at least 2-year follow-up (with 100% oral tongue/
floor of mouth patients)
Age range of participants not reported
Interventions Comparison 2: Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy
alone
Randomised after surgery (+/- radiotherapy) when patient regarded as in remission of 3 groups
Gr A (n = 32): adjuvant chemotherapy (methotrexate 400 mg per month IV) followed by IM
injection of 100 mg of citrovorum (leucovorin or folinic acid) factor and bleomycin in 2 15
mg doses intramuscularly per week. The total dose of bleomycin never exceeded 450 mg in
15 weeks of treatment. Methotrexate was administered for 2 years
Gr B (n = 30): adjuvant immunotherapy (subcutaneous or intramuscular injections of 2 ml
of C. parvum weekly over 2 years)
Gr C (n = 33): surgery (+/- radiotherapy) alone
Outcomes Total mortality* IPD
Notes *Some information on trial and data supplied from Pignon 2000 .Total mortality: log [hazard
ratio] SE calculated from data provided from Pignon 2000 (based on patients with oral cavity
cancer not necessarily specifically those of the anterior tongue or floor of mouth)
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Szpirglas 1979 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “randomized into three groups”
Allocation concealment? Unclear Insufficent detail
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All participants accounted for, and IPD data
used within review
Free of selective reporting? Yes
Free of other bias? Yes No reported threats to validity
Szpirglas 1988
Methods Randomised controlled trial conducted in: Paris, France
Number of centres: 1
Recruitment period: 1981-1985
Funding source: CNAMTS
Trial identification number: Pitie 81
Participants Inclusion: unresectable T3/T4 carcinoma or the oral and oropharyngeal cavity most with
clinically involved nodes
Exclusion: no criteria given
116 patients randomised, 103 evaluable after completing treatment
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A (n = 58): 3 courses of neoadjuvant GIFA protocol each over 5 days (D1 Adriamycin 60
mg IV over 6 hours, D2 vincristine 2 mg IV+ bleomycin 15 mg IM, D3 & 4 bleomycin 15
mg IM, D5 cisplatin 150 mg + Diuretics) followed by radiotherapy randomised in 3 arms,
classical , bi-fractioned and tri-fractioned
Gr B (n = 58): radiotherapy in 3 arms (classical, bi-fractioned and tri-fractioned). 55 evaluable
patients, (2 patients died before radiotherapy, 1 excluded due to general status)
No details on radiotherapy doses given
Outcomes Complete response, disease free survival
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Szpirglas 1988 (Continued)
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Radiotherapy “randomised in three arms”, pa-
tients randomised to CT + RT or RT alone -
no further details given
Allocation concealment? Unclear Not mentioned
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Protocol violations, withdrawals due adverse
events clearly described for each group. Gr
A 56/58 evaluable patients after chemo, 46
evaluable after chemo + radiotherapy (8 pa-
tients did not receive radiotherapy (2 in com-
plete remission after chemo, 1 left country, 2
with little or no response to chemodied before
radiotherapy, 3 died during radiotherapy))
Gr B 55/58 evaluable
Free of selective reporting? Unclear Little information available
Free of other bias? Unclear Distribution of prognostic factors in each
group at baseline not presented
Tejedor 1992
Methods Randomised controlled trial conducted in Spain
Single centre
Randomisation process: unreported
Recruitment period: January 1987 to July 1989
Funding source: unknown
Trial identification number: Las Palmas
Participants Inclusion: adults with locally advanced SCC of the head and neck. Stage III-IV, M0
(11 (31%) patients with oral cavity and 13 (36%) with oropharyngeal cancer, combined OC/
OP were 67%)
42 randomised, 36 evaluable
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Tejedor 1992 (Continued)
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
Gr A: neoadjuvant CT (carboplatin + ftorafur analogue of 5-FU) plus radiotherapy (n = 19)
Gr B: RT alone (n = 17)
RT consisted 66-74 Gy (mean 68.8 Gy) by conventional fractionation scheme of 2 Gy per
day, 5 times a week. Doses delivered to subclinical disease areas was 50 Gy
CT consisted of 3 cycles of Carb 400 mg/m2 iv on day 1, ftorafur 1000 mg/m2 orally once a
day for 14 days. Cycles were given every 4 weeks
Outcomes Total mortality*IPD
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomised but method not described
Allocation concealment? Unclear Not described
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 6/42 participants (14%) were excluded from
analysis (4 did not complete treatment and 2
had inadequate follow-up). Not stated which
group these were from, and exclusions may
possibly influence results. However, IPD data
used within the review
Free of selective reporting? Yes
Free of other bias? Yes Groups comparable at baseline
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UKHAN 2010
Methods Randomised controlled trial conducted in: United Kingdom (34), Malta (1) & Turkey (1)
Number of centres: 36
Recruitment period: 15 January 1990 to 20 June 2000
Funding source: Cancer Research UK with support from University College London and
University College London Hospital Comprehensive Biomedical Research Centre
Participants Inclusion: patients with locally advanced squamous cell carcinoma of the head& neck, judged
suitable for radical radiotherapy as either initial treatment or following surgery (generally
patients at high risk of recurrence following surgery due to margin status or advanced stage
of disease at presentation). Age > 18 years, considered fit enough to receive any of the treat-
ments, histological confirmation of squamous cell carcinoma with T2 to T4 primary lesions
(including node negative cases) or node positive, normal full blood count, normal creatinine
& urea levels, no evidence of distant metastases and no prior treatment other than surgical
excision
966 patients randomised, 966 patients evaluable 187 oral cavity (19%) & 315 oropharynx
(33%) total OC/OP = 52%
Interventions Comparison 2: Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy
alone
Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Factorial design: patients who had NOT had surgery (npo) were randomised to 1 of 4 treat-
ment groups, while those whoHADundergone surgery (po) were randomised to either group
A or B
Gr A (n = 233 (npo) + 135 (po)): radiotherapy alone (RT)
Gr B (n = 166 (npo) + 118 (po)): radiotherapy plus simultaneous chemotherapy (RT+ SIM)
Gr C (n = 160 (npo)): radiotherapy plus subsequent chemotherapy (RT + SUB)
Gr D (n = 154 (npo)): radiotherapy plus simultaneous & subsequent chemotherapy
(RT+SIM+SUB)
Radiotherapy was given according to local practice at each participating centre, was approved
by trial steering committee and was constant for all patients at that centre. 3 regimens in
common use
• Manchester regimen - radical course to primary tumour and lymph nodes in 15-16
fractions (5 fr/week) over 3-3.5 weeks to minimum dose of 50-55 Gy for field area of 25-40
cm2 reduced to 45 Gy for larger fields
• SWOG regimen 1.8-2 Gy daily, 5 days/week, to primary tumour and lymph-node
drainage area to min total dose of 60 Gy (higher doses permitted)
• 55 Gy given in 20 fractions (2.75 Gy/fraction) over 4 weeks to primary tumour & first
station lymphatic drainage, & 41.25 Gy to the elective neck. 50 Gy in 20 fractions (2.5 Gy/
fraction) given post-operatively
Chemotherapy regimens were either methotrexate alone (MTX mono) or vincristine,
bleomycin, methotrexate & fluorouracil (VBMF), either started on days 1-14 concurrent
with RT (SIM) or 14 & 28 days after completing RT (SUB)
Methotrexate given IV in 2 doses of 100 mg/m2, dose 1, 24 hour before RT and dose 2 on
day 14 of RT. Folinic acid rescue was given if serum MTX levels >0.4 µmol/L24 hrs post-
treatment
VBMF comprised vincristine 1.4 mg/m2 (max 2 mg), bleomycin 30 mg, fluorouracil 500
mg, methotrexate 100 mg - IV by slow bolus injection except for bleomycin which was IM.
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UKHAN 2010 (Continued)
Hydrocortisone (100 mg IM) was available to minimise bleomycin adverse reactions, and
antiemetics were given according to local practice
Outcomes Primary endpoints: overall survival, event free survival (defined as recurrence, new tumour or
death, among patients disease free 6 months post-randomisation)
Secondary endpoints: locoregional disease control at 6 months, time to recurrence, death
from H&N cancer, toxicity
Notes Data in Pignon 2009 taken from unpublished study. Because there are more complete data
from published study UKHAN 2009 was used in the analyses
Sample size calculation estimated 100 patients would be required to detect an increase in 5-
year survival from 25% in RT alone group to 35% in CT groups combined, with 90% power
and 5% two sided level of significance
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Block stratified randomisation, block size of
9 (3:2:2:2 for Gr A, B, C & D giving ratio 2:
1 of chemo to RT alone). Stratified on centre
& CT regimen
Allocation concealment? Yes Random number lists generated at co-ordi-
nating centre, each centre obtained randomi-
sation by phone call to co-ordinating cen-
tre, who assigned treatment allocation after
recording eligibility and stratification factors
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes All randomised patients are included in the
analysis (ITT)
Free of selective reporting? Yes Primary and secondary outcomes clearly de-
scribed, defined and reported
Free of other bias? Yes No other sources of bias identified
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Vermorken 2007
Methods Randomised controlled trial conducted in: Europe
Number of centres: 15
Recruitment period: April 1999 to March 2002
Funding source: Sanofi-Aventis
Trial identification: TAX 323
Participants Inclusion: adults aged 18-70 years with squamous cell carcinoma of head & neck confirmed
by histology or cytology, previously untreated, TNM stage III or IV, M0,WHO performance
status ≤1 & adequate haematological, renal & hepatic function
Exclusion: patients with tumours of nasopharynx and nasal & paranasal sinuses
N = 358
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 177): (TPF) docetaxel 75 mg/m2 as 1 hour infusion Day 1 + cisplatin 75 mg/m2
as 1 hour infusion Day 1 + 5-FU 750 mg/m2/day as continuous infusion Days 1-5. Repeated
every 3 weeks for 4 cycles
Gr B (n = 181): (PF) cisplatin 100 mg/m2 as 1 hour infusion on Day 1 + 5-FU 1000 mg/m
2/day as continuous infusion Days 1-5. Repeated every 3 weeks for 4 cycles
If there was no disease progression, patients from both groups then had radiotherapy starting
4-7 weeks after end of CT (either conventional or hyperfractionated)
Outcomes Progression free survival, overall survival, response rate & duration, time to failure, toxicity,
HRQOL
Notes Power calculation given: “a total of 358 patients ... the trial had a power of 90% to detect and
improvement of 15% percentage points in the 1 year survival rate (85% in the TPF group
and 70% in the TF group)”
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomisation was balanced according to
primary tumour site (OC/OP/HP/L) and
centre with the use of variance minimisation
method
Allocation concealment? Unclear Not described
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes Reasons for small number of post-randomi-
sation exclusions and withdrawals clearly de-
scribed (Fig 1) and similar in each group. Ef-
ficacy analysis is by intention-to-treat
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Vermorken 2007 (Continued)
Free of selective reporting? Yes Primary and secondary endpoints clearly
stated and reported
Free of other bias? Yes No other threats to validity detected
Vokes 1990
Methods Randomised controlled trial conducted in: Chicago, USA
Number of centres: 1
Recruitment period: January 1986 to March 1987
Funding source: not stated
Participants Inclusion: adults with stage 3 or 4 locoregionally advanced, biopsy proven squamous cell
carcinoma of head and neck. Creatinine clearance > 50 ml/min&measurable disease, ECOG
performance status 0-2 and carbon monoxide diffusion capacity >/= 50%
29 randomised
Interventions Comparison 4: Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Gr A (n = 16): MPF day 1 Methotrexate (120 mg/m2) + day 2 leucovorin (100 mg/m2 as 6-
hour infusion) followed by 1000 mg/m2/day infusion 5-FU for 5 days, cycle repeated every
21 days - 4 cycles
Gr B (n = 13): PBM/PF
Cycles 1 & 3 - Days 1-5 cisplatin (20 mg/m2) over 2 hours, days 3-7 bleomycin 10 mg/m2
as continuous infusion, + days 14 & 21 methotrexate (200 mg/m2) with leucovorin rescue
on days 15 & 22
Cycles 2, 4 & 6 - Day 1 cisplatin (100 mg/m2), then 5-day continuous infusion 5-FU (1000
mg/m2/day) cycle repeated every 21 days
Cycle 5 - Days 1-3 cisplatin, days 2-4 bleomycin
All patients received standard hydration and antiemetic medications
Gr C (n = 13) - those with ECOGperformance status > 2, carbonmonoxide diffusion capacity
< 50% were not randomised but were treated with MPF protocol
Outcomes Overall survival, response to treatment and toxicity
Notes It was not possible to extract data in a form suitable for meta-analysis from this paper. Study
was stopped early
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Pre-randomisation stratification based on T,
N stage and performance status. No details
given on method of randomisation
Allocation concealment? Unclear No information given
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Vokes 1990 (Continued)
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear 2/16 excluded from arm A (1 death, 1 refused
treatment), protocol violations in 19% and
15% of groups A & B
Free of selective reporting? Yes Planned outcomes described and reported
Free of other bias? Unclear Small study, 6 strata and 29 patients. Trial
stopped early due to lack of efficacy in both
arms. Several changes to original protocol
noted (p 209)
Volling 1999
Methods Randomised controlled trial conducted in Germany
Multicentre (2 centres, 3 departments) (Departments of ENT and Radiotherapy &Oncology
at University Hospital Cologne and Hospital ENT, Kassel)
Recruitment period: 1988-1995
Funding source: unknown
Trial identification: Cologne
Participants Inclusion: adults with previously untreated histologically proven stage T2-3, N0-2 carcinoma
of oral cavity, oropharynx or hypopharynx, withWHOperformance status > 2,WBC> 4000/
mm3, platelets >100,000/mm3 & 24 hour creatinine clearance > 60 ml/min
Exclusion: distant metastases, second malignancy, prior chemotherapy or radiotherapy,
chronic disease (diabetes or rheumatoid arthritis requiring long term treatment) any active
neurological disorder
144 randomised 140 patients evaluable (withdrawals and drop outs accounted for)
100% oral cavity/oropharyngeal cancer
Interventions Comparison 1: Induction chemotherapy plus Locoregional treatment (LRT) versus LRT
alone
GrA (n=70 ): neoadjuvant/induction chemotherapy carboplatin 360mg/m2 as short infusion
over 30 mins on day 1, followed by 120 hour continuous infusion of 5-FU 1000 mg/m2/day.
If no response to first cycle CT, patients proceeded to surgery. Patients with partial response
or better to first cycle, had up to 3 cycles, before proceeding to surgery and radiotherapy
Gr B (n = 74): standard treatment with surgery and radiotherapy
Surgery was performed 3-5 weeks after the end of the chemotherapy - radical surgical resec-
tion of the primary tumour (resection was orientated to the original tumour margins before
chemotherapy)
Radiotherapy was started after complete wound healing but at least 6 weeks after surgery.
(If wound healing insufficient radiotherapy was not given.) Radiotherapy to a total dose of
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60-66 Gy to the primary tumour site and the involved neck node regions. In patients with
pathologically negative nodes, an adjuvant dose of 48 Gy was given to these regions
Outcomes Total mortality (overall survival presented as Kaplan-Meier estimates). Tumour response
Total mortality* IPD
Death or recurrent disease (disease free survival presented as Kaplan-Meier estimates)
Notes Pignon 2000 data not used (based on Volling 1994) as Volling 1999 provided more complete
data
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Quote: “Patients were selected randomly for
the different treatment arms by the secretariat.
..”
Stratified by primary tumour site and neck
node status.No details of sequence generation
given
Allocation concealment? Unclear Insufficient information
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes 1 patient in each group died post-operatively
so were not available for survival evaluation.
40/48 and 40/47 patients in groups A&B re-
spectively had the planned surgery and radio-
therapy. Reasons for drop outs given and sim-
ilar in each group
Free of selective reporting? Yes Tumour response and overall survival out-
comes planned and reported
Free of other bias? Yes No other threats to validity identified
169Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Weissler 1992
Methods Randomised controlled trial conducted in USA
Single centre but with 3 departments/divisions recruiting
Randomisation: insufficient details of randomisation given
Recruitment period: 1988-1995
Funding source: unknown
Trial identification: CH-7401
Participants 58 patients recruited, age range 34-78 years; all evaluable
Inclusion: patients with advanced stage III - IV, biopsy proven SCC of the H&N. Other
inclusion criteria: age > 18 years, life expectancy > 2 months, ECOG performance status 0-2,
adequate nutritional status, non-pregnant, no previous history of malignancy, no prior treat-
ment with chemotherapy or radiation therapy to the head and neck, adequate haematological,
renal and liver function
Exclusion: pregnant, prior malignancy, prior treatment
(16% oral cavity, 39% oropharyngeal, combined OC/OP = 55%)
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
GrA (n=17): unresectablewithmultiple dose/day radiation therapy plusCTDay1 cisplatin at
100 mg/m2 via rapid intravenous infusion, followed by 5-FU at 1000 mg/m2/day continuous
infusion over via 96 hours on days 1-4. Chemotherapy was repeated on days 29-32. Vigorous
hydration prior to commencement of treatment
Gr B (n = 15): unresectable with radiation alone
Gr C (n = 13): resectable with multiple dose/day radiation therapy plus CTDay 1 cisplatin at
100 mg/m2 via rapid intravenous infusion, followed by 5-FU at 1000 mg/m2/day continuous
infusion over via 96 hours on days 1-4. Chemotherapy was repeated on days 29-32. Vigorous
hydration prior to commencement of treatment
Gr D (n = 13): resectable plus radiation alone
Radiation therapy was delivered using a 6-MV linear accelerator. Initially treated with 1.5 Gy
twice/day for 10 days (total 30 Gy) followed by a 2-week break. The field was then reduced
to exclude spinal cord and an additional 1.5 Gy fraction was given twice daily for 8-13 days.
The minimum dose was 69 Gy for the unresectable group, 54 Gy for the high-risk resected
group with negative margins and 60Gy for the high-risk resected group with positive margins.
Radioactive implants were used in 6 patients in the unresectable group
Outcomes Overall survival, response to treatment, time to progression and disease free survival
Notes Pignon 2000 total mortality: log [hazard ratio] SE available
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Stratified into 2 groups: an inoperable group
(1 or more of the following: tumour exten-
sion into the middle or posterior fossa of the
skull, carotid artery, vertebral bone or high
surgical risk due to underlying medical con-
dition) and an operable group with less than a
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50%chance of 5-year disease free survival (ad-
vanced stage III-IV malignancies, advanced
nodal disease N2-N3 and patients with un-
favourable pathological findings such as close
(less than 5 mm) or positive margins, or ex-
tracapsular spread)
“Following stratification patients were ran-
domly selected to multiple dose radiotherapy
with or without concomitant chemotherapy”.
No details of method of sequence generation
provided
Allocation concealment? Unclear No details given
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Yes
Free of selective reporting? Yes
Free of other bias? Unclear Some imbalance between groups at baseline
Wendt 1998
Methods Randomised controlled trial conducted in: Germany
Number of centres: probably 1
Recruitment period: November 1989 - October 1993
Funding source: not stated
Trial identification number: BAVARIA - 89
Participants Inclusion: adults with histologically confirmed squamous cell carcinoma of the head & neck
, unresectable, Stages 3&4 (UICC) aged < 65 years, with no previous treatment except neck
dissection, performance status </= 2 (ECOG), no major impairment of of kidney, liver, bone
marrow, heart or lung function
Exclusions: patients with small tumours and severemedical problemswhich precluded surgery
298 randomised, 270 analysed. (112 (38%) oropharynx and 60 (20%) oral cavity = 172/298
= 58%)
Interventions Comparison 3: Concomitant chemoradiotherapy versus radiotherapy alone (non-re-
sectable)
GrA (n=130): concomitantRCT: hyperhydrationwith saline 200ml/hr onday 1, followedby
cisplatin 60 mg/m2 IV as short infusion, then 5-FU 350 mg/m2 by IV bolus, then leucovorin
(LV) 50 mg/m2 IV bolus on day 2, then 5-FU 350 mg/m2/24 hours and LV 50 mg/m2/
24hours as continuous infusion from day 2 to 5 of each cycle. Cycle repeated on days 22 and
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44. RT given with CT 15 fractions, each 1.8 Gy given twice daily with 6-hour interfraction
interval on weeks 1&2, 4&5 and 7&8 with breaks in between
Gr B (n = 140): RT alone. RT comprised 39 fractions of 1.8 Gy each, given twice daily with
a 6-hour interfraction interval, to a total dose of 70.2 Gy over 51 days. 3 cycles of 23.4 Gy
each, separated by a rest period of 11 days
Outcomes Overall survival , adverse effects, locoregional control
Notes *Data supplied from Pignon 2000. Total mortality: log [hazard ratio] SE calculated from data
provided from Pignon 2000; based on individual patient data
Sample size calculation given “to detect increase in 2-year survival from 45% to 60% by
combined modality at significance of 5% and power of 80% a sample of 172 patients per
arm is required.” Although the study only recruited 270 participants they found a significant
difference in 3-year survival rates suggesting the study had adequate power
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “By telephone randomisation at an indepen-
dent organisation (Algora,MunichGermany)
”. Stratified by centre, tumour site and nodal
stage
Allocation concealment? Yes
Blinding of participants? No Not mentioned
Blinding of carers? No Not mentioned
Blinding of outcome assessors? No Not mentioned
Incomplete outcome data addressed? Unclear Clear reporting of adverse events causing
withdrawal. 4 fromRT group and 7 fromRT/
CT group. Also 3 had contraindications to
CT and 14 (6%) had incomplete documen-
tation so were excluded from analysis - allo-
cated group unknown
Free of selective reporting? Yes Planned outcomes reported
Free of other bias? Yes Groups comparable at baseline
AF = accelerated fraction; BLM = bleomycin; Carb = carboplatin; CF = conventional fraction; Cis = Cisplatin; CR = complete
response; CT = chemotherapy; CRT = chemoradiotherapy; CYC = cyclophosphamide; Gr = group; H&N = head and neck; Hfx =
hyperfractionation; IA= intra-arterially; IL-2= interleukin-2; IM= intramuscularly; IPD= individual patient data; IV = intravenously;
LRT = locoregional treatment; LV= leucovorin; MMC = mitomycin C; MTX = methotrexate; OC/OP = oral cancer/oropharyngeal
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cancer; PORT = post-operative radiotherapy; RT = radiotherapy; SCC = squamous cell carcinoma; SE = standard error; vin =
vincristine; 5-FU = 5-fluorouracil.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abele 1984 Abstract only includes patients with recurrent disease and a low proportion of oral cavity/oropharyngeal
cancer
Abele 1985 Abstract only includes patients with recurrent disease and a low proportion of oral cavity/oropharyngeal
cancer
Adelstein 1997 Less than 50% of participants had oral cavity/oropharynx cancers
Adelstein 2000 Less than 50% of participants had oral cavity/oropharynx cancers
Amichetti 1989 Non-randomised study
Andreadis 1999 Abstract only, and no subsequent publication found September 09
Anonymous 1976 Less than 50% oral cavity cancer
Ansfield 1970 Non-randomised study
Antanadou 2002 Patients are randomised to receive amifostine or not
Asif 2003 Unclear percentage of oral cavity and oropharyngeal cancer, and it is likely that duration of follow-up for
published outcomes is 3 months
Auersperg 1977 Non-randomised study including patients with recurrent disease
Bachaud 1996 28% oral cavity/oropharynx cancers in this combined head and neck cancer trial (see 1991 paper)
Bakowski 1978 Unclear percentage of oral cavity/oropharynx cancer in this combined head and neck cancer trial
Berger 1995 Non-randomised study
Bezwoda 1979 Concern as to validity of the data from this study published in 1979. Unable to verify data
Bier 1986 Abstract only, and no subsequent publication found September 09. No response from email sent to first
author
Boidi 1991 50% oral cavity or oropharyngeal cancer and some patients included have metastatic disease
Bolla 1994 Etretinate is not a chemotherapy agent
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Bonner 2006 This trial deals with radiotherapy plus Cetuximab an immunotherapy/biotherapy agent. Therefore, this
trial is more suited for analysis in the Cochrane reviews: 1. Interventions for the treatment of oral cancer:
radiotherapy treatment and 2. Interventions for the treatment of oral cancer: immunotherapy/biotherapy
treatment
Bradley 1982 Abstract only, less than 50% oral cavity/oropharynx cancer patients included, and no subsequent publi-
cation found September 09
Brigham 1998 Abstract only. Patients included those with a variety of primary sites - unsure of proportion with oral cavity
or oropharyngeal cancer
Browman 1983 Includes patients with recurrent disease
Browman 1988 Includes patients with recurrent disease
Browman 1990 Includes patients with recurrent disease
Buentzel 2006 Patients randomised to amifostine or none
Buntzel 1998 Less than 50% of participants had oral cavity/oropharynx cancers
Buntzel 1998a Less than 50% of participants had oral cavity/oropharynx cancers
Campbell 1987 Less than 50% of patients had oral cavity/oropharyngeal cancer. Includes patients with recurrent and
metastatic disease
Caponigro 2002 Randomisation stopped after accrual of 36 patients to each armbut all 97 treated patients analysed together.
Only randomised data is tumour response published in an abstract (Caponigro 2001)
Cappelaere 1981 Less than 50% of patients had oral cavity/oropharyngeal cancer
Cappelaere 1990 Includes patients who have undergone prior treatment for oral cancer
Carugati 1988 Abstract only; insufficient information available
Clavel 1987 Includes patients with recurrent disease
Coates 1984 Study includes patients with recurrent disease
Coninx 1986 Quasi-randomised study
Coninx 1988 Study includes patients with metastatic disease
Corvo 1997 Pilot clinical trial with no relevant outcomes
Cruz 1997 Abstract only - no subsequent publication found October 09
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Cummings 2007 Less than 50% of participants in trial have oral cavity or oropharyngeal cancer
Dalley 1995 Abstract only; insufficient information available
De la Torre 1991 1991 abstract - no subsequent publication identified. Unclear what proportion of patients in this study
had oral cavity/oropharyngeal cancer
DeConti 1981 Less than 50% of patients have oral cavity cancer and some have recurrent disease
Deka 1983 Methodology concerning randomisation unclear - alternation?
Di Blasio 1994 Abstract only; insufficient information available
Dobrowsky 1996 3 months follow-up only
Domenge 1987 Abstract only. No full publication found and insufficient data in abstract to enable inclusion in review
Domenge 1988 Patients have nasopharyngeal cancer
Drelichman 1983 Includes patients with recurrent disease
Ebeling 1994 Non-randomised study
Eschwege 1997 Head and neck cancer study with < 50% oral cancer/oropharyngeal cancer. Wrote to authors requesting
data on oral/oropharyngeal cancer patients separately from head and neck cancers - no response
Ezzat 2005 Less than 50% of patients have oral cavity or oropharyngeal cancer
Fety 1994 Less than 50% of participants had oral cavity/oropharynx cancers
Fety 1998 Less than 50% participants had oral cavity cancer
Fonseca 1997 Intervention being compared is the addition of folinic acid to chemotherapy
Fonseca 2005 Less than 50% of participants have oral cavity or oropharyngeal cancer
Forastiere 2001 Includes patients with recurrent disease
Fountzalis 2004 Head and neck cancer study with < 50% oral cancer/oropharyngeal cancer. Wrote to authors requesting
data on oral/oropharyngeal cancer patients separately from head and neck cancers - not received
Fu 1987 Less than 50% of participants had oral cavity or oropharyngeal cancer
Fujii 1996 Not a randomised study
Fujii 1999 Not a randomised study
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Furukawa 1994 Less than 50% of participants had oral cavity/oropharynx cancers
Gabriele 1994 Abstract only. No full publication found and no response from correspondence to first author
Gabriele 1996 Abstract only, less than 50% oral cavity/oropharynx cancer patients included, and no subsequent publi-
cation found September 09
Gasparini 1992 15% of patients had recurrent disease
Gedouin 1986 Less than 50% of participants had oral cavity/oropharynx cancers
Gedouin 1996 Less than 50% of participants had oral cavity/oropharynx cancers
Gehanno 1992 Less than 50% of participants had oral cavity/oropharynx cancers
Gibson 2005 Includes patients with recurrent disease
Gollin 1972 Quasi-randomised (patients paired and then blinded drawing of cards to allocate first member of pair to
treatment, other patient received alternate treatment). Variation in treatment used over the course of the
study. Publication too old to be able to contact authors
Grose 1985 Includes patients with metastatic disease
Haas 1985 Abstract only, and no subsequent publication found September 09
Haas 1986 Less than 50% of participants had oral cavity/oropharynx cancers
Haffty 1993 Less than 50% of participants had oral cavity/oropharynx cancers
Haffty 1997 Less than 50% of participants had oral cavity/oropharynx cancers
Haffty 1997a Less than 50% of participants had oral cavity/oropharynx cancers
Haffty 2005 Some patients had recurrent disease and prior chemotherapy
Handa 1980 Allocation to intervention not truly random
Hasegawa 1996 Abstract only; insufficient information available
Haselow 1990 Preliminary results of a study with less than 50% oral cavity oropharyngeal cancer
Henk 1984 Less than 50% participants had oral cavity/oropharynx cancers
Hitt 2005 Less than 50% of participants had oral cavity or oropharyngeal cancer
Homma 2004 Less than 50% participants had oral cavity/oropharynx cancers
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Hussey 1975 Less than 50% participants had oral cavity/oropharynx cancers
Jain 1979 Methods used described very briefly - unclear if patients were randomised to treatment
Jones 1992 Less than 50% participants had oral cavity/oropharynx cancers, including patients with recurrent disease
Jortay 1990 Less than 50% participants had oral cavity/oropharynx cancers
Kamioner 1994 Abstract only more than 10 years old. No subsequent publication found. Insufficient information in
abstract to include in review
Kaneda 1987 Non-randomised study which includes patients with prior treatment for oral cancer
Kapstad 1978 Less than 50% participants had oral cavity/oropharynx cancers
Kapstad 1979 Less than 50% participants had oral cavity/oropharynx cancers
Katori 2007 Not randomised
Klima 1988 Trial includes patients with metastatic disease
Kotani 1994 Based on translation by ToruNaito it appears that the included patients had a variety of primary treatments
before being allocated to subsequent chemotherapy or not
Laccourreye 1983 Less than 50% participants had oral cavity/oropharynx cancers
Lavertu 1998 Less than 50% participants had oral cavity/oropharynx cancers
Le 1998 Abstract only, and no subsequent publication of randomised study found September 09
Lee 1989 Includes patients with recurrent disease
Lippman 1988 Less than 50% or particpants have oral cavity cancer
Liverpool HNOG 1990 Includes patients with recurrent disease
Lopes 1991 Abstract only, less than 50% oral cavity/oropharynx cancer patients included, and no subsequent publi-
cation found September 09
Magno 1994 Less than 50% participants had oral cavity/oropharynx cancers
Manocha 2006 Described as randomised controlled trial but patients in group 1 were selected by good KPS score perfor-
mance status and ability to afford chemotherapy. Email requesting further information sent 1/10/09 - no
reply received
Mantovani 1998 Chemotherapy is same in both groups - patients randomised to immunotherapy or not
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Martin 1994 Head and neck cancer study with < 50% oral cancer/oropharyngeal cancer. Wrote to authors requesting
data on oral/oropharyngeal cancer patients separately from head and neck cancers - no response. Pignon
has individual patient data for all patients - trial identification CRETEIL 86
Mechl 1987 Less than 50% of participants have oral cavity cancer
Moro 1994 Abstract more than 10 years old. Insufficient information in abstract to include this trial. No subsequent
publication identified
Morton 1985 Low percentage oral cavity and oropharyngeal cancer and some participants had recurrent disease
Morton 1987 Low percentage oral cavity and oropharyngeal cancer and some participants had recurrent disease
Nissenbaum 1984 Less than 6 months follow-up
O’Connor 1979 Some patients had prior treatment
Olasz 2004 Quasi-randomised study - patients allocated to treatment by alternation
Panis 1984 35% of participants had received prior treatment for oral cancer
Pant 1973 Pseudo-randomised (Pignon)
Papac 1978 Unclear what proportion of patients in this study have oral cavity cancer
Pearlman 1985 Includes patients with recurrent disease
Peng 2007 Paper published in Chinese with English abstract. Email sent to Dr Peng requesting more information
concerning eligibility of study for inclusion in this review. Reply received 5/11/09, stating that data are
lost
Phillips 1980 Abstract only, less than 50% oral cavity/oropharynx cancer patients included, and no subsequent publi-
cation found September 09
Platzer 1990 Abstract only, outcomes not relevant, and no subsequent publication found September 09
Price 1978 Linked to Shaw 1978. Many participants had prior treatment
Proto 1993 Interim report of 8 oral cavity cancer patients randomised to 3 treatment arms. No usable data. No follow-
up publication found
Racadot 2008 Less than 50% of participants have oral cavity or oropharyngeal cancer
Rodrigo 2004 Less than 50% of participants had oral cavity/oropharynx cancers
Rosen 2003 Randomised comparison of erythropoietin versus no erythropoietin, therefore does not meet intervention
inclusion criteria for this review
178Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Sanchiz 1990 Less than 50% participants had oral cavity/oropharynx cancers
Sanguineti 1999 Data analysis of case series including some patients randomised to treatment and others not randomised
Sarkar 2008 Less than 50% of participants have oral cavity or oropharyngeal cancer
Schildhauer 2005 Patients have primary metastatic or recurrent disease
Schuller 1989 Less than 50% of participants had oral cavity/oropharynx cancers
Sealy 1978 Unclear concerning proportion of patients with oral cavity/oropharyngeal cancer. Unclear methodology
concerning randomisation
SECOG 1986 43% oral cavity cancers only
Shaw 1978 Linked to Price 1978. Many participants had prior treatment
Shetty 1985 Abstract only, unable to find subsequent publication. Insufficient information to include in systematic
review
Siodlak 1989 Less than 50% participants had oral cavity/oropharynx cancers
Smid 2003 Less than 50% patients had oral cavity or oropharyngeal cancer
Snow 1981 Less than 50% of patients had oral cavity/oropharyngeal cancer
Soo 2005 Less than 50% of patients have oral cavity or oropharyngeal cancer
Stefani 1971 Includes participants with metastatic disease. Linked to Stefani 1980
Stefani 1980 Includes participants with metastatic disease. Linked to Stefani 1971
Stell 1983 Less than 50% participants had oral cavity/oropharynx cancers
Stell 1990 Less than 50% of patients had oral cavity/oropharyngeal cancer
Stolwijk 1985 Less than 50% participants had oral cavity/oropharynx cancers
Suwinski 2005 Less than 50% of participants have oral cavity or oropharyngeal cancer
Taylor 1979 Includes patients who had prior treatment
Taylor 1984 Includes patients who had prior treatment
Taylor 1985 Allocated to treatment by alternation, and post-radiotherapymaintenance chemotherapy regimen changed
after 29/82 patients treated. Data not available for each regimen separately
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Taylor 1994 9% of included patients have recurrent disease and only 51% of patients have oral cavity/oropharynx
disease. It is likely that less than 50% of patients included have untreated advanced cancer of oral cavity
or oropharynx
Taylor 1997 Follow-up of patients, only some were randomised to treatment and < 50% had oral cavity cancer
Toohill 1987 50% participants had oral cavity/oropharynx cancers, interim report
Tsukuda 1994 Less than 50% of participants have oral cavity or oropharyngeal cancer
Tsukuda 2005 Less than 50% of participants have oral cavity or oropharyngeal cancer
Vega 1981 [Spanish] Some patients in this study have recurrent or metastatic disease and less than 50% have oral
cavity/oropharynx primary tumours
Venkatachalam 1998 Chemotherapy is same in both groups - patients randomised to immunotherapy or not
Vermund 1985 Less than 50% participants had oral cavity/oropharynx cancers
Veronesi 1985 60% of participants have undergone previous treatment and 19% have metastatic disease. Requested data
on participants without prior treatment - no response received
Von Heyden 1984 Cross-over design. Onkologie reference gives results of patients without pre-treatment but 4 and 9 patients
from each group received both chemotherapy regimens
Von Heyden 1982 Cross-over study included 23/52 patients who had undergone previous surgery or radiotherapy, and
patients with no response to allocated treatment then received the alternative treatment
Von Heyden 1984 Cross-over study
Von Heyden 1985 Cross-over study - (n = 79) some patients had prior treatment
Weissberg 1989 Less than 50% oral cavity and oropharynx cancer. Data in Pignon 2000 is for all the included patients.
No separate data for oral cavity and oropharyngeal cancer patients available
Woods 1977 Less than 50% oral cavity or oropharyngeal cancer and includes patients with recurrent disease
Woods 1981 Includes patients with recurrent disease
Woods 1981a Proportion of patients with oral cavity/oropharyngeal cancer unknown and some patients had prior
treatment
Woods 1984 Abstract only - some patients had prior treatment
Yoshino 1991 Less than 50% of participants have oral cavity or oropharyngeal cancer
Yoshino 1994 Less than 50% of participants have oral cavity or oropharyngeal cancer
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Characteristics of studies awaiting assessment [ordered by study ID]
Abdel Wahab 2006
Methods Randomised controlled trial conducted in: Egypt
Number of centres: ?one
Recruitment period: January 2000 to December 2005
Funding source: not stated
Participants Patients with locally advanced squamous cell carcinoma of head and neck
Interventions Group A (n = 35) chemoradiotherapy. 70 Gy over 7 weeks using standard portals and techniques of radiotherapy +
concomitant cisplatin (30 mg/m2 weekly from week 1-7 followed by 3 cycles adjuvant cisplatin (20 mg/m2) on days
1-4 and fluorouracil (1000 mg/m2) on days 1-4 on weeks 11,15 &19
Group B (n = 36) radiotherapy alone, 70 Gy over 7 weeks using standard portals and techniques of radiotherapy
Outcomes Tumour response, 2 & 3 yr OS, 2 & 3 yr PFS, ITT, f/up 29 months
Notes Abstract, no full publication found August 2010
Bouillet 2007
Methods
Participants Patients with inoperable locally advanced head and neck cancer, T3/T4, PS <2, buccal cavity 38% oro-hypopharynx
47%, larynx 11% - unclear percentage of oral cavity/oropharynx
Interventions Group A (n = 35) 7 cycles weekly docetaxel 20 mg/m2 before radiotherapy and cisplatin 20 mg/m2 D1-3 every 3
weeks (3 cycles) + 70 Gy radiotherapy over 7 weeks
Group B (n = 47) 7 cycles weekly docetaxel 20 mg/m2 before radiotherapy (70 Gy over 7 weeks)
Both groups offered G-CSF secondary prophylaxis and ciprofloxacin
Outcomes ITT ORR, median TTP, median OS
Docetaxel/cisplatin arm discontinued for insufficient efficacy
Notes Abstract, no full publication found August 2010
Bourhis 2002
Methods Randomised controlled trial conducted in: France
Number of centres: multi
Recruitment period: 1996-2000
GORTEC 96-01
Participants 109 participants
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Interventions Group A 62-64 Gy in 3 to 3.5 weeks
Group B 62-64 Gy in 5 weeks plus concomitant cisplatin 100 mg/m2 on days 1, 16, 32, and 5-FU 1000 mg/m2/
day on days 1-5 and 31-35
Outcomes Locorregional control, distant metyastases, disease free survival and overall survival
Notes Emailed author 27/10/09 seeking more information on GORTEC 96-01 - no reply. Study was stopped early due to
an excess of deaths in the RT-CT arm (Group B)
Datta 1991
Methods
Participants
Interventions
Outcomes
Notes Unclear whether this is an RCT. Waiting to obtain paper copy August 2010
Ghosh 2006
Methods Randomised controlled trial conducted in: Mumbai, India
Number of centres: 1
Recruitment period: April 2000 to December 2004
Participants Stage III & IV non-nasopharyngeal squamous cancers of the head and neck region. Randomisation stratified by
tumour site and stage
Interventions Group A conventional fractionated radiotherapy 66-70 Gy in 6-7 weeks @ 5 fractions/week
Group B conventional fractionated radiotherapy 66-70 Gy in 6-7 weeks @ 5 fractions/week + concomitant weekly
inj cisplatin 30 mg/m2
Grroup C accelerated fractionated radiotherapy 66-70 Gy in 6.5 weeks @ 6 fractions/week (6th fraction used reduced
fields)
150 randomised
Outcomes Tumour response, toxicity
Notes Abstract, no full publication found August 2010
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Hitt 2009
Methods Randomised controlled trial conducted in: Spain
Recruitment period: December 2002 to June 2007
Funding source: not stated
Participants Unresectable measurable locally advanced head and neck cancer, with good performance status
Interventions Group A PF induction - cisplatin 100 mg/m2/day on day 1 then 5-FU 1000 mg/m2/day days 1-5 repeated every 3
weeks for 3 cycles followed by chemoradiotherapy - conventional radiotherapy up to 70 Gy plus cisplatin 100 mg/
m2 on days 1, 22 and 43
Group B TPF induction - docetaxel 75 mg/m2 on day 1, cisplatin 75 mg/m2 day 1 and 5-FU 750 mg/m2 by
continuous infusion on days 1-5 repeated every 3 weeks for 3 cycles (G-CSF and ciprofloxacin as well) followed by
chemoradiotherapy - conventional radiotherapy up to 70 Gy plus cisplatin 100 mg/m2 on days 1, 22 and 43
Group C chemoradiotherapy only - conventional radiotherapy up to 70 Gy plus cisplatin 100 mg/m2 on days 1, 22
and 43
Outcomes Time to treatment failure, locoregional control, adverse evenets
Notes Unclear percentage of oral cavity + oropharyngeal cancers. No subsequent publication found August 2010
Rapoport 1991
Methods
Participants
Interventions
Outcomes
Notes Unclear whether this is an RCT. Waiting to obtain paper copy August 2010
Saber 2005
Methods Recruitment period: August 2001 to July 2004
Participants Locally advanced squamous cell carcinoma of head and neck
Interventions Group A conventional radiotherapy alone (60-70 Gy over 6-7 weeks)
Group B concomitant chemoradiotherapy - conventional radiotherapy + cisplatin 30 mg/m2 weekly on day 1 of
chemo then weekly till the end of radiotherapy
Outcomes Tumour response, toxicity
Notes Abstract, no full publication found August 2010
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Sharma 2007
Methods Randomised controlled trial conducted in: India
Participants Previously untreated stage II-IV oropharyngeal and nasopharyngeal cancer
Interventions Group A radiotherapy 70 Gy in 35 fractions over 7 weeks
Group B cisplatin 40 mg/m2 weekly for 6 doses beginning on day 1 of radiotherapy total 70 Gy in 35 fractions over
7 weeks
153 randomised, 137 evaluated
Outcomes Response, toxicity and overall survival
Notes Abstract, no full publication found August 2010. Imbalance at baseline - 83% of nasopharyngeal cancer patients in
Group B (combined therapy)
Tepmongkol 1989
Methods
Participants
Interventions
Outcomes
Notes Unclear whether this is an RCT. Waiting to obtain translation paper copy January 2011
RCT = randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Induction chemotherapy plus locoregional treatment (LRT) versus LRT alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality 25 Hazard Ratio (Random, 95% CI) 0.92 [0.84, 1.00]
1.1 Cisplatin or carboplatin +
5-FU + RT ± surgery vs RT ±
surgery
7 Hazard Ratio (Random, 95% CI) 0.90 [0.80, 1.02]
1.2 Carboplatin and ftorofur
+ RT vs RT alone
1 Hazard Ratio (Random, 95% CI) 0.45 [0.19, 1.08]
1.3 Cisplatin + 5-FU + folinic
acid + RT vs RT alone
1 Hazard Ratio (Random, 95% CI) 0.69 [0.39, 1.25]
1.4 Cisplatin + 5-FU +
vindesine + RT vs RT alone
1 Hazard Ratio (Random, 95% CI) 1.09 [0.69, 1.70]
1.5 Cisplatin + 5-FU +
bleomycin + methotrexate +
RT vs RT alone
1 Hazard Ratio (Random, 95% CI) 1.46 [0.93, 2.29]
1.6 Cisplatin + bleomycin +
vinblastine + mitomycin C +
RT vs RT alone
1 Hazard Ratio (Random, 95% CI) 1.04 [0.57, 1.87]
1.7 Cisplatin + bleomycin +
vindesine + mitomycin C + RT
vs RT alone
1 Hazard Ratio (Random, 95% CI) 1.13 [0.74, 1.72]
1.8 Cisplatin + bleomycin +
vincristine + adriamycin + RT
vs RT alone
1 Hazard Ratio (Random, 95% CI) 0.92 [0.62, 1.37]
1.9 Cisplatin + bleomycin +
vincristine + methotrexate +
RT + surgery vs RT + surgery
1 Hazard Ratio (Random, 95% CI) 1.07 [0.77, 1.49]
1.10 Cisplatin + bleomycin +
methotrexate + surgery + RT vs
surgery + RT
1 Hazard Ratio (Random, 95% CI) 1.07 [0.56, 2.05]
1.11 Cisplatin + epirubicin +
surgery vs RT plus surgery (5
years)
1 Hazard Ratio (Random, 95% CI) 0.88 [0.56, 1.38]
1.12 Methotrexate + RT vs
RT alone
4 Hazard Ratio (Random, 95% CI) 0.90 [0.72, 1.14]
1.13 Methotrexate +
vincristine + RT vs RT alone
1 Hazard Ratio (Random, 95% CI) 0.57 [0.24, 1.34]
1.14 Methotrexate +
bleomycin + 5-FU +
cyclophosphamide + RT ±
surgery vs RT ± surgery
1 Hazard Ratio (Random, 95% CI) 1.48 [0.91, 2.42]
1.15 Bleomycin + vincristine
+ surgery ± RT vs surgery ± RT
2 Hazard Ratio (Random, 95% CI) 0.67 [0.50, 0.91]
2 Disease free survival 8 Hazard Ratio (Random, 95% CI) 0.78 [0.67, 0.90]
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2.1 Carboplatin + 5-FU + RT
+ surgery vs RT + surgery
2 Hazard Ratio (Random, 95% CI) 0.66 [0.48, 0.89]
2.2 Carboplatin + ftorafur +
RT vs RT alone
1 Hazard Ratio (Random, 95% CI) 0.86 [0.34, 2.21]
2.3 Cisplatin + fluorouracil +
RT + surgery vs RT + surgery
(5 years)
2 Hazard Ratio (Random, 95% CI) 0.78 [0.62, 0.97]
2.4 Cisplatin + bleomycin +
vindesine + mitomycin C + RT
vs RT alone
1 Hazard Ratio (Random, 95% CI) 0.93 [0.58, 1.49]
2.5 Bleomycin + vincristine
+ surgery vs surgery (floor of
mouth)
1 Hazard Ratio (Random, 95% CI) 0.86 [0.56, 1.32]
2.6 Bleomycin +
cyclophosphamide + MTX +
5-FU plus RT ± surgery versus
RT ± surgery
1 Hazard Ratio (Random, 95% CI) 0.92 [0.48, 1.76]
3 Progression free survival 2 Hazard Ratio (Fixed, 95% CI) 0.80 [0.64, 1.00]
3.1 Cisplatin + 5-FU + RT +
surgery vs RT + surgery
1 Hazard Ratio (Fixed, 95% CI) 0.83 [0.63, 1.09]
3.2 Carboplatin + 5-FU + RT
+ surgery vs RT + surgery
1 Hazard Ratio (Fixed, 95% CI) 0.76 [0.52, 1.10]
4 Disease free survival 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.1 Cisplatin + 5-FU + surgery
vs surgery alone (5 years)
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5 Recurrent disease - Locoregional 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Cisplatin + 5-FU + surgery
vs surgery alone (5 years)
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 2. Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality 10 Hazard Ratio (Fixed, 95% CI) 0.88 [0.79, 0.99]
1.1 Surgery + CT
(methotrexate/ bleomycin/
vincristine) vs surgery + RT
1 Hazard Ratio (Fixed, 95% CI) 0.32 [0.08, 1.35]
1.2 Surgery + CT
(methotrexate) vs surgery alone
1 Hazard Ratio (Fixed, 95% CI) 1.07 [0.48, 2.38]
1.3 Surgery + CT (levamisole/
UFT) vs surgery alone
1 Hazard Ratio (Fixed, 95% CI) 0.70 [0.36, 1.37]
1.4 Surgery ± RT + CT
(methotrexate/bleomycin/
leucovorin) vs surgery ± RT
1 Hazard Ratio (Fixed, 95% CI) 1.01 [0.50, 2.05]
1.5 Surgery + RT + CT
(methotrexate) vs surgery + RT
alone
1 Hazard Ratio (Fixed, 95% CI) 1.04 [0.75, 1.45]
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1.6 Surgery +CT (cisplatin/
5-FU) + RT vs surgery + RT
alone
1 Hazard Ratio (Fixed, 95% CI) 0.91 [0.73, 1.13]
1.7 Surgery + RT + CT
(concom cisplatin) vs surgery +
RT alone
2 Hazard Ratio (Fixed, 95% CI) 0.80 [0.66, 0.97]
1.8 Surgery + RT + CT
(concom carboplatin) vs
surgery + RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.90 [0.42, 1.92]
1.9 Surgery + RT + CT
(concom MTX or VBMF) vs
surgery + RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.94 [0.70, 1.26]
2 Disease free survival 8 Hazard Ratio (Fixed, 95% CI) 0.89 [0.78, 1.01]
2.1 Surgery + CT
(methotrexate/ bleomycin/
vincristine) vs surgery + RT
1 Hazard Ratio (Fixed, 95% CI) 0.90 [0.19, 4.21]
2.2 Surgery + CT
(methotrexate) vs surgery alone
1 Hazard Ratio (Fixed, 95% CI) 0.47 [0.26, 0.87]
2.3 Surgery + RT + CT
(methotrexate) vs surgery + RT
alone
1 Hazard Ratio (Fixed, 95% CI) 0.84 [0.38, 1.83]
2.4 Surgery +CT (cisplatin/
5-FU) + RT vs surgery + RT
alone
1 Hazard Ratio (Fixed, 95% CI) 0.90 [0.72, 1.14]
2.5 Surgery + RT + CT
(concom cisplatin) vs surgery +
RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.78 [0.62, 0.99]
2.6 Surgery + RT + CT
(concom carboplatin) vs
surgery + RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.82 [0.40, 1.66]
2.7 Surgery + RT + CT
(concom MTX or VBMF) vs
surgery + RT alone
1 Hazard Ratio (Fixed, 95% CI) 1.03 [0.78, 1.36]
2.8 Induction cis/BLM +
surgery + RT + adjuvant
cisplatin versus surgery + RT
alone
1 Hazard Ratio (Fixed, 95% CI) 1.55 [0.93, 2.58]
3 Progression free survival 2 Hazard Ratio (Fixed, 95% CI) 0.88 [0.72, 1.07]
3.1 Surgery + RT + CT
(concom cisplatin) vs surgery +
RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.75 [0.57, 0.99]
3.2 Surgery + RT + CT
(concom MTX or VBMF) vs
surgery + RT alone
1 Hazard Ratio (Fixed, 95% CI) 1.03 [0.78, 1.36]
4 Locoregional recurrence 1 Hazard Ratio (Fixed, 95% CI) Totals not selected
4.1 Surgery + RT + CT
(cisplatin) vs surgery + RT
alone
1 Hazard Ratio (Fixed, 95% CI) Not estimable
5 Recurrent disease (overall) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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5.1 Surgery + RT + CT
(methotrexate) vs surgery + RT
alone (2 years)
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 3. Concomitant chemoradiotherapy versus radiotherapy alone (non-resectable)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality 26 Hazard Ratio (Fixed, 95% CI) 0.78 [0.73, 0.83]
1.1 Cisplatin or carboplatin +
RT vs RT alone
5 Hazard Ratio (Fixed, 95% CI) 0.66 [0.57, 0.77]
1.2 Cisplatin or carboplatin +
5-FU + RT vs RT alone
8 Hazard Ratio (Fixed, 95% CI) 0.71 [0.62, 0.81]
1.3 Cisplatin + bleomycin +
RT vs RT alone
1 Hazard Ratio (Fixed, 95% CI) 1.21 [0.67, 2.19]
1.4 1-FU+ RT vs RT alone 1 Hazard Ratio (Fixed, 95% CI) 0.83 [0.58, 1.21]
1.5 Mitomycin + 5-FU + RT
vs RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.77 [0.61, 0.98]
1.6 Methotrexate + RT vs RT
alone
1 Hazard Ratio (Fixed, 95% CI) 0.96 [0.76, 1.23]
1.7 Sim CRT (MTX or
VBMF) versus RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.82 [0.65, 1.04]
1.8 Sim CRT (MTX or
VBMF) + Sub CT (MTX or
VBMF) vs RT alone
1 Hazard Ratio (Fixed, 95% CI) 1.06 [0.84, 1.34]
1.9 Bleomycin + RT vs RT
alone
4 Hazard Ratio (Fixed, 95% CI) 0.79 [0.62, 1.00]
1.10 Bleomycin + mitomycin
+ RT vs RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.64 [0.36, 1.14]
1.11 Mitomycin + RT versus
RT alone
2 Hazard Ratio (Fixed, 95% CI) 0.92 [0.76, 1.12]
1.12 Cisplatin + 5-FU
alternating with RT vs RT
alone
2 Hazard Ratio (Fixed, 95% CI) 0.69 [0.53, 0.90]
2 Disease free survival 9 Hazard Ratio (Fixed, 95% CI) 0.77 [0.70, 0.84]
2.1 Cisplatin or carboplatin +
5-FU + RT versus RT alone
4 Hazard Ratio (Fixed, 95% CI) 0.70 [0.59, 0.84]
2.2 Carboplatin + RT versus
RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.83 [0.68, 1.01]
2.3 Cisplatin + 5-FU
alternating with RT vs RT
alone
1 Hazard Ratio (Fixed, 95% CI) 0.78 [0.55, 1.11]
2.4 MTX + RT versus RT
alone
1 Hazard Ratio (Fixed, 95% CI) 0.65 [0.43, 0.98]
2.5 Bleomycin + mitomycin +
RT versus RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.45 [0.22, 0.93]
2.6 Sim CRT (MTX or
VBMF) versus RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.72 [0.57, 0.91]
188Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2.7 Sim CRT (MTX or
VBMF) + Sub CT (MTX or
VBMF) vs RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.92 [0.74, 1.15]
3 Locoregional control 8 Hazard Ratio (Fixed, 95% CI) 0.72 [0.64, 0.81]
3.1 Cisplatin or carboplatin +
RT vs RT alone
2 Hazard Ratio (Fixed, 95% CI) 0.78 [0.65, 0.94]
3.2 Cisplatin or carboplatin
+ 5-FU + RT ± surgery vs RT
alone
3 Hazard Ratio (Fixed, 95% CI) 0.75 [0.61, 0.93]
3.3 Methotrexate + RT vs RT
alone
1 Hazard Ratio (Fixed, 95% CI) 0.71 [0.49, 1.02]
3.4 Mitomycin + 5-FU + RT
vs RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.48 [0.33, 0.71]
3.5 Cisplatin +5-FU
alternating with RT
1 Hazard Ratio (Fixed, 95% CI) 0.35 [0.14, 0.87]
4 Progression free survival 6 Hazard Ratio (Fixed, 95% CI) 0.77 [0.67, 0.89]
4.1 Cisplatin + post-op RT vs
post-op RT
2 Hazard Ratio (Fixed, 95% CI) 0.84 [0.66, 1.08]
4.2 1-FU + RT vs RT alone 1 Hazard Ratio (Fixed, 95% CI) 0.79 [0.54, 1.14]
4.3 Mitomycin + 5-FU + RT
vs RT alone
1 Hazard Ratio (Fixed, 95% CI) 0.60 [0.44, 0.83]
4.4 Alternating cisplatin +
5-FU + RT
2 Hazard Ratio (Fixed, 95% CI) 0.82 [0.62, 1.07]
5 Locoregional control 4 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Mitomycin + HFxAcc
RT versus HFxAcc RT alone
(median 4 years)
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 Bleomycin + LRT versus
LRT
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.3 Gemcitabine + RT versus
RT alone
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.4 Pepleomycin + RT
± hyperthermia vs RT +
hyperthermia
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 4. Chemotherapy A (± LRT) versus chemotherapy B (± LRT)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Total mortality 20 Hazard Ratio (Fixed, 95% CI) Totals not selected
1.1 Induction cisplatin + UFT
versus induction cisplatin +
5-FU
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.2 Induction carboplatin +
5-FU versus induction cisplatin
+ 5-FU
1 Hazard Ratio (Fixed, 95% CI) Not estimable
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1.3 Induction cisplatin +
vinorelbine ± LRT versus
induction cisplatin + 5-FU ±
LRT
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.4 Induction cisplatin
+ etoposide + RT versus
induction cisplatin + RT
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.5 Induction cisplatin +
methotrexate + bleomycin +
vincristine versus induction
cisplatin
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.6 Induction simultaneous
MTX + 5-FU versus sequential
MTX + 5-FU
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.7 Induction cisplatin +
docetaxel + 5-FU (TPF) ± RT
versus induction cisplatin +
5-FU (PF) ±RT
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.8 Induction TPF + CRT
± surg versus induction PF +
CRT + surg
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.9 Induction
CT(cis/5-FU/TPZ) then
CRT(cis/5-FU/TPZ/RT)
versus induction CT (PF) then
CRT (PF+RT)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.10 Concomitant
CRT (carboplatin) versus
concomitant CRT (cisplatin)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.11 Concomitant
CRT(cis/TPZ) versus
concomitant CRT (cis/5-FU)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.12 Concomitant CRT
(cis/TPZ) versus concomitant
CRT (cis)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.13 Concomitant
CRT(HU/5-FU) versus
concomitant CRT (cis/FU)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.14 Concomitant CRT
(cis/paclitaxel) versus
concomitant CRT (cis/FU)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.15 Concomitant CRT
(cis/paclitaxel) versus
concomitant CRT (HU/5-FU)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.16 Concomitant
intra-arterial CRT vs
concomitant intravenous CRT
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.17 Concomitant CRT
(MTX or VBMF) versus RT
then CT (MTX or VBMF)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
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1.18 Concomitant CRT
(MTX or VBMF) then CT
versus RT then CT (MTX or
VBMF)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.19 Concomitant CRT
(MTX or VBMF) then CT
versus concomitant CRT
(MTX or VBMF)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.20 Induction CT (PF) then
RT vs concomitant CRT +
maint CT (PF)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.21 Induction sequential
cisplatin then RT versus
concomitant CRT (cis/5-FU)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.22 Induction CT (PF)
then concomitant CRT versus
concomitant CRT (PF)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.23 Induction CT (TPF)
then CRT versus CRT alone
1 Hazard Ratio (Fixed, 95% CI) Not estimable
1.24 Induction CT
(BLM/MTX/VINB) then RT
vs alternating CRT
1 Hazard Ratio (Fixed, 95% CI) Not estimable
2 Disease free survival 7 Hazard ratio (Fixed, 95% CI) Totals not selected
2.1 Induction CT(cis/BLM)
then surg/RT then CT (cis) vs
induction CT (cis/BLM) then
surg/RT
1 Hazard ratio (Fixed, 95% CI) Not estimable
2.2 Induction CT (cis/5-FU)
then concomitant CRT versus
concomitant CRT (cisplatin +
5-FU)
1 Hazard ratio (Fixed, 95% CI) Not estimable
2.3 Concomitant CRT
(cis/TPZ) versus concomitant
CRT (cis/5-FU)
1 Hazard ratio (Fixed, 95% CI) Not estimable
2.4 Concomitant CRT
(cis/TPZ) versus concomitant
CRT (cis)
1 Hazard ratio (Fixed, 95% CI) Not estimable
2.5 Concomitant CRT
(carboplatin) versus
concomitant CRT (cisplatin)
1 Hazard ratio (Fixed, 95% CI) Not estimable
2.6 Concomitant intra-arterial
CRT vs concomitant
intravenous CRT
1 Hazard ratio (Fixed, 95% CI) Not estimable
2.7 Induction CT
(BLM/MTX/VINB/Leucov)
then RT vs alternating CRT
1 Hazard ratio (Fixed, 95% CI) Not estimable
3 Progression free survival 7 Hazard Ratio (Fixed, 95% CI) Totals not selected
3.1 Induction cisplatin + UFT
versus induction cisplatin +
5-FU
1 Hazard Ratio (Fixed, 95% CI) Not estimable
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3.2 Induction cisplatin +
docetaxel + 5-FU (TPF) ± RT
versus induction cisplatin +
5-FU (PF) ± RT induction
cisplatin + FU ±RT versus
induction cisplatin + docetaxel
+ 5FU ± RT
1 Hazard Ratio (Fixed, 95% CI) Not estimable
3.3 Induction (TPF) versus
induction (PF)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
3.4 Concomitant CRT (MTX
or VBMF) versus RT then CT
(MTX or VBMF)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
3.5 Concomitant CRT (MTX
or VBMF) then CT versus RT
then CT (MTX or VBMF)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
3.6 Concomitant CRT (MTX
or VBMF) then CT versus neo
concomitant CRT (MTX or
VBMF)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
3.7 Induction CT (PF) then
RT versus concomitant CRT +
maint CT (PF)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
3.8 Induction sequential
cisplatin then RT versus
concomitant CRT (cis/5-FU)
1 Hazard Ratio (Fixed, 95% CI) Not estimable
3.9 Induction CT (TPF) then
CRT versus CRT alone
1 Hazard Ratio (Fixed, 95% CI) Not estimable
4 Locoregional control 3 hazard ratio (Fixed, 95% CI) Totals not selected
4.1 Neo concomitant
CRT (cis/TPZ) versus neo
concomitant CRT (cis/5-FU)
1 hazard ratio (Fixed, 95% CI) Not estimable
4.2 Concomitant intra-arterial
CRT vs concomitant
intravenous CRT
1 hazard ratio (Fixed, 95% CI) Not estimable
4.3 Concomitant CRT
(cis/TPZ) versus concomitant
CRT (cis)
1 hazard ratio (Fixed, 95% CI) Not estimable
5 Total mortality (2-5 years) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Induction CT (BVCM)
+ surgery vs induction CT
(BVM) + surgery
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
6 Disease free survival (5 years) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 Induction carboplatin +
5-FU versus induction cisplatin
+ 5-FU
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7 Locoregional control 5 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
7.1 Induction CT
(BLM/MTX/VINB/Leucov)
then RT vs alternating CRT
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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7.2 Induction CT
(BLM/MTX/HU) then RT
versus alternating CR
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7.3 Induction cisplatin +
5-FU + RT versus induction
cisplatin + etoposide + RT
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7.4 Induction methotrexate
(intra-arterial) versus
bleomycin (intra-arterial)
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7.5 Concomitant cisplatin
(daily) + RT versus concomitant
cisplatin (weekly) + RT
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7.6 Concomitant cisplatin
(weekly) + RT versus
concomitant cisplatin (once/3
weeks) + RT
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7.7 Concomitant cisplatin
(daily) + RT versus concomitant
cisplatin (once/3weeks) + RT
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
8 Locoregional recurrence (2 years) 1 Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 Induction CT (BVCM)
+ surgery vs induction CT
(BVM)
1 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
Analysis 1.1. Comparison 1 Induction chemotherapy plus locoregional treatment (LRT) versus LRT alone,
Outcome 1 Total mortality.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 1 Induction chemotherapy plus locoregional treatment (LRT) versus LRT alone
Outcome: 1 Total mortality
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Cisplatin or carboplatin + 5-FU + RT surgery vs RT surgery
Depondt 1993 (1) -0.178 (0.147) 6.7 % 0.84 [ 0.63, 1.12 ]
Paccagnella 1994 (2) -0.18 (0.146) 6.8 % 0.84 [ 0.63, 1.11 ]
Lewin 1997 (3) 0.046 (0.104) 10.3 % 1.05 [ 0.85, 1.28 ]
Volling 1999 (4) -0.3 (0.29) 2.2 % 0.74 [ 0.42, 1.31 ]
Domenge 2000 -0.41 (0.25) 2.9 % 0.66 [ 0.41, 1.08 ]
Licitra 2003 (5) -0.01 (0.23) 3.3 % 0.99 [ 0.63, 1.55 ]
Olmi 2003 (6) -0.193 (0.214) 3.8 % 0.82 [ 0.54, 1.25 ]
Subtotal (95% CI) 36.0 % 0.90 [ 0.80, 1.02 ]
(8) Intra-arterial
(Continued . . . )
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(. . . Continued)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.0; Chi2 = 4.90, df = 6 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.091)
2 Carboplatin and ftorofur + RT vs RT alone
Tejedor 1992 -0.8 (0.4472) 1.0 % 0.45 [ 0.19, 1.08 ]
Subtotal (95% CI) 1.0 % 0.45 [ 0.19, 1.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.074)
3 Cisplatin + 5-FU + folinic acid + RT vs RT alone
Giglio 1997 -0.366 (0.299) 2.1 % 0.69 [ 0.39, 1.25 ]
Subtotal (95% CI) 2.1 % 0.69 [ 0.39, 1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
4 Cisplatin + 5-FU + vindesine + RT vs RT alone
Jaulerry 1992 0.084 (0.229) 3.4 % 1.09 [ 0.69, 1.70 ]
Subtotal (95% CI) 3.4 % 1.09 [ 0.69, 1.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
5 Cisplatin + 5-FU + bleomycin + methotrexate + RT vs RT alone
Mazeron 1992 0.3789 (0.2294) 3.4 % 1.46 [ 0.93, 2.29 ]
Subtotal (95% CI) 3.4 % 1.46 [ 0.93, 2.29 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.099)
6 Cisplatin + bleomycin + vinblastine + mitomycin C + RT vs RT alone
Salvajoli 1992 0.036 (0.302) 2.1 % 1.04 [ 0.57, 1.87 ]
Subtotal (95% CI) 2.1 % 1.04 [ 0.57, 1.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
7 Cisplatin + bleomycin + vindesine + mitomycin C + RT vs RT alone
Brunin 1989 0.123 (0.213) 3.8 % 1.13 [ 0.74, 1.72 ]
Subtotal (95% CI) 3.8 % 1.13 [ 0.74, 1.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
8 Cisplatin + bleomycin + vincristine + adriamycin + RT vs RT alone
Szpirglas 1988 -0.08 (0.2) 4.2 % 0.92 [ 0.62, 1.37 ]
Subtotal (95% CI) 4.2 % 0.92 [ 0.62, 1.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
9 Cisplatin + bleomycin + vincristine + methotrexate + RT + surgery vs RT + surgery
Schuller 1988 0.072 (0.167) 5.6 % 1.07 [ 0.77, 1.49 ]
Subtotal (95% CI) 5.6 % 1.07 [ 0.77, 1.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
10 Cisplatin + bleomycin + methotrexate + surgery + RT vs surgery + RT
(8) Intra-arterial
(Continued . . . )
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Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Maipang 1995 0.067 (0.333) 1.7 % 1.07 [ 0.56, 2.05 ]
Subtotal (95% CI) 1.7 % 1.07 [ 0.56, 2.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.84)
11 Cisplatin + epirubicin + surgery vs RT plus surgery (5 years)
Szabo 1999 -0.13 (0.23) 3.3 % 0.88 [ 0.56, 1.38 ]
Subtotal (95% CI) 3.3 % 0.88 [ 0.56, 1.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.57 (P = 0.57)
12 Methotrexate + RT vs RT alone
Richard 1974 -0.37 (0.31) 2.0 % 0.69 [ 0.38, 1.27 ]
Knowlton 1975 0.15 (0.21) 3.9 % 1.16 [ 0.77, 1.75 ]
Nervi 1978 -0.38 (0.19) 4.6 % 0.68 [ 0.47, 0.99 ]
Fazekas 1980 -0.0064 (0.0894) 11.9 % 0.99 [ 0.83, 1.18 ]
Subtotal (95% CI) 22.4 % 0.90 [ 0.72, 1.14 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 5.19, df = 3 (P = 0.16); I2 =42%
Test for overall effect: Z = 0.88 (P = 0.38)
13 Methotrexate + vincristine + RT vs RT alone
Petrovich 1981 -0.559 (0.436) 1.0 % 0.57 [ 0.24, 1.34 ]
Subtotal (95% CI) 1.0 % 0.57 [ 0.24, 1.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
14 Methotrexate + bleomycin + 5-FU + cyclophosphamide + RT surgery vs RT surgery
Holoye 1985 0.394 (0.25) 2.9 % 1.48 [ 0.91, 2.42 ]
Subtotal (95% CI) 2.9 % 1.48 [ 0.91, 2.42 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.12)
15 Bleomycin + vincristine + surgery RT vs surgery RT
Luboinski 1985 (7) -0.57 (0.28) 2.4 % 0.57 [ 0.33, 0.98 ]
Richard 1991 (8) -0.317 (0.186) 4.7 % 0.73 [ 0.51, 1.05 ]
Subtotal (95% CI) 7.1 % 0.67 [ 0.50, 0.91 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.55 (P = 0.011)
Total (95% CI) 100.0 % 0.92 [ 0.84, 1.00 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 29.91, df = 24 (P = 0.19); I2 =20%
Test for overall effect: Z = 1.87 (P = 0.061)
0.1 0.2 0.5 1 2 5 10
Favours CT + LRT Favours LRT alone
(1) Carboplatin
(8) Intra-arterial
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(. . . Continued)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
(2) Cisplatin
(3) Cisplatin
(4) Carboplatin
(5) Cisplatin
(6) Carboplatin
(7) Intra-arterial
(8) Intra-arterial
Analysis 1.2. Comparison 1 Induction chemotherapy plus locoregional treatment (LRT) versus LRT alone,
Outcome 2 Disease free survival.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 1 Induction chemotherapy plus locoregional treatment (LRT) versus LRT alone
Outcome: 2 Disease free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
1 Carboplatin + 5-FU + RT + surgery vs RT + surgery
Volling 1999 -0.6 (0.27) 8.0 % 0.55 [ 0.32, 0.93 ]
Olmi 2003 -0.33 (0.19) 16.1 % 0.72 [ 0.50, 1.04 ]
Subtotal (95% CI) 24.1 % 0.66 [ 0.48, 0.89 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.67, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0069)
2 Carboplatin + ftorafur + RT vs RT alone
Tejedor 1992 -0.15 (0.48) 2.5 % 0.86 [ 0.34, 2.21 ]
Subtotal (95% CI) 2.5 % 0.86 [ 0.34, 2.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.75)
3 Cisplatin + fluorouracil + RT + surgery vs RT + surgery (5 years)
Paccagnella 1994 -0.29 (0.19) 16.1 % 0.75 [ 0.52, 1.09 ]
Domenge 2000 -0.23 (0.14) 29.7 % 0.79 [ 0.60, 1.05 ]
Subtotal (95% CI) 45.9 % 0.78 [ 0.62, 0.97 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.23 (P = 0.026)
4 Cisplatin + bleomycin + vindesine + mitomycin C + RT vs RT alone
0.01 0.1 1 10 100
Favours CT + LRT Favours LRT alone
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Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Random,95% CI IV,Random,95% CI
Brunin 1989 -0.07 (0.24) 10.1 % 0.93 [ 0.58, 1.49 ]
Subtotal (95% CI) 10.1 % 0.93 [ 0.58, 1.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
5 Bleomycin + vincristine + surgery vs surgery (floor of mouth)
Richard 1991 -0.15 (0.22) 12.0 % 0.86 [ 0.56, 1.32 ]
Subtotal (95% CI) 12.0 % 0.86 [ 0.56, 1.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.68 (P = 0.50)
6 Bleomycin + cyclophosphamide + MTX + 5-FU plus RT surgery versus RT surgery
Holoye 1985 -0.08 (0.33) 5.3 % 0.92 [ 0.48, 1.76 ]
Subtotal (95% CI) 5.3 % 0.92 [ 0.48, 1.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
Total (95% CI) 100.0 % 0.78 [ 0.67, 0.90 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.00, df = 7 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 3.27 (P = 0.0011)
0.01 0.1 1 10 100
Favours CT + LRT Favours LRT alone
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Analysis 1.3. Comparison 1 Induction chemotherapy plus locoregional treatment (LRT) versus LRT alone,
Outcome 3 Progression free survival.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 1 Induction chemotherapy plus locoregional treatment (LRT) versus LRT alone
Outcome: 3 Progression free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Cisplatin + 5-FU + RT + surgery vs RT + surgery
Domenge 2000 -0.19 (0.14) 64.8 % 0.83 [ 0.63, 1.09 ]
Subtotal (95% CI) 64.8 % 0.83 [ 0.63, 1.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.36 (P = 0.17)
2 Carboplatin + 5-FU + RT + surgery vs RT + surgery
Olmi 2003 -0.28 (0.19) 35.2 % 0.76 [ 0.52, 1.10 ]
Subtotal (95% CI) 35.2 % 0.76 [ 0.52, 1.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI) 100.0 % 0.80 [ 0.64, 1.00 ]
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
Test for subgroup differences: Chi2 = 0.15, df = 1 (P = 0.70), I2 =0.0%
0.01 0.1 1 10 100
Favours CT + LRT Favours LRT
Analysis 1.4. Comparison 1 Induction chemotherapy plus locoregional treatment (LRT) versus LRT alone,
Outcome 4 Disease free survival.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 1 Induction chemotherapy plus locoregional treatment (LRT) versus LRT alone
Outcome: 4 Disease free survival
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cisplatin + 5-FU + surgery vs surgery alone (5 years)
Licitra 2003 51/96 46/95 1.10 [ 0.83, 1.45 ]
0.01 0.1 1 10 100
Favours CT + LRT Favours LRT
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Analysis 1.5. Comparison 1 Induction chemotherapy plus locoregional treatment (LRT) versus LRT alone,
Outcome 5 Recurrent disease - Locoregional.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 1 Induction chemotherapy plus locoregional treatment (LRT) versus LRT alone
Outcome: 5 Recurrent disease - Locoregional
Study or subgroup Experimental Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Cisplatin + 5-FU + surgery vs surgery alone (5 years)
Licitra 2003 28/96 30/95 0.92 [ 0.60, 1.42 ]
0.01 0.1 1 10 100
Favours CT + LRT Favours LRT
Analysis 2.1. Comparison 2 Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy alone,
Outcome 1 Total mortality.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 2 Surgery radiotherapy + chemotherapy versus surgery radiotherapy alone
Outcome: 1 Total mortality
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Surgery + CT (methotrexate/ bleomycin/ vincristine) vs surgery + RT
Bitter 1979 -1.13 (0.73) 0.6 % 0.32 [ 0.08, 1.35 ]
Subtotal (95% CI) 0.6 % 0.32 [ 0.08, 1.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.55 (P = 0.12)
2 Surgery + CT (methotrexate) vs surgery alone
Rao 1994 0.0667 (0.408) 2.0 % 1.07 [ 0.48, 2.38 ]
Subtotal (95% CI) 2.0 % 1.07 [ 0.48, 2.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.16 (P = 0.87)
3 Surgery + CT (levamisole/ UFT) vs surgery alone
Lam 2001 -0.35 (0.34) 2.9 % 0.70 [ 0.36, 1.37 ]
Subtotal (95% CI) 2.9 % 0.70 [ 0.36, 1.37 ]
0.01 0.1 1 10 100
Favours Surgery RT + CT Favours Surgery RT
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(. . . Continued)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
4 Surgery RT + CT (methotrexate/bleomycin/leucovorin) vs surgery RT
Szpirglas 1979 0.01 (0.36) 2.6 % 1.01 [ 0.50, 2.05 ]
Subtotal (95% CI) 2.6 % 1.01 [ 0.50, 2.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
5 Surgery + RT + CT (methotrexate) vs surgery + RT alone
Rentschler 1987 0.04 (0.17) 11.6 % 1.04 [ 0.75, 1.45 ]
Subtotal (95% CI) 11.6 % 1.04 [ 0.75, 1.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
6 Surgery +CT (cisplatin/ 5-FU) + RT vs surgery + RT alone
Laramore 1992 -0.093 (0.11) 27.8 % 0.91 [ 0.73, 1.13 ]
Subtotal (95% CI) 27.8 % 0.91 [ 0.73, 1.13 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.85 (P = 0.40)
7 Surgery + RT + CT (concom cisplatin) vs surgery + RT alone
Cooper 2004 -0.139 (0.127) 20.9 % 0.87 [ 0.68, 1.12 ]
Bernier 2004 -0.354 (0.153) 14.4 % 0.70 [ 0.52, 0.95 ]
Subtotal (95% CI) 35.2 % 0.80 [ 0.66, 0.97 ]
Heterogeneity: Chi2 = 1.17, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 2.32 (P = 0.020)
8 Surgery + RT + CT (concom carboplatin) vs surgery + RT alone
Argiris 2008 -0.11 (0.39) 2.2 % 0.90 [ 0.42, 1.92 ]
Subtotal (95% CI) 2.2 % 0.90 [ 0.42, 1.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
9 Surgery + RT + CT (concom MTX or VBMF) vs surgery + RT alone
UKHAN 2010 -0.06 (0.15) 15.0 % 0.94 [ 0.70, 1.26 ]
Subtotal (95% CI) 15.0 % 0.94 [ 0.70, 1.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
Total (95% CI) 100.0 % 0.88 [ 0.79, 0.99 ]
Heterogeneity: Chi2 = 6.16, df = 9 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Chi2 = 4.99, df = 8 (P = 0.76), I2 =0.0%
0.01 0.1 1 10 100
Favours Surgery RT + CT Favours Surgery RT
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Analysis 2.2. Comparison 2 Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy alone,
Outcome 2 Disease free survival.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 2 Surgery radiotherapy + chemotherapy versus surgery radiotherapy alone
Outcome: 2 Disease free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Surgery + CT (methotrexate/ bleomycin/ vincristine) vs surgery + RT
Bitter 1979 -0.11 (0.79) 0.7 % 0.90 [ 0.19, 4.21 ]
Subtotal (95% CI) 0.7 % 0.90 [ 0.19, 4.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
2 Surgery + CT (methotrexate) vs surgery alone
Rao 1994 -0.75 (0.31) 4.5 % 0.47 [ 0.26, 0.87 ]
Subtotal (95% CI) 4.5 % 0.47 [ 0.26, 0.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.42 (P = 0.016)
3 Surgery + RT + CT (methotrexate) vs surgery + RT alone
Rentschler 1987 -0.18 (0.4) 2.7 % 0.84 [ 0.38, 1.83 ]
Subtotal (95% CI) 2.7 % 0.84 [ 0.38, 1.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
4 Surgery +CT (cisplatin/ 5-FU) + RT vs surgery + RT alone
Laramore 1992 -0.1 (0.12) 30.1 % 0.90 [ 0.72, 1.14 ]
Subtotal (95% CI) 30.1 % 0.90 [ 0.72, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.83 (P = 0.40)
5 Surgery + RT + CT (concom cisplatin) vs surgery + RT alone
Cooper 2004 -0.25 (0.12) 30.1 % 0.78 [ 0.62, 0.99 ]
Subtotal (95% CI) 30.1 % 0.78 [ 0.62, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.037)
6 Surgery + RT + CT (concom carboplatin) vs surgery + RT alone
Argiris 2008 -0.2 (0.36) 3.3 % 0.82 [ 0.40, 1.66 ]
Subtotal (95% CI) 3.3 % 0.82 [ 0.40, 1.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.58)
7 Surgery + RT + CT (concom MTX or VBMF) vs surgery + RT alone
UKHAN 2010 0.03 (0.14) 22.1 % 1.03 [ 0.78, 1.36 ]
0.1 0.2 0.5 1 2 5 10
Favours Surgery RT + CT Favours Surgery RT
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(. . . Continued)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 22.1 % 1.03 [ 0.78, 1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
8 Induction cis/BLM + surgery + RT + adjuvant cisplatin versus surgery + RT alone
HNCProg 1987 0.44 (0.26) 6.4 % 1.55 [ 0.93, 2.58 ]
Subtotal (95% CI) 6.4 % 1.55 [ 0.93, 2.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
Total (95% CI) 100.0 % 0.89 [ 0.78, 1.01 ]
Heterogeneity: Chi2 = 11.19, df = 7 (P = 0.13); I2 =37%
Test for overall effect: Z = 1.77 (P = 0.076)
Test for subgroup differences: Chi2 = 11.19, df = 7 (P = 0.13), I2 =37%
0.1 0.2 0.5 1 2 5 10
Favours Surgery RT + CT Favours Surgery RT
Analysis 2.3. Comparison 2 Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy alone,
Outcome 3 Progression free survival.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 2 Surgery radiotherapy + chemotherapy versus surgery radiotherapy alone
Outcome: 3 Progression free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Surgery + RT + CT (concom cisplatin) vs surgery + RT alone
Bernier 2004 -0.288 (0.143) 48.9 % 0.75 [ 0.57, 0.99 ]
Subtotal (95% CI) 48.9 % 0.75 [ 0.57, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.01 (P = 0.044)
2 Surgery + RT + CT (concom MTX or VBMF) vs surgery + RT alone
UKHAN 2010 0.03 (0.14) 51.1 % 1.03 [ 0.78, 1.36 ]
Subtotal (95% CI) 51.1 % 1.03 [ 0.78, 1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
0.1 0.2 0.5 1 2 5 10
Favours Surgery RT +CT Favours Surgery RT
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Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Total (95% CI) 100.0 % 0.88 [ 0.72, 1.07 ]
Heterogeneity: Chi2 = 2.53, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 2.53, df = 1 (P = 0.11), I2 =60%
0.1 0.2 0.5 1 2 5 10
Favours Surgery RT +CT Favours Surgery RT
Analysis 2.4. Comparison 2 Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy alone,
Outcome 4 Locoregional recurrence.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 2 Surgery radiotherapy + chemotherapy versus surgery radiotherapy alone
Outcome: 4 Locoregional recurrence
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Surgery + RT + CT (cisplatin) vs surgery + RT alone
Cooper 2004 -0.49 (0.2) 0.61 [ 0.41, 0.91 ]
0.1 0.2 0.5 1 2 5 10
Favours Surgery RT + CT Favours Surgery RT
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Analysis 2.5. Comparison 2 Surgery ± radiotherapy + chemotherapy versus surgery ± radiotherapy alone,
Outcome 5 Recurrent disease (overall).
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 2 Surgery radiotherapy + chemotherapy versus surgery radiotherapy alone
Outcome: 5 Recurrent disease (overall)
Study or subgroup Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Surgery + RT + CT (methotrexate) vs surgery + RT alone (2 years)
Rao 1994 18/51 30/53 0.62 [ 0.40, 0.97 ]
0.01 0.1 1 10 100
Favours Surgery RT +CT Favours Surgery RT
Analysis 3.1. Comparison 3 Concomitant chemoradiotherapy versus radiotherapy alone (non-resectable),
Outcome 1 Total mortality.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 3 Concomitant chemoradiotherapy versus radiotherapy alone (non-resectable)
Outcome: 1 Total mortality
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Cisplatin or carboplatin + RT vs RT alone
Jeremic 1997 -0.48 (0.22) 2.2 % 0.62 [ 0.40, 0.95 ]
Jeremic 2000 -0.61 (0.22) 2.2 % 0.54 [ 0.35, 0.84 ]
Adelstein 2003 -0.47 (0.16) 4.2 % 0.63 [ 0.46, 0.86 ]
Huguenin 2004 -0.27 (0.18) 3.3 % 0.76 [ 0.54, 1.09 ]
Ruo 2010 -0.36 (0.13) 6.3 % 0.70 [ 0.54, 0.90 ]
Subtotal (95% CI) 18.3 % 0.66 [ 0.57, 0.77 ]
Heterogeneity: Chi2 = 1.82, df = 4 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 5.40 (P < 0.00001)
2 Cisplatin or carboplatin + 5-FU + RT vs RT alone
Weissler 1992 (1) -0.2 (0.3) 1.2 % 0.82 [ 0.45, 1.47 ]
Haddad 1996 (2) -0.64 (0.33) 1.0 % 0.53 [ 0.28, 1.01 ]
Wendt 1998 (3) -0.58 (0.19) 3.0 % 0.56 [ 0.39, 0.81 ]
(8) Cisplatin
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(. . . Continued)
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Brizel 1998 (4) -0.24 (0.36) 0.8 % 0.79 [ 0.39, 1.59 ]
Staar 2001 (5) -0.29 (0.15) 4.8 % 0.75 [ 0.56, 1.00 ]
Adelstein 2003 (6) -0.22 (0.15) 4.8 % 0.80 [ 0.60, 1.08 ]
Denis 2004 (7) -0.3 (0.15) 4.8 % 0.74 [ 0.55, 0.99 ]
Bensadoun 2006 (8) -0.48 (0.19) 3.0 % 0.62 [ 0.43, 0.90 ]
Subtotal (95% CI) 23.2 % 0.71 [ 0.62, 0.81 ]
Heterogeneity: Chi2 = 4.07, df = 7 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 5.12 (P < 0.00001)
3 Cisplatin + bleomycin + RT vs RT alone
Salvajoli 1992 0.1909 (0.3015) 1.2 % 1.21 [ 0.67, 2.19 ]
Subtotal (95% CI) 1.2 % 1.21 [ 0.67, 2.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
4 1-FU+ RT vs RT alone
Browman 1994 -0.182 (0.189) 3.0 % 0.83 [ 0.58, 1.21 ]
Subtotal (95% CI) 3.0 % 0.83 [ 0.58, 1.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.34)
5 Mitomycin + 5-FU + RT vs RT alone
Budach 2005 -0.26 (0.121) 7.3 % 0.77 [ 0.61, 0.98 ]
Subtotal (95% CI) 7.3 % 0.77 [ 0.61, 0.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.15 (P = 0.032)
6 Methotrexate + RT vs RT alone
Gupta 2001 -0.036 (0.123) 7.1 % 0.96 [ 0.76, 1.23 ]
Subtotal (95% CI) 7.1 % 0.96 [ 0.76, 1.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
7 Sim CRT (MTX or VBMF) versus RT alone
UKHAN 2010 -0.2 (0.12) 7.4 % 0.82 [ 0.65, 1.04 ]
Subtotal (95% CI) 7.4 % 0.82 [ 0.65, 1.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.67 (P = 0.096)
8 Sim CRT (MTX or VBMF) + Sub CT (MTX or VBMF) vs RT alone
UKHAN 2010 0.06 (0.12) 7.4 % 1.06 [ 0.84, 1.34 ]
Subtotal (95% CI) 7.4 % 1.06 [ 0.84, 1.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.50 (P = 0.62)
9 Bleomycin + RT vs RT alone
Shanta 1980 -1.28 (0.27) 1.5 % 0.28 [ 0.16, 0.47 ]
Morita 1980 0.38 (0.43) 0.6 % 1.46 [ 0.63, 3.40 ]
(8) Cisplatin
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Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Parvinen 1985 -0.22 (0.33) 1.0 % 0.80 [ 0.42, 1.53 ]
Eschwege 1988 0.03 (0.158) 4.3 % 1.03 [ 0.76, 1.40 ]
Subtotal (95% CI) 7.3 % 0.79 [ 0.62, 1.00 ]
Heterogeneity: Chi2 = 19.84, df = 3 (P = 0.00018); I2 =85%
Test for overall effect: Z = 1.97 (P = 0.048)
10 Bleomycin + mitomycin + RT vs RT alone
Smid 1995 -0.44 (0.29) 1.3 % 0.64 [ 0.36, 1.14 ]
Subtotal (95% CI) 1.3 % 0.64 [ 0.36, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
11 Mitomycin + RT versus RT alone
Dobrowsky 2000 -0.15 (0.18) 3.3 % 0.86 [ 0.60, 1.22 ]
Grau 2003 -0.05 (0.12) 7.4 % 0.95 [ 0.75, 1.20 ]
Subtotal (95% CI) 10.7 % 0.92 [ 0.76, 1.12 ]
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
12 Cisplatin + 5-FU alternating with RT vs RT alone
Merlano 1992 -0.4766 (0.1826) 3.2 % 0.62 [ 0.43, 0.89 ]
Corvo 2001 -0.242 (0.208) 2.5 % 0.79 [ 0.52, 1.18 ]
Subtotal (95% CI) 5.7 % 0.69 [ 0.53, 0.90 ]
Heterogeneity: Chi2 = 0.72, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 2.73 (P = 0.0064)
Total (95% CI) 100.0 % 0.78 [ 0.73, 0.83 ]
Heterogeneity: Chi2 = 49.55, df = 27 (P = 0.01); I2 =46%
Test for overall effect: Z = 7.47 (P < 0.00001)
Test for subgroup differences: Chi2 = 22.89, df = 11 (P = 0.02), I2 =52%
0.01 0.1 1 10 100
Favours concom CRT Favours RT alone
(1) Cisplatin
(2) Cisplatin
(3) Cisplatin
(4) Cisplatin
(5) Carboplatin
(6) Cisplatin
(7) Carboplatin
(8) Cisplatin
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Analysis 3.2. Comparison 3 Concomitant chemoradiotherapy versus radiotherapy alone (non-resectable),
Outcome 2 Disease free survival.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 3 Concomitant chemoradiotherapy versus radiotherapy alone (non-resectable)
Outcome: 2 Disease free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Cisplatin or carboplatin + 5-FU + RT versus RT alone
Brizel 1998 (1) -0.15 (0.33) 2.1 % 0.86 [ 0.45, 1.64 ]
Staar 2001 (2) -0.25 (0.14) 11.6 % 0.78 [ 0.59, 1.02 ]
Denis 2004 (3) -0.34 (0.16) 8.9 % 0.71 [ 0.52, 0.97 ]
Bensadoun 2006 (4) -0.63 (0.19) 6.3 % 0.53 [ 0.37, 0.77 ]
Subtotal (95% CI) 28.8 % 0.70 [ 0.59, 0.84 ]
Heterogeneity: Chi2 = 3.05, df = 3 (P = 0.38); I2 =2%
Test for overall effect: Z = 3.98 (P = 0.000068)
2 Carboplatin + RT versus RT alone
Ruo 2010 -0.19 (0.1) 22.7 % 0.83 [ 0.68, 1.01 ]
Subtotal (95% CI) 22.7 % 0.83 [ 0.68, 1.01 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
3 Cisplatin + 5-FU alternating with RT vs RT alone
Merlano 1992 -0.25 (0.18) 7.0 % 0.78 [ 0.55, 1.11 ]
Subtotal (95% CI) 7.0 % 0.78 [ 0.55, 1.11 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.39 (P = 0.16)
4 MTX + RT versus RT alone
Gupta 2001 -0.43 (0.207) 5.3 % 0.65 [ 0.43, 0.98 ]
Subtotal (95% CI) 5.3 % 0.65 [ 0.43, 0.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.038)
5 Bleomycin + mitomycin + RT versus RT alone
Smid 1995 -0.789 (0.366) 1.7 % 0.45 [ 0.22, 0.93 ]
Subtotal (95% CI) 1.7 % 0.45 [ 0.22, 0.93 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.16 (P = 0.031)
6 Sim CRT (MTX or VBMF) versus RT alone
UKHAN 2010 -0.33 (0.12) 15.8 % 0.72 [ 0.57, 0.91 ]
Subtotal (95% CI) 15.8 % 0.72 [ 0.57, 0.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.75 (P = 0.0060)
7 Sim CRT (MTX or VBMF) + Sub CT (MTX or VBMF) vs RT alone
(4) Cisplatin
(Continued . . . )
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Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
UKHAN 2010 -0.08 (0.11) 18.8 % 0.92 [ 0.74, 1.15 ]
Subtotal (95% CI) 18.8 % 0.92 [ 0.74, 1.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Total (95% CI) 100.0 % 0.77 [ 0.70, 0.84 ]
Heterogeneity: Chi2 = 10.42, df = 9 (P = 0.32); I2 =14%
Test for overall effect: Z = 5.57 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.37, df = 6 (P = 0.29), I2 =19%
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(4) Cisplatin
Analysis 3.3. Comparison 3 Concomitant chemoradiotherapy versus radiotherapy alone (non-resectable),
Outcome 3 Locoregional control.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 3 Concomitant chemoradiotherapy versus radiotherapy alone (non-resectable)
Outcome: 3 Locoregional control
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Cisplatin or carboplatin + RT vs RT alone
Huguenin 2004 -0.28 (0.17) 13.4 % 0.76 [ 0.54, 1.05 ]
Ruo 2010 (1) -0.23 (0.11) 31.9 % 0.79 [ 0.64, 0.99 ]
Subtotal (95% CI) 45.2 % 0.78 [ 0.65, 0.94 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0080)
2 Cisplatin or carboplatin + 5-FU + RT surgery vs RT alone
Haddad 1996 (2) -0.03 (0.32) 3.8 % 0.97 [ 0.52, 1.82 ]
Wendt 1998 (3) -0.32 (0.16) 15.1 % 0.73 [ 0.53, 0.99 ]
Staar 2001 (4) -0.32 (0.17) 13.4 % 0.73 [ 0.52, 1.01 ]
Subtotal (95% CI) 32.2 % 0.75 [ 0.61, 0.93 ]
(4) Carboplatin
(Continued . . . )
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Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Heterogeneity: Chi2 = 0.73, df = 2 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.61 (P = 0.0090)
3 Methotrexate + RT vs RT alone
Gupta 2001 -0.34 (0.186) 11.2 % 0.71 [ 0.49, 1.02 ]
Subtotal (95% CI) 11.2 % 0.71 [ 0.49, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
4 Mitomycin + 5-FU + RT vs RT alone
Budach 2005 -0.73 (0.2) 9.6 % 0.48 [ 0.33, 0.71 ]
Subtotal (95% CI) 9.6 % 0.48 [ 0.33, 0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.65 (P = 0.00026)
5 Cisplatin +5-FU alternating with RT
Merlano 1992 -1.06 (0.47) 1.7 % 0.35 [ 0.14, 0.87 ]
Subtotal (95% CI) 1.7 % 0.35 [ 0.14, 0.87 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Total (95% CI) 100.0 % 0.72 [ 0.64, 0.81 ]
Heterogeneity: Chi2 = 8.21, df = 7 (P = 0.31); I2 =15%
Test for overall effect: Z = 5.31 (P < 0.00001)
Test for subgroup differences: Chi2 = 7.43, df = 4 (P = 0.11), I2 =46%
0.01 0.1 1 10 100
Favours concom CRT Favours RT alone
(1) Carboplatin
(2) Cisplatin
(3) Cisplatin
(4) Carboplatin
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Analysis 3.4. Comparison 3 Concomitant chemoradiotherapy versus radiotherapy alone (non-resectable),
Outcome 4 Progression free survival.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 3 Concomitant chemoradiotherapy versus radiotherapy alone (non-resectable)
Outcome: 4 Progression free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Weight Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Cisplatin + post-op RT vs post-op RT
Jeremic 2000 -0.404 (0.28) 7.0 % 0.67 [ 0.39, 1.16 ]
Huguenin 2004 -0.11 (0.14) 27.9 % 0.90 [ 0.68, 1.18 ]
Subtotal (95% CI) 34.9 % 0.84 [ 0.66, 1.08 ]
Heterogeneity: Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
2 1-FU + RT vs RT alone
Browman 1994 -0.24 (0.19) 15.2 % 0.79 [ 0.54, 1.14 ]
Subtotal (95% CI) 15.2 % 0.79 [ 0.54, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.26 (P = 0.21)
3 Mitomycin + 5-FU + RT vs RT alone
Budach 2005 -0.51 (0.163) 20.6 % 0.60 [ 0.44, 0.83 ]
Subtotal (95% CI) 20.6 % 0.60 [ 0.44, 0.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.13 (P = 0.0018)
4 Alternating cisplatin + 5-FU + RT
Merlano 1992 -0.25 (0.18) 16.9 % 0.78 [ 0.55, 1.11 ]
Corvo 2001 -0.14 (0.21) 12.4 % 0.87 [ 0.58, 1.31 ]
Subtotal (95% CI) 29.3 % 0.82 [ 0.62, 1.07 ]
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
Total (95% CI) 100.0 % 0.77 [ 0.67, 0.89 ]
Heterogeneity: Chi2 = 4.11, df = 5 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.51 (P = 0.00044)
Test for subgroup differences: Chi2 = 3.07, df = 3 (P = 0.38), I2 =2%
0.01 0.1 1 10 100
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Analysis 3.5. Comparison 3 Concomitant chemoradiotherapy versus radiotherapy alone (non-resectable),
Outcome 5 Locoregional control.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 3 Concomitant chemoradiotherapy versus radiotherapy alone (non-resectable)
Outcome: 5 Locoregional control
Study or subgroup CT + RT RT alone Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Mitomycin + HFxAcc RT versus HFxAcc RT alone (median 4 years)
Dobrowsky 2000 38/80 25/78 1.48 [ 1.00, 2.20 ]
2 Bleomycin + LRT versus LRT
Parvinen 1985 8/23 8/23 1.00 [ 0.45, 2.21 ]
3 Gemcitabine + RT versus RT alone
Chauhan 2008 33/40 20/40 1.65 [ 1.17, 2.32 ]
4 Pepleomycin + RT hyperthermia vs RT + hyperthermia
Krishnamurthi 1990 30/65 25/36 0.66 [ 0.47, 0.93 ]
0.01 0.1 1 10 100
Favours concom CRT Favours RT alone
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Analysis 4.1. Comparison 4 Chemotherapy A (± LRT) versus chemotherapy B (± LRT), Outcome 1 Total
mortality.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 4 Chemotherapy A ( LRT) versus chemotherapy B ( LRT)
Outcome: 1 Total mortality
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Induction cisplatin + UFT versus induction cisplatin + 5-FU
Gonzalez-Larriba 1997 0.39 (0.34) 1.48 [ 0.76, 2.88 ]
2 Induction carboplatin + 5-FU versus induction cisplatin + 5-FU
De Andres 1995 0.43 (0.24) 1.54 [ 0.96, 2.46 ]
3 Induction cisplatin + vinorelbine LRT versus induction cisplatin + 5-FU LRT
Segura 2002 -0.29 (0.34) 0.75 [ 0.38, 1.46 ]
4 Induction cisplatin + etoposide + RT versus induction cisplatin + RT
Marechal 1987 -0.07 (0.16) 0.93 [ 0.68, 1.28 ]
5 Induction cisplatin + methotrexate + bleomycin + vincristine versus induction cisplatin
Chauvergne 1988 -0.07 (0.11) 0.93 [ 0.75, 1.16 ]
6 Induction simultaneous MTX + 5-FU versus sequential MTX + 5-FU
Browman 1986 -0.18 (0.47) 0.84 [ 0.33, 2.10 ]
7 Induction cisplatin + docetaxel + 5-FU (TPF) RT versus induction cisplatin + 5-FU (PF) RT
Vermorken 2007 -0.31 (0.13) 0.73 [ 0.57, 0.95 ]
8 Induction TPF + CRT surg versus induction PF + CRT + surg
Posner 2007 -0.36 (0.13) 0.70 [ 0.54, 0.90 ]
9 Induction CT(cis/5-FU/TPZ) then CRT(cis/5-FU/TPZ/RT) versus induction CT (PF) then CRT (PF+RT)
Le 2006 -0.807 (0.542) 0.45 [ 0.15, 1.29 ]
10 Concomitant CRT (carboplatin) versus concomitant CRT (cisplatin)
Gasparini 1993 -0.36 (0.31) 0.70 [ 0.38, 1.28 ]
11 Concomitant CRT(cis/TPZ) versus concomitant CRT (cis/5-FU)
Rischin 2005 -0.36 (0.31) 0.70 [ 0.38, 1.28 ]
12 Concomitant CRT (cis/TPZ) versus concomitant CRT (cis)
Rischin 2010 -0.07 (0.11) 0.93 [ 0.75, 1.16 ]
13 Concomitant CRT(HU/5-FU) versus concomitant CRT (cis/FU)
Garden 2004 -0.5 (0.3) 0.61 [ 0.34, 1.09 ]
14 Concomitant CRT (cis/paclitaxel) versus concomitant CRT (cis/FU)
Garden 2004 -0.3 (0.25) 0.74 [ 0.45, 1.21 ]
15 Concomitant CRT (cis/paclitaxel) versus concomitant CRT (HU/5-FU)
0.05 0.2 1 5 20
Favours Regimen A Favours Regimen B
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(. . . Continued)
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
Garden 2004 -0.25 (0.3) 0.78 [ 0.43, 1.40 ]
16 Concomitant intra-arterial CRT vs concomitant intravenous CRT
Rasch 2010 -0.14 (0.17) 0.87 [ 0.62, 1.21 ]
17 Concomitant CRT (MTX or VBMF) versus RT then CT (MTX or VBMF)
UKHAN 2010 -0.3 (0.13) 0.74 [ 0.57, 0.96 ]
18 Concomitant CRT (MTX or VBMF) then CT versus RT then CT (MTX or VBMF)
UKHAN 2010 -0.04 (0.13) 0.96 [ 0.74, 1.24 ]
19 Concomitant CRT (MTX or VBMF) then CT versus concomitant CRT (MTX or VBMF)
UKHAN 2010 0.25 (0.13) 1.28 [ 1.00, 1.66 ]
20 Induction CT (PF) then RT vs concomitant CRT + maint CT (PF)
Adelstein 1993 -0.508 (0.405) 0.60 [ 0.27, 1.33 ]
21 Induction sequential cisplatin then RT versus concomitant CRT (cis/5-FU)
Pinnaro 1994 -0.36 (0.21) 0.70 [ 0.46, 1.05 ]
22 Induction CT (PF) then concomitant CRT versus concomitant CRT (PF)
Gupta 2009 -0.82 (0.44) 0.44 [ 0.19, 1.04 ]
23 Induction CT (TPF) then CRT versus CRT alone
Paccagnella 2010 -0.16 (0.3) 0.85 [ 0.47, 1.53 ]
24 Induction CT (BLM/MTX/VINB) then RT vs alternating CRT
Merlano 1991 0.5328 (0.209) 1.70 [ 1.13, 2.57 ]
0.05 0.2 1 5 20
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Analysis 4.2. Comparison 4 Chemotherapy A (± LRT) versus chemotherapy B (± LRT), Outcome 2 Disease
free survival.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 4 Chemotherapy A ( LRT) versus chemotherapy B ( LRT)
Outcome: 2 Disease free survival
Study or subgroup log [Hazard ratio] Hazard ratio Hazard ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Induction CT(cis/BLM) then surg/RT then CT (cis) vs induction CT (cis/BLM) then surg/RT
HNCProg 1987 -0.51 (0.28) 0.60 [ 0.35, 1.04 ]
2 Induction CT (cis/5-FU) then concomitant CRT versus concomitant CRT (cisplatin + 5-FU)
Gupta 2009 -0.65 (0.34) 0.52 [ 0.27, 1.02 ]
3 Concomitant CRT (cis/TPZ) versus concomitant CRT (cis/5-FU)
Rischin 2005 -0.33 (0.28) 0.72 [ 0.42, 1.24 ]
4 Concomitant CRT (cis/TPZ) versus concomitant CRT (cis)
Rischin 2010 0.01 (0.1) 1.01 [ 0.83, 1.23 ]
5 Concomitant CRT (carboplatin) versus concomitant CRT (cisplatin)
Gasparini 1993 -0.35 (0.41) 0.70 [ 0.32, 1.57 ]
6 Concomitant intra-arterial CRT vs concomitant intravenous CRT
Rasch 2010 0.14 (0.26) 1.15 [ 0.69, 1.91 ]
7 Induction CT (BLM/MTX/VINB/Leucov) then RT vs alternating CRT
Merlano 1991 0.45 (0.16) 1.57 [ 1.15, 2.15 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 4.3. Comparison 4 Chemotherapy A (± LRT) versus chemotherapy B (± LRT), Outcome 3
Progression free survival.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 4 Chemotherapy A ( LRT) versus chemotherapy B ( LRT)
Outcome: 3 Progression free survival
Study or subgroup log [Hazard Ratio] Hazard Ratio Hazard Ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Induction cisplatin + UFT versus induction cisplatin + 5-FU
Gonzalez-Larriba 1997 0.15 (0.34) 1.16 [ 0.60, 2.26 ]
2 Induction cisplatin + docetaxel + 5-FU (TPF) RT versus induction cisplatin + 5-FU (PF) RT induction cisplatin + FU RT versus induction cisplatin + docetaxel +
5FU RT
Vermorken 2007 -0.33 (0.12) 0.72 [ 0.57, 0.91 ]
3 Induction (TPF) versus induction (PF)
Posner 2007 -0.34 (0.12) 0.71 [ 0.56, 0.90 ]
4 Concomitant CRT (MTX or VBMF) versus RT then CT (MTX or VBMF)
UKHAN 2010 -0.39 (0.12) 0.68 [ 0.54, 0.86 ]
5 Concomitant CRT (MTX or VBMF) then CT versus RT then CT (MTX or VBMF)
UKHAN 2010 -0.13 (0.12) 0.88 [ 0.69, 1.11 ]
6 Concomitant CRT (MTX or VBMF) then CT versus neo concomitant CRT (MTX or VBMF)
UKHAN 2010 0.24 (0.12) 1.27 [ 1.00, 1.61 ]
7 Induction CT (PF) then RT versus concomitant CRT + maint CT (PF)
Adelstein 1993 -0.78 (0.59) 0.46 [ 0.14, 1.46 ]
8 Induction sequential cisplatin then RT versus concomitant CRT (cis/5-FU)
Pinnaro 1994 0.07 (0.21) 1.07 [ 0.71, 1.62 ]
9 Induction CT (TPF) then CRT versus CRT alone
Paccagnella 2010 -0.26 (0.27) 0.77 [ 0.45, 1.31 ]
0.1 0.2 0.5 1 2 5 10
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Analysis 4.4. Comparison 4 Chemotherapy A (± LRT) versus chemotherapy B (± LRT), Outcome 4
Locoregional control.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 4 Chemotherapy A ( LRT) versus chemotherapy B ( LRT)
Outcome: 4 Locoregional control
Study or subgroup log [hazard ratio] hazard ratio hazard ratio
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Neo concomitant CRT (cis/TPZ) versus neo concomitant CRT (cis/5-FU)
Rischin 2005 -0.77 (0.41) 0.46 [ 0.21, 1.03 ]
2 Concomitant intra-arterial CRT vs concomitant intravenous CRT
Rasch 2010 -0.05 (0.23) 0.95 [ 0.61, 1.49 ]
3 Concomitant CRT (cis/TPZ) versus concomitant CRT (cis)
Rischin 2010 -0.12 (0.14) 0.89 [ 0.67, 1.17 ]
0.001 0.01 0.1 1 10 100 1000
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Analysis 4.5. Comparison 4 Chemotherapy A (± LRT) versus chemotherapy B (± LRT), Outcome 5 Total
mortality (2-5 years).
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 4 Chemotherapy A ( LRT) versus chemotherapy B ( LRT)
Outcome: 5 Total mortality (2-5 years)
Study or subgroup Chemo A Chemo B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Induction CT (BVCM) + surgery vs induction CT (BVM) + surgery
Olasz 2000 7/19 12/19 0.58 [ 0.30, 1.15 ]
0.01 0.1 1 10 100
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Analysis 4.6. Comparison 4 Chemotherapy A (± LRT) versus chemotherapy B (± LRT), Outcome 6 Disease
free survival (5 years).
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 4 Chemotherapy A ( LRT) versus chemotherapy B ( LRT)
Outcome: 6 Disease free survival (5 years)
Study or subgroup Treatment A Treatment B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Induction carboplatin + 5-FU versus induction cisplatin + 5-FU
De Andres 1995 11/46 23/49 0.51 [ 0.28, 0.92 ]
0.01 0.1 1 10 100
Favours cisplatin/5FU Favours carboplatin/5FU
Analysis 4.7. Comparison 4 Chemotherapy A (± LRT) versus chemotherapy B (± LRT), Outcome 7
Locoregional control.
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 4 Chemotherapy A ( LRT) versus chemotherapy B ( LRT)
Outcome: 7 Locoregional control
Study or subgroup Treatment A Treatment B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Induction CT (BLM/MTX/VINB/Leucov) then RT vs alternating CRT
Merlano 1991 37/57 25/48 1.25 [ 0.89, 1.74 ]
2 Induction CT (BLM/MTX/HU) then RT versus alternating CR
Buffoli 1992 13/29 6/20 1.49 [ 0.68, 3.27 ]
3 Induction cisplatin + 5-FU + RT versus induction cisplatin + etoposide + RT
Prevost 2005 47/98 32/99 1.48 [ 1.04, 2.11 ]
4 Induction methotrexate (intra-arterial) versus bleomycin (intra-arterial)
Molinari 1982 9/42 26/43 0.35 [ 0.19, 0.66 ]
5 Concomitant cisplatin (daily) + RT versus concomitant cisplatin (weekly) + RT
Gladkov 2007 6/22 5/26 1.42 [ 0.50, 4.02 ]
6 Concomitant cisplatin (weekly) + RT versus concomitant cisplatin (once/3 weeks) + RT
Gladkov 2007 5/26 5/12 0.46 [ 0.16, 1.30 ]
0.01 0.1 1 10 100
Favours Regimen A Favours Regimen B
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Study or subgroup Treatment A Treatment B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
7 Concomitant cisplatin (daily) + RT versus concomitant cisplatin (once/3weeks) + RT
Gladkov 2007 6/22 2/12 1.64 [ 0.39, 6.89 ]
0.01 0.1 1 10 100
Favours Regimen A Favours Regimen B
Analysis 4.8. Comparison 4 Chemotherapy A (± LRT) versus chemotherapy B (± LRT), Outcome 8
Locoregional recurrence (2 years).
Review: Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy
Comparison: 4 Chemotherapy A ( LRT) versus chemotherapy B ( LRT)
Outcome: 8 Locoregional recurrence (2 years)
Study or subgroup Treatment A Treatment B Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Induction CT (BVCM) + surgery vs induction CT (BVM)
Olasz 2000 7/19 14/19 0.50 [ 0.26, 0.96 ]
0.01 0.1 1 10 100
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A D D I T I O N A L T A B L E S
Table 1. Classification of chemotherapy agents
Drugs included in review
ALKYLATING AGENTS - ’platins’ - work by directly damaging
DNA and preventing cancer cells from dividing
Cisplatin
Carboplatin
ANTIMETABOLITES - interfere with DNA and RNA growth.
Kill cancer cells in specific phase of cell division
5-FU, 5 fluorouracil
1-FU, 1 fluorouracil
Etoposide
Methotrexate
Ftorafur (tegafur + uracil) UFT or uftoral
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Table 1. Classification of chemotherapy agents (Continued)
ANTITUMOUR ANTIBIOTICS - interfere with enzymes re-
quired for DNA replication
Bleomycin
Mitomycin
VINCA ALKALOIDS - inhibit mitosis or or inhibit enzymes
from making proteins necessary for cell reproduction
Vinblastine
Vincristine
TAXANES - diterpines from the genus Taxus. Inhibit mitosis by
disrupting microtubule function
Paclitaxel
Docetaxel
OTHER Tirapazamine
Table 2. Proportion of patients with oral cavity or oropharyngeal cancer in studies included in this review
Trial ID % oral cavity cancer % oropharyngeal cancer Total % OC/OP Mortality data from Pignon
meta-analyses
Bitter 1979 100% 100%
Denis 2004 100% 100% Pignon 2009
Domenge 2000 100% 100%
Eschwege 1988 100% 100% Pignon 2000
Gladhov 2007 100%
Gupta 2009 100% 100%
HNC Prog 1987 100% 100%
Krishnamurthi 1990 100% 100%
Licitra 2003 100% 100%
Luboinski 1985 100% 100%
Mazeron 1992 37% 63% 100% Pignon 2000
Mohr 1994 100%
Molinari 1982 100% 100%
Morita 1980* 100%
Olmi 2003 100% 100% Pignon 2009
Rao 1994 100% 100% Pignon 2000
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Table 2. Proportion of patients with oral cavity or oropharyngeal cancer in studies included in this review (Continued)
Richard 1974 100% Pignon 2000
Richard 1991 100% 100% Pignon 2000
Shanta 1980 100% 100% Pignon 2000
Szabo 1999 100% 100%
Szpirglas 1979 100% 100% Pignon 2000
Szpirglas 1988 100% Pignon 2000
Volling 1999* 100%
Maipang 1995 76% 9% 85% Pignon 2000
Chauhan 2008 84%
Garden 2004 16% 67% 83%
Adelstein 1993 48% 35% 83% Pignon 2000
Nervi 1978 58% 25% 83%
Smid 1995 16% 64% 80% Pignon 2000
Fazekas 1980 23% 56% 79% Pignon 2000
Parvinen 1985 71% 8% 79% Pignon 2000
Grau 2003 48% 29% 77% Pignon 2009
Salvajoli 1992 47% 30% 77% Pignon 2000
Lewin 1997 41% 34% 75% Pignon 2000
Rischin 2005 5% 70% 75%
Brunin 1989 37% 37% 74% Pignon 2000
Petrovich 1981 17% 57% 74%
Starr 2001 74% 74% Pignon 2009
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Table 2. Proportion of patients with oral cavity or oropharyngeal cancer in studies included in this review (Continued)
Buffoli 1992 73%
Dobrowsky 2000 29% 44% 73% Pignon 2009
Paccagnella 1994 16% 57% 73% Pignon 2000
Adelstein 2003 13% 59% 72% Pignon 2009
Merlano 1991 25% 47% 72% Pignon 2000
Bensadoun 2006 0% 75% 75%
Rasch 2010 18% 63% 71%
Merlano 1992 29% 42% 71% Pignon 2000
Cooper 2004 27% 43% 70% Pignon 2009
Paccagnella 2009 18% 54% 70%
Le 2006* 6% 63% 69%
Pinnaro 1994 45% 24% 69%
Gasparini 1993 28% 40% 68%
Staar 2001 68% 68% Pignon 2009
Schuller 1988 38% 30% 68% Pignon 2000
Argiris 2008 35% 32% 67%
Budach 2005 8% 59% 67% Pignon 2009
Tejedor 1992 31% 36% 67% Pignon 2000
Rischin 2010 13% 54% 67%
Ruo 2010 17% 49% 66%
Posner 2007 14% 52% 66%
Kumar 1996 24% 42% 66% Pignon 2009
Vermorken 2007 18% 46% 64%
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Table 2. Proportion of patients with oral cavity or oropharyngeal cancer in studies included in this review (Continued)
Browman 1986 64% 64%
Haddad 1996 20% 43% 63%
Segura 2002 62% 62%
Holoye 1985 28% 33% 61% Pignon 2000
Depondt 1993 26% 35% 61% Pignon 2000
Hugenin 2004 8% 53% 61% Pignon 2009
Knowlton 1975 31% 30% 61%
Prevost 2005 33% 26% 59%
Chauvergne 1988 59%
Jaulerry 1992 30% 28% 58% Pignon 2000
Wendt 1998 38% 20% 58% Pignon 2000
Jeremic 2000 21% 37% 58% Pignon 2009
Corvo 2001 19% 38% 57% Pignon 2009
Bernier 2004 26% 30% 56% Pignon 2009
De Andres 1995 16% 39% 55%
Gupta 2001* 22% 33% 55% Pignon 2000
Marechal 1987 15% 40% 55%
Rentschler 1987 33% 22% 55%
Vokes 1990 12% 43% 55%
Weissler 1992 16% 39% 55% Pignon 2000
Browman 1994 12% 42% 54% Pignon 2000
Giglio 1997 33% 20% 53% Pignon 2009
Jeremic 1997 16% 37% 53% Pignon 2000
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Table 2. Proportion of patients with oral cavity or oropharyngeal cancer in studies included in this review (Continued)
Lam 2001 32% 21% 53%
Laramore 1992 27% 25% 52% Pignon 2000
UKHAN 2009 19% 33% 52%
Gonzalez-Larriba 1997 12% 39% 51%
Brizel 1998 5% 45% 50%
*Oral cavity (OC) and/or oropharyngeal (OP) data available as a separate entity (in trial report or provided by author). i OC/OP
combined. ii OC alone. iii OP alone.
A P P E N D I C E S
Appendix 1. MEDLINE via OVID search strategy
1. “head and neck neoplasms”/ or mouth neoplasms/ or gingival neoplasms/ or palatal neoplasms/ or tongue neoplasms/
2. ((cancer$ or tumour$ or tumor$ or neoplas$ or malignan$ or carcinoma$ or metatasta$) adj5 (oral$ or intra-oral$ or gingiva$ or
oropharyn$ or mouth$ or tongue$ or cheek or cheeks or gum or gums or palatal or palate or intraoral or “head and neck”)).ti,ab.
3. or/1-2
4. chemoradiotherap$.ti,ab.
5. surg$.ti,ab.
6. radiotherap$.ti,ab.
7. chemotherap$.ti,ab.
8. (neck adj1 dissection$).ti,ab.
9. brachytherap$.ti,ab.
10. (adjuvant or neo-adjuvant).ti,ab.
11. photodynamic.ti,ab.
12. teletherap$.ti,ab.
13. plesiotherap$.ti,ab.
14. excision$.ti,ab.
15. excise$.ti,ab.
16. (hyperfractionate$ or hyper-fractionate$).ti,ab.
17. dahanca.ti,ab.
18. arcon.ti,ab.
19. radiat$.ti,ab.
20. irradiat$.ti,ab.
21. resect$.ti,ab.
22. lymphadenectom$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
23. curett$.ti,ab.
24. neoadjuvant.ti,ab.
25. glossectom$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
26. antineoplas$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
27. ((alternative or combined or gene or genetic) adj2 (therapy or therapies)).ti,ab.
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28. (onyx-015 or amifostine$ or misonidazole$ or erythropoietin$).mp. [mp=title, original title, abstract, name of substance word,
subject heading word]
29. fluorouracil$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
30. 5-fluorouracil$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
31. cisplatin$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
32. paclitaxel$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
33. vinblastine$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
34. bleomycin$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
35. 5fu.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
36. adriamycin$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
37. doxorubicin$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
38. methotrexa$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
39. docetaxel$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
40. carboplatin$.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
41. hydroxyurea.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
42. ((vitamin or nutrition$) adj2 supplement$).ti,ab.
43. (herb or herbs or herbal).ti,ab.
44. cetuximab.mp. [mp=title, original title, abstract, name of substance word, subject heading word]
45. (locoregional$ adj5 (recurren$ or control$ or treat$ or lymph$)).ti,ab.
46. surgery.mp. or surgical$.ti,ab. [mp=title, original title, abstract, name of substance word, subject heading word]
47. exp Radiotherapy/
48. exp Antineoplastic Agents/
49. exp surgical procedures, operative/ or lymph node excision/
50. exp Antimetabolites/
51. exp combined modality therapy/ or exp complementary therapies/
52. or/4-25
53. or/26-51
54. 52 or 53
55. 3 and 54
The above subject search was combined with the Cochrane Highly Sensitive Search Strategy (CHSSS) for identifying randomised
trials in MEDLINE: sensitivity maximising version (2009 revision) as referenced in Chapter 6.4.11.1 and detailed in box 6.4.c of the
Cochrane Handbook for Systematic Reviews of Interventions version 5.0.2 (updated September 2009):
1. randomized controlled trial.pt.
2. controlled clinical trial.pt.
3. randomized.ab.
4. placebo.ab.
5. drug therapy.fs.
6. randomly.ab.
7. trial.ab.
8. groups.ab.
9. or/1-8
10. exp animals/ not humans.sh.
11. 9 not 10
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Appendix 2. Cochrane Oral Health Group’s Trials Register search strategy
((mouth or oral or intraoral or intra-oral or gingiva* or oropharyn* or cheek* or gum* or palat* or lip or tongue or “head and neck”)
AND (tumour* or tumor* or cancer* or carcinoma* or neoplas* or malignan*))
Appendix 3. The Cochrane Central Register of Controlled Clinical Trials (CENTRAL) search
strategy
#1 MeSH descriptor HEAD AND NECK NEOPLASMS this term only
#2 MeSH descriptor MOUTH NEOPLASMS this term only
#3 MeSH descriptor GINGIVAL NEOPLASMS this term only
#4 MeSH descriptor PALATAL NEOPLASMS this term only
#5 MeSH descriptor TONGUE NEOPLASMS this term only
#6 ( (oral in Title, Abstract or Keywords near/6 cancer* in Title, Abstract or Keywords) or (oral in Title, Abstract or Keywords
near/6 tumour* in Title, Abstract or Keywords) or (oral in Title, Abstract or Keywords near/6 tumor* in Title, Abstract or Keywords)
or (oral in Title, Abstract or Keywords near/6 neoplas* in Title, Abstract or Keywords) or (oral in Title, Abstract or Keywords near/6
malignan* in Title, Abstract or Keywords) or (oral in Title, Abstract or Keywords near/6 carcinoma* in Title, Abstract or Keywords)
or (oral in Title, Abstract or Keywords near/6 metastas* in Title, Abstract or Keywords) or (cancer* in Title, Abstract or Keywords
near/6 intra-oral* in Title, Abstract or Keywords) or (intra-oral* in Title, Abstract or Keywords near/6 tumour* in Title, Abstract
or Keywords) or (intra-oral* in Title, Abstract or Keywords near/6 tumor* in Title, Abstract or Keywords) or (intra-oral* in Title,
Abstract or Keywords near/6 neoplas* in Title, Abstract or Keywords) or (intra-oral* in Title, Abstract or Keywords near/6 malignan*
in Title, Abstract or Keywords) or (intra-oral* in Title, Abstract or Keywords near/6 carcinoma* in Title, Abstract or Keywords) or
(intra-oral* in Title, Abstract or Keywords near/6 metastas* in Title, Abstract or Keywords) or (cancer* in Title, Abstract or Keywords
near/6 intraoral* in Title, Abstract or Keywords) or (intraoral* in Title, Abstract or Keywords near/6 tumour* in Title, Abstract or
Keywords) or (intraoral* in Title, Abstract or Keywords near/6 tumor* in Title, Abstract or Keywords) or (intraoral* in Title, Abstract
or Keywords near/6 neoplas* in Title, Abstract or Keywords) or (intraoral* in Title, Abstract or Keywords near/6 malignan* in Title,
Abstract or Keywords) or (intraoral* in Title, Abstract or Keywords near/6 carconoma* in Title, Abstract or Keywords) or (intraoral*
in Title, Abstract or Keywords near/6 metasta* in Title, Abstract or Keywords) or (gingiva* in Title, Abstract or Keywords near/6
cancer* in Title, Abstract or Keywords) or (gingiva* in Title, Abstract or Keywords near/6 tumour* in Title, Abstract or Keywords)
or (gingiva* in Title, Abstract or Keywords near/6 tumor* in Title, Abstract or Keywords) or (gingiva* in Title, Abstract or Keywords
near/6 neoplas* in Title, Abstract or Keywords) or (gingiva* in Title, Abstract or Keywords near/6 malignan* in Title, Abstract or
Keywords) or (gingiva* in Title, Abstract or Keywords near/6 carcinoma* in Title, Abstract or Keywords) or (gingiva* in Title, Abstract
or Keywords near/6 metastas* in Title, Abstract or Keywords) or (oropharyn* in Title, Abstract or Keywords near/6 cancer* in Title,
Abstract or Keywords) or (oropharyn* in Title, Abstract or Keywords near/6 tumour* in Title, Abstract or Keywords) or (oropharyn*
in Title, Abstract or Keywords near/6 tumor* in Title, Abstract or Keywords) or (oropharyn* in Title, Abstract or Keywords near/6
neoplas* in Title, Abstract or Keywords) or (oropharyn* in Title, Abstract or Keywords near/6malignan* in Title, Abstract or Keywords)
or (oropharyn* in Title, Abstract or Keywords near/6 carcinoma* in Title, Abstract or Keywords) or (oropharyn* in Title, Abstract or
Keywords near/6 metastas* in Title, Abstract or Keywords) or (mouth* in Title, Abstract or Keywords near/6 cancer* in Title, Abstract
or Keywords) or (mouth* in Title, Abstract or Keywords near/6 tumour* in Title, Abstract or Keywords) or (mouth* in Title, Abstract
or Keywords near/6 tumor* in Title, Abstract or Keywords) or (mouth* in Title, Abstract or Keywords near/6 neoplas* in Title, Abstract
or Keywords) or (mouth* in Title, Abstract or Keywords near/6 malignan* in Title, Abstract or Keywords) or (mouth* in Title, Abstract
or Keywords near/6 carcinoma* in Title, Abstract or Keywords) or (mouth* in Title, Abstract or Keywords near/6 metastas* in Title,
Abstract or Keywords) or (tongue* in Title, Abstract or Keywords near/6 cancer* in Title, Abstract or Keywords) or (tongue* in Title,
Abstract or Keywords near/6 tumour* in Title, Abstract or Keywords) or (tongue* in Title, Abstract or Keywords near/6 tumor* in
Title, Abstract or Keywords) or (tongue* in Title, Abstract or Keywords near/6 neoplas* in Title, Abstract or Keywords) or (tongue*
in Title, Abstract or Keywords near/6 malignan* in Title, Abstract or Keywords) or (tongue* in Title, Abstract or Keywords near/6
carcinoma* in Title, Abstract or Keywords) or (tongue* in Title, Abstract or Keywords near/6 metastas* in Title, Abstract or Keywords)
or (cheek in Title, Abstract or Keywords near/6 cancer* in Title, Abstract or Keywords) or (cheek in Title, Abstract or Keywords near/
6 tumour* in Title, Abstract or Keywords) or (cheek in Title, Abstract or Keywords near/6 tumor* in Title, Abstract or Keywords) or
(cheek in Title, Abstract or Keywords near/6 neoplas* in Title, Abstract or Keywords) or (cheek in Title, Abstract or Keywords near/6
malignan* in Title, Abstract or Keywords) or (cheek in Title, Abstract or Keywords near/6 carcinoma* in Title, Abstract or Keywords)
or (cheek in Title, Abstract or Keywords near/6 metastas* in Title, Abstract or Keywords) or (cheeks in Title, Abstract or Keywords
near/6 cancer* in Title, Abstract or Keywords) or (cheeks in Title, Abstract or Keywords near/6 tumour* in Title, Abstract or Keywords)
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or (cheeks in Title, Abstract or Keywords near/6 tumor* in Title, Abstract or Keywords) or (cheeks in Title, Abstract or Keywords near/
6 neoplas* in Title, Abstract or Keywords) or (cheeks in Title, Abstract or Keywords near/6 malignan* in Title, Abstract or Keywords)
or (cheeks in Title, Abstract or Keywords near/6 carcinoma* in Title, Abstract or Keywords) or (cheeks in Title, Abstract or Keywords
near/6 metastas* in Title, Abstract or Keywords) or (gum in Title, Abstract or Keywords near/6 cancer* in Title, Abstract or Keywords)
or (gum in Title, Abstract or Keywords near/6 tumour* in Title, Abstract or Keywords) or (gum in Title, Abstract or Keywords near/
6 tumor* in Title, Abstract or Keywords) or (gum in Title, Abstract or Keywords near/6 neoplas* in Title, Abstract or Keywords) or
(gum in Title, Abstract or Keywords near/6 malignan* in Title, Abstract or Keywords) or (gum in Title, Abstract or Keywords near/6
carcinoma* in Title, Abstract or Keywords) or (gum in Title, Abstract or Keywords near/6 metastas* in Title, Abstract or Keywords)
or (gums in Title, Abstract or Keywords near/6 cancer* in Title, Abstract or Keywords) or (gums in Title, Abstract or Keywords near/
6 tumour* in Title, Abstract or Keywords) or (gums in Title, Abstract or Keywords near/6 tumor* in Title, Abstract or Keywords) or
(gums in Title, Abstract or Keywords near/6 neoplas* in Title, Abstract or Keywords) or (gums in Title, Abstract or Keywords near/6
malignan* in Title, Abstract or Keywords) or (gums in Title, Abstract or Keywords near/6 carcinoma* in Title, Abstract or Keywords)
or (gums in Title, Abstract or Keywords near/6 metastas* in Title, Abstract or Keywords) or (palate in Title, Abstract or Keywords near/
6 cancer* in Title, Abstract or Keywords) or (palate in Title, Abstract or Keywords near/6 tumour* in Title, Abstract or Keywords) or
(palate in Title, Abstract or Keywords near/6 tumor* in Title, Abstract or Keywords) or (palate in Title, Abstract or Keywords near/6
neoplas* in Title, Abstract or Keywords) or (palate in Title, Abstract or Keywords near/6 malignan* in Title, Abstract or Keywords) or
(palate in Title, Abstract or Keywords near/6 carcinoma* in Title, Abstract or Keywords) or (palate in Title, Abstract or Keywords near/
6 metastas* in Title, Abstract or Keywords) or (palatal in Title, Abstract or Keywords near/6 cancer* in Title, Abstract or Keywords) or
(palatal in Title, Abstract or Keywords near/6 tumour* in Title, Abstract or Keywords) or (palatal in Title, Abstract or Keywords near/
6 tumor* in Title, Abstract or Keywords) or (palatal in Title, Abstract or Keywords near/6 neoplas* in Title, Abstract or Keywords)
or (palatal in Title, Abstract or Keywords near/6 malignan* in Title, Abstract or Keywords) or (palatal in Title, Abstract or Keywords
near/6 carcinoma* in Title, Abstract or Keywords) or (palatal in Title, Abstract or Keywords near/6 metastas* in Title, Abstract or
Keywords) or (“head and neck” in Title, Abstract or Keywords near/6 cancer* in Title, Abstract or Keywords) or (“head and neck” in
Title, Abstract or Keywords near/6 tumour* in Title, Abstract or Keywords) or (“head and neck” in Title, Abstract or Keywords near/
6 tumor* in Title, Abstract or Keywords) or (“head and neck” in Title, Abstract or Keywords near/6 neoplas* in Title, Abstract or
Keywords) or (“head and neck” in Title, Abstract or Keywords near/6 malignan* in Title, Abstract or Keywords) or (“head and neck”
in Title, Abstract or Keywords near/6 carcinoma* in Title, Abstract or Keywords) or (“head and neck” in Title, Abstract or Keywords
near/6 metastas* in Title, Abstract or Keywords) )
#7 (#1 or #2 or #3 or #4 or #5 or #6)
#8 (chemotherap* in Record Title or chemoradiotherap* in Record Title or (surg* in Record Title and curett* in Record Title)
or radiotherap* in Record Title or “neck dissection*” in Record Title or brachytherap* in Record Title or adjuvant in Record Title
or neo-adjuvant in Record Title or neoadjuvant in Record Title or photodynamic in Record Title or teletherap* in Record Title or
plesiotherap* in Record Title or excision* in Record Title or excise* in Record Title or hyperfractionate* in Record Title or hyper-
fractionate* in Record Title or dahanca in Record Title or arcon in Record Title or radiat* in Record Title or irradiat* in Record Title
or resect* in Record Title)
#9 (chemotherap* in Abstract or chemoradiotherap* in Abstract or (surg* in Abstract and curett* in Abstract) or radiotherap*
in Abstract or “neck dissection*” in Abstract or brachytherap* in Abstract or adjuvant in Abstract or neo-adjuvant in Abstract or
neoadjuvant in Abstract or photodynamic in Abstract or teletherap* in Abstract or plesiotherap* in Abstract or excision* in Abstract
or excise* in Abstract or hyperfractionate* in Abstract or hyper-fractionate* in Abstract or dahanca in Abstract or arcon in Abstract or
radiat* in Abstract or irradiat* in Abstract or resect* in Abstract)
#10 (lymphadenectom* in Title, Abstract or Keywords or glossectom* in Title, Abstract or Keywords)
#11 antineoplas* in Title, Abstract or Keywords
#12 ( (alternative in Title, Abstract or Keywords near/6 therap* in Title, Abstract or Keywords) or (combined in Title, Abstract or
Keywords near/6 therap* in Title, Abstract or Keywords) or (gene in Title, Abstract or Keywords near/6 therap* in Title, Abstract or
Keywords) or (genetic in Title, Abstract or Keywords near/6 therap* in Title, Abstract or Keywords) )
#13 (onyx-015 in Title, Abstract or Keywords or amifostine* in Title, Abstract or Keywords or misonidazole* in Title, Abstract or
Keywords or erythropoietin* in Title, Abstract or Keywords)
#14 (fluorouracil* in Title, Abstract or Keywords or 5-fluorouracil* in Title, Abstract or Keywords or cisplatin* in Title, Abstract or
Keywords or paclitaxel* in Title, Abstract or Keywords or vinblastine* in Title, Abstract or Keywords or bleomycin* in Title, Abstract
or Keywords or “5fu” in Title, Abstract or Keywords or adriamycin* in Title, Abstract or Keywords or doxorubicin* in Title, Abstract or
Keywords or methotrexa* in Title, Abstract or Keywords or docetaxel* in Title, Abstract or Keywords or carboplatin* in Title, Abstract
or Keywords or hydroxyurea in Title, Abstract or Keywords)
#15 (“vitamin supplement*” in Title, Abstract or Keywords or “nutrition* supplement*” in Title, Abstract or Keywords)
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#16 (herb in Title, Abstract or Keywords or herbs in Title, Abstract or Keywords or herbal in Title, Abstract or Keywords)
#17 cetuximab in Title, Abstract or Keywords
#18 ( (locoregional* in Title, Abstract or Keywords near/6 recurren* in Title, Abstract or Keywords) or (loco-regional* in Title,
Abstract or Keywords near/6 recurren* in Title, Abstract or Keywords) or (locoregional* in Title, Abstract or Keywords near/6 control*
in Title, Abstract or Keywords) or (loco-regional* in Title, Abstract or Keywords near/6 control* in Title, Abstract or Keywords) or
(locoregional* in Title, Abstract or Keywords near/6 treat* in Title, Abstract or Keywords) or (loco-regional* in Title, Abstract or
Keywords near/6 treat* in Title, Abstract or Keywords) or (locoregional in Title, Abstract or Keywords near/6 lymph* in Title, Abstract
or Keywords) or (loco-regional* in Title, Abstract or Keywords near/6 lymph in Title, Abstract or Keywords) )
#19 MeSH descriptor RADIOTHERAPY explode all trees
#20 MeSH descriptor ANTINEOPLASTIC AGENTS explode all trees
#21 MeSH descriptor SURGICAL PROCEDURES, OPERATIVE explode all trees
#22 MeSH descriptor LYMPH NODE EXCISION explode all trees
#23 MeSH descriptor ANTIMETABOLITES explode all trees
#24 MeSH descriptor COMBINED MODALITY THERAPY explode all trees
#25 MeSH descriptor COMPLEMENTARY THERAPIES explode all trees
#26 (surgery in Record Title or surgical* in Record Title)
#27 (surgery in Abstract or surgical* in Abstract)
#28 (#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25
or #26 or #27)
#29 (#7 and #28)
Appendix 4. EMBASE via OVID search strategy
1. “head and neck neoplasms”/ or mouth neoplasms/ or gingival neoplasms/ or palatal neoplasms/ or tongue neoplasms/
2. ((cancer$ or tumour$ or tumor$ or neoplas$ or malignan$ or carcinoma$ or metatasta$) adj5 (oral$ or intra-oral$ or gingiva$ or
oropharyn$ or mouth$ or tongue$ or cheek or cheeks or gum or gums or palatal or palate or intraoral or “head and neck”)).ti,ab.
3. or/1-2
4. chemoradiotherap$.ti,ab.
5. surg$.ti,ab.
6. radiotherap$.ti,ab.
7. chemotherap$.ti,ab.
8. (neck adj1 dissection$).ti,ab.
9. brachytherap$.ti,ab.
10. (adjuvant or neo-adjuvant).ti,ab.
11. photodynamic.ti,ab.
12. teletherap$.ti,ab.
13. plesiotherap$.ti,ab.
14. excision$.ti,ab.
15. excise$.ti,ab.
16. (hyperfractionate$ or hyper-fractionate$).ti,ab.
17. dahanca.ti,ab.
18. arcon.ti,ab.
19. radiat$.ti,ab.
20. irradiat$.ti,ab.
21. resect$.ti,ab.
22. lymphadenectom$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
23. curett$.ti,ab.
24. neoadjuvant.ti,ab.
25. glossectom$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
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26. antineoplas$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
27. ((alternative or combined or gene or genetic) adj2 (therapy or therapies)).ti,ab.
28. (onyx-015 or amifostine$ or misonidazole$ or erythropoietin$).mp. [mp=title, abstract, subject headings, heading word, drug trade
name, original title, device manufacturer, drug manufacturer name]
29. fluorouracil$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
30. 5-fluorouracil$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
31. cisplatin$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
32. paclitaxel$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
33. vinblastine$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
34. bleomycin$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
35. 5fu.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drugmanufacturer
name]
36. adriamycin$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
37. doxorubicin$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
38. methotrexa$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
39. docetaxel$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
40. carboplatin$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
41. hydroxyurea.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
42. ((vitamin or nutrition$) adj2 supplement$).ti,ab.
43. (herb or herbs or herbal).ti,ab.
44. cetuximab.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
45. (locoregional$ adj5 (recurren$ or control$ or treat$ or lymph$)).ti,ab.
46. surgery.mp. or surgical$.ti,ab. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufac-
turer, drug manufacturer name]
47. exp Radiotherapy/ or cancer radiotherapy/ or cancerchemotherapy/
48. exp Antineoplastic Agent/
49. lymphadenectomy.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer,
drug manufacturer name]
50. exp Antimetabolites/
51. multimodality cancer therapy/ or alternative medicine/
52. or/4-25
53. or/26-51
54. 52 or 53
55. 3 and 54
The above subject search was combined with the Cochrane Oral Health Group’s RCT filter for searching EMBASE:
1. random$.ti,ab.
2. factorial$.ti,ab.
3. (crossover$ or cross over$ or cross-over$).ti,ab.
4. placebo$.ti,ab.
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5. (doubl$ adj blind$).ti,ab.
6. (singl$ adj blind$).ti,ab.
7. assign$.ti,ab.
8. allocat$.ti,ab.
9. volunteer$.ti,ab.
10. CROSSOVER PROCEDURE.sh.
11. DOUBLE-BLIND PROCEDURE.sh.
12. RANDOMIZED CONTROLLED TRIAL.sh.
13. SINGLE BLIND PROCEDURE.sh.
14. or/1-13
15. ANIMAL/ or NONHUMAN/ or ANIMAL EXPERIMENT/
16. HUMAN/
17. 16 and 15
18. 15 not 17
19. 14 not 18
Appendix 5. Allied and Complementary Medicine Database (AMED) via OVID search strategy
1. ((cancer$ or tumor$ or tumour$ or neoplasm$ or malignan$ or carcinoma$ or metasta$) adj5 (oral$ or intra-oral$ or gingiva$ or
oropharyn$ or mouth$ or tongue$ or cheek or cheeks or gum or gums or palatal or palate or intraoral or (head adj2 neck))).mp. [mp=
abstract, heading words, title]
2. (head and neck neoplasms).mp. [mp=abstract, heading words, title]
3. mouth neoplasms/
4. ((((gingiva$ adj4 neoplasm$) or tongue) adj4 neoplasm$) or ((palatal or palate) adj4 neoplasm$)).mp. [mp=abstract, heading words,
title]
5. or/1-4
6. palliative care/
7. Palliative treatment/
8. chemotherapy.mp.
9. chemoradiotherap$.mp. [mp=abstract, heading words, title]
10. exp radiotherapy/
11. (radiotherap$ or chemotherap$ or brachytherap$).mp. [mp=abstract, heading words, title]
12. surg$.mp. [mp=abstract, heading words, title]
13. (neck adj1 dissection$).mp. [mp=abstract, heading words, title]
14. (adjuvant or neo-adjuvant).mp. [mp=abstract, heading words, title]
15. photodynamic.mp.
16. teletherap$.mp. [mp=abstract, heading words, title]
17. pleisiotherap$.mp. [mp=abstract, heading words, title]
18. (excision$ or excise$).mp. [mp=abstract, heading words, title]
19. (hyperfractionate$ or hyper-fractionate$).mp. [mp=abstract, heading words, title]
20. dahanca.mp. [mp=abstract, heading words, title]
21. arcon.mp.
22. (radiat$ or irradiat$).mp. [mp=abstract, heading words, title]
23. resect$.mp. [mp=abstract, heading words, title]
24. lymphadenectom$.mp. [mp=abstract, heading words, title]
25. curett$.mp. [mp=abstract, heading words, title]
26. neoadjuvant.mp. [mp=abstract, heading words, title]
27. glossectom$.mp. [mp=abstract, heading words, title]
28. antineoplas$.mp. [mp=abstract, heading words, title]
29. ((alternative or combined or gene or genetic or nutrition$) adj2 (therapy or therapies)).mp. [mp=abstract, heading words, title]
30. onyx-015.mp. [mp=abstract, heading words, title]
31. (fluorouracil$ or cisplatin$ or paclitaxel$ or vinblastine$ or bleomycin$).mp. [mp=abstract, heading words, title]
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32. (adriamycin$ or doxorubicin$ or methotrexa$ or docetaxel$ or carboplatin$ or hydroxyurea).mp. [mp=abstract, heading words,
title]
33. 5fu.mp. [mp=abstract, heading words, title]
34. ((vitamin or nutrition$) adj2 supplement$).mp. [mp=abstract, heading words, title]
35. (herb or herbs).mp. [mp=abstract, heading words, title]
36. herbal.mp. [mp=abstract, heading words, title]
37. (locoregional$ adj5 (recurren$ or control$ or treat$ or lymph$)).mp. [mp=abstract, heading words, title]
38. (aromatherap$ or homeopath$ or osteopath$ or naturopath$).mp. [mp=abstract, heading words, title]
39. (wholistic or holistic).mp. [mp=abstract, heading words, title]
40. reflexolog$.mp. [mp=abstract, heading words, title]
41. massage$.mp. [mp=abstract, heading words, title]
42. (essential adj1 oil$).mp. [mp=abstract, heading words, title]
43. exp antineoplastic agents/
44. surgery operative/
45. lymph node excision.mp.
46. exp antimetabolites/
47. exp nursing care/
48. exp terminal care/
49. perioperative care.mp. [mp=abstract, heading words, title]
50. combined modality therapy/
51. exp complementary therapies/
52. exp nutrition therapy/
53. rehabilitation.mp. [mp=abstract, heading words, title]
54. remission induction.mp.
55. salvage therapy.mp.
56. or/6-55
57. 5 and 56
The above subject search was combined with an RCT filter for searching AMED:
1. exp randomized controlled trials/
2. exp double blind method/
3. exp random allocation/
4. (random$ or control$ or placebo$ or factorial).mp. [mp=abstract, heading words, title]
5. (double adj blind).mp. [mp=abstract, heading words, title]
6. (single adj blind).mp. [mp=abstract, heading words, title]
7. exp comparative study/
8. or/1-7
WH A T ’ S N E W
Last assessed as up-to-date: 27 February 2011.
Date Event Description
28 February 2011 New citation required and conclusions have changed Conclusions changed, summary of findings tables
added, together with minor changes to the way results
are presented
28 February 2011 New search has been performed Searches updated.
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Internal sources
• School of Dentistry, The University of Manchester, UK.
• Cochrane Oral Health Group, UK.
• The University of Dundee, UK.
• The University of Glasgow, UK.
• Manchester Academic Health Sciences Centre (MAHSC) and NIHR Manchester Biomedical Research Centre, UK.
External sources
• National Institute of Health, National Institute of Dental & Craniofacial Research, USA.
• Central Manchester & Manchester Children’s University Hospitals NHS Trust, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Types of studies - As the primary outcome for this review is total mortality we have added a requirement that included studies have a
minimum of 6 months of follow-up of participants after the end of treatment. Where participants in a trial have head and neck cancer
in general, we have only included studies where at least 50% of the participants have either oral cavity or oropharyngeal cancer, or
where data for the oral cavity and oropharyngeal patients only are available.
The protocol for this review stated that quality of life would be a primary outcome for this review. Quality of life is an important
outcome, for both patients with oral cavity and oropharyngeal cancers and their doctors. In this deadly and disfiguring disease, searching
for treatments that offer an improvement in both quantity and quality of life for patients motivates the large body of research into the
management of this disease. The search for effective chemotherapies is motivated at least in part by the desire to avoid patients having
to undergo radical disfiguring surgery with resultant loss of function.
However, as the reviewhas progressedwe have found the large quantity of research on chemotherapy focused on finding better treatments
that prolong overall survival, disease free survival and progression free survival. Quality of life is inconsistently reported in trials which
address a primary outcome of overall survival. Therefore we have opted to transfer this outcome to the list of secondary outcomes to
be considered in future updates of this review as appropriate.
Secondary outcome measures to be considered in future updates of this review include:
• Quality of life (using any appropriate scales)
• Morbidity including: function (ability to talk, eat including need for tube feeding, swallow, need for permanent tracheostomy),
psychosocial, and disfigurement
• Harms associated with treatment (for example nerve damage, nutritional problems)
• Complications of treatment (such as wound infection, flap necrosis, late treatment effects, nerve damage, fistula, bleeding,
treatment related death)
• Salvage treatment
• Direct and indirect costs to patients and health services
• Length of hospital stay/hospital days of treatment
• Hospital readmission
• Patient satisfaction.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Antineoplastic Combined Chemotherapy Protocols [adverse effects; ∗therapeutic use]; Carcinoma, Squamous Cell [∗drug therapy;
mortality; radiotherapy; surgery]; Combined Modality Therapy [methods; mortality]; Mouth Neoplasms [∗drug therapy; mortality;
radiotherapy; surgery]; Oropharyngeal Neoplasms [∗drug therapy; mortality; radiotherapy; surgery]; Randomized Controlled Trials as
Topic; Remission Induction; Survival Analysis
MeSH check words
Humans
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